REPORT ON CANCER IN NEVADA 1996-2000

A Comprehensive Report on Cancer from:

Nevada Central Cancer Registry

Nevada Death Registry

Nevada Inpatient Hospital Discharge (UB92)


Behavioral Risk Factor Surveillance Survey (BRFSS)

Center for Health Data and Research Bureau of Health Planning and Statistics Nevada State Health Division Department of Human Resources



Kenny Guinn, Governor Michael J. Willden, Director Department of Human Resources Yvonne Sylva, Administrator Vacant, State Health Officer Nevada State Health Division

REPORT ON CANCER IN NEVADA 1996-2000



Center for Health Data and Research Bureau of Health Planning and Statistics Emil DeJan, Bureau Chief Nevada State Health Division Department of Human Resources State of Nevada

ACKNOWLEDGEMENTS

Report Prepared by:

Tim Pollard, B.A. Health Resource Analyst Center for Health Data and Research

Wei Yang, Ph.D. State Biostatistician and Director Center for Health Data and Research

Data Provided By:

Karen Power, M.P.H.
Program Manager – Central Cancer Registry
Bureau of Health Planning and Statistics
3811 West Charleston, Suite 208
Las Vegas, Nevada 89102
Phone (702) 486-6260
Fax (702) 486-7602
http://health2k.state.nv.us/cancer/

Joseph Greenway, Director Center for Health Information Analysis University of Nevada, Las Vegas 4505 Maryland Parkway, Box 455058 Las Vegas, Nevada 89154-5058 Phone (702) 895-4389 Fax (702) 895-4276 http://www.unlv.edu/Research_Centers/chia/

Jean Gunter, Program Officer Office of Vital Statistics Bureau of Health Planning and Statistics 505 East King Street, Room 102 Carson City, NV 89701 Phone: (775) 684-4162 Fax: (775) 684-4156

http://health2k.state.nv.us/vital/

Judy Calder, Ed.D., Director Center for Applied Research College of Human and Community Sciences University of Nevada, Reno Reno, Nevada 89557-0017 Phone: (775) 784-6718

Fax: (775) 784-4506

http://sabcar.unr.edu/index.php

ACKNOWLEDGEMENTS (CONTINUED)

Editing Review and Comments:

Ihsan Azzam, M.P.H. Health Program Specialist Bureau of Community Health

Emil DeJan, M.P.H. Bureau Chief Bureau of Health Planning and Statistics

Chris Jacobson, M.H.A.
Health Resource Analyst
Bureau of Health Planning and Statistics

Deborah McBride, M.B.A. Health Program Manager Women's Health Connections Bureau of Community Health

Karen Power, M.P.H.
Program Manager – Central Cancer Registry
Bureau of Health Planning and Statistics

Randall Todd, Dr.P.H. State Epidemiologist

Cover Art Courtesy of:

Earl L. Hinrichs, © 2002. For information on this and other images by Mr. Hinrichs, please visit: http://computerart.org/index.html.

More health information can be found online at the Center for Health Data and Research's Nevada Interactive Health Databases System at: http://health2k.state.nv.us/nihds/center.htm.

Readers of this publication are welcome to offer their suggestions and/or comments concerning this publication by filling out the attached form at the end of this report. Readers are also welcome to submit requests for additional information by submitting them to:

Center for Health Data and Research Bureau of Health Planning and Statistics Nevada State Health Division 505 E. King Street, Room 102 Carson City, NV 89701-4749 Phone: (775) 684-4161

Fax: (775) 684-4156 E-mail: tpollard@nvhd.state.nv.us

PREFACE

This report provides a comprehensive overview of the risks and burden of cancer in Nevada from 1996 to 2000. Cancer represents a group of diseases that will affect nearly half of the population at some time during their lifetime. Nationally, cancer-related costs total billions of dollars in treatment annually. Cancer has also consistently been the second leading cause of death for Nevada and the Nation for the last 20 years. This report provides a variety of information on cancer from four different data sources and has been organized to focus on specific aspects of cancer, (e.g. screening, diagnosis, inpatient treatment, mortality, and survival rate) with each section adding to the overall picture of cancer in Nevada.

The first section provides a comparison of the 22 leading types of cancer that comprise 91.8% of all types of cancer in Nevada; including incidence, inpatient hospital discharges, mortality, and survival rate subsections for comparison.

The second section includes various statistics on all cancers, reported among Nevada residents, to provide a complete look at cancer in the state. There are subsections for diagnosis, treatment, mortality and survival rate statistics for the 1996 to 2000 period.

The top ten leading types of cancer diagnosed in Nevada from 1996 to 2000, which accounts for 74.9% of the total number of cancer cases, are then highlighted within their own section to provide a more detailed look at the types of cancer that are most prevalent in Nevada. The reader should note that these types of cancer are presented based on the number of cases reported. Therefore, those cancers whose ranking is within the top ten based on inpatient discharges or mortality are not necessarily highlighted within their own section.

Statistics on those cancers not highlighted in the top ten sections are available in the Overview section and in a general section for All Other Cancers at the end of this report, where the remaining twelve leading cancers are briefly profiled.

Each major section in this report includes regional, gender, racial/ethnic, and age statistics in order to draw attention to potential targets for prevention and treatment efforts. These efforts in prevention and treatment will help to achieve progress toward reducing the risks and burden of Cancer in Nevada.

For note, trend statistics are not included in this edition of the *Report on Cancer in Nevada* since the estimated completeness of earlier cancer reporting was significantly lower than in more recent years, which would significantly affect any trends that would be included in this report. However, trend information will be included in the next edition.

This report is also available online at the Center for Health Data and Research's website: http://health2k.state.nv.us/nihds/center.htm

TABLE OF CONTENTS

ACKNOWLEDGEMENTS	i
PREFACE	1
TABLE OF CONTENTS	2
LIST OF FIGURES AND TABLES	
TECHNICAL NOTES	28
OVERVIEW	35
HIGHLIGHTS	36
INCIDENCE	44
HIGHLIGHTS	44
INPATIENT HOSPITAL DISCHARGES	57
HIGHLIGHTS	57
MORTALITY	65
HIGHLIGHTS	65
SURVIVAL RATE	74
HIGHLIGHTS	
ALL CANCERS	79
HIGHLIGHTS	81
INCIDENCE	84
INPATIENT HOSPITAL DISCHARGES	92
MORTALITY	99
SURVIVAL RATE	106
LUNG AND BRONCHUS CANCER	109
GENERAL PROFILE	110
HIGHLIGHTS	111
INCIDENCE	113
INPATIENT HOSPITAL DISCHARGES	121
MORTALITY	128
SURVIVAL RATE	135
BREAST CANCER	138
GENERAL PROFILE	139
HIGHLIGHTS	140

SCREENING (BRFSS)	142
INCIDENCE	143
INPATIENT HOSPITAL DISCHARGES	151
MORTALITY	158
SURVIVAL RATE	165
PROSTATE CANCER	168
GENERAL PROFILE	169
HIGHLIGHTS	170
SCREENING (BRFSS)	173
INCIDENCE	174
INPATIENT HOSPITAL DISCHARGES	182
MORTALITY	189
SURVIVAL RATE	196
COLORECTAL CANCER	199
GENERAL PROFILE	200
HIGHLIGHTS	201
SCREENING (BRFSS)	204
INCIDENCE	205
INPATIENT HOSPITAL DISCHARGES	213
MORTALITY	220
SURVIVAL RATE	227
URINARY BLADDER CANCER	230
GENERAL PROFILE	231
HIGHLIGHTS	232
INCIDENCE	234
INPATIENT HOSPITAL DISCHARGES	242
MORTALITY	249
SURVIVAL RATE	256
NON-HODGKIN'S LYMPHOMA	259
GENERAL PROFILE	260
HIGHLIGHTS	261
INCIDENCE	263
INPATIENT HOSPITAL DISCHARGES	271

MORTALITY	278
SURVIVAL RATE	285
KIDNEY AND RENAL PELVIS CANCER	288
GENERAL PROFILE	289
HIGHLIGHTS	290
INCIDENCE	292
INPATIENT HOSPITAL DISCHARGES	300
MORTALITY	307
SURVIVAL RATE	314
LEUKEMIA	317
GENERAL PROFILE	318
HIGHLIGHTS	319
INCIDENCE	321
INPATIENT HOSPITAL DISCHARGES	329
MORTALITY	336
SURVIVAL RATE	343
LIP, ORAL CAVITY AND PHARYNX CANCER	346
GENERAL PROFILE	347
HIGHLIGHTS	348
INCIDENCE	350
INPATIENT HOSPITAL DISCHARGES	358
MORTALITY	365
SURVIVAL RATE	372
PANCREATIC CANCER	375
GENERAL PROFILE	376
HIGHLIGHTS	377
INCIDENCE	379
INPATIENT HOSPITAL DISCHARGES	387
MORTALITY	394
SURVIVAL RATE	401
ALL OTHER CANCERS	404
SKIN CANCER	406
UTERINE CANCER	410

OVARIAN CANCER	414
THYROID GLAND CANCER	418
BRAIN AND OTHER CENTRAL NERVOUS SYSTEM CANCER	422
STOMACH CANCER	426
LIVER AND INTRAHEPATIC BILE DUCTS CANCER	430
CERVICAL CANCER	434
ESOPHAGEAL CANCER	439
LARYNX CANCER	443
MULTIPLE MYELOMA	447
HODGKIN'S LYMPHOMA	451
ALL OTHER SITES	455
APPENDIX A – CODES USED FOR GROUPING	458
APPENDIX B – FORMULAS	463
REFERENCES	466
FEEDBACK AND SUGGESTIONS	467

LIST OF FIGURES AND TABLES

O	$I\mathbf{E}$	R	V	IE	W	1
---	---------------	---	---	----	---	---

HIGHLIGHTS
Figure 1. Top Ten Leading Types of Cancer by Percentage of Total Incidence, Discharges and Mortality, Nevada Residents, 1996-2000
Figure 2. Highest Incidence to Mortality Age-Adjusted Rate Ratios by Type of Cancer, Nevada Residents, 1996-2000
Figure 3. Lowest Incidence to Mortality Age-Adjusted Rate Ratios by Type of Cancer, Nevada Residents, 1996-2000
Table 1. Nevada Incidence, Inpatient Hospital Discharges and Mortality by Type of Cancer, Nevada, 1996-2000
Table 2. Leading Types of Cancer for Nevada Incidence, Inpatient Hospital Discharges and Mortality, Nevada Residents, 1996-2000
Table 3. Top Ten Types of Cancer by Gender, Incidence, Hospital Discharges, and Mortality, Nevada Residents, 1996-2000
Table 4. Incidence to Mortality Age-Adjusted Rate Ratios for the Leading Types of Cancer, Nevada Residents, 1996-2000
INCIDENCE
HIGHLIGHTS
Figure 4. Top Ten Leading Cancers as a Percentage of Total Cases, Nevada (1996-2000) and SEER-11 (1995-1999)
Figure 5. Comparison of Age-Adjusted (2000) Incidence Rates of Blacks compared to Whites, Nevada Residents, 1996-2000
Figure 6. Comparison of Age-Adjusted (2000) Incidence Rates of Native Americans compared to Whites, Nevada Residents, 1996-2000
Figure 7. Comparison of Age-Adjusted (2000) Incidence Rates of Asians compared to Whites, Nevada Residents, 1996-2000
Figure 8. Comparison of Age-Adjusted (2000) Incidence Rates of Hispanics compared to Whites, Nevada Residents, 1996-2000
Table 5. Nevada Incidence by Type of Cancer, Nevada (1996-2000) and SEER-11 (1995-1999)48 Table 6. Nevada Incidence by Type of Cancer and Gender, Nevada, 1996-2000
Table 7. Nevada Incidence by Type of Cancer and Stage of Cancer, Nevada, 1996-200052
Table 8. Top Ten Types of Cancer Incidence by County/Region of Residence, Nevada Residents, 1996-2000
Table 9. Top Ten Types of Cancer Incidence by Age Group, Nevada Residents, 1996-2000
INPATIENT HOSPITAL DISCHARGES
HIGHLIGHTS
Figure 9. Top Ten Leading Cancers in Total Inpatient Discharge Charges, Nevada Residents, 1996-2000
Figure 10. Top Ten Leading Cancers in Average Inpatient Discharge Charges, Nevada Residents, 1996-2000
Figure 11. Top Ten Leading Cancers in Median Inpatient Discharge Charges, Nevada Residents,

1996-2000	59
Figure 12. Top Ten Leading Cancers in Total Number of Days Stayed for Inpatient Hospital	
Discharges, Nevada Residents, 1996-2000.	59
Figure 13. Top Ten Leading Cancers in Average Length of Stay (Days) for Inpatient Hospital Discharges, Nevada Residents, 1996-2000.	60
Figure 14. Top Ten Leading Cancers in Median Length of Stay (Days) for Inpatient Hospital	
Discharges, Nevada Residents, 1996-2000	00
Table 11. Nevada Inpatient Hospital Discharges by Type of Cancer and Gender, Nevada, 1996-2000	61
Table 12. Top Ten Types of Cancer Inpatient Hospital Discharges by County/Region of Resident Nevada Residents, 1996-2000	
Table 13. Top Ten Types of Cancer Hospital Discharges by Age Group, Nevada Residents, 1996-2000	64
MORTALITY	
HIGHLIGHTS	
Figure 15. Top Ten Leading Cancers by Percentage of Total Cancer Mortality, Nevada Residents	
Figure 16. Comparison of Age-Adjusted (2000) Mortality Rates of Blacks compared to Whites, Nevada Residents, 1996-2000	
Figure 17. Comparison of Age-Adjusted (2000) Mortality Rates of Native Americans compared t Whites, Nevada Residents, 1996-2000	to
Figure 18. Comparison of Age-Adjusted (2000) Mortality Rates of Asians compared to Whites, Nevada Residents, 1996-2000	
Figure 19. Comparison of Age-Adjusted (2000) Mortality Rates of Hispanics compared to White Nevada Residents, 1996-2000	es,
Table 14. Nevada Mortality by Type of Cancer and Gender, Nevada, 1996-2000	
Table 15. Top Ten Types of Cancer Mortality by County/Region of Residence, Nevada Residents	s,
Table 16. Top Ten Types of Cancer Mortality by Age Group, Nevada Residents, 1996-2000	
Table 17. Median Age at Time of Death by Leading Types of Cancer and Race/Ethnicity, Nevada	a
Residents, 1996-2000	/3
SURVIVAL RATE	
HIGHLIGHTS	
Figure 20. Ten Highest One-Year Survival Rates by Type of Cancer, Nevada Residents,	75
1996-2000	/3
1996-2000	75
Figure 22. Ten Highest Five-Year Survival Rates by Type of Cancer, Nevada Residents,	/ 5
1996-2000	76
Figure 23. Ten Lowest Five-Year Survival Rates by Type of Cancer, Nevada Residents,	
1996-2000	76
Table 18. One-Year, Five-Year and Median Survival Rates by Type of Cancer, Nevada Residents	s,
1996-2000	
Table 19. One- and Five-Year Survival Rates by Type of Cancer and Gender, Nevada Residents,	
1996-2000	/8

Table 20. One- and Five-Year Survival Rates by Type of Cancer and Race/Ethnicity, Nevada Residents, 1996-2000	79
ALL CANCERS	
INCIDENCE	
Figure 24. Age-Adjusted (2000) Incidence Rates for All Cancers, Nevada Residents, 1996-2000	84
Figure 25. All Cancers Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1996-2000	85
Figure 26. All Cancers Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents,	85
Table 21. All Cancers Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)	86
Table 22. All Cancers Cases by Age Group and County/Region of Residence at Diagnosis, Nevac Residents (1996-2000) and SEER-11 (1995-1999)	
Table 23. All Cancers Cases by County of Residence at Diagnosis, Nevada Residents, 1996-2000	88
Table 24. All Cancers Cases by Race/Ethnicity and Gender, Nevada Residents, 1996-2000	88
Table 25. All Cancers Cases by Age Group and Gender, Nevada Residents, 1996-2000	89
Table 26. All Cancers Cases by Age Group and Stage, Nevada Residents, 1996-2000	
Table 27. Cancer Incidence by Stage and Race/Ethnicity, Nevada Residents, 1996-2000	91
Table 28. Median Age at Diagnosis of All Cancers by Race/Ethnicity and Gender, Nevada Residents, 1996-2000	91
INPATIENT HOSPITAL DISCHARGES	
Figure 27. All Cancers Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents, 1996-2000	92
Figure 28. All Cancers Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1996-2000	, 93
Figure 29. Median Charges for All Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000	93
Figure 30. Average Length of Stay for All Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000	94
Table 29. All Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Regi of Residence, Nevada Residents, 1996-2000	
Table 30. Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1996-2000	96
Table 31. All Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1996-2000	97
Table 32. All Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000	98
Table 33. All Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1996-2000	98
MORTALITY	
Figure 31. Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 1996-2000	99
Figure 32. Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1996-2000	.100
Figure 33. Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents,	.100

Table 34. All Cancers Mortality by Gender, Race/Ethnicity and County/Region of Residence,	101
Nevada Residents, 1996-2000	.101
Table 35. All Cancers Mortality by Age Group and County/Region of Residence, Nevada Reside	
Table 36. Cancer Mortality by County of Residence, Nevada Residents, 1996-2000	
Table 37. Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1996-2000	
Table 38. Cancer Mortality by Age Group and Gender, Nevada Residents, 1996-2000	
Table 39. Median Age at Death from All Cancers by Race/Ethnicity and Gender, Nevada Reside	
1996-2000	-
	.105
SURVIVAL RATE Figure 24. Supplied Botton for All Company has Bone / Education Name do Bonidanto, 1006, 2000	100
Figure 34. Survival Rates for All Cancers by Race/Ethnicity, Nevada Residents, 1996-2000	.106
Figure 35. Survival Rates for All Cancers by Stage of Cancer at Diagnosis, Nevada Residents,	106
1996-2000	
Residents, 1996-2000	
Table 41. Cause-Specific Survival Rates for All Cancers by Stage of Cancer at Diagnosis and	.107
Gender, Nevada Residents, 1996-2000	108
Gender, Nevada Residents, 1990 2000	.100
LUNG AND BRONCHUS CANCER	
GENERAL PROFILE	
Figure 36. Anatomy of the Respiratory Tract	.110
INCIDENCE	
Figure 37. Lung and Bronchus Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents,	
1996-2000	
Figure 38. Lung and Bronchus Cancer Age-Adjusted Incidence Rates by County/Region of	.115
Residence, Nevada Residents, 1996-2000	.114
Figure 39. Lung and Bronchus Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada	
Residents, 1996-2000.	
Table 42. Lung and Bronchus Cancer Cases by Gender, Race/Ethnicity and County/Region of	
Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)	.115
Table 43. Lung and Bronchus Cancer Cases by Age Group and County/Region of Residence at	
Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)	.116
Table 44. Lung and Bronchus Cancer Cases by County of Residence at Diagnosis, Nevada	
Residents, 1996-2000.	.117
Table 45. Lung and Bronchus Cancer Cases by Race/Ethnicity and Gender, Nevada Residents,	
1996-2000	117
Table 46. Lung and Bronchus Cancer Cases by Age Group and Gender, Nevada Residents,	
1996-2000	.118
Table 47. Lung and Bronchus Cancer Cases by Age Group and Stage, Nevada Residents,	110
1996-2000	.119
Table 48. Lung and Bronchus Cancer Cases by Stage and Race/Ethnicity, Nevada Residents,	120
1996-2000	
Table 49. Median Age at Diagnosis of Lung and Bronchus Cancer by Race/Ethnicity and Gender Nevada Residents, 1996-2000	
	.120
INPATIENT HOSPITAL DISCHARGES	
Figure 40. Lung and Bronchus Cancer Age-Adjusted (2000) Inpatient Hospital Discharge Rates,	

Nevada Residents, 1996-2000	121
Figure 41. Lung and Bronchus Cancer Age-Adjusted Inpatient Discharge Rates by County/Reg	ion of
Residence, Nevada Residents, 1996-2000	
Figure 42. Median Charges for Lung and Bronchus Cancer Inpatient Discharges by County/Reg	
of Residence, Nevada Residents, 1996-2000	122
Figure 43. Average Length of Stay for Lung and Bronchus Cancer Inpatient Discharges by	
County/Region of Residence, Nevada Residents, 1996-2000	123
Table 50. Lung and Bronchus Cancer Inpatient Discharges by Gender, Charges, Length of Stay	, and
County/Region of Residence, Nevada Residents, 1996-2000	
Table 51. Lung and Bronchus Cancer Inpatient Discharges by Age Group and County/Region of	
Residence, Nevada Residents, 1996-2000	
Table 52. Lung and Bronchus Cancer Inpatient Discharges by Age Group and Gender, Nevada	
Residents, 1996-2000	
Table 53. Lung and Bronchus Cancer Inpatient Discharges by County/Region of Residence, Ne	
Residents, 1996-2000	
Table 54. Lung and Bronchus Cancer Inpatient Discharges by Age Group, Charges and Length	
Stay, Nevada Residents, 1996-2000	127
MORTALITY	
Figure 44. Lung and Bronchus Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents	S,
1996-2000	
Figure 45. Lung and Bronchus Cancer Age-Adjusted Mortality Rates by County/Region of	
Residence, Nevada Residents, 1996-2000	129
Figure 46. Lung and Bronchus Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevac	la
Residents, 1996-2000	129
Table 55. Lung and Bronchus Cancer Mortality by Gender, Race/Ethnicity and County/Region	
Residence, Nevada Residents, 1996-2000	
Table 56. Lung and Bronchus Cancer Mortality by Age Group and County/Region of Residence	
Nevada Residents, 1996-2000	131
Table 57. Lung and Bronchus Cancer Mortality by County of Residence, Nevada Residents,	
1996-2000	
Table 58. Lung and Bronchus Cancer Mortality by Race/Ethnicity and Gender, Nevada Resider	
1996-2000	132
Table 59. Lung and Bronchus Cancer Mortality by Age Group and Gender, Nevada Residents,	100
1996-2000	
Table 60. Median Age at Death from Lung and Bronchus Cancer by Race/Ethnicity and Gende	-
Nevada Residents, 1996-2000	134
SURVIVAL RATE	
Figure 47. Survival Rates for Lung and Bronchus Cancer by Race/Ethnicity, Nevada Residents.	
Figure 48. Survival Rates for Lung and Bronchus Cancer by Stage of Cancer at Diagnosis, Nev	
Residents, 1996-2000.	
Table 61. Cause-Specific Survival Rates for Lung and Bronchus Cancer by Race/Ethnicity and	
Gender, Nevada Residents, 1996-2000	
Table 62. Cause-Specific Survival Rates for Lung and Bronchus Cancer by Stage of Cancer at	
Diagnosis and Gender, Nevada Residents, 1996-2000.	137

BREAST CANCER

GENERAL PROFILE Figure 49. Anatomy of the Breast	.139
SCREENING (BRFSS) Table 63. Female Breast Cancer Screening by County/Region of Residence, Education, Age Ground Income, Nevada Residents, 1996-2000	
INCIDENCE	
Figure 50. Female Breast Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents,	.143
Figure 51. Female Breast Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1996-2000	,
Figure 52. Female Breast Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1996-2000	
Table 64. Breast Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)	
Table 65. Female Breast Cancer Cases by Age Group and County/Region of Residence at Diagnot Nevada Residents (1996-2000) and SEER-11 (1995-1999)	osis,
Table 66. Female Breast Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1996-2000	
Table 67. Breast Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1996-2000	
Table 68. Breast Cancer Cases by Age Group and Gender, Nevada Residents, 1996-2000	.148
Table 69. Breast Cancer Cases by Age Group and Stage, Nevada Residents, 1996-2000	.149
Table 70. Breast Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1996-2000	.150
Table 71. Median Age at Diagnosis of Breast Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000	.150
INPATIENT HOSPITAL DISCHARGES Figure 53. Female Breast Cancer Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Reside 1996-2000	
Figure 54. Female Breast Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1996-2000	
Figure 55. Median Charges for Breast Cancer Inpatient Discharges by County/Region of Residen Nevada Residents, 1996-2000	ice,
Figure 56. Average Length of Stay for Breast Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000	
Table 72. Breast Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000	
Table 73. Female Breast Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1996-2000	
Table 74. Breast Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1996-2000	
Table 75. Female Breast Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000	
Table 76. Breast Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevad Residents, 1996-2000	la
MORTALITY	
Figure 57. Female Breast Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 1996-2000	.158

Figure 58. Female Breast Cancer Age-Adjusted Mortality Rates by County/Region of Residence Nevada Residents, 1996-2000	
Figure 59. Female Breast Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1996-2000	
Table 77. Breast Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1996-2000	,
Table 78. Female Breast Cancer Mortality by Age Group and County/Region of Residence, New Residents, 1996-2000	vada
Table 79. Female Breast Cancer Mortality by County of Residence, Nevada Residents, 1996-2000	
Table 80. Breast Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1996-2000	
Table 81. Breast Cancer Mortality by Age Group and Gender, Nevada Residents, 1996-2000 Table 82. Median Age at Death from Breast Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000	163
SURVIVAL RATE	
Figure 60. Survival Rates for Breast Cancer by Race/Ethnicity, Nevada Residents, 1996-2000 Figure 61. Survival Rates for Breast Cancer by Stage of Cancer at Diagnosis, Nevada Residents 1996-2000	s,
Table 83. Cause-Specific Survival Rates for Breast Cancer by Race/Ethnicity and Gender, Neva Residents, 1996-2000.	ada
Table 84. Cause-Specific Survival Rates for Breast Cancer by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1996-2000.	1
PROSTATE CANCER	
GENERAL PROFILE	
Figure 62. Anatomy of the Male Urogenital System	169
SCREENING (BRFSS) Table 85. Prostate Cancer Screening by County/Region of Residence, Education, Age Group, an Income, Nevada Residents, 1997, 1999 and 2001	
INCIDENCE	
Figure 63. Prostate Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents, 1996-2000	
Figure 64. Prostate Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nev Residents, 1996-2000.	175
Figure 65. Prostate Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents 1996-2000	
Table 86. Prostate Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)	
Table 87. Prostate Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)	
Table 88. Prostate Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1996-2000	
Table 89. Prostate Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1996-2000.	178
Table 90. Prostate Cancer Cases by Age Group and Gender, Nevada Residents, 1996-2000	
Table 91. Prostate Cancer Cases by Age Group and Stage, Nevada Residents, 1996-2000	180

Table 92. Prostate Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1996-2000181
Table 93. Median Age at Diagnosis of Prostate Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000
INPATIENT HOSPITAL DISCHARGES
Figure 66. Prostate Cancer Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents,
1996-2000
Figure 67. Prostate Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1996-2000
Figure 68. Median Charges for Prostate Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000
Figure 69. Average Length of Stay for Prostate Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000
Table 94. Prostate Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000
Table 95. Prostate Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1996-2000
Table 96. Prostate Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1996-2000
Table 97. Prostate Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000
Table 98. Prostate Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1996-2000
MORTALITY
Figure 70. Prostate Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 1996-2000
Figure 71. Prostate Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1996-2000
Figure 72. Prostate Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1996-2000
Table 99. Prostate Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1996-2000
Table 100. Prostate Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000
Table 101. Prostate Cancer Mortality by County of Residence, Nevada Residents, 1996-2000193 Table 102. Prostate Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1996-2000
Table 103. Prostate Cancer Mortality by Age Group and Gender, Nevada Residents, 1996-2000
Table 104. Median Age at Death from Prostate Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000
SURVIVAL RATE
Figure 73. Survival Rates for Prostate Cancer by Race/Ethnicity, Nevada Residents, 1996-2000
Figure 74. Survival Rates for Prostate Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 1996-2000
Table 105. Cause-Specific Survival Rates for Prostate Cancer by Race/Ethnicity and Gender.

Nevada Residents, 1996-2000	
Table 106. Cause-Specific Survival Rates for Prostate Cancer by Stage of Cancer at Diagnosis a	
Gender, Nevada Residents, 1996-2000	198
COLORECTAL CANCER	
GENERAL PROFILE	
Figure 75. Anatomy of the Digestive System	200
SCREENING (BRFSS)	
Table 107. Colorectal Cancer Screening by County/Region of Residence, Gender, Education, A Group, and Income, Nevada Residents, 1997, 1999 and 2001	_
INCIDENCE	
Figure 76. Colorectal Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents,	205
Figure 77. Colorectal Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1996-2000	206
Figure 78. Colorectal Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Resider 1996-2000	
Table 108. Colorectal Cancer Cases by Gender, Race/Ethnicity and County/Region of Residenc Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)	e at
Table 109. Colorectal Cancer Cases by Age Group and County/Region of Residence at Diagnos Nevada Residents (1996-2000) and SEER-11 (1995-1999)	sis,
Table 110. Colorectal Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1996-2000	209
Table 111. Colorectal Cancer Cases by Race/Ethnicity and Gender, Nevada Residents,	209
Table 112. Colorectal Cancer Cases by Age Group and Gender, Nevada Residents, 1996-2000	210
Table 113. Colorectal Cancer Cases by Age Group and Stage, Nevada Residents, 1996-2000	211
Table 114. Colorectal Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1996-2000	212
Table 115. Median Age at Diagnosis of Colorectal Cancer by Race/Ethnicity and Gender, Neva Residents, 1996-2000	
INPATIENT HOSPITAL DISCHARGES	
Figure 79. Colorectal Cancer Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Resident	S
1996-2000	213
Figure 80. Colorectal Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of	
Residence, Nevada Residents, 1996-2000	214
Figure 81. Median Charges for Colorectal Cancer Inpatient Discharges by County/Region of	
Residence, Nevada Residents, 1996-2000	214
Figure 82. Average Length of Stay for Colorectal Cancer Inpatient Discharges by County/Region Residence, Nevada Residents, 1996-2000	on of 215
Table 116. Colorectal Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000	216
Table 117. Colorectal Cancer Inpatient Discharges by Age Group and County/Region of Reside Nevada Residents, 1996-2000	ence,
Table 118. Colorectal Cancer Inpatient Discharges by Age Group and Gender, Nevada Resident	ts, 218

Table 119. Colorectal Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000	9
Table 120. Colorectal Cancer Inpatient Discharges by Age Group, Charges and Length of Stay,	
Nevada Residents, 1996-2000	9
MORTALITY	
Figure 83. Colorectal Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents,	
1996-2000	.U
Nevada Residents, 1996-200022	21
Figure 85. Colorectal Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents,	
1996-2000	
Table 121. Colorectal Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence Nevada Residents, 1996-2000	
Nevada Residents, 1996-2000	.2
Residents, 1996-2000	,3
Table 123. Colorectal Cancer Mortality by County of Residence, Nevada Residents, 1996-200022	
Table 124. Colorectal Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents,	
1996-2000	.4
Table 125. Colorectal Cancer Mortality by Age Group and Gender, Nevada Residents, 1996-2000	25
Table 126. Median Age at Death from Colorectal Cancer by Race/Ethnicity and Gender, Nevada	
Residents, 1996-2000	6
SURVIVAL RATE	
Figure 86. Survival Rates for Colorectal Cancer by Race/Ethnicity, Nevada Residents, 1996-2000	27
Figure 87. Survival Rates for Colorectal Cancer by Stage of Cancer at Diagnosis, Nevada Residents 1996-2000	-
Table 127. Cause-Specific Survival Rates for Colorectal Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000	28
Table 128. Cause-Specific Survival Rates for Colorectal Cancer by Stage of Cancer at Diagnosis an Gender, Nevada Residents, 1996-2000	
	,,
URINARY BLADDER CANCER	
GENERAL PROFILE	. 1
Figure 88. Anatomy of the Urinary System	<i>1</i>
INCIDENCE	
Figure 89. Urinary Bladder Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents,	4
Figure 90. Urinary Bladder Cancer Age-Adjusted Incidence Rates by County/Region of Residence,	
Nevada Residents, 1996-200023	
Figure 91. Urinary Bladder Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada	
Residents, 1996-2000	5
Table 129. Urinary Bladder Cancer Cases by Gender, Race/Ethnicity and County/Region of	
Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)23 Table 130. Urinary Bladder Cancer Cases by Age Group and County/Region of Residence at	O
Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)23	7

Table 131. Urinary Bladder Cancer Cases by County of Residence at Diagnosis, Nevada Residen	nts, 238
Table 132. Urinary Bladder Cancer Cases by Race/Ethnicity and Gender, Nevada Residents,	.230
1996-2000	238
Table 133. Urinary Bladder Cancer Cases by Age Group and Gender, Nevada Residents,	.250
1996-2000	239
Table 134. Urinary Bladder Cancer Cases by Age Group and Stage, Nevada Residents,	
1996-2000	240
Table 135. Urinary Bladder Cancer Cases by Stage and Race/Ethnicity, Nevada Residents,	
1996-2000	241
Table 136. Median Age at Diagnosis of Urinary Bladder Cancer by Race/Ethnicity and Gender,	
Nevada Residents, 1996-2000	241
INPATIENT HOSPITAL DISCHARGES	
Figure 92. Urinary Bladder Cancer Age-Adjusted (2000) Inpatient Discharge Rates, Nevada	
Residents, 1996-2000	242
Figure 93. Urinary Bladder Cancer Age-Adjusted Inpatient Discharge Rates by County/Region o	of
Residence, Nevada Residents, 1996-2000	.243
Figure 94. Median Charges for Urinary Bladder Cancer Inpatient Discharges by County/Region of	of
Residence, Nevada Residents, 1996-2000	243
Figure 95. Average Length of Stay for Urinary Bladder Cancer Inpatient Discharges by	
County/Region of Residence, Nevada Residents, 1996-2000	244
Table 137. Urinary Bladder Cancer Inpatient Discharges by Gender, Charges, Length of Stay, an	
County/Region of Residence, Nevada Residents, 1996-2000	.245
Table 138. Urinary Bladder Cancer Inpatient Discharges by Age Group and County/Region of	244
Residence, Nevada Residents, 1996-2000	246
Table 139. Urinary Bladder Cancer Inpatient Discharges by Age Group and Gender, Nevada	2.45
Residents, 1996-2000.	247
Table 140. Urinary Bladder Cancer Inpatient Discharges by County/Region of Residence, Nevad	ıa 248
Residents, 1996-2000	
Stay, Nevada Residents, 1996-2000	248
	.240
MORTALITY Fig. 26 Hz & Rest of Cooperation (2000) Marketing Rest of Rest of Cooperation (2000) Marketing Rest of Rest of Rest of Cooperation (2000) Marketing Rest of Rest of Rest of Cooperation (2000) Marketing Rest of Re	
Figure 96. Urinary Bladder Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents,	240
1996-2000	249
Nevada Residents, 1996-2000	250
Figure 98. Urinary Bladder Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada	230
Residents, 1996-2000	250
Table 142. Urinary Bladder Cancer Mortality by Gender, Race/Ethnicity and County/Region of	.230
Residence, Nevada Residents, 1996-2000	.251
Table 143. Urinary Bladder Cancer Mortality by Age Group and County/Region of Residence,	.201
Nevada Residents, 1996-2000	252
Table 144. Urinary Bladder Cancer Mortality by County of Residence, Nevada Residents,	
1996-2000	253
Table 145. Urinary Bladder Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents,	
1996-2000	253
Table 146. Urinary Bladder Cancer Mortality by Age Group and Gender, Nevada Residents,	

1996-2000	254
Table 147. Median Age at Death from Urinary Bladder Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000	255
SURVIVAL RATE	
Figure 99. Survival Rates for Urinary Bladder Cancer by Race/Ethnicity, Nevada Residents, 1996-2000	256
Figure 100. Survival Rates for Urinary Bladder Cancer by Stage of Cancer at Diagnosis, Nevad Residents, 1996-2000.	la 256
Table 148. Cause-Specific Survival Rates for Urinary Bladder Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000	257
Table 149. Cause-Specific Survival Rates for Urinary Bladder Cancer by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1996-2000	
NON-HODGKIN'S LYMPHOMA	
GENERAL PROFILE	
Figure 101. Anatomy of the Lymphatic System	260
INCIDENCE	
Figure 102. Non-Hodgkin's Lymphoma Age-Adjusted (2000) Incidence Rates, Nevada Resider 1996-2000	
Figure 103. Non-Hodgkin's Lymphoma Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1996-2000	
Figure 104. Non-Hodgkin's Lymphoma Age-Adjusted Incidence Rates by Race/Ethnicity, Nev Residents, 1996-2000	ada
Table 150. Non-Hodgkin's Lymphoma Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)	f
Table 151. Non-Hodgkin's Lymphoma Cases by Age Group and County/Region of Residence Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)	at
Table 152. Non-Hodgkin's Lymphoma Cases by County of Residence at Diagnosis, Nevada Residents, 1996-2000	
Table 153. Non-Hodgkin's Lymphoma Cases by Race/Ethnicity and Gender, Nevada Residents 1996-2000	S,
Table 154. Non-Hodgkin's Lymphoma Cases by Age Group and Gender, Nevada Residents, 1996-2000	
Table 155. Non-Hodgkin's Lymphoma Cases by Age Group and Stage, Nevada Residents, 1996-2000	
Table 156. Non-Hodgkin's Lymphoma Cases by Stage and Race/Ethnicity, Nevada Residents, 1996-2000	270
Table 157. Median Age at Diagnosis of Non-Hodgkin's Lymphoma by Race/Ethnicity and Ger Nevada Residents, 1996-2000	
INPATIENT HOSPITAL DISCHARGES	
Figure 105. Non-Hodgkin's Lymphoma Age-Adjusted (2000) Inpatient Discharge Rates, Nevac Residents, 1996-2000	da 271
Figure 106. Non-Hodgkin's Lymphoma Age-Adjusted Inpatient Discharge Rates by County/Re of Residence, Nevada Residents, 1996-2000.	egion
Figure 107. Median Charges for Non-Hodgkin's Lymphoma Discharges by County/Region of Residence Nevada Residents 1996-2000	272

Figure 108. Average Length of Stay for Non-Hodgkin's Lymphoma Discharges by County/Reg	gion
of Residence, Nevada Residents, 1996-2000.	273
Table 158. Non-Hodgkin's Lymphoma Discharges by Gender, Charges, Length of Stay, and	
County/Region of Residence, Nevada Residents, 1996-2000	274
Table 159. Non-Hodgkin's Lymphoma Discharges by Age Group and County/Region of Resid	
Nevada Residents, 1996-2000	275
Table 160. Non-Hodgkin's Lymphoma Discharges by Age Group and Gender, Nevada Resider	ıts,
1996-2000	276
Table 161. Non-Hodgkin's Lymphoma Discharges by County/Region of Residence, Nevada Residents, 1996-2000	277
Table 162. Non-Hodgkin's Lymphoma Discharges by Age Group, Charges and Length of Stay Nevada Residents, 1996-2000	,
MORTALITY	
Figure 109. Non-Hodgkin's Lymphoma Age-Adjusted (2000) Mortality Rates, Nevada Resider	
Figure 110. Non-Hodgkin's Lymphoma Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1996-2000	279
Figure 111. Non-Hodgkin's Lymphoma Age-Adjusted Mortality Rates by Race/Ethnicity, Nev Residents, 1996-2000	279
Table 163. Non-Hodgkin's Lymphoma Mortality by Gender, Race/Ethnicity and County/Region Residence, Nevada Residents, 1996-2000	280
Table 164. Non-Hodgkin's Lymphoma Mortality by Age Group and County/Region of Resider Nevada Residents, 1996-2000	
Table 165. Non-Hodgkin's Lymphoma Mortality by County of Residence, Nevada Residents, 1996-2000	282
Table 166. Non-Hodgkin's Lymphoma Mortality by Race/Ethnicity and Gender, Nevada Resid	282
Table 167. Non-Hodgkin's Lymphoma Mortality by Age Group and Gender, Nevada Residents 1996-2000	283
Table 168. Median Age at Death from Non-Hodgkin's Lymphoma by Race/Ethnicity and Geno Nevada Residents, 1996-2000	
SURVIVAL RATE	
Figure 112. Survival Rates for Non-Hodgkin's Lymphoma by Race/Ethnicity, Nevada Residen 1996-2000	ts, 285
Figure 113. Survival Rates for Non-Hodgkin's Lymphoma by Stage of Cancer at Diagnosis, No Residents, 1996-2000	285
Table 169. Cause-Specific Survival Rates for Non-Hodgkin's Lymphoma by Race/Ethnicity and Gender, Nevada Residents, 1996-2000	
Table 170. Cause-Specific Survival Rates for Non-Hodgkin's Lymphoma by Stage of Cancer a Diagnosis and Gender, Nevada Residents, 1996-2000	ıt
KIDNEY AND RENAL PELVIS CANCER	
GENERAL PROFILE Figure 114. Anatomy of the Urinary System	289
INCIDENCE Figure 115. Kidney and Renal Pelvis Cancer Age-Adjusted (2000) Incidence Rates, Nevada	

Residents, 1996-2000	.292
Figure 116. Kidney and Renal Pelvis Cancer Age-Adjusted Incidence Rates by County/Region of	ì
, , , , , , , , , , , , , , , , , , ,	.293
Figure 117. Kidney and Renal Pelvis Cancer Age-Adjusted Incidence Rates by Race/Ethnicity,	• • •
,	.293
Table 171. Kidney and Renal Pelvis Cancer Cases by Gender, Race/Ethnicity and County/Region	
Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)	
Table 172. Kidney and Renal Pelvis Cancer Cases by Age Group and County/Region of Residence	
at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)	
Table 173. Kidney and Renal Pelvis Cancer Cases by County of Residence at Diagnosis, Nevada	.296
Residents, 1996-2000	
	.11ts, .296
Table 175. Kidney and Renal Pelvis Cancer Cases by Age Group and Gender, Nevada Residents,	
	.297
Table 176. Kidney and Renal Pelvis Cancer Cases by Age Group and Stage, Nevada Residents,	
	.298
Table 177. Kidney and Renal Pelvis Cancer Cases by Stage and Race/Ethnicity, Nevada Resident	ts,
	.299
Table 178. Median Age at Diagnosis of Kidney and Renal Pelvis Cancer by Race/Ethnicity and	
Gender, Nevada Residents, 1996-2000.	.299
INPATIENT HOSPITAL DISCHARGES	
Figure 118. Kidney and Renal Pelvis Cancer Age-Adjusted (2000) Inpatient Discharge Rates,	
Nevada Residents, 1996-2000	.300
Figure 119. Kidney and Renal Pelvis Cancer Age-Adjusted Inpatient Discharge Rates by	
, , , , , , , , , , , , , , , , , , , ,	.301
Figure 120. Median Charges for Kidney and Renal Pelvis Cancer Inpatient Discharges by	
, ,	.301
Figure 121. Average Length of Stay for Kidney and Renal Pelvis Cancer Inpatient Discharges by	
County/Region of Residence, Nevada Residents, 1996-2000	
Table 179. Kidney and Renal Pelvis Cancer Inpatient Discharges by Gender, Charges, Length of	
Stay, and County/Region of Residence, Nevada Residents, 1996-2000	
	.304
Table 181. Kidney and Renal Pelvis Cancer Inpatient Discharges by Age Group and Gender, Nev	
	.305
Table 182. Kidney and Renal Pelvis Cancer Inpatient Discharges by County/Region of Residence	
	.306
Table 183. Kidney and Renal Pelvis Cancer Inpatient Discharges by Age Group, Charges and	
Length of Stay, Nevada Residents, 1996-2000.	306
MORTALITY	
Figure 122. Kidney and Renal Pelvis Cancer Age-Adjusted (2000) Mortality Rates, Nevada	
	.307
Figure 123. Kidney and Renal Pelvis Cancer Age-Adjusted Mortality Rates by County/Region of	
	.308
Figure 124. Kidney and Renal Pelvis Cancer Age-Adjusted Mortality Rates by Race/Ethnicity,	
	308

2001
309
310
510 S,
311
311
nts,
312
313
314
314
and
315
r at 316
310
318
321
<i>J</i> 2 1
322
322
323
a
324
225
325 325
325
327
328
nts,
328
-
329

Figure 132. Leukemia Age-Adjusted Inpatient Discharge Rates by County/Region of Residence,	
,	.330
Figure 133. Median Charges for Leukemia Inpatient Discharges by County/Region of Residence,	
Nevada Residents, 1996-2000	.330
Figure 134. Average Length of Stay for Leukemia Inpatient Discharges by County/Region of	
Residence, Nevada Residents, 1996-2000	.331
Table 200. Leukemia Inpatient Discharges by Gender, Charges, Length of Stay, and County/Regi	ion
of Residence, Nevada Residents, 1996-2000.	
Table 201. Leukemia Inpatient Discharges by Age Group and County/Region of Residence, Neva	ada
Residents, 1996-2000.	.333
Table 202. Leukemia Inpatient Discharges by Age Group and Gender, Nevada Residents,	
1996-2000	.334
Table 203. Leukemia Inpatient Discharges by County/Region of Residence, Nevada Residents,	
1996-2000	.335
Table 204. Leukemia Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada	
Residents, 1996-2000.	.335
,	
MORTALITY Fig. 125 J. J. J. A. A.F. A. J. (2000) M. A.F. P. A. N. J. P. J. A. 1006 2000	226
Figure 135. Leukemia Age-Adjusted (2000) Mortality Rates, Nevada Residents, 1996-2000	.330
Figure 136. Leukemia Age-Adjusted Mortality Rates by County/Region of Residence, Nevada	227
Residents, 1996-2000.	
Figure 137. Leukemia Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1996	
2000	
Table 205. Leukemia Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nev	
Residents, 1996-2000.	
Table 206. Leukemia Mortality by Age Group and County/Region of Residence, Nevada Residen	
1996-2000	
Table 207. Leukemia Mortality by County of Residence, Nevada Residents, 1996-2000	
Table 208. Leukemia Mortality by Race/Ethnicity and Gender, Nevada Residents, 1996-2000	
Table 209. Leukemia Mortality by Age Group and Gender, Nevada Residents, 1996-2000	
Table 210. Median Age at Death from Leukemia by Race/Ethnicity and Gender, Nevada Residen	
1996-2000	.342
SURVIVAL RATE	
Figure 138. Survival Rates for Leukemia by Race/Ethnicity, Nevada Residents, 1996-2000	.343
Figure 139. Survival Rates for Leukemia by Stage of Cancer at Diagnosis, Nevada Residents,	
1996-2000	.343
Table 211. Cause-Specific Survival Rates for Leukemia by Race/Ethnicity and Gender, Nevada	
	.344
Table 212. Cause-Specific Survival Rates for Leukemia by Stage of Cancer at Diagnosis and	
Gender, Nevada Residents, 1996-2000.	.345
A DE CARLON AND DIVADENT CANCED	
LIP, ORAL CAVITY AND PHARYNX CANCER	
GENERAL PROFILE	
Figure 140. Anatomy of the Oral Cavity	.347
INCIDENCE	
Figure 141. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted (2000) Incidence Rates, Nevada	
	350

Figure 142. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Incidence Rates by County/Regio	
of Residence, Nevada Residents, 1996-2000.	
Figure 143. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Incidence Rates by Race/Ethnicity Nevada Residents, 1996-2000	
Table 213. Lip, Oral Cavity and Pharynx Cancer Cases by Gender, Race/Ethnicity and	/31
County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995	-
1999)	
Table 214. Lip, Oral Cavity and Pharynx Cancer Cases by Age Group and County/Region of	152
	353
Table 215. Lip, Oral Cavity and Pharynx Cancer Cases by County of Residence at Diagnosis,	دد
	354
Table 216. Lip, Oral Cavity and Pharynx Cancer Cases by Race/Ethnicity and Gender, Nevada	,54
Residents, 1996-2000	354
Table 217. Lip, Oral Cavity and Pharynx Cancer Cases by Age Group and Gender, Nevada)54
	355
Table 218. Lip, Oral Cavity and Pharynx Cancer Cases by Age Group and Stage, Nevada Resident	
	ıs, 356
Table 219. Lip, Oral Cavity and Pharynx Cancer Cases by Stage and Race/Ethnicity, Nevada	,50
	357
Table 220. Median Age at Diagnosis of Lip, Oral Cavity and Pharynx Cancer by Race/Ethnicity and	-
Gender, Nevada Residents, 1996-2000	
	,5,
INPATIENT HOSPITAL DISCHARGES	
Figure 144. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted (2000) Inpatient Discharge Rates,	
,	358
Figure 145. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1996-2000	359
Figure 146. Median Charges for Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by	
County/Region of Residence, Nevada Residents, 1996-2000	359
Figure 147. Average Length of Stay for Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges	3
by County/Region of Residence, Nevada Residents, 1996-2000	360
Table 221. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000	
Table 222. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by Age Group and	,01
County/Region of Residence, Nevada Residents, 1996-2000	362
Table 223. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by Age Group and Gender,	.02
Nevada Residents, 1996-2000	363
Table 224. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by County/Region of	, 05
Residence, Nevada Residents, 1996-2000	364
Table 225. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by Age Group, Charges and	
Length of Stay, Nevada Residents, 1996-2000.	
MORTALITY	
Figure 148. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted (2000) Mortality Rates, Nevada	
Residents, 1996-2000	165
Figure 149. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Mortality Rates by County/Region	
of Residence, Nevada Residents, 1996-2000.	
Figure 150. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Mortality Rates by Race/Ethnicity	
	y, 366

Table 226. Lip, Oral Cavity and Pharynx Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1996-2000	367
Table 227. Lip, Oral Cavity and Pharynx Cancer Mortality by Age Group and County/Region Residence, Nevada Residents, 1996-2000	of
Table 228. Lip, Oral Cavity and Pharynx Cancer Mortality by County of Residence, Nevada Residents, 1996-2000	
Table 229. Lip, Oral Cavity and Pharynx Cancer Mortality by Race/Ethnicity and Gender, New Residents, 1996-2000.	ada
Table 230. Lip, Oral Cavity and Pharynx Cancer Mortality by Age Group and Gender, Nevada Residents, 1996-2000	
Table 231. Median Age at Death from Lip, Oral Cavity and Pharynx Cancer by Race/Ethnicity Gender, Nevada Residents, 1996-2000	and
SURVIVAL RATE	
Figure 151. Survival Rates for Lip, Oral Cavity and Pharynx Cancer by Race/Ethnicity, Nevad Residents, 1996-2000	
Figure 152. Survival Rates for Lip, Oral Cavity and Pharynx Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 1996-2000	372
Table 232. Cause-Specific Survival Rates for Lip, Oral Cavity and Pharynx Cancer by	
Race/Ethnicity and Gender, Nevada Residents, 1996-2000	
Table 233. Cause-Specific Survival Rates for Lip, Oral Cavity and Pharynx Cancer by Stage o Cancer at Diagnosis and Gender, Nevada Residents, 1996-2000	
PANCREATIC CANCER	
GENERAL PROFILE Figure 153. Anatomy of the Endocrine System	376
INCIDENCE	
Figure 154. Pancreatic Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents, 1996-2000	379
Figure 155. Pancreatic Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1996-2000	
Figure 156. Pancreatic Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Resid	
Table 234. Pancreatic Cancer Cases by Gender, Race/Ethnicity and County/Region of Residen Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)	ce at
Table 235. Pancreatic Cancer Cases by Age Group and County/Region of Residence at Diagno Nevada Residents (1996-2000) and SEER-11 (1995-1999)	sis,
Table 236. Pancreatic Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1996-2000	
Table 237. Pancreatic Cancer Cases by Race/Ethnicity and Gender, Nevada Residents,	
Table 238. Pancreatic Cancer Cases by Age Group and Gender, Nevada Residents, 1996-2000. Table 239. Pancreatic Cancer Cases by Age Group and Stage, Nevada Residents, 1996-2000 Table 240. Pancreatic Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1996-2000. Table 241. Median Age at Diagnosis of Pancreatic Cancer by Race/Ethnicity and Gender, Nevada Residents, Nevada Residents, 1996-2000.	384 385 00386 ada
Residents, 1996-2000INPATIENT HOSPITAL DISCHARGES	386

Figure 157. Pancreatic Cancer Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents 1996-2000	s, .387
Figure 158. Pancreatic Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of	.301
	.388
Figure 159. Median Charges for Pancreatic Cancer Inpatient Discharges by County/Region of	
	.388
Figure 160. Average Length of Stay for Pancreatic Cancer Inpatient Discharges by County/Regio	
,	.389
, ,	.390
Table 243. Pancreatic Cancer Inpatient Discharges by Age Group and County/Region of Residence Nevada Residents, 1996-2000	ce, .391
Table 244. Pancreatic Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents,	, .392
Table 245. Pancreatic Cancer Inpatient Discharges by County/Region of Residence, Nevada	.393
Table 246. Pancreatic Cancer Inpatient Discharges by Age Group, Charges and Length of Stay,	.393
MORTALITY	
Figure 161. Pancreatic Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 1996-2000	.394
Figure 162. Pancreatic Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1996-2000	.395
Figure 163. Pancreatic Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residen	
Table 247. Pancreatic Cancer Mortality by Gender, Race/Ethnicity and County/Region of Resider Nevada Residents, 1996-2000	nce, .396
Table 248. Pancreatic Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000	.397
Table 249. Pancreatic Cancer Mortality by County of Residence, Nevada Residents, 1996-2000 Table 250. Pancreatic Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents,	
1996-2000	.398
Table 251. Pancreatic Cancer Mortality by Age Group and Gender, Nevada Residents, 1996-2000	.399
Table 252. Median Age at Death from Pancreatic Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000	.400
SURVIVAL RATE	
Figure 164. Survival Rates for Pancreatic Cancer by Race/Ethnicity, Nevada Residents,	.401
Figure 165. Survival Rates for Pancreatic Cancer by Stage of Cancer at Diagnosis, Nevada	.401
Table 253. Cause-Specific Survival Rates for Pancreatic Cancer by Race/Ethnicity and Gender,	.402
Table 254. Cause-Specific Survival Rates for Pancreatic Cancer by Stage of Cancer at Diagnosis	
Gender, Nevada Residents, 1996-2000	

Table 255. Cancer Incidence, Inpatient Hospital Discharges and Mortality by Type of Cancer,	40.5
Nevada Residents, 1996-2000	405
SKIN CANCER	
Figure 166. Anatomy of the Skin.	406
Table 256. Skin Cancer Cases by Age Group and County/Region of Residence at Diagnosis, New Residents (1996-2000) and SEER-11 (1995-1999)	
Table 257. Skin Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000	408
Table 258. Skin Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000	409
UTERINE CANCER	
Figure 167. Anatomical Drawing of Female Reproductive System	410
Table 259. Uterine Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)	
Table 260. Uterine Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000	
Table 261. Uterine Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000	413
OVARIAN CANCER	
Figure 168. Anatomical Drawing of Female Reproductive System	414
Table 262. Ovarian Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)	
Table 263. Ovarian Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000	
Table 264. Ovarian Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000	
THYROID GLAND CANCER	
Figure 169. Anatomical Drawing of the Thyroid Gland	418
Table 265. Thyroid Gland Cancer Cases by Age Group and County/Region of Residence at	
Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)	419
Table 266. Thyroid Gland Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and	
County/Region of Residence, Nevada Residents, 1996-2000	420
Table 267. Thyroid Gland Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000	421
BRAIN AND OTHER CENTRAL NERVOUS SYSTEM CANCER	
Figure 170. Anatomical Drawing of the Brain and Nearby Structures	422
Table 268. Brain and Other Central Nervous System Cancer Cases by Age Group and	722
County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11	
(1995-1999)	423
Table 269. Brain and Other Central Nervous System Cancer Inpatient Discharges by Gender,	
Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000	424
Table 270. Brain and Other Central Nervous System Cancer Mortality by Age Group and	
County/Region of Residence, Nevada Residents, 1996-2000.	425

STOMACH CANCER	
Figure 171. Anatomical Drawing of the Esophagus and Stomach	426
Table 271. Stomach Cancer Mortality by Age Group and County/Region of Residence at Diagno	
Nevada Residents, 1996-2000	427
Table 272. Stomach Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and	
County/Region of Residence, Nevada Residents, 1996-2000	428
Table 273. Stomach Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000	429
LIVER AND INTRAHEPATIC BILE DUCTS CANCER	
Figure 172. Anatomical Drawing of the Digestive System	
Table 274. Liver and Intrahepatic Bile Ducts Cancer Cases by Age Group and County/Region of	
Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)	431
Table 275. Liver and Intrahepatic Bile Ducts Cancer Inpatient Discharges by Gender, Charges,	
Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000	
Table 276. Liver and Intrahepatic Bile Ducts Cancer Mortality by Age Group and County/Regio Residence, Nevada Residents, 1996-2000	
CERVICAL CANCER	
Figure 173. Anatomical Drawing of the Female Reproductive System	
Table 277. Cervical Cancer Screening by County/Region of Residence, Education, Age Group, a Income, Nevada Residents, 1996-2000	435
Table 278. Cervical Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)	
Table 279. Cervical Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000	437
Table 280. Cervical Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000.	
ESOPHAGEAL CANCER	
Figure 174. Anatomical Drawing of the Esophagus and Stomach	439
Table 281. Esophageal Cancer Cases by Age Group and County/Region of Residence at Diagnos	
Nevada Residents (1996-2000) and SEER-11 (1995-1999)	
Table 282. Esophageal Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000	
Table 283. Esophageal Cancer Mortality by Age Group and County/Region of Residence, Nevac	da
Residents, 1996-2000	442
LARYNX CANCER	
Figure 175. Anatomy of the Oral Cavity	443
Table 284. Larynx Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)	444
Table 285. Larynx Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and	445
County/Region of Residence, Nevada Residents, 1996-2000	443
Residents, 1996-2000	446
MULTIPLE MYELOMA	
Figure 176. Picture of Myeloma Cells	447

Table 287. Multiple Myeloma Cases by Age Group and County/Region of Residence at Diagnos Nevada Residents (1996-2000) and SEER-11 (1995-1999)	-
Table 288. Multiple Myeloma Inpatient Discharges by Gender, Charges, Length of Stay, and	440
County/Region of Residence, Nevada Residents, 1996-2000	440
Table 289. Multiple Myeloma Mortality by Age Group and County/Region of Residence, Nevad	
Residents, 1996-2000	430
HODGKIN'S LYMPHOMA	
Figure 177. Anatomy of the Lymphatic System ⁴	451
Table 290. Hodgkin's Lymphoma Cases by Age Group and County/Region of Residence at	151
Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)	452
Table 291. Hodgkin's Lymphoma Inpatient Discharges by Gender, Charges, Length of Stay, and	
County/Region of Residence, Nevada Residents, 1996-2000	
Table 292. Hodgkin's Lymphoma Mortality by Age Group and County/Region of Residence,	733
Nevada Residents, 1996-2000	454
Nevada Residents, 1770-2000	דטד
ALL OTHER SITES	
Table 293. Cancer Cases for All Other Sites by Age Group and County/Region of Residence at	
Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)	455
Table 294. Inpatient Discharges for All Other Sites by Gender, Charges, Length of Stay, and	
County/Region of Residence, Nevada Residents, 1996-2000	456
Table 295. All Other Sites Cancer Mortality by Age Group and County/Region of Residence,	
Nevada Residents, 1996-2000	457
APPENDIX A – CODES USED FOR GROUPING	
Table 296. ICD-O Codes Used	459
Table 297. ICD-O Codes Used (Continued)	
Table 298. ICD-9 and ICD-10 Codes Used	461
Table 299 ICD-9 and ICD-10 Codes Used (Continued)	462

TECHNICAL NOTES

This report brings together information from four primary data sources. The Nevada Central Cancer Registry (NCCR) within the Bureau of Health Planning and Statistics provided cancer incidence data. The Center for Health Information Analysis at the University of Nevada, Las Vegas (UNLV) provided inpatient hospital discharge (UB92) data. The Office of Vital Records (OVR), also within the Bureau of Health Planning and Statistics, provided the mortality data for this report. The Center for Applied Research at the University of Nevada, Reno (UNR) provided the Behavioral Risk Factor Surveillance System (BRFSS) data that were used to determine the rates of cancer screening.

General considerations that were made for this report include:

Aggregation of Data

This is a statistical report. Every attempt has been made to present the data in a format that does not allow the identification of an individual to be possible. While demographic information such as sex, race/ethnicity and age has been included in aggregate form, no attempt should be made to identify any individual detailed in this report.

Types of Cancer Classification Systems

The classification of the types of cancer was based upon a different coding system for each data source. The NCCR uses the International Classification of Disease, Oncology coding structure (ICD-O) that includes Topography (Primary Site) as well as Morphology (Tumor Type). This is similar to the ICD-10 system used in the 1999 and 2000 mortality data, to classify types of cancers. The 1996 to 1998 mortality data were coded using the ICD-9 classification system, which was also used by the inpatient hospital discharge data. A more detailed description of the codes used for this report is listed under considerations for each data source below, as well as in Appendix B.

Each data source is exclusive

While this report presents cancer data from four different sources, it is important to remember that each dataset is external to the others shown. Individual records were not linked for this report, so caution should be used when comparing data from each data source.

Selection of Residence

Only those events where the person was recorded as a Nevada resident at the time of diagnosis, time of discharge or time of death were included in this report. Those individuals who were listed as an Out of State resident were excluded.

County/Region of Residence

This report details regional data as: Clark County, Washoe County and All Other Counties, as regions. This aggregation of the 15 remaining counties within

Nevada was implemented to accommodate the significantly smaller population sizes in these counties. Aggregation of the smaller population minimizes any extraneous fluctuations in the disease rates presented in this report that may occur due to the large variance in the number of cancer events for each area due to the small size of the resident population for these remaining counties. The counties included in the All Other Counties region are: Carson City, Churchill, Douglas, Elko, Esmeralda, Eureka, Humboldt, Lander, Lincoln, Lyon, Mineral, Nye, Pershing, Storey, and White Pine.

Map Representation

The maps presented in this report are provided to facilitate visual comparisons of rates within the state. However, caution should be used when interpreting these rates due to the small cell size and large variance that are present with many of the smaller counties in Nevada.

Gender Specific Cancer Rates

For gender specific cancers, such as Prostate, Female Breast, Cervix Uteri, Corpus Uteri & Uterus Not Otherwise Specified (NOS), and Ovary Cancers the rates listed in this report are per 100,000 gender-specific population, unless otherwise noted.

Calculation of Rates and Confidence Intervals

Rates and their respective confidence intervals were not calculated for those categories where the number of events was less than ten.

Racial/Ethnic Groups

Race/ethnicity groups used in this report: White, Black, Native American, Asian, and Hispanic were calculated to be mutually exclusive, except for the National rates where a similar population base could not be calculated. So, National rates for racial/ethnic groups are calculated based on either the race or ethnicity listed on the record. These rates may not be directly comparable with others listed in this report.

While every effort was made to develop reliable comparisons between all the data sources, each source had their own unique factors to consider. Below, in detail, are the specific differences between each source and how this report uses each type of information.

CANCER INCIDENCE STATISTICS:

The cancer incidence statistics used for this report are from the NCCR, which compiles cancer cases that are reported by, or abstracted from, hospitals and pathology labs in Nevada. Both Chapter 457 of the Nevada Revised Statutes and those regulations adopted by the State Board of Health regulate the Nevada Central Cancer Registry. More information on the reporting of information on cancer can be found under Chapter 457 of the Nevada Administrative Code. The NCCR also receives information from other states on Nevada residents who were diagnosed, or are being treated, in other states.

The main considerations for this data source include:

Cancer Registry Reporting

The NCCR is a population-based registry. The validity of the numbers and rates used in this report depend on the completeness of cancer reporting, as well as the accuracy of the population estimates used. The North American Association of Central Cancer Registries (NAACCR) estimates the most current year of data presented in this report (2000) at 100% complete for case ascertainment and meets all other requirements for gold certification. The estimated average completeness for case ascertainment over the five years of data presented in this report is 93.2%, which exceeds the 90% case ascertainment requirement set by NAACR for silver certification.

Updated Data

The NCCR is constantly being updated with new information, so the numbers published in this report may not match, or be directly comparable, with previously published data. The data that are presented in this report are from the NCCR as of January 2003.

Type of Cancers Reported

The number of cases included in this report are those reported as having an invasive disease, except for Breast and Urinary Bladder Cancer that also include those diagnosed with an in situ cancer. This distinction is not available in the other data sources.

Type of Cancer Classification System

The type of cancer was classified based on ICD-O2 Topography and Morphology codes. These codes provide levels of detail to the type of cancer that are not included in either the inpatient hospital discharge or mortality data. A detailed list of the actual groupings used for cancer incidence data, using both Topography and Morphology codes, can be found in Appendix B.

Survival Rates & Calculation

The survival rates listed in this report may not be directly comparable to National survival statistics. The reader should exercise caution in comparing statistics listed in this report to those nationally reported. Major factors that should be considered are:

- 1. The rates do not include those reported as an Autopsy Only or Death Certificate Only (DCO) case.
- 2. Only those individuals who died from cancer and those still alive at last update are included in these calculations. Those dying from other causes of death are not included. However, it should be noted that the cause of death is not necessarily specific to the type of cancer listed at time of

- diagnosis. This is to include those cases where the cancer may have metastasized to another site.
- 3. The NCCR actively matches registry records to the Nevada Death Registry on a continuous basis. National statistics are usually based on data submitted at a certain point in time without future updates and data improvements. While calculations account for this difference, caution should be used when comparing the two areas.
- 4. Those individuals who are recorded as having multiple primaries are included for the first primary only.
- 5. Calculations exclude records with invalid dates and unknown ages.
- 6. National statistics typically exclude those cases not actively followed. This report does not make this exclusion.

INPATIENT HOSPITAL DISCHARGE STATISTICS:

The Inpatient Hospital Discharge data used for this report were compiled by the Center for Health Information Analysis (CHIA) at the University of Nevada, Las Vegas (UNLV/CHIA) from the universal billing form *92, (UB92) for inpatient hospital discharges. These data represent patients discharged from January 1, 1996 through December 31, 2000, inclusive. This information was gathered and computerized by UNLV/CHIA as part of a contractual agreement between the Department of Human Resources and the University of Nevada under the authority granted in Section 439B of the Nevada Revised Statutes. The information was then given to the Center for Health Data and Research where it was analyzed for this report.

The main considerations for this data source include:

Primary Diagnosis Selection

The number of resident inpatient discharges detailed in this report is based on a primary diagnosis of cancer. However, the database contains up to fourteen additional diagnoses. The difference between the two classifications is that there were 56,737 inpatient discharges that had cancer as any of the fifteen diagnoses. The number drops to 32,109 for those with cancer as the primary diagnosis. So, approximately 56.6% of the inpatient discharges related to cancer are published in this report. This was done to minimize any confusion that might occur from someone being treated for different types of cancer, as well as to focus on those discharges where cancer was the primary reason for being admitted.

Occurrence Based Data

These statistics are based on the occurrence of inpatient hospital discharges. An individual could be counted more than once had they been admitted to the hospital for cancer more than once during this period. So, caution should be used when comparing inpatient hospital discharge data to the other data sources in this report.

Type of Cancer Classification System

The inpatient hospital discharge statistics were coded with the ICD-9 system. This is the same structure that is used for the 1996 to 1998 mortality data. However, mortality data changed in 1999 to the ICD-10 version. A detailed list of the codes used to produce the groupings provided in this report for inpatient hospital discharge statistics can be found in Appendix B.

Racial/Ethnic Groups

Race/ethnicity information is not available in this database.

MORTALITY STATISTICS:

The mortality statistics used in this report are from the Nevada Death Registry maintained by the Office of Vital Records. The OVR, within the Bureau of Health Planning and Statistics, is the official government entity that collects, processes and maintains the State of Nevada's vital records. Deaths are first recorded at the county level before being forwarded to the State Registrar. Funeral Directors, or persons acting as such, are legally charged with filing death certificates.

These certificates are checked for completeness and accuracy and then entered into a database on the State mainframe computer system. When a certificate is found to be inaccurate or incomplete, staff follow up with the providing entity in accordance with NRS 440.150 to make the necessary corrections and/or additions to make the record satisfactory and complete. It should be noted that the quality of mortality data presented in this report is directly related to the accuracy and completeness of the information contained on the death certificates

The main considerations for this data source include:

Underlying Cause of Death

The mortality data presented in this report are classified by the underlying (primary) cause responsible for death. Only those deaths where the underlying cause of death was cancer are included in this report.

Type of Cancer Classification System

The 1996 to 1998 data used for this report were originally coded using the ICD-9 coding structure, while the 1999 and 2000 data were coded using the ICD-10 system. The ICD-9 system is a purely numeric coding system while the ICD-10 is an alphanumeric system. While there are many similarities between the ICD-9 and ICD-10 groupings, there are some differences between the types of cancer within the two versions. While there are comparability ratios available for the conversion between the two systems, the groups used in this report are based upon some customized groupings of which comparability ratios are unavailable. The mortality numbers in this report have not been adjusted for coding differences that may have occurred with the transition from the ICD-9 to ICD-10 system. A detailed list of the actual groupings used for cancer mortality data, with both the ICD-9 and ICD-10 codes, can be found in Appendix B.

CANCER SCREENING STATISTICS:

The cancer screening data shown in this report come from the Behavioral Risk Factor Surveillance System (BRFSS), which is funded by the Center for Disease Control and Prevention (CDC). The data were compiled by the Center for Applied Research at the University of Nevada, Reno (UNR/CAR), through the nation's largest telephone survey. The survey covers years from 1996 to 2001. This information was gathered and computerized by the Center for Applied Research as part of a contractual agreement between the Department of Human Resources and the University of Nevada. The information was then given to the Center for Health Data and Research where it was analyzed for this report.

The main considerations for this data source include:

Age of Respondents

The survey covers only those people 18 years of age and older.

Frequency of questions

The tables presented in this report are not for 1996 to 2001 inclusively. Some of the questions were asked on alternate years, while some have only been asked once. So, caution should be used when comparing these data.

Weighted percentages

The percentages listed in this report are weighted on the survey population characteristics and may not match percentages that are directly calculated from the numbers listed in the table.

NATIONAL STATISTICS:

The only national cancer statistics provided in this report are for cancer incidence. This information is from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) program. This program is the most comprehensive source of population-based cancer incidence information available for the United States. SEER covers approximately 14 percent of the US population through 11 population-based cancer registries and three supplemental registries.

The information presented in this report is based upon the customized use of SEER's public-use data featured within the SEER*Stat program. The databases used for calculations were the "SEER 11 Registries Public-Use Nov 2001 Sub for Expanded Races (1992-1999)" and "SEER 11 Registries Public-Use Nov 2001 Sub for Hispanics (1992-1999)". These databases are based upon SEER's 11 population-based cancer registries, which are: Atlanta, Connecticut, Detroit, Hawaii, Iowa, Los Angeles, New Mexico, San Francisco-Oakland, San Jose-Monterey, Seattle-Puget Sound, and Utah. These registries have been designed to represent the incidence of cancer within the aggregate population of the United States.

The main considerations for this data source include:

Aggregation of Data

National statistics published in this report follow the guidelines in the SEER Public-Use data agreement. Therefore, those categories where the number is less than five are not shown.

Cancer Registry Reporting

The national data in this report are based upon data collected from population-based registries. The validity of the numbers and rates used in this report depend upon the completeness of the cancer reporting, as well as the accuracy of the population estimates used.

Period of Reportable Data

The most recent SEER data available are for the 1995 to 1999 period. So, it should be noted that comparisons in this report are based upon the 1996 to 2000 period for Nevada and the 1995 to 1999 period nationally.

Type of Cancers Reported

The number of cases listed in this report are those cases reported as having malignant behavior, except for Breast and Urinary Bladder Cancer that include those diagnosed with an in situ behavior, in order to be comparable with Nevada data.

Prostate Cancer Stage Revision

Prostate Cancer cases where the stage of cancer at time of diagnosis was originally coded as "Localized/regional (Prostate Cases 1995+)" are shown as localized within this report. Therefore, there will not be any regionally diagnosed cases of Prostate Cancer for the Nation listed in this report.

Racial/Ethnic Groups

Race/ethnicity groupings, similar to Nevada, were not available for rates, since the population estimates provided in SEER*Stat were not organized in a similar format. Rates were available by either race or ethnicity, which means that the national rates presented in this report represent rates of Whites, Blacks, Native Americans and Asians (of any ethnicity) and Hispanics (of any race). Caution should be used when interpreting these rates, which may not be directly comparable with others listed in this report.

POPULATION ESTIMATES:

The Nevada population data used in this report are based on the database established by the Nevada State Demographer's Office and the Nevada Department of Taxations, as well as 1990 and 2000 Census data from the US Bureau of the Census.

OVERVIEW

OVERVIEW

HIGHLIGHTS

- Lung and Bronchus Cancer was the leading type of cancer for incidence, inpatient hospital discharges and mortality in Nevada from 1996 to 2000. This type of cancer accounted for 18.7% of the total cancer incidence, 15.2% of all cancer inpatient hospital discharges, and 32.0% of cancer mortality during this period.
- Thyroid Gland Cancer by far had the highest comparison ratio of incidence to mortality age-adjusted rates of any type of cancer in Nevada, with a ratio of 16.43, from 1996 to 2000. This means that for every 100 deaths from Thyroid Gland Cancer there would be 1,643 cases. The second leading type was Uterine Cancer with a ratio of 6.15.
- Pancreatic Cancer had the lowest comparison ratio of incidence to mortality age-adjusted rates of any type of cancer in Nevada, with a ratio of 1.12 during this period. This means that for every 100 deaths from Pancreatic Cancer there were 112 cases. The second leading type of cancer, Esophagus Cancer, had a ratio of 1.21.

Lung and Bronchus

| 18.7% | 18.7% | 14.7% | 14.7% | 14.7% | 12.6% | 11.4% | 12.6% | 12.6% | 12.6% | 10.7% | 12.6% | 12.6% | 12.6% | 12.6% | 12.6% | 12.6% | 12.6% | 12.6% | 12.6% | 12.6% | 12.6% | 12.6% | 12.6% | 12.6% | 12.6% | 12.6% | 12.6% | 12.6% | 12.6% | 12.6% | 12.6% | 12.6% | 12.6% | 12.6% | 12.6% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 13.2% | 1

Figure 1. Top Ten Leading Types of Cancer by Percentage of Total Incidence, Discharges and Mortality, Nevada Residents, 1996-2000

Note: "N/A" indicates that this type of Cancer was not in the Top Ten for the respective data source.

10.0%

5.0%

0.0%

Figure 2. Highest Incidence to Mortality Age-Adjusted Rate Ratios by Type of Cancer, Nevada Residents, 1996-2000

15.0%

Percent of Total

20.0%

25.0%

30.0%

35.0%




Figure 3. Lowest Incidence to Mortality Age-Adjusted Rate Ratios by Type of Cancer, Nevada Residents, 1996-2000




Table 1. Nevada Incidence, Inpatient Hospital Discharges and Mortality by Type of Cancer, Nevada, 1996-2000

Time of Course	Incide	nce	Inpatient Dis	scharges	Morta	lity
Type of Cancer	Number	Rate*	Number	Rate*	Number	Rate*
Total	38,261	449.20	32,109	372.23	16,806	207.63
Lip, Oral Cavity and Pharynx	921	10.40	505	5.65	213	2.52
Lip	46	0.53	9		2	
Base of Tongue	122	1.32	74	0.80	3	
Other & Unspecified Parts of Tongue	142	1.59	81	0.92	51	0.58
Parotid Gland	58	0.67	42	0.47	12	0.13
Other & Unspecified Major Salivary glands	21	0.24	9		2	
Floor of Mouth	77	0.87	60	0.64	6	
Gum	18	0.20	24	0.27	2	
Palate	38	0.42	12	0.14	4	
Other & Unspecified Parts of Mouth	48	0.58	32	0.37	26	0.32
Nasopharynx	45	0.50	23	0.25	21	0.24
Tonsil	116	1.30	51	0.57	12	0.13
Oropharynx	42	0.48	22	0.23	9	
Pyriform Sinus	42	0.47	20	0.22	1	
Hypopharynx	35	0.40	19	0.22	5	
Other & Unspecified Oral (Buccal) Cavity & Pharynx	71	0.83	27	0.31	57	0.68
Digestive System	7,048	85.81	6,346	76.94	3,818	47.74
Esophagus	444	5.16	293	3.37	368	4.26
Stomach	544	6.84	571	6.89	326	4.16
Small Intestine	98	1.14	128	1.46	22	0.26
Colon (excluding Rectum)	3,091	38.40	2,741	33.99	1,522	19.62
Cecum	622	7.84	531	6.70	10	0.14
Appendix	36	0.41	23	0.27	1	
Ascending Colon	402	5.10	510	6.41	2	
Hepatic Flexure	101	1.25	95	1.22	0	
Transverse Colon	234	2.89	235	2.95	1	
Splenic Flexure	89	1.07	100	1.24	0	
Descending Colon	140	1.62	158	1.86	0	
Sigmoid Colon	871	10.40	786	9.60	10	0.12
Large Intestine, NOS	596	7.83	303	3.74	1,498	19.29
Rectum	718	8.47	616	7.40	187	2.24
Rectosigmoid Junction	424	5.00	559	6.62	63	0.82
Anus, Anal Canal and Anorectum	112	1.25	118	1.39	20	0.23
Liver	429	5.05	301	3.42	323	3.92
Intrahepatic Bile Ducts	72	0.88	37	0.45	65	0.81
Gallbladder	62	0.79	40	0.53	40	0.52
Other & Unspecified Biliary Tract	93	1.19	133	1.68	35	0.47
Pancreas	917	11.14	708	8.58	810	9.95
Retroperitoneum	29	0.34	52	0.58	6	
Peritoneum, Omentum and Mesentery	8		46	0.54	8	
Other Digestive Organs	7		3		23	0.30
Respiratory System	7,686	90.21	5,278	60.93	5,548	66.34
Nasal Cavity and Middle Ear	23	0.29	9		0	
Accessory Sinuses	25	0.29	18	0.20	12	0.16
Larynx	371	4.26	226	2.54	136	1.62
Lung and Bronchus	7,162	84.09	4,895	56.53	5,385	64.36
Pleura	87	1.08	61	0.77	8	
Trachea	5		18	0.20	2	
Mediastinum and Other Respiratory Organs	13	0.15	51	0.59	5	
Bones, Joints and Articular Cartilage	89	0.13	112	1.26	32	0.40
Bones, Joints & Articular Cartilage of Limbs	43	0.99	50	0.57	0	0.40
Bones, Joints & Articular Cartilage of Other & Unspec Sites	46	0.46	62	0.57	32	0.40
Soft Tissue (Including Heart)	190	2.20	126	1.47	133	1.56
Heart	190		3		133 8	
Peripheral Nerves & Autonomic Nervous System	4		0		3	
Connective, Subcutaneous & Other Soft Tissues	185	2.15	123	1.44	3 122	
Confidence, Subcutaneous & Other Soft Fissues	100			1.44	122	1.44

^{*} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 1. Nevada Incidence, Inpatient Hospital Discharges and Mortality by Type of Cancer, Nevada, 1996-2000 (Continued)

Time of Courses	Incide	nce	Inpatient Dis	scharges	Morta	lity
Type of Cancer	Number	Rate*	Number	Rate*	Number	Rate*
Total	38,261	449.20	32,109	372.23	16,806	207.63
Skin (Excluding Basal And Squamous)	994	11.20	234	2.79	322	3.80
Melanomas Of The Skin	875	9.80	71	0.82	249	2.86
Other Non-Epithelial Skin	119	1.40	163	1.97	73	0.94
Breast	5,643	64.83	2,542	29.21	1,139	14.11
Female Genital System*	2,246	49.88	2,285	50.47	661	15.24
Cervix Uteri*	497	10.89	611	13.30	133	3.01
Corpus Uteri*	800	17.67	828	18.27	55	1.27
Uterus, NOS*	50	1.14	25	0.58	76	1.79
Ovary*	741	16.56	635	14.08	361	8.33
Vagina*	41	0.93	52	1.16	9	
Vulva*	102	2.37	105	2.48	15	0.38
Placenta*	1		1		1	
Other Female Genital Organs*	14	0.30	28	0.59	11	0.25
Male Genital System*	4,831	119.56	2,521	58.82	901	29.58
Prostate*	4,572	114.17	2,450	57.26	883	29.19
Testis*	231	4.70	56	1.14	15	0.32
Penis*	17	0.42	11	0.35	3	
Other Male Genital Organs*	11	0.27	4		0	
Urinary System	2,924	34.80	1,908	22.60	724	9.15
Urinary Bladder	1,866	22.65	989	12.20	379	5.01
Kidney	913	10.44	748	8.41	320	3.86
Renal Pelvis	82	0.96	94	1.10	6	
Ureter	46	0.55	60	0.70	13	0.15
Other Urinary Organs	17	0.20	17	0.18	6	
Eye and Orbit	41	0.44	7		5	
Brain and Other Central Nervous System	560	6.41	728	8.11	320	3.73
Brain	524	5.99	680	7.58	318	3.71
Meninges	17	0.19	28	0.32	1	
Spinal Cord, Cranial Nerves, & Other Parts of CNS	19	0.23	20	0.22	1	
Endocrine System	618	6.66	792	8.46	54	0.65
Thyroid Gland	563	6.05	750	8.01	29	0.37
Adrenal Gland	28	0.31	19	0.20	14	0.16
Other Endocrine (Including Thymus)	27	0.30	23	0.25	11	0.12
Hodgkin's Lymphoma	187	2.01	116	1.25	39	0.44
Non-Hodgkin's Lymphoma	1,252	14.75	966	11.31	587	7.35
Multiple Myeloma	337	4.04	320	3.69	229	2.79
Leukemia	973	11.70	1,040	11.99	568	7.18
Lymphocytic	371	4.43	425	4.81	145	1.89
Acute Lymphocytic	106	1.12	262	2.79	24	0.26
Chronic Lymphocytic	250	3.13	160	1.98	109	1.45
Other Lymphocytic	15	0.18	3		12	0.18
Granulocytic (Myeloid)	413	4.86	526	6.11	233	2.87
Acute Myeloid	288	3.35	422	4.86	163	1.98
Chronic Myeloid	112	1.36	104	1.25	54	0.69
Other Myeloid	13	0.15	0		16	0.20
Monocytic	31	0.37	9		4	
Acute Monocytic	22	0.25	9		2	
Chronic Monocytic	7		0		1	
Other Monocytic	2		0		1	
Other	158	2.04	80	0.96	186	2.37
Other Acute	55	0.71	53	0.64	88	1.07
Other Chronic	14	0.21	8		8	
Aleukemic, Subleukemic and NOS	89	1.12	19	0.22	90	1.17
Other, Ill-Defined and Unspecified Sites	1,721	21.23	6,283	72.60	1,513	19.28

^{*} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 2. Leading Types of Cancer for Nevada Incidence, Inpatient Hospital Discharges and Mortality, Nevada Residents, 1996-2000

Type of Cancer	Incide	ence		pital ssions	Mor	tality
7	Number	Percent	Number	Percent	Number	Percent
Lung and Bronchus	7,162	18.7%	4,895	15.2%	5,385	32.0%
Breast	5,643	14.7%	4,034	12.6%	1,792	10.7%
Prostate	4,572	11.9%	2,542	7.9%	1,139	6.8%
Colorectal	4,345	11.4%	2,450	7.6%	883	5.3%
Urinary Bladder	1,866	4.9%	1,040	3.2%	810	4.8%
Non-Hodgkin's Lymphoma	1,252	3.3%	989	3.1%	587	3.5%
Kidney and Renal Pelvis	995	2.6%	966	3.0%	568	3.4%
Leukemia	973	2.5%	853	2.7%	388	2.3%
Lip, Oral Cavity and Pharynx	921	2.4%	842	2.6%	379	2.3%
Pancreas	917	2.4%	750	2.3%	368	2.2%
Skin	875	2.3%	728	2.3%	361	2.1%
Corpus Uteri & Uterus NOS	850	2.2%	708	2.2%	326	1.9%
Ovary	741	1.9%	635	2.0%	326	1.9%
Thyroid Gland	563	1.5%	611	1.9%	320	1.9%
Brain and Other Central Nervous System	560	1.5%	571	1.8%	249	1.5%
Stomach	544	1.4%	505	1.6%	229	1.4%
Liver and Intrahepatic Bile Ducts	501	1.3%	338	1.1%	213	1.3%
Cervix Uteri	497	1.3%	320	1.0%	136	0.8%
Esophagus	444	1.2%	293	0.9%	133	0.8%
Larynx	371	1.0%	226	0.7%	131	0.8%
Multiple Myeloma	337	0.9%	116	0.4%	39	0.2%
Hodgkin's Lymphoma	187	0.5%	71	0.2%	29	0.2%
All Other Sites	3,145	8.2%	7,626	23.8%	2,015	12.0%
Total	38,261	100.0%	32,109	100.0%	16,806	100.0%

Note: Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 3. Top Ten Types of Cancer by Gender, Incidence, Hospital Discharges, and Mortality, Nevada Residents, 1996-2000

				То	tal				
Ranking	Incidence	е		Hospital Admissions		Mortality			
	Type	Number	Percent	Туре	Number	Percent	Туре	Number	Percent
1	Lung and Bronchus	7,162	18.7%	Lung and Bronchus	4,895	15.2%	Lung and Bronchus	5,385	32.0%
2	Breast	5,643	14.7%	Colorectal	4,034	12.6%	Colorectal	1,792	10.7%
3	Prostate	4,572	11.9%	Breast	2,542	7.9%	Breast	1,139	6.8%
4	Colorectal	4,345	11.4%	Prostate	2,450	7.6%	Prostate	883	5.3%
5	Urinary Bladder	1,866	4.9%	Leukemia	1,040	3.2%	Pancreas	810	4.8%
6	Non-Hodgkin's Lymphoma	1,252	3.3%	Urinary Bladder	989	3.1%	Non-Hodgkin's Lymphoma	587	3.5%
7	Kidney and Renal Pelvis	995	2.6%	Non-Hodgkin's Lymphoma	966	3.0%	Leukemia	568	3.4%
8	Leukemia	973	2.5%	Corpus Uteri & Uterus NOS	853	2.7%	Liver and Intrahepatic Bile Ducts	388	2.3%
9	Lip, Oral Cavity and Pharynx	921	2.4%	Kidney and Renal Pelvis	842	2.6%	Urinary Bladder	379	2.3%
10	Pancreas	917	2.4%	Thyroid Gland	750	2.3%	Esophagus	368	2.2%
	Total of Top 10	28,646	74.9%	Total of Top 10	19,361	60.3%	Total of Top 10	12,299	73.2%
-	Total	38,261	100.0%	Total	32,109	100.0%	Total	16,806	100.0%

				Male					
Ranking	Incidenc	Incidence		Hospital Admis	sions		Mortality		
	Type	Number	Percent	Туре	Number	Percent	Туре	Number	Percent
1	Prostate	4,572	23.0%	Lung and Bronchus	2,592	16.5%	Lung and Bronchus	3,032	33.1%
2	Lung and Bronchus	3,947	19.8%	Prostate	2,450	15.6%	Colorectal	1,011	11.0%
3	Colorectal	2,343	11.8%	Colorectal	2,095	13.3%	Prostate	883	9.6%
4	Urinary Bladder	1,414	7.1%	Urinary Bladder	740	4.7%	Pancreas	420	4.6%
5	Non-Hodgkin's Lymphoma	716	3.6%	Leukemia	609	3.9%	Non-Hodgkin's Lymphoma	340	3.7%
6	Kidney and Renal Pelvis	641	3.2%	Non-Hodgkin's Lymphoma	553	3.5%	Leukemia	330	3.6%
7	Lip, Oral Cavity and Pharynx	625	3.1%	Kidney and Renal Pelvis	540	3.4%	Esophagus	288	3.1%
8	Leukemia	568	2.9%	Brain and Other Central Nervous	426	2.7%	Urinary Bladder	268	2.9%
9	Skin	526	2.6%	Stomach	389	2.5%	Liver and Intrahepatic Bile Ducts	257	2.8%
10	Pancreas	471	2.4%	Pancreas	360	2.3%	Kidney and Renal Pelvis	227	2.5%
	Total of Top 10	15,823	79.5%	Total of Top 10	10,754	68.4%	Total of Top 10	7,056	76.9%
-	Total	19,907	100.0%	Total	15,724	100.0%	Total	9,173	100.0%

				Fem	ale				
Ranking	Incidenc	е		Hospital Adm	nissions		Mortality		
	Type	Number	Percent	Туре	Number	Percent	Type	Number	Percent
1	Breast	5,582	30.4%	Breast	2,524	15.4%	Lung and Bronchus	2,353	30.8%
2	Lung and Bronchus	3,214	17.5%	Lung and Bronchus	2,303	14.1%	Breast	1,128	14.8%
3	Colorectal	2,000	10.9%	Colorectal	1,939	11.8%	Colorectal	781	10.2%
4	Corpus Uteri & Uterus NOS	850	4.6%	Corpus Uteri & Uterus NOS	853	5.2%	Pancreas	390	5.1%
5	Ovary	741	4.0%	Ovary	635	3.9%	Ovary	361	4.7%
6	Non-Hodgkin's Lymphoma	535	2.9%	Cervix Uteri	611	3.7%	Non-Hodgkin's Lymphoma	247	3.2%
7	Cervix Uteri	497	2.7%	Thyroid Gland	583	3.6%	Leukemia	238	3.1%
8	Urinary Bladder	452	2.5%	Leukemia	431	2.6%	Cervix Uteri	133	1.7%
9	Pancreas	446	2.4%	Non-Hodgkin's Lymphoma	413	2.5%	Liver and Intrahepatic Bile Ducts	131	1.7%
10	Thyroid Gland	434	2.4%	Pancreas	348	2.1%	Corpus Uteri & Uterus NOS	131	1.7%
	Total of Top 10	14,751	80.4%	Total of Top 10	10,640	64.9%	Total of Top 10	5,893	77.2%
-	Total	18,347	100.0%	Total	16,385	100.0%	Total	7,633	100.0%

Note: Those of other/unknown gender are not listed separately, but are included in the total.

Table 4. Incidence to Mortality Age-Adjusted Rate Ratios for the Leading Types of Cancer, Nevada Residents, 1996-2000

T (0		Incidenc	е		D.C.		
Type of Cancer	Number	Rate*	95% C.I.	Number	Rate*	95% C.I.	Ratio
Lung and Bronchus	7,162	84.1	(82.1-86.1)	5,385	64.4	(62.6-66.2)	1.31
Breast*	5,582	124.3	(121.0-127.6)	1,128	26.1	(24.6-27.7)	4.76
Prostate*	4,572	114.2	(110.6-117.8)	883	29.2	(27.1-31.5)	3.91
Colorectal	4,345	53.1	(51.5-54.8)	1,792	22.9	(21.8-24.0)	2.32
Urinary Bladder	1,866	22.6	(21.6-23.7)	379	5.0	(4.5-5.6)	4.52
Non-Hodgkin's Lymphoma	1,252	14.8	(13.9-15.6)	587	7.4	(6.8-8.0)	2.01
Kidney and Renal Pelvis	995	11.4	(10.7-12.2)	326	3.9	(3.5-4.4)	2.90
Leukemia	973	11.7	(11.0-12.5)	568	7.2	(6.6-7.8)	1.63
Lip, Oral Cavity and Pharynx	921	10.4	(9.7-11.1)	213	2.5	(2.2-2.9)	4.12
Pancreas	917	11.1	(10.4-11.9)	810	10.0	(9.3-10.7)	1.12
Skin	875	9.8	(9.2-10.5)	249	2.9	(2.5-3.3)	3.43
Corpus Uteri & Uterus NOS*	850	18.8	(17.6-20.1)	131	3.1	(2.6-3.6)	6.15
Ovary*	741	16.6	(15.4-17.8)	361	8.3	(7.5-9.3)	1.99
Thyroid Gland	563	6.0	(5.6-6.6)	29	0.4	(0.2-0.5)	16.43
Brain and Other Central Nervous System	560	6.4	(5.9-7.0)	320	3.7	(3.3-4.2)	1.72
Stomach	544	6.8	(6.3-7.5)	326	4.2	(3.7-4.7)	1.64
Liver and Intrahepatic Bile Ducts	501	5.9	(5.4-6.5)	388	4.7	(4.3-5.3)	1.25
Cervix Uteri*	497	10.9	(9.9-11.9)	133	3.0	(2.5-3.6)	3.62
Esophagus	444	5.2	(4.7-5.7)	368	4.3	(3.8-4.7)	1.21
Larynx	371	4.3	(3.8-4.7)	136	1.6	(1.4-1.9)	2.63
Multiple Myeloma	337	4.0	(3.6-4.5)	229	2.8	(2.4-3.2)	1.45
Hodgkin's Lymphoma	187	2.0	(1.7-2.3)	39	0.4	(0.3-0.6)	4.59
All Other Sites	3,145	37.8	(36.4-39.1)	2,015	25.5	(24.3-26.7)	1.48
Total	38,261	449.2	(444.6-453.9)	16,806	207.6	(204.4-210.9)	2.16


^{*} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

INCIDENCE

HIGHLIGHTS

- Lung and Bronchus Cancer was the leading type of cancer in Nevada from 1996 to 2000. This type of cancer accounted for 18.7% of all resident cancer cases during this period. The second leading type, Breast Cancer, accounted for 14.7% of all cancer incidence.
- ➤ When compared to National (1995-1999) incidence, Nevada had a much higher percentage of Lung and Bronchus Cancer, 18.7% vs 12.9%, and a considerably lower percentage of Breast Cancer cases, 14.7% vs 18.2% during the 1996-2000 period.
- While Blacks had the highest ratio of the remaining racial/ethnic groups when compared to the age-adjusted cancer incidence rates for Whites, their ratio was still at 0.87. This means that for every 100 White cancer cases Blacks would be expected to have 87 cases. Asians, Hispanics and Native Americans had comparison ratios of 0.52, 0.42 and 0.39, respectively, for Nevada from 1996 to 2000.
- ➤ Multiple Myeloma had the highest age-adjusted incidence comparison ratio for Blacks when compared to Whites in Nevada from 1996 to 2000 with a comparison ratio of 1.72. This means that for every 100 White Multiple Myeloma cases Blacks would be expected to have 172 cases. The type with the highest comparison ratio for Asians and Hispanics was Liver and Intrahepatic Bile Ducts, with ratios of 2.99 and 1.51, respectively. Stomach Cancer had the highest comparison ratio for Native Americans when compared to Whites with a ratio of 1.34.
- Skin Cancer had the lowest age-adjusted incidence comparison ratio for Asians, Blacks and Hispanics, when compared to Whites, in Nevada from 1996 to 2000 with ratios of 0.03, 0.09 and 0.17. This means that for every 100 White cancer cases Asians, Blacks and Hispanics would be expected to have 3, 9 and 17 cases, respectively, of Skin Cancer. The type of Cancer with the lowest comparison ratio for Native Americans was Urinary Bladder with a ratio of 0.08 during this period.
- ➤ Hodgkin's Lymphoma had the lowest median age at time of diagnosis for Nevada residents from 1996 to 2000 at 40 years. The median age for females diagnosed with Hodgkin's Lymphoma was 37 years, while for males it was 43 years.
- ➤ Stomach Cancer had the highest median age at time of diagnosis for Nevada residents during the 1996 to 2000 period at 71 years. The median age for females diagnosed with Stomach Cancer was 72 years, while for males it was 70 years, which was a tie with the median age at diagnosis of Urinary Bladder Cancer for males during this period.

Figure 4. Top Ten Leading Cancers as a Percentage of Total Cases, Nevada (1996-2000) and SEER-11 (1995-1999)



Note: "N/A" indicates that this type of Cancer was not in the Top Ten for the SEER region.

Figure 5. Comparison of Age-Adjusted (2000) Incidence Rates of Blacks compared to Whites, Nevada Residents, 1996-2000





Figure 6. Comparison of Age-Adjusted (2000) Incidence Rates of Native Americans compared to Whites, Nevada Residents, 1996-2000



Note: "N/A" indicates that a comparison ratio could not be calculated.

Figure 7. Comparison of Age-Adjusted (2000) Incidence Rates of Asians compared to Whites, Nevada Residents, 1996-2000




Figure 8. Comparison of Age-Adjusted (2000) Incidence Rates of Hispanics compared to Whites, Nevada Residents, 1996-2000




Table 5. Nevada Incidence by Type of Cancer, Nevada (1996-2000) and SEER-11 (1995-1999)

T (2	Inci	dence (1996-	-2000)	SE	ER-11 (1995-	1999)
Type of Cancer	Number	Rate*	95% C.I.	Number	Rate*	95% C.I.
Total	38,261	449.20	(444.6-453.9)	815,121	483.42	(482.4-484.5)
Lip, Oral Cavity and Pharynx	921	10.40	(9.7-11.1)	18,648	11.04	(10.9-11.2)
Lip	46	0.53	(0.4-0.7)	1,789	1.06	(1.0-1.1)
Base of Tongue	122	1.32	(1.1-1.6)	1,855	1.11	(1.1-1.2)
Other & Unspecified Parts of Tongue	142	1.59	(1.3-1.9)	2,400	1.42	(1.4-1.5)
Parotid Gland	58	0.67	(0.5-0.9)	1,594	0.93	(0.9-1.0)
Other & Unspecified Major Salivary glands	21	0.24	(0.1-0.4)	441	0.26	(0.2-0.3)
Floor of Mouth	77	0.87	(0.7-1.1)	1,513	0.91	(0.9-1.0)
Gum	18	0.20	(0.1-0.3)	736	0.44	(0.4-0.5)
Palate	38	0.42	(0.3-0.6)	1,127	0.66	(0.6-0.7)
Other & Unspecified Parts of Mouth	48	0.58	(0.4-0.8)	1,207	0.72	(0.7-0.8)
Nasopharynx	45	0.50	(0.4-0.7)	1,331	0.77	(0.7-0.8)
Tonsil Osophon rov	116 42	1.30 0.48	(1.1-1.6)	2,064 529	1.23 0.32	(1.2-1.3)
Oropharynx Pyriform Sinus	42 42	0.48	(0.3-0.7) (0.3-0.6)	978	0.32	(0.3-0.3) (0.5-0.6)
Hypopharynx	35	0.40	(0.3-0.6)	552	0.33	(0.3-0.4)
Other & Unspecified Oral (Buccal) Cavity & Pharynx	71	0.40	(0.6-1.1)	532	0.32	(0.3-0.4)
Digestive System	7,048	85.81	(83.8-87.9)	151,274	90.82	(90.4-91.3)
Esophagus	444	5.16	(4.7-5.7)	7,483	4.49	(4.4-4.6)
Stomach	544	6.84	(6.3-7.5)	15,187	9.10	(9.0-9.2)
Small Intestine	98	1.14	(0.9-1.4)	2,753	1.64	(1.6-1.7)
Colon (excluding Rectum)	3,091	38.40	(37.0-39.8)	64,345	38.75	(38.5-39.1)
Cecum	622	7.84	(7.2-8.5)	14,990	9.05	(8.9-9.2)
Appendix	36	0.41	(0.3-0.6)	714	0.42	(0.4-0.4)
Ascending Colon	402	5.10	(4.6-5.6)	9,862	5.95	(5.8-6.1)
Hepatic Flexure	101	1.25	(1.0-1.5)	3,655	2.21	(2.1-2.3)
Transverse Colon	234	2.89	(2.5-3.3)	5,972	3.60	(3.5-3.7)
Splenic Flexure	89	1.07	(0.9-1.3)	2,483	1.49	(1.4-1.6)
Descending Colon	140	1.62	(1.4-1.9)	3,907	2.34	(2.3-2.4)
Sigmoid Colon	871	10.40	(9.7-11.1)	19,474	11.70	(11.5-11.9)
Large Intestine, NOS	596	7.83	(7.2-8.5)	3,288	1.99	(1.9-2.1)
Rectum	718	8.47	(7.8-9.1)	16,598	9.93	(9.8-10.1)
Rectosigmoid Junction	424	5.00	(4.5-5.5)	8,180	4.91	(4.8-5.0)
Anus, Anal Canal and Anorectum	112	1.25	(1.0-1.5)	2,189	1.29	(1.2-1.3)
Liver	429	5.05	(4.6-5.6)	8,044	4.79	(4.7-4.9)
Intrahepatic Bile Ducts	72	0.88	(0.7-1.1)	1,460	0.88	(0.8-0.9)
Gallbladder	62 93	0.79 1.19	(0.6-1.0)	2,064	1.24	(1.2-1.3)
Other & Unspecified Biliary Tract Pancreas	93 917	11.19	(1.0-1.5) (10.4-11.9)	2,372 18,152	1.43 10.93	(1.4-1.5) (10.8-11.1)
Retroperitoneum	29	0.34	(0.2-0.5)	737	0.43	(0.4-0.5)
Peritoneum, Omentum and Mesentery	8	0.54	(0.2-0.3)	1,033	0.43	(0.6-0.7)
Other Digestive Organs	7			677	0.41	(0.4-0.4)
Respiratory System	7,686	90.21	(88.2-92.3)	114,569	68.69	(68.3-69.1)
Nasal Cavity and Middle Ear	23	0.29	(0.2-0.4)	563	0.33	(0.3-0.4)
Accessory Sinuses	25	0.29	(0.2-0.4)	621	0.37	(0.3-0.4)
Larynx	371	4.26	(3.8-4.7)	6,718	4.02	(3.9-4.1)
Lung and Bronchus	7,162	84.09	(82.1-86.1)	104,761	62.85	(62.5-63.2)
Pleura	87	1.08	(0.9-1.3)	1,529	0.92	(0.9-1.0)
Trachea	5			117	0.07	(0.1-0.1)
Mediastinum and Other Respiratory Organs	13	0.15	(0.1-0.3)	260	0.14	(0.1-0.2)
Bones, Joints and Articular Cartilage	89	0.99	(0.8-1.2)	1,618	0.90	(0.9-0.9)
Bones, Joints & Articular Cartilage of Limbs	43	0.48	(0.3-0.7)	866	0.48	(0.4-0.5)
Bones, Joints & Articular Cartilage of Other & Unspec Sites	46	0.52	(0.4-0.7)	752	0.42	(0.4-0.5)
Soft Tissue (Including Heart)	190	2.20	(1.9-2.6)	4,924	2.81	(2.7-2.9)
Heart	1			48	0.03	(0.0-0.0)
Peripheral Nerves & Autonomic Nervous System	4			281	0.15	(0.1-0.2)
Connective, Subcutaneous & Other Soft Tissues	185	2.15	(1.8-2.5)	4,595	2.63	(2.6-2.7)

^{*} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Table 5. Nevada Incidence by Type of Cancer, Nevada (1996-2000) and SEER-11 (1995-1999) (Continued)

		Incidence		SE	ER-11 (1995-	1999)
Type of Cancer	Number	Rate*	95% C.I.	Number	Rate*	95% C.I.
Total	38,261	449.2	(444.6-453.9)	815,121	483.42	(482.4-484.5)
Skin (Excluding Basal And Squamous)	994	11.20	(10.5-11.9)	34,077	19.53	(19.3-19.7)
Melanomas Of The Skin	875	9.80	(9.2-10.5)	28,292	16.31	(16.1-16.5)
Other Non-Epithelial Skin	119	1.40	(1.2-1.7)	5,785	3.22	(3.1-3.3)
Breast*	5,582	124.31	(121.0-127.6)	147,688	161.28	(160.5-162.1)
Female Genital System*	2,246	49.88	(47.8-52.0)	50,905	55.03	(54.5-55.5)
Cervix Uteri*	497	10.89	(9.9-11.9)	9,206	9.83	(9.6-10.0)
Corpus Uteri*	800	17.67	(16.5-19.0)	22,211	24.26	(23.9-24.6)
Uterus, NOS*	_50	1.14	(0.8-1.5)	423	0.44	(0.4-0.5)
Ovary*	741	16.56	(15.4-17.8)	15,611	16.84	(16.6-17.1)
Vagina*	41	0.93	(0.7-1.3)	657	0.70	(0.6-0.8)
Vulva*	102	2.37	(1.9-2.9)	2,117	2.22	(2.1-2.3)
Placenta*	1		(0.0.0.5)	86	0.09	(0.1-0.1)
Other Female Genital Organs*	14 4,831	0.30 119.56	(0.2-0.5)	594 125,029	0.64 171.72	(0.6-0.7)
Male Genital System* Prostate*	,		(116.0-123.3)	119,272	165.54	(170.8-172.7)
Testis*	4,572 231	114.17 4.70	(110.6-117.8) (4.1-5.4)	4,967	5.08	(164.6-166.5) (4.9-5.2)
Penis*	17	0.42	(0.2-0.8)	529	0.74	(0.7-0.8)
Other Male Genital Organs*	11	0.42	(0.1-0.6)	261	0.74	(0.3-0.4)
Urinary System	2,924	34.80	(33.5-36.1)	0		(0.0-0.4)
Urinary Bladder	1,866	22.65	(21.6-23.7)	33,284	20.01	(19.8-20.2)
Kidney	913	10.44	(9.8-11.2)	16,592	9.85	(9.7-10.0)
Renal Pelvis	82	0.96	(0.8-1.2)	1,558	0.94	(0.9-1.0)
Ureter	46	0.55	(0.4-0.8)	877	0.53	(0.5-0.6)
Other Urinary Organs	17	0.20	(0.1-0.3)	578	0.35	(0.3-0.4)
Eye and Orbit	41	0.44	(0.3-0.6)	1,376	0.79	(0.7-0.8)
Brain and Other Central Nervous System	560	6.41	(5.9-7.0)	11,214	6.41	(6.3-6.5)
Brain	524	5.99	(5.5-6.5)	10,541	6.03	(5.9-6.1)
Meninges	17	0.19	(0.1-0.3)	190	0.11	(0.1-0.1)
Spinal Cord, Cranial Nerves, & Other Parts of CNS	19	0.23	(0.1-0.4)	483	0.27	(0.2-0.3)
Endocrine System	618	6.66	(6.1-7.2)	13,034	7.22	(7.1-7.3)
Thyroid Gland	563	6.05	(5.6-6.6)	11,885	6.58	(6.5-6.7)
Adrenal Gland	28	0.31	(0.2-0.5)	513	0.28	(0.3-0.3)
Other Endocrine (Including Thymus)	27	0.30	(0.2-0.5)	636	0.36	(0.3-0.4)
Hodgkin's Lymphoma	187	2.01	(1.7-2.3)	5,019	2.71	(2.6-2.8)
Non-Hodgkin's Lymphoma	1,252	14.75	(13.9-15.6)	32,597	19.13	(18.9-19.3)
Multiple Myeloma	337	4.04	(3.6-4.5)	9,106	5.47	(5.4-5.6)
Leukemia	973	11.70	(11.0-12.5)	20,646	12.06	(11.9-12.2)
Lymphocytic	371	4.43	(4.0-4.9)	8,924	5.18	(5.1-5.3)
Acute Lymphocytic	106	1.12	(0.9-1.4)	2,830	1.51	(1.5-1.6)
Chronic Lymphocytic	250	3.13	(2.7-3.6)	5,798	3.49	(3.4-3.6)
Other Lymphocytic Granulocytic (Myeloid)	15	0.18 4.86	(0.1-0.3)	296 9,175	0.18 5.36	(0.2-0.2)
	413 288	3.35	(4.4-5.4)		3.59	(5.3-5.5)
Acute Myeloid Chronic Myeloid	112	1.36	(3.0-3.8) (1.1-1.7)	6,141 2,871	1.68	(3.5-3.7) (1.6-1.7)
Other Myeloid	13	0.15	(0.1-0.3)	163	0.10	(0.1-0.1)
Monocytic	31	0.13	(0.2-0.5)	439	0.10	(0.2-0.3)
Acute Monocytic	22	0.25	(0.2-0.4)	407	0.24	(0.2-0.3)
Chronic Monocytic	7	0.25	(0.2-0.4)	18	0.24	(0.0-0.0)
Other Monocytic	2			14	0.01	(0.0-0.0)
Other	158	2.04	(1.7-2.4)	2,108	1.26	(1.2-1.3)
Other Acute	55	0.71	(0.5-0.9)	775	0.47	(0.4-0.5)
Other Chronic	14	0.21	(0.1-0.4)	50	0.03	(0.0-0.0)
Aleukemic, Subleukemic and NOS	89	1.12	(0.9-1.4)	1,283	0.76	(0.7-0.8)
Other, III-Defined and Unspecified Sites	1,721	21.23	(20.2-22.3)	19,585	11.78	(11.6-11.9)
Tanan, in Donnou and Onopounda Oitou		21.20	(20.2 22.0)	10,000	11.70	(11.0 11.0)

^{*} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Table 6. Nevada Incidence by Type of Cancer and Gender, Nevada, 1996-2000

	Total	*	Male	9	Fema	le
Type of Cancer	Number	Rate**	Number	Rate**	Number	Rate**
Total	38,261	449.20	19,907	497.35	18,347	414.03
Lip, Oral Cavity and Pharynx	921	10.40	625	14.51	296	6.60
Lip	46	0.53	42	1.01	4	
Base of Tongue	122	1.32	93	2.06	29	0.62
Other & Unspecified Parts of Tongue	142	1.59	92	2.15	50	1.10
Parotid Gland	58	0.67	39	0.97	19	0.42
Other & Unspecified Major Salivary glands	21	0.24	11	0.28	10	0.22
Floor of Mouth	77	0.87	46	1.00	31	0.71
Gum	18	0.20	7		11	0.24
Palate	38	0.42	18	0.39	20	0.44
Other & Unspecified Parts of Mouth	48	0.58	25	0.60	23	0.54
Nasopharynx	45	0.50	35	0.77	10	0.22
Tonsil	116	1.30	85	1.94	31	0.69
Oropharynx	42	0.48	31	0.80	11	0.23
Pyriform Sinus	42	0.47	32	0.69	10	0.23
Hypopharynx	35	0.40	24	0.53	11	0.26
Other & Unspecified Oral (Buccal) Cavity & Pharynx	71	0.83	45	1.15	26	0.58
Digestive System	7,048	85.81	4,005	102.86	3,041	70.81
Esophagus	444	5.16	344	8.40	100	2.27
Stomach	544	6.84	353	9.44	191	4.59
Small Intestine	98	1.14	49	1.16	49	1.11
Colon (excluding Rectum)	3,091	38.40	1,641	43.46	1,449	34.06
Cecum	622	7.84	315	8.61	306	7.20
Appendix	36	0.41	20	0.43	16	0.37
Ascending Colon	402	5.10	196	5.19	206	4.93
Hepatic Flexure	101	1.25	52	1.38	49	1.15
Transverse Colon	234	2.89	119	3.11	115	2.69
Splenic Flexure	89	1.07	46	1.26	43	0.97
Descending Colon	140	1.62	72	1.69	68	1.54
Sigmoid Colon	871	10.40	502	12.67	369	8.44
Large Intestine, NOS	596	7.83	319	9.13	277	6.78
Rectum	718	8.47	421	10.44	296	6.73
Rectosigmoid Junction	424	5.00	241	5.90	183	4.18
Anus, Anal Canal and Anorectum	112	1.25	40	0.89	72	1.59
Liver	429	5.05	301	7.24	128	2.96
Intrahepatic Bile Ducts	72	0.88	44	1.17	28	0.65
Gallbladder	62	0.79	17	0.40	45	1.08
Other & Unspecified Biliary Tract	93	1.19	54	1.40	39	0.96
Pancreas	917	11.14	471	12.29	446	10.29
Retroperitoneum	29	0.34	19	0.44	10	0.23
Peritoneum, Omentum and Mesentery	8		5		3	
Other Digestive Organs	7		5		2	
Respiratory System	7,686	90.21	4,340	108.58	3,345	75.13
Nasal Cavity and Middle Ear	23	0.29	15	0.45	8	
Accessory Sinuses	25	0.29	14	0.31	11	0.25
Larynx	371	4.26	285	6.73	86	1.96
Lung and Bronchus	7,162	84.09	3,947	98.85	3,214	72.17
Pleura	87	1.08	69	1.99	18	0.39
Trachea	5		3		2	
Mediastinum and Other Respiratory Organs	13	0.15	7	4.00	6	
Bones, Joints and Articular Cartilage	89	0.99	46	1.02	43	0.97
Bones, Joints & Articular Cartilage of Limbs	43	0.48	19	0.41	24	0.54
Bones, Joints & Articular Cartilage of Other & Unspec Sites	46	0.52	27	0.61	19	0.43
Soft Tissue (Including Heart)	190	2.20	111	2.66	79	1.80
Heart	1		0		1	
Peripheral Nerves & Autonomic Nervous System	4		2		2	
Connective, Subcutaneous & Other Soft Tissues	185	2.15	109	2.61	76	1.73

^{*} Those of unknown gender are not shown separately, but are included in the total.

^{**} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Table 6. Nevada Incidence by Type of Cancer and Gender, Nevada, 1996-2000 (Continued)

T of O	Tota	 *	Mal	е	Fema	ile
Type of Cancer	Number	Rate**	Number	Rate**	Number	Rate**
Total	38,261	449.20	19,907	497.35	18,347	414.03
Skin (Excluding Basal And Squamous)	994	11.20	614	14.29	380	8.42
Melanomas Of The Skin	875	9.80	526	12.12	349	7.71
Other Non-Epithelial Skin	119	1.40	88	2.17	31	0.71
Breast	5,643	64.83	59	1.50	5,582	124.31
Female Genital System	2,246	25.70	0		2,246	49.88
Cervix Uteri	497	5.46	0		497	10.89
Corpus Uteri	800	9.11	0		800	17.67
Uterus, NOS	50	0.61	0		50	1.14
Ovary	741	8.60	0		741	16.56
Vagina	41	0.49	0		41	0.93
Vulva	102	1.27	0		102	2.37
Placenta	1		0		1	
Other Female Genital Organs	14	0.15	0		14	0.30
Male Genital System	4,831	55.82	4,831	119.56	0	
Prostate	4,572	53.08	4,572	114.17	0	
Testis	231	2.42	231	4.70	0	
Penis	17	0.20	17	0.42	0	
Other Male Genital Organs	11	0.13	11	0.27	0	
Urinary System	2,924	34.80	2,103	53.71	821	18.72
Urinary Bladder	1,866	22.65	1,414	37.34	452	10.43
Kidney	913	10.44	586	13.74	327	7.35
Renal Pelvis	82	0.96	55	1.39	27	0.60
Ureter	46	0.55	35	0.91	11	0.25
Other Urinary Organs	17	0.20	13	0.32	4	
Eye and Orbit	41	0.44	26	0.57	15	0.32
Brain and Other Central Nervous System	560	6.41	311	7.28	249	5.60
Brain	524	5.99	292	6.81	232	5.22
Meninges	17	0.19	7		10	0.22
Spinal Cord, Cranial Nerves, & Other Parts of CNS	19	0.23	12	0.31	7	0.01
Endocrine System Thyroid Cloud	618	6.66	160	3.60	458	9.91
Thyroid Gland	563	6.05	129	2.87	434	9.40
Adrenal Gland	28 27	0.31 0.30	14 17	0.35 0.39	14 10	0.30 0.22
Other Endocrine (Including Thymus) Hodgkin's Lymphoma	187	2.01	106	2.20	81	1.78
Non-Hodgkin's Lymphoma	1,252	14.75	716	17.60	535	12.21
Multiple Myeloma	337	4.04	198	5.11	139	3.17
Leukemia	973	11.70	568	14.19	405	9.41
Lymphocytic	371	4.43	220	5.52	151	3.47
Acute Lymphocytic	106	1.12	59	1.22	47	1.01
Chronic Lymphocytic	250	3.13	151	4.07	99	2.34
Other Lymphocytic	15	0.18	10	0.24	5	2.04
Granulocytic (Myeloid)	413	4.86	241	5.83	172	3.94
Acute Myeloid	288	3.35	164	3.94	124	2.80
Chronic Myeloid	112	1.36	69	1.70	43	1.02
Other Myeloid	13	0.15	8		5	
Monocytic	31	0.37	15	0.36	16	0.37
Acute Monocytic	22	0.25	11	0.26	11	0.25
Chronic Monocytic	7		3		4	
Other Monocytic	2		1		1	
Other	158	2.04	92	2.47	66	1.63
Other Acute	55	0.71	36	1.00	19	0.46
Other Chronic	14	0.21	6		8	
Aleukemic, Subleukemic and NOS	89	1.12	50	1.28	39	0.96
Other, III-Defined and Unspecified Sites	1,721	21.23	1,088	28.14	632	15.00

^{*} Those of unknown gender are not shown separately, but are included in the total.

^{**} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Table 7. Nevada Incidence by Type of Cancer and Stage of Cancer, Nevada, 1996-2000

Type of Cancer	Total	In city	Localizad	Pagional	Distant	Unotogod
	Total	In situ	Localized	Regional	Distant	Unstaged
Total	38,261	1,165	14,320	7,074	7,298	8,404
Lip, Oral Cavity and Pharynx	921	0	296	346	88	191
Lip	46	0	33	6	3	4
Base of Tongue	122	0	21	78	9	14
Other & Unspecified Parts of Tongue	142	0	69	29	12	32
Parotid Gland	58	0	29	16	2	11
Other & Unspecified Major Salivary glands	21	0	7	7	5	2
Floor of Mouth	77	0	35	24	10	8
Gum	18	0	7	6	1	4
Palate	38	0	21	8	4	5
Other & Unspecified Parts of Mouth	48	0	11	16	4	17
Nasopharynx	45	0	5	15	5	20
Tonsil	116	0	23	66	5	22
Oropharynx	42	0	8	9	12	13
Pyriform Sinus	42	0	7	25	2	8
Hypopharynx	35	0	10	12	3	10
Other & Unspecified Oral (Buccal) Cavity & Pharynx	71	0	10	29	11	21
Digestive System	7,048	0	1,672	2,242	1,497	1,637
Esophagus	444	0	62	105	108	169
Stomach	544	0	78	169	161	136
Small Intestine	98	0	20	34	26	18
Colon (excluding Rectum)	3,091	0	851	1,179	616	445
Cecum	622	0	166	280	144	32
Appendix	36 402	0	13	12	9	2
Ascending Colon	101	0	127	188	67	20
Hepatic Flexure			32 66	46	19	4 8
Transverse Colon	234	0		116 44	44	
Splenic Flexure Descending Colon	89 140	0	30 39	55	12 37	3 9
Sigmoid Colon	871	0	309	363	164	35
Large Intestine, NOS	596	0	69	75	120	332
Rectum	718	0	263	220	108	127
Rectorigmoid Junction	424	0	127	172	96	29
Anus, Anal Canal and Anorectum	112	0	53	25	14	20
Liver	429	0	82	24	71	252
Intrahepatic Bile Duct	72	0	13	13	12	34
Gallbladder	62	0	18	22	16	6
Other & Unspecified Biliary Tract	93	0	22	29	9	33
Pancreas	917	0	75	246	248	348
Retroperitoneum	29	0	8	4	5	12
Peritoneum, Omentum and Mesentery	8	0	0	0	4	4
Other Digestive Organs	7	0	0	0	3	4
Respiratory System	7,686	0	1,293	1,441	2,573	2,379
Nasal Cavity and Middle Ear	23	0	13	[′] 1	3	6
Accessory Sinuses	25	0	7	8	6	4
Larynx	371	0	145	85	27	114
Lung and Bronchus	7,162	0	1,106	1,337	2,522	2,197
Pleura	87	0	18	7	12	50
Trachea	5	0	0	2	1	2
Mediastinum and Other Respiratory Organs	13	0	4	1	2	6
Bones, Joints and Articular Cartilage	89	0	30	12	19	28
Bones, Joints & Articular Cartilage of Limbs	43	0	21	6	9	7
Bones, Joints & Articular Cartilage of Other & Unspec Sites	46	0	9	6	10	21
Soft Tissue (Including Heart)	190	0	80	7	29	74
Heart	1	0	1	0	0	0
Peripheral Nerves & Autonomic Nervous System	4	0	2	0	0	2
Connective, Subcutaneous & Other Soft Tissues	185	0	77	7	29	72

Table 7. Nevada Incidence by Type of Cancer and Stage of Cancer, Nevada, 1996-2000 (Continued)

Type of Cancer	Total	In situ	Localized	Regional	Distant	Unstaged
Total	38,261	1,165	14,320	7,074	7,298	8,404
Total	30,201	1,100	14,520	1,014	1,230	0,707
Skin (Excluding Basal And Squamous)	994	0	647	75	94	178
Melanomas Of The Skin	875	0	588	69	72	146
Other Non-Epithelial Skin	119	0	59	6	22	32
Breast	5,643	743	2,755	1,380	285	480
Female Genital System	2,246	0	1,136	397	482	231
Cervix Uteri	497	0	237	160	48	52
Corpus Uteri	800 50	0	623 16	87 6	49 10	41 18
Uterus, NOS Ovary	741	0	180	106	356	99
Vagina	41	0	17	8	9	7
Vulva	102	0	61	26	4	, 11
Placenta	1	0	0	0	1	0
Other Female Genital Organs	14	0	2	4	5	3
Male Genital System	4,831	0	3,124	573	284	850
Prostate	4,572	0	2,963	533	248	828
Testis	231	0	146	36	36	13
Penis	17	0	8	3	0	6
Other Male Genital Organs	11	0	7	1	0	3
Urinary System	2,924	422	1,572	307	245	378
Urinary Bladder	1,866	422	1,007	177	66	194
Kidney	913	0	480	95	168	170
Renal Pelvis	82	0	50	24	5	3
Ureter	46	0	27	6	5	8
Other Urinary Organs	17	0	8	5	1	3
Eye and Orbit Brain and Other Nervous System	41	0	12 377	0 13	3	26 159
Brain Brain	560 524	0	364	11	11 10	139
Meninges	17	0	8	1	10	7
Spinal Cord, Cranial Nerves, & Other Parts of CNS	19	0	5	1	0	13
Endocrine System	618	0	395	118	39	66
Thyroid Gland	563	0	379	113	28	43
Adrenal Gland	28	0	5	4	8	11
Other Endocrine (Including Thymus)	27	0	11	1	3	12
Hodgkin's Lymphoma	187	0	72	20	50	45
Non-Hodgkin's Lymphoma	1,252	0	336	110	401	405
Multiple Myeloma	337	0	1	1	298	37
Leukemia	973	0	0	0	858	115
Lymphocytic	371	0	0	0	353	18
Acute Lymphocytic	106	0	0	0	104	2
Chronic Lymphocytic	250	0	0	0	235	15
Other Lymphocytic	15	0	0	0	14	1
Granulocytic (Myeloid)	413 288	0	0	0	391 275	22
Acute Myeloid Chronic Myeloid	200 112	0	0	0	104	13 8
Other Myeloid	13	0	0	0	104	1
Monocytic	31	0	0	0	29	2
Acute Monocytic	22	0	0	0	22	0
Chronic Monocytic	7	0	0	0	6	1
Other Monocytic	2	0	0	0	1	1
Other	158	0	0	0	85	73
Other Acute	55	0	0	0	35	20
Other Chronic	14	0	0	0	3	11
Aleukemic, Subleukemic and NOS	89	0	0	0	47	42
Other, III-Defined and Unspecified Sites	1,721	0	522	32	42	1,125

Table 8. Top Ten Types of Cancer Incidence by County/Region of Residence, Nevada Residents, 1996-2000

			County/Region of Residence						
Rank	Type of Cance	r	Nevada Total	Clark	Washoe	All Other Counties			
1	Lung and Bronchus	Incidence	7,162	4,930	1,122	1,108			
		Rate*	84.09	87.51	78.23	77.08			
		95% C.I.	(82.1-86.1)	(85.0-90.1)	(73.7-83.0)	(72.5-81.9)			
2	Breast*	Incidence	5,582	3,572	1,156	853			
		Rate*	124.31	119.63	148.07	117.84			
		95% C.I.	(121.0-127.6)	(115.7-123.7)	(139.6-156.9)	(110.0-126.1)			
3	Prostate*	Incidence	4,572	2,771	969	830			
		Rate*	114.17	104.28	144.83	122.72			
		95% C.I.	(110.6-117.8)	(100.1-108.7)	(135.4-154.9)	(114.1-132.0)			
4	Colorectal	Incidence	4,345	2,965	746	634			
		Rate*	53.13	54.69	53.45	46.51			
		95% C.I.	(51.5-54.8)	(52.7-56.8)	(49.6-57.5)	(42.9-50.4)			
5	Urinary Bladder	Incidence	1,866	1,221	327	318			
	,	Rate*	22.65	22.54	23.15	22.72			
		95% C.I.	(21.6-23.7)	(21.2-23.9)	(20.7-25.9)	(20.2-25.5)			
6	Non-Hodgkin's Lymphoma	Incidence	1,252	773	253	226			
		Rate*	14.75	13.85	17.00	16.31			
		95% C.I.	(13.9-15.6)	(12.9-14.9)	(14.9-19.3)	(14.2-18.7)			
7	Kidney and Renal Pelvis	Incidence	995	637	182	175			
		Rate*	11.40	10.98	12.33	12.13			
		95% C.I.	(10.7-12.2)	(10.1-11.9)	(10.6-14.3)	(10.4-14.1)			
8	Leukemia	Incidence	973	649	165	158			
		Rate*	11.70	11.74	11.48	11.75			
		95% C.I.	(11.0-12.5)	(10.8-12.7)	(9.8-13.5)	(10.0-13.8)			
9	Lip, Oral Cavity and Pharynx	Incidence	921	593	180				
		Rate*	10.40	10.09	11.83				
		95% C.I.	(9.7-11.1)	(9.3-11.0)	(10.1-13.8)				
10	Pancreas	Incidence	917	614		154			
		Rate*	11.14	11.27		11.20			
		95% C.I.	(10.4-11.9)	(10.4-12.3)		(9.5-13.2)			
	Total	Incidence	38,261	24,899	7,248	6,099			
		Rate*	449.20	441.05	496.40	433.57			
		95% C.I.	(444.6-453.9)	(435.4-446.8)	(484.9-508.2)	(422.6-444.8)			

^{*} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Note: The "---" indicates that this type of cancer was not in the Top Ten for this specific region.

Table 9. Top Ten Types of Cancer Incidence by Age Group, Nevada Residents, 1996-2000

Ranking	Age Group										
Ranking	0-14	15-24	25-34	35-44	45-54	55-64	65-74	75+	Total		
1	Leukemia	Thyroid Gland	Thyroid Gland	Breast	Breast	Lung and Bronchus	Lung and Bronchus	Lung and Bronchus	Lung and Bronchus		
	94	31	116	594	1,233	1,695	2,739	1,951	7,162		
	36.0%	12.2%	14.2%	28.2%	25.5%	19.8%	23.1%	20.4%	18.7%		
2	Brain and OCNS	Leukemia	Breast	Colorectal	Lung and Bronchus	Breast	Prostate	Colorectal	Breast		
	53	30	98	147	630	1,313	1,918	1,458	5,643		
	20.3%	11.8%	12.0%	7.0%	13.0%	15.3%	16.1%	15.3%	14.7%		
3	NHL	HL	Skin	Thyroid Gland	Colorectal	Prostate	Colorectal	Prostate	Prostate		
	19	24	70	134	412	1,271	1,430	1,077	4,572		
	7.3%	9.4%	8.6%	6.4%	8.5%	14.8%	12.0%	11.3%	11.9%		
4	KRP	Skin	NHL	Cervix Uteri	Prostate	Colorectal	Breast	Breast	Colorectal		
	11	22	62	127	291	865	1,387	1,014	4,345		
	4.2%	8.7%	7.6%	6.0%	6.0%	10.1%	11.7%	10.6%	11.4%		
5	Liver and IBD	Brain and OCNS	Cervix Uteri	Lung and Bronchus	LOCP	Urinary Bladder	Urinary Bladder	Urinary Bladder	Urinary Bladder		
	9	20	59	127	175	367	663	631	1,866		
	3.4%	7.9%	7.2%	6.0%	3.6%	4.3%	5.6%	6.6%	4.9%		
6	HL	NHL	HL	Skin	NHL	LOCP	NHL	NHL	NHL		
	7	20	43	122	163	271	316	334	1,252		
	2.7%	7.9%	5.3%	5.8%	3.4%	3.2%	2.7%	3.5%	3.3%		
7	LOCP	Ovary	Brain and OCNS	NHL	Skin	KRP	Pancreas	Pancreas	KRP		
	3	6	41	103	161	260	304	296	995		
	1.1%	2.4%	5.0%	4.9%	3.3%	3.0%	2.6%	3.1%	2.6%		
8	Ovary	LOCP	Leukemia	Ovary	KRP	NHL	KRP	Leukemia	Leukemia		
	2	5	37	74	156	235	292	273	973		
	0.8%	2.0%	4.5%	3.5%	3.2%	2.7%	2.5%	2.9%	2.5%		
9	Thyroid Gland	Cervix Uteri	Ovary	LOCP	CU & Uterus NOS	CU & Uterus NOS	CU & Uterus NOS	Stomach	LOCP		
	2	4	34	63	153	208	252	211	921		
	0.8%	1.6%	4.2%	3.0%	3.2%	2.4%	2.1%	2.2%	2.4%		
10	Urinary Bladder	Breast	Colorectal	KRP	Urinary Bladder	Pancreas	LOCP	KRP	Pancreas		
	2	3	30	56	148	208	252	206	917		
	0.8%	1.2%	3.7%	2.7%	3.1%	2.4%	2.1%	2.2%	2.4%		
Sum	202	165	590	1,547	3,522	6,693	9,553	7,451	28,646		
Percent	77.4%	65.0%	72.2%	73.6%	72.9%	78.1%	80.4%	78.1%	74.9%		
Total	261	254	817	2,103	4,831	8,567	11,877	9,545	38,261		
	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%		

Abbreviations: Brain and OCNS = Brain and Other Central Nervous System, CU & Uterus NOS = Corpus Uteri and Uterus NOS, HL = Hodgkin's Lymphoma, KRP = Kidney and Renal Pelvis, LOCP = Lip, Oral Cavity and Pharynx, Liver and IBD = Liver and Intrahepatic Bile Ducts, NHL = Non-Hodgkin's Lymphoma. Note: Those cases with unknown ages are not shown separately, but are included in the total.

Table 10. Median Age at Time of Diagnosis by Leading Types of Cancer and Race/Ethnicity, Nevada Residents, 1996-2000

- ,	Race/Ethnicity								
Type of Cancer	White	Black	Native American	Asian	Hispanic	Total			
Lung and Bronchus	69.0	66.0	68.5	66.0	64.0	69.0			
Breast	62.0	56.0	60.0	52.0	53.0	61.0			
Prostate	68.0	65.0	69.0	71.0	66.0	68.0			
Colorectal	70.0	64.0	65.0	64.5	64.0	70.0			
Urinary Bladder	70.0	75.0		71.0	61.0	70.0			
Non-Hodgkin's Lymphoma	66.0	58.0		64.0	58.0	65.0			
Kidney and Renal Pelvis	65.0	62.0	68.5	60.0	56.0	65.0			
Leukemia	68.0	66.5	42.0	15.0	35.0	66.0			
Lip, Oral Cavity and Pharynx	62.0	58.0		54.5	59.0	62.0			
Pancreas	70.0	67.0	65.0	66.0	68.0	69.0			
Skin	58.0				72.0	58.0			
Corpus Uteri & Uterus NOS	65.0	62.0	54.0	54.0	60.0	64.0			
Ovary	64.0	63.0		62.0	47.0	63.0			
Thyroid Gland	45.0	39.0		50.0	36.0	44.0			
Stomach Brain and Other Central	72.0	63.0	70.0	62.0	61.5	71.0			
Nervous System	60.0	61.0		35.0	39.0	58.5			
Cervix Uteri Liver and Intrahepatic Bile	48.0	49.0		54.5	50.0	49.0			
Ducts	69.0	59.5	73.0	58.0	60.0	68.0			
Esophagus	66.5	61.0		63.0	63.0	66.0			
Larynx	65.0	64.0			60.0	64.0			
Multiple Myeloma	69.0	62.0		70.0	66.0	69.0			
Hodgkin's Lymphoma	41.0	40.0			26.0	40.0			
All Other Sites	67.0	62.0	71.0	62.0	51.0	66.0			
Total	67.0	63.0	65.0	62.0	59.0	66.0			

Note: Those of other/unknown race/ethnicity are not shown separately, but are included in the total. Those deaths of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

HIGHLIGHTS

- ➤ Lung and Bronchus Cancer was the leading type of Cancer for inpatient discharges in Nevada from 1996 to 2000. This type of cancer accounted for 15.2% of all resident cancer inpatient hospital discharges during this period. The second leading type of cancer was Colorectal Cancer, which accounted for 12.6% of all cancer inpatient discharges during this period.
- The two leading types of cancer for inpatient hospital discharges, Lung and Bronchus and Colorectal Cancer accounted for 283.9 million dollars in total billed amounts in Nevada from 1996 to 2000. This accounted for 30.9% of the total 922.4 million dollars in billed amounts for cancer inpatient hospital discharges during this period.
- ➤ The five types of cancer that had the highest average total billed amount for Nevada from 1996 to 2000 were: Leukemia (\$53,265), Stomach (\$48,948), Esophagus (\$42,562), Larynx (\$39,744), and Pancreatic (\$37,747) Cancer.
- ➤ The five types of cancer that had the highest median total billed amount for Nevada from 1996 to 2000 were: Stomach (\$34,005), Larynx (\$29,728), Brain and Other Central Nervous System (\$29,375), Leukemia (\$25,696), and Colorectal (\$25,540) Cancer.
- ➤ The five types of cancer that had the highest average length of stay (days) for cancer inpatient hospital discharges for Nevada from 1996 to 2000 were: Leukemia (12.33), Stomach (11.06), Esophagus (10.05), Larynx (9.62), and Pancreas (9.43) Cancer.
- ➤ The five types of cancer that had the highest average daily billed amount for Nevada from 1996 to 2000 were: Breast (\$5,632), Prostate (\$5,415), Thyroid Gland (\$4,942), Uterine (\$4,694), and Ovary (\$4,668) Cancer.

Figure 9. Top Ten Leading Cancers in Total Inpatient Discharge Charges, Nevada Residents, 1996-2000




Figure 10. Top Ten Leading Cancers in Average Inpatient Discharge Charges, Nevada Residents, 1996-2000




Figure 11. Top Ten Leading Cancers in Median Inpatient Discharge Charges, Nevada Residents, 1996-2000




Figure 12. Top Ten Leading Cancers in Total Number of Days Stayed for Inpatient Hospital Discharges, Nevada Residents, 1996-2000




Figure 13. Top Ten Leading Cancers in Average Length of Stay (Days) for Inpatient Hospital Discharges, Nevada Residents, 1996-2000




Figure 14. Top Ten Leading Cancers in Median Length of Stay (Days) for Inpatient Hospital Discharges, Nevada Residents, 1996-2000




Table 11. Nevada Inpatient Hospital Discharges by Type of Cancer and Gender, Nevada, 1996-2000

Type of Cancer	Total		Male		Fema	
Type of Cancer	Number	Rate**	Number	Rate**	Number	Rate**
Total	32,109	372.23	15,724	384.33	16,385	367.20
Lip, Oral Cavity and Pharynx	505	5.65	332	7.61	173	3.81
Lip	9		8		1	
Base of Tongue	74	0.80	45	0.96	29	0.62
Other & Unspecified Parts of Tongue	81	0.92	49	1.16	32	0.71
Parotid Gland	42	0.47	27	0.64	15	0.33
Other & Unspecified Major Salivary glands	9		7		2	
Floor of Mouth	60	0.64	37	0.79	23	0.49
Gum	24	0.27	18	0.40	6	
Palate	12	0.14	7		5	
Other & Unspecified Parts of Mouth	32	0.37	17	0.42	15	0.33
Nasopharynx	23	0.25	16	0.35	7	
Tonsil	51	0.57	40	0.89	11	0.25
Oropharynx	22	0.23	15	0.32	7	
Pyriform Sinus	20	0.22	15	0.32	5	
Hypopharynx	19	0.22	11	0.24	8	
Other & Unspecified Oral (Buccal) Cavity & Pharynx	27	0.31	20	0.49	7	
Digestive System	6,346	76.94	3,503	89.45	2,843	65.93
Esophagus	293	3.37	223	5.33	70	1.59
Stomach	571	6.89	389	10.17	182	4.18
Small Intestine	128	1.46	72	1.70	56	1.24
Colon (excluding Rectum)	2,741	33.99	1,367	36.06	1,374	32.21
Cecum	531	6.70	245	6.51	286	6.78
Appendix	23	0.27	8		15	0.34
Ascending Colon	510	6.41	240	6.49	270	6.38
Hepatic Flexure	95	1.22	48	1.29	47	1.13
Transverse Colon	235	2.95	113	3.09	122	2.86
Splenic Flexure	100	1.24	47	1.37	53	1.21
Descending Colon	158	1.86	90	2.29	68	1.52
Sigmoid Colon	786	9.60	430	11.03	356	8.31
Large Intestine, NOS	303	3.74	146	3.79	157	3.68
Rectum	616	7.40	346	8.69	270	6.23
Rectosigmoid Junction	559	6.62	324	7.80	235	5.42
Anus, Anal Canal and Anorectum	118	1.39	58	1.47	60	1.36
Liver	301	3.42	214	5.05	87	1.93
Intrahepatic Bile Ducts	37	0.45	20	0.51	17	0.40
Gallbladder	40	0.53	16	0.44	24	0.59
Other & Unspecified Biliary Tract	133	1.68	70	1.94	63	1.49
Pancreas	708	8.58	360	9.21	348	8.03
Retroperitoneum	52	0.58	30	0.67	22	0.49
Peritoneum, Omentum and Mesentery	46	0.54	12	0.31	34	0.76
Other Digestive Organs	3		2		1	
Respiratory System	5,278	60.93	2,873	70.23	2,405	53.41
Nasal Cavity and Middle Ear	9		6		3	
Accessory Sinuses	18	0.20	13	0.29	5	
Larynx	226	2.54	172	4.02	54	1.18
Lung and Bronchus	4,895	56.53	2,592	63.34	2,303	51.17
Pleura	61	0.77	50	1.45	11	0.25
Trachea	18	0.20	11	0.26	7	
Mediastinum and Other Respiratory Organs	51	0.59	29	0.74	22	0.48
Bones, Joints and Articular Cartilage	112	1.26	56	1.23	56	1.27
Bones, Joints & Articular Cartilage of Limbs	50	0.57	25	0.57	25	0.58
Bones, Joints & Articular Cartilage of Other & Unspec Sites	62	0.69	31	0.67	31	0.69
Soft Tissue (Including Heart)	126	1.47	65	1.65	61	1.37
Heart	3		2		1	
Peripheral Nerves & Autonomic Nervous System	0		0		0	
Connective, Subcutaneous & Other Soft Tissues	123	1.44	63	1.61	60	1.35

^{*} Those of unknown gender are not shown separately, but are included in the total.

^{**} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Table 11. Nevada Inpatient Hospital Discharges by Type of Cancer and Gender, Nevada, 1996-2000 (Continued)

	Tota	*	Male		Female	
Type of Cancer	Number	Rate**	Number	Rate**	Number	Rate**
Total	32,109	372.23	15,724	384.33	16,385	367.20
Skin (Excluding Basal And Squamous)	234	2.79	145	3.69	89	2.04
Melanomas Of The Skin	71	0.82	42	1.07	29	0.64
Other Non-Epithelial Skin	163	1.97	103	2.62	60	1.40
Breast	2,542	29.21	18	0.49	2,524	56.21
Female Genital System	2,285	25.83	0		2,285	50.47
Cervix Uteri	611	6.61	0		611	13.30
Corpus Uteri	828	9.41	0		828	18.27
Uterus, NOS	25	0.31	0		25	0.58
Ovary	635	7.23	0		635	14.08
Vagina	52	0.61	0		52	1.16
Vulva	105	1.35	0		105	2.48
Placenta	103	1.33	0		103	2.40
Other Female Genital Organs	28	0.29	0		28	0.59
	2,521	28.08		58.82	0	0.59
Male Genital System			2,521		0	
Prostate	2,450	27.31	2,450	57.26		
Testis	56	0.59	56	1.14	0	
Penis	11	0.15	11	0.35	0	
Other Male Genital Organs	4		4		0	40.07
Urinary System	1,908	22.60	1,332	33.83	576	13.07
Urinary Bladder	989	12.20	740	20.02	249	5.82
Kidney	748	8.41	481	11.05	267	5.92
Renal Pelvis	94	1.10	59	1.48	35	0.78
Ureter	60	0.70	44	1.10	16	0.36
Other Urinary Organs	17	0.18	8		9	
Eye and Orbit	7		2		5	
Brain and Other Central Nervous System	728	8.11	426	9.52	302	6.72
Brain	680	7.58	405	9.06	275	6.12
Meninges	28	0.32	10	0.23	18	0.40
Spinal Cord, Cranial Nerves, & Other Parts of CNS	20	0.22	11	0.23	9	
Endocrine System	792	8.46	187	4.05	605	13.09
Thyroid Gland	750	8.01	167	3.62	583	12.62
Adrenal Gland	19	0.20	10	0.21	9	
Other Endocrine (Including Thymus)	23	0.25	10	0.22	13	0.28
Hodgkin's Lymphoma	116	1.25	61	1.26	55	1.21
Non-Hodgkin's Lymphoma	966	11.31	553	13.25	413	9.44
Multiple Myeloma	320	3.69	189	4.60	131	2.93
Leukemia	1,040	11.99	609	14.68	431	9.66
Lymphocytic	425	4.81	254	5.85	171	3.83
Acute Lymphocytic	262	2.79	157	3.28	105	2.28
Chronic Lymphocytic	160	1.98	95	2.52	65	1.53
Other Lymphocytic	3		2		1	
Granulocytic (Myeloid)	526	6.11	301	7.51	225	5.01
Acute Myeloid	422	4.86	239	5.79	183	4.08
Chronic Myeloid	104	1.25	62	1.73	42	0.94
Other Myeloid	0		0		0	
Monocytic	9		7		2	
Acute Monocytic	9		7		2	
Chronic Monocytic	0		0		0	
Other Monocytic	0		0		0	
Other	80	0.96	47	1.14	33	0.77
Other Acute	53	0.64	28	0.65	25	0.77
Other Acute Other Chronic	8	0.04	20 5	0.00	3	0.38
Aleukemic, Subleukemic and NOS		0.22		0.33	5 5	
·	19		14			
Other, III-Defined and Unspecified Sites	6,283	72.60	2,852	69.90	3,431	76.4

^{*} Those of unknown gender are not shown separately, but are included in the total.

^{**} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Table 12. Top Ten Types of Cancer Inpatient Hospital Discharges by County/Region of Residence, Nevada Residents, 1996-2000

			County/Region of Residence							
Rank	Type of Cance	er	Nevada Total	Clark	Washoe	All Other Counties				
1	Lung and Bronchus	Admissions	4,895	3,532	709	651				
		Rate*	56.53	61.39	49.02	44.81				
		95% C.I.	(54.9-58.2)	(59.3-63.5)	(45.4-52.9)	(41.4-48.5)				
2	Colorectal	Admissions	4,034	2,832	661	541				
		Rate*	49.40	52.21	47.87	39.70				
		95% C.I.	(47.8-51.0)	(50.2-54.3)	(44.2-51.8)	(36.4-43.3)				
3	Breast*	Admissions	2,524	1,668	489	365				
		Rate*	56.21	55.91	62.43	50.76				
		95% C.I.	(54.0-58.5)	(53.2-58.7)	(57.0-68.3)	(45.7-56.3)				
4	Prostate*	Admissions	2,450	1,631	383	436				
		Rate*	57.26	57.62	53.28	59.89				
		95% C.I.	(54.9-59.7)	(54.7-60.8)	(47.9-59.4)	(54.2-66.2)				
5	Leukemia	Admissions	1,040	771	132	136				
		Rate*	11.99	13.32	8.69	10.08				
		95% C.I.	(11.3-12.8)	(12.4-14.3)	(7.3-10.4)	(8.4-12.0)				
6	Urinary Bladder	Admissions	989	710	129	149				
		Rate*	12.20	13.39	9.37	10.48				
		95% C.I.	(11.4-13.0)	(12.4-14.5)	(7.8-11.2)	(8.8-12.4)				
7	Non-Hodgkin's Lymphoma	Admissions	966	662	164	140				
		Rate*	11.31	11.65	11.18	10.05				
		95% C.I.	(10.6-12.1)	(10.8-12.6)	(9.5-13.1)	(8.4-11.9)				
8	Corpus Uteri & Uterus NOS	Admissions	853	613	127	113				
		Rate*	18.85	20.32	16.27	15.61				
		95% C.I.	(17.6-20.2)	(18.7-22.0)	(13.6-19.4)	(12.9-18.8)				
9	Kidney and Renal Pelvis	Admissions	842	569	129	144				
		Rate*	9.52	9.66	8.66	9.82				
		95% C.I.	(8.9-10.2)	(8.9-10.5)	(7.2-10.4)	(8.3-11.6)				
10	Thyroid Gland	Admissions	750	546	134					
		Rate*	8.01	8.65	8.01					
		95% C.I.	(7.4-8.6)	(7.9-9.4)	(6.7-9.6)					
	Total	Admissions	32,109	22,597	5,220	4,280				
		Rate*	372.23	393.81	356.30	301.61				
		95% C.I.	(368.1-376.4)	(388.6-399.1)	(346.6-366.3)	(292.5-311.0)				

^{*} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Note: The "---" indicates that this type of cancer was not in the Top Ten for this specific region.

Table 13. Top Ten Types of Cancer Hospital Discharges by Age Group, Nevada Residents, 1996-2000

Donkina	Age Group										
Ranking	0-14	15-24	25-34	35-44	45-54	55-64	65-74	75+	Total		
1	Leukemia	Leukemia	Thyroid Gland	Breast	Breast	Lung and Bronchus	Lung and Bronchus	Colorectal	Lung and Bronchus		
	194	58	158	291	512	1,277	1,837	1,403	4,895		
	45.3%	23.6%	20.5%	14.9%	12.4%	16.8%	18.9%	19.3%	15.2%		
2	Brain and OCNS	Thyroid Gland	Cervix Uteri	Thyroid Gland	Lung and Bronchus	Prostate	Colorectal	Lung and Bronchus	Colorectal		
	77	37	71	208	480	900	1,320	1,167	4,034		
	18.0%	15.0%	9.2%	10.7%	11.7%	11.9%	13.6%	16.0%	12.6%		
3	NHL	Brain and OCNS	Breast	Cervix Uteri	Colorectal	Colorectal	Prostate	Breast	Breast		
	22	23	57	178	356	807	965	480	2,542		
	5.1%	9.3%	7.4%	9.1%	8.6%	10.6%	9.9%	6.6%	7.9%		
4	KRP	NHL	Leukemia	Lung and Bronchus	Prostate	Breast	Breast	Urinary Bladder	Prostate		
	21	20	57	123	220	582	618	379	2,450		
	4.9%	8.1%	7.4%	6.3%	5.3%	7.7%	6.4%	5.2%	7.6%		
5	Liver and IBD	HL	Brain and OCNS	Colorectal	Thyroid Gland	KRP	Urinary Bladder	Prostate	Leukemia		
	16	16	55	117	161	224	352	352	1,040		
	3.7%	6.5%	7.1%	6.0%	3.9%	3.0%	3.6%	4.8%	3.2%		
6	Thyroid Gland	Cervix Uteri	NHL	Brain and OCNS	CU & Uterus NOS	CU & Uterus NOS	CU & Uterus NOS	NHL	Urinary Bladder		
	6	8	54	88	150	195	272	245	989		
	1.4%	3.3%	7.0%	4.5%	3.6%	2.6%	2.8%	3.4%	3.1%		
7	HL	Liver and IBD	Colorectal	Ovary	KRP	Urinary Bladder	NHL	Pancreas	NHL		
	4	5	29	68	131	182	264	214	966		
	0.9%	2.0%	3.8%	3.5%	3.2%	2.4%	2.7%	2.9%	3.0%		
8	Ovary	Ovary	HL	NHL	Ovary	NHL	KRP	Leukemia	CU & Uterus NOS		
	2	5	23	61	131	178	262	202	853		
	0.5%	2.0%	3.0%	3.1%	3.2%	2.3%	2.7%	2.8%	2.7%		
9	Prostate	KRP	Ovary	Leukemia	Cervix Uteri	Leukemia	Pancreas	Stomach	KRP		
	2	3	21	54	129	171	240	175	842		
	0.5%	1.2%	2.7%	2.8%	3.1%	2.3%	2.5%	2.4%	2.6%		
10	Urinary Bladder		CU & Uterus NOS	CU & Uterus NOS	NHL	Pancreas	Leukemia	CU & Uterus NOS	Thyroid Gland		
	2	2	20	49	122	163	213	166	750		
	0.5%	0.8%	2.6%	2.5%	3.0%	2.1%	2.2%	2.3%	2.3%		
Sum	346	177	545	1,237	2,392	4,679	6,343	4,783	19,361		
Percent	80.8%	72.0%	70.8%	63.4%	58.1%	61.7%	65.2%	65.7%	60.3%		
Total	428	246	770	1,952	4,120	7,587	9,726	7,279	32,109		
	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%		

Abbreviations: Brain and OCNS = Brain and Other Central Nervous System, CU & Uterus NOS = Corpus Uteri and Uterus NOS, HL = Hodgkin's Lymphoma, KRP = Kidney and Renal Pelvis, LOCP = Lip, Oral Cavity and Pharynx, Liver and IBD = Liver and Intrahepatic Bile Ducts, NHL = Non-Hodgkin's Lymphoma. Note: Those cases with unknown ages are not shown separately, but are included in the total.

MORTALITY

HIGHLIGHTS

- ➤ Lung and Bronchus Cancer was the leading type of cancer for cancer mortality in Nevada from 1996 to 2000. This type of cancer accounted for 32.0% of all resident Cancer deaths during this period. The second leading type of cancer for mortality was Colorectal Cancer, which accounted for 10.7% of all Cancer deaths.
- ▶ Blacks had the highest ratio of the remaining racial/ethnic groups when compared to the age-adjusted cancer mortality rates for Whites with a comparison ratio of 1.07. This means that for every 100 White cancer deaths Blacks would be expected to have 107 deaths. Native Americans, Asians and Hispanics had comparison ratios of 0.52, 0.42 and 0.39, respectively, for Nevada from 1996 to 2000.
- ➤ Stomach Cancer had the highest age-adjusted mortality rate comparison ratio for Blacks when compared to Whites in Nevada from 1996 to 2000 with a ratio of 2.05. This means that for every 100 White Stomach Cancer deaths, Blacks would be expected to have 205 deaths. The type with the highest comparison ratio for Native Americans and Asians was Liver and Intrahepatic Bile Ducts, with ratios of 1.76 and 2.06, respectively. Hodgkin's Lymphoma had the highest comparison ratio for Hispanics when compared to Whites with a ratio of 1.23.
- Skin Cancer had the lowest age-adjusted mortality rate comparison ratio for Blacks and Asians when compared to Whites in Nevada from 1996 to 2000 with ratios of 0.17 and 0.06. This means that for every 100 White cancer cases Blacks and Asians would be expected to have 17 and six deaths, respectively, from Skin Cancer. The type of cancer with the lowest age-adjusted mortality rate comparison ratio for Native Americans was Urinary Bladder Cancer with a ratio of 0.15 during this period. While the type of cancer with the lowest age-adjusted mortality rate comparison ratio for Hispanics was Larynx Cancer with a ratio of 0.21.
- ➤ Cervix Uteri Cancer had the lowest median age at time of death for Nevada residents from 1996 to 2000 at 53 years. Prostate Cancer had the highest median age at time of death for Nevada residents during this same period at 76 years.
- ➤ Hodgkin's Lymphoma had the lowest median age at time of death for male Nevada residents from 1996 to 2000 at 55 years, while the highest median age was for males in Nevada was for Prostate Cancer at 76 years.
- ➤ Cervix Uteri Cancer had the lowest median age at time of death for Female Nevada Residents during this same period at 53 years, while the highest median age for females in Nevada was for Stomach and Urinary Bladder Cancer at 75 years.

Figure 15. Top Ten Leading Cancers by Percentage of Total Cancer Mortality, Nevada Residents, 1996-2000




Figure 16. Comparison of Age-Adjusted (2000) Mortality Rates of Blacks compared to Whites, Nevada Residents, 1996-2000






Figure 17. Comparison of Age-Adjusted (2000) Mortality Rates of Native Americans compared to Whites, Nevada Residents, 1996-2000



Note: "N/A" indicates that a comparison ratio could not be calculated.

Figure 18. Comparison of Age-Adjusted (2000) Mortality Rates of Asians compared to Whites, Nevada Residents, 1996-2000



Note: "N/A" indicates that a comparison ratio could not be calculated.

Figure 19. Comparison of Age-Adjusted (2000) Mortality Rates of Hispanics compared to Whites, Nevada Residents, 1996-2000




Table 14. Nevada Mortality by Type of Cancer and Gender, Nevada, 1996-2000

	Total*		Male	Α	Female	
Type of Cancer	Number	Rate**	Number	Rate**	Number	Rate**
Total	16,806	207.63	9,173	247.07	7,633	177.55
Lip, Oral Cavity and Pharynx	213	2.52	137	3.23	76	1.79
Lip	2		2		0	
Base of Tongue	3		2		1	
Other & Unspecified Parts of Tongue	51	0.58	32	0.75	19	0.42
Parotid Gland	12	0.13	7		5	
Other & Unspecified Major Salivary glands	2		2		0	
Floor of Mouth	6		4		2	
Gum	2		0		2	
Palate	4		3		1	
Other & Unspecified Parts of Mouth	26	0.32	13	0.29	13	0.32
Nasopharynx	21	0.24	14	0.31	7	
Tonsil	12	0.13	9		3	
Oropharynx	9		6		3	
Pyriform Sinus	1		1		0	
Hypopharynx	5		5		0	
Other & Unspecified Oral (Buccal) Cavity & Pharynx	57	0.68	37	0.87	20	0.48
Digestive System	3,818	47.74	2,241	59.68	1,577	37.49
Esophagus	368	4.26	288	6.88	80	1.84
Stomach	326	4.16	199	5.30	127	3.10
Small Intestine	22	0.26	12	0.32	10	0.23
Colon (excluding Rectum)	1,522	19.62	859	24.08	663	16.03
Cecum	10	0.14	5		5	
Appendix	1		1		0	
Ascending Colon	2		0		2	
Hepatic Flexure	0		0		0	
Transverse Colon	1		0		1	
Splenic Flexure	0		0		0	
Descending Colon	0		0		0	
Sigmoid Colon	10	0.12	6		4	
Large Intestine, NOS	1,498	19.29	847	23.70	651	15.73
Rectum	187	2.24	109	2.75	78	1.78
Rectosigmoid Junction	63	0.82	33	0.88	30	0.75
Anus, Anal Canal and Anorectum	20	0.23	10	0.24	10	0.22
Liver	323	3.92	220	5.65	103	2.42
Intrahepatic Bile Ducts	65	0.81	37	0.98	28	0.66
Gallbladder	40	0.52	13	0.41	27	0.64
Other & Unspecified Biliary Tract	35	0.47	22	0.64	13	0.32
Pancreas	810	9.95	420	11.00	390	9.09
Retroperitoneum	6		3		3	
Peritoneum, Omentum and Mesentery	8		2		6	
Other Digestive Organs	23	0.30	14	0.40	9	
Respiratory System	5,548	66.34	3,150	81.22	2,398	54.48
Nasal Cavity and Middle Ear	0		0		0	
Accessory Sinuses	12	0.16	9		3	
Larynx	136	1.62	98	2.49	38	0.87
Lung and Bronchus	5,385	64.36	3,032	78.09	2,353	53.44
Pleura	8		7		1	
Trachea	2		1		1	
Mediastinum and Other Respiratory Organs	5		3		2	
Bones, Joints and Articular Cartilage	32	0.40	20	0.59	12	0.28
Bones, Joints & Articular Cartilage of Limbs	0		0		0	
Bones, Joints & Articular Cartilage of Other & Unspec Sites	32	0.40	20	0.59	12	0.28
Soft Tissue (Including Heart)	133	1.56	77	1.88	56	1.27
Heart	8		5		3	
Peripheral Nerves & Autonomic Nervous System	3		2		1	
Connective, Subcutaneous & Other Soft Tissues	122	1.44	70	1.72	52	1.19

^{*} Those of unknown gender are not shown separately, but are included in the total.

Note: The "---" is used for rates calculated on numbers less than ten.

^{**}Rates are per 100,000 population and age-adjusted to the 2000 US Standard population.

Table 14. Nevada Mortality by Type of Cancer and Gender, Nevada, 1996-2000 (Continued)

	Total	*	Mal	е	Female	
Type of Cancer	Number	Rate**	Number	Rate**	Number	Rate**
Total	16,806	207.63	9,173	247.07	7,633	177.55
Skin (Excluding Basal And Squamous)	322	3.80	221	5.47	101	2.32
Melanomas Of The Skin	249	2.86	170	4.08	79	1.77
Other Non-Epithelial Skin	73	0.94	51	1.38	22	0.55
Breast	1,139	14.11	11	0.26	1,128	26.10
Female Genital System	661	8.13	0		661	15.24
Cervix Uteri	133	1.55	0		133	3.01
Corpus Uteri	55	0.68	0		55	1.27
Uterus, NOS	76	0.97	0		76	1.79
Ovary	361	4.47	0		361	8.33
Vagina	9		0		9	
Vulva	15	0.22	0		15	0.38
Placenta	1		0		1	
Other Female Genital Organs	11	0.13	0		11	0.25
Male Genital System	901	12.38	901	29.58	0	
Prostate	883	12.18	883	29.19	0	
Testis	15	0.16	15	0.32	0	
Penis	3		3		0	
Other Male Genital Organs	0		0		0	
Urinary System	724	9.15	503	13.90	221	5.30
Urinary Bladder	379	5.01	268	7.97	111	2.74
Kidney	320	3.86	225	5.70	95	2.23
Renal Pelvis	6		2		4	
Ureter	13	0.15	5		8	
Other Urinary Organs	6		3		3	
Eye and Orbit	5		3		2	
Brain and Other Central Nervous System	320	3.73	191	4.66	129	2.92
Brain	318	3.71	190	4.64	128	2.90
Meninges	1		1		0	
Spinal Cord, Cranial Nerves, & Other Parts of CNS	1		0		1	
Endocrine System	54	0.65	31	0.82	23	0.53
Thyroid Gland	29	0.37	16	0.44	13	0.31
Adrenal Gland	14	0.16	8		6	
Other Endocrine (Including Thymus)	11	0.12	7		4	
Hodgkin's Lymphoma	39	0.44	23	0.51	16	0.36
Non-Hodgkin's Lymphoma	587	7.35	340	9.31	247	5.81
Multiple Myeloma	229	2.79	137	3.63	92	2.12
Leukemia	568	7.18	330	8.90	238	5.69
Lymphocytic	145	1.89	77	2.20	68	1.65
Acute Lymphocytic	24	0.26	12	0.26	12	0.26
Chronic Lymphocytic	109	1.45	59	1.73	50	1.23
Other Lymphocytic	12	0.18	6		6	
Granulocytic (Myeloid)	233	2.87	136	3.55	97	2.28
Acute Myeloid	163	1.98	90	2.30	73	1.70
Chronic Myeloid	54	0.69	35	0.93	19	0.47
Other Myeloid	16	0.20	11	0.33	5	
Monocytic	4		2		2	
Acute Monocytic	2		0		2	
Chronic Monocytic	1		1		0	
Other Monocytic	1		1		0	
Other	186	2.37	115	3.09	71	1.72
Other Acute	88	1.07	57	1.46	31	0.71
Other Chronic	8		5		3	
Aleukemic, Subleukemic and NOS	90	1.17	53	1.41	37	0.92
Other, III-Defined and Unspecified Sites	1,513	19.28	857	23.38	656	15.79

^{*} Those of unknown gender are not shown separately, but are included in the total.

Note: The "---" is used for rates calculated on numbers less than ten.

^{**}Rates are per 100,000 population and age-adjusted to the 2000 US Standard population.

Table 15. Top Ten Types of Cancer Mortality by County/Region of Residence, Nevada Residents, 1996-2000

				County/Region	n of Residence	
Rank	Type of Cancer		Nevada Total	Clark	Washoe	All Other Counties
1	Lung and Bronchus	Mortality	5,385	3,692	864	829
		Rate*	64.36	66.89	61.43	58.07
		95% C.I.	(62.6-66.2)	(64.7-69.2)	(57.3-65.8)	(54.1-62.3)
2	Colorectal	Mortality	1,792	1,223	294	275
		Rate*	22.91	23.60	21.96	21.05
		95% C.I.	(21.8-24.0)	(22.2-25.0)	(19.5-24.7)	(18.6-23.8)
3	Breast*	Mortality	1,128	759	218	151
		Rate*	26.10	26.43	28.82	21.75
		95% C.I.	(24.6-27.7)	(24.6-28.4)	(25.1-32.9)	(18.4-25.6)
4	Prostate*	Mortality	883	568	166	149
		Rate*	29.19	28.19	33.45	28.24
		95% C.I.	(27.1-31.5)	(25.6-31.0)	(28.2-39.5)	(23.6-33.7)
5	Pancreas	Mortality	810	556	125	129
		Rate*	9.95	10.34	9.11	9.33
		95% C.I.	(9.3-10.7)	(9.5-11.3)	(7.6-10.9)	(7.8-11.2)
6	Non-Hodgkin's Lymphoma	Mortality	587	395	100	92
		Rate*	7.35	7.60	7.09	6.77
		95% C.I.	(6.8-8.0)	(6.8-8.4)	(5.7-8.7)	(5.4-8.4)
7	Leukemia	Mortality	568	372	100	96
		Rate*	7.18	7.17	7.10	7.51
		95% C.I.	(6.6-7.8)	(6.4-8.0)	(5.8-8.7)	(6.0-9.3)
8	Liver and Intrahepatic Bile Ducts	Mortality	388	278		57
		Rate*	4.73	5.16		4.16
		95% C.I.	(4.3-5.3)	(4.6-5.9)		(3.1-5.5)
9	Urinary Bladder	Mortality	379	260	64	55
		Rate*	5.01	5.33	4.69	4.24
		95% C.I.	(4.5-5.6)	(4.7-6.1)	(3.6-6.1)	(3.2-5.6)
10	Esophagus	Mortality	368		72	
		Rate*	4.26		5.00	
		95% C.I.	(3.8-4.7)		(3.9-6.4)	
	Total	Mortality	16,806	11,300	2,878	2,628
		Rate*	207.63	210.94	208.92	193.56
		95% C.I.	(204.4-210.9)	(206.9-215.1)	(201.2-216.9)	(186.1-201.3)

^{*} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Note: The "---" indicates that this type of cancer was not in the Top Ten for this specific region.

Table 16. Top Ten Types of Cancer Mortality by Age Group, Nevada Residents, 1996-2000

Daniela a					Age Group				
Ranking	0-14	15-24	25-34	35-44	45-54	55-64	65-74	75+	Total
1	Brain and OCNS	Leukemia	Brain and OCNS	Breast	Lung and Bronchus				
	12	15	14	90	430	1,174	2,036	1,659	5,385
	30.0%	35.7%	13.5%	18.8%	28.8%	36.0%	37.1%	28.2%	32.0%
2	Leukemia	Brain and OCNS	NHL	Lung and Bronchus	Breast	Colorectal	Colorectal	Colorectal	Colorectal
	11	3	12	77	174	308	579	736	1,792
	27.5%	7.1%	11.5%	16.1%	11.6%	9.4%	10.5%	12.5%	10.7%
3	Liver and IBD	Liver and IBD	Cervix Uteri	Colorectal	Colorectal	Breast	Prostate	Prostate	Breast
	2	3	10	43	117	241	283	521	1,139
	5.0%	7.1%	9.6%	9.0%	7.8%	7.4%	5.2%	8.8%	6.8%
4	NHL	NHL	Breast	Brain and OCNS	Pancreas	Pancreas	Pancreas	Breast	Prostate
	1	3	8	30	76	169	280	347	883
	2.5%	7.1%	7.7%	6.3%	5.1%	5.2%	5.1%	5.9%	5.3%
5		Breast	Colorectal	Skin	NHL	Esophagus	Breast	Pancreas	Pancreas
		2	8	28	59	119	277	275	810
		4.8%	7.7%	5.8%	3.9%	3.6%	5.0%	4.7%	4.8%
6		HL	Lung and Bronchus	Cervix Uteri	Liver and IBD	NHL	NHL	NHL	NHL
		2	7	24	56	91	167	232	587
		4.8%	6.7%	5.0%	3.7%	2.8%	3.0%	3.9%	3.5%
7		Colorectal	Leukemia	NHL	Ovary	Leukemia	Leukemia	Leukemia	Leukemia
		1	6	22	54	86	155	226	568
		2.4%	5.8%	4.6%	3.6%	2.6%	2.8%	3.8%	3.4%
8		LOCP	Skin	Leukemia	Leukemia	KRP	Liver and IBD	Urinary Bladder	Liver and IBD
		1	5	21	48	81	126	180	388
		2.4%	4.8%	4.4%	3.2%	2.5%	2.3%	3.1%	2.3%
9		Lung and Bronchus	HL	Stomach	Skin	Prostate	Urinary Bladder	Stomach	Urinary Bladder
		1	4	14	41	73	126	142	379
		2.4%	3.8%	2.9%	2.7%	2.2%	2.3%	2.4%	2.3%
10		Pancreas & Skin	Ovary	Esophagus	Cervix Uteri	Brain and OCNS	Esophagus	Liver and IBD	Esophagus
		1 (each)	2	11	38	72	115	120	368
		2.4%	1.9%	2.3%	2.5%	2.2%	2.1%	2.0%	2.2%
Sum	26	31	76	360	1,093	2,414	4,144	4,438	12,299
Percent	65.0%	73.8%	73.1%	75.2%	73.2%	74.0%	75.4%	75.3%	73.2%
Total	40	42	104	479	1,494	3,262	5,493	5,891	16,806
	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Abbreviations: Brain and OCNS = Brain and Other Central Nervous System, CU & Uterus NOS = Corpus Uteri and Uterus NOS, HL = Hodgkin's Lymphoma, KRP = Kidney and Renal Pelvis, LOCP = Lip, Oral Cavity and Pharynx, Liver and IBD = Liver and Intrahepatic Bile Ducts, NHL = Non-Hodgkin's Lymphoma. Note: Those cases with unknown ages are not shown separately, but are included in the total.

Table 17. Median Age at Time of Death by Leading Types of Cancer and Race/Ethnicity, Nevada Residents, 1996-2000

Towns	Race/Ethnicity								
Type of Cancer	White	Black	Native American	Asian	Hispanic	Total			
Lung and Bronchus	70.0	66.0	68.0	68.5	66.0	70.0			
Breast	68.0	62.5	58.0	54.5	59.0	67.0			
Prostate	77.0	75.0		74.0	74.0	76.0			
Colorectal	72.0	65.0	67.5	67.5	69.0	72.0			
Urinary Bladder	74.0	77.0		69.0	70.0	74.0			
Non-Hodgkin's Lymphoma	72.0	66.5		73.0	66.5	72.0			
Kidney and Renal Pelvis	70.0	72.0			65.5	70.0			
Leukemia	72.0	73.0	46.5	63.0	61.0	71.0			
Lip, Oral Cavity and Pharynx	67.0	66.0			73.5	67.0			
Pancreas	70.0	68.0	67.5	67.0	67.0	70.0			
Skin	64.0					64.0			
Corpus Uteri & Uterus NOS	70.0	67.0		68.0	67.0	70.0			
Ovary	69.0	66.0		59.0	72.0	69.0			
Thyroid Gland	71.0					71.0			
Stomach Brain and Other Central	73.0	73.0		63.0	62.0	73.0			
Nervous System	64.0	66.0		54.5	59.0	64.0			
Cervix Uteri Liver and Intrahepatic Bile	54.0	53.0		48.0	52.0	53.0			
Ducts	71.0	55.0	70.0	57.0	61.0	69.0			
Esophagus	68.0	63.0		61.0	67.5	67.0			
Larynx	68.5	62.5				68.0			
Multiple Myeloma	71.5	67.0		60.0	69.5	71.0			
Hodgkin's Lymphoma	62.0					61.0			
All Other Sites	71.0	65.0	73.0	65.0	63.0	70.0			
Total	71.0	66.0	68.0	65.0	65.0	70.0			

Note: Those of other/unknown race/ethnicity are not shown separately, but are included in the total. Those deaths of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE

HIGHLIGHTS

- ➤ Thyroid Gland Cancer had the highest one-year survival rate of all types of cancer in Nevada from 1996 to 2000 with a rate of 96.1%. This was followed by Prostate, Breast, Uterine, and Skin Cancers, which had one-year survival rates of 94.4%, 94.2%, 92.0%, and 89.0%, respectively.
- ➤ Pancreatic Cancer had the lowest one-year survival rate of all types of cancer in Nevada from 1996 to 2000 with a rate of 21.9%. This was followed by Liver and Intrahepatic Bile Ducts, Stomach, Esophagus, and Lung and Bronchus Cancer, which had One-Year Survival rates of 23.8%, 31.9%, 35.8%, and 37.0%, respectively.
- The five types of cancer with the highest five-year survival rates in Nevada from 1996 to 2000 were Thyroid Gland (91.9%), Breast (72.8%), Hodgkin's Lymphoma (72.2%), Prostate (67.1%), and Cervix Uteri (62.2%) Cancers.
- ➤ The five types of cancer with the lowest five-year survival rates in Nevada from 1996 to 2000 were Pancreatic (3.3%), Liver and Intrahepatic Bile Ducts (4.9%), Esophagus (5.9%), Stomach (6.7%), and Lung and Bronchus (8.4%) Cancers.

Figure 20. Ten Highest One-Year Survival Rates by Type of Cancer, Nevada Residents, 1996-2000




Figure 21. Ten Lowest One-Year Survival Rates by Type of Cancer, Nevada Residents, 1996-2000




Figure 22. Ten Highest Five-Year Survival Rates by Type of Cancer, Nevada Residents, 1996-2000




Figure 23. Ten Lowest Five-Year Survival Rates by Type of Cancer, Nevada Residents, 1996-2000




Table 18. One-Year, Five-Year and Median Survival Rates by Type of Cancer, Nevada Residents, 1996-2000

Type of Cancer	1-Year	5-Year	Median Survival (Years)	
Lung and Bronchus	37.0%	8.4%	0.79	
Colorectal	72.6%	33.3%	2.64	
Breast	94.2%	72.8%	>5 years	
Prostate	94.4%	67.1%	>5 years	
Pancreas	21.9%	3.3%	0.64	
Non-Hodgkin's Lymphoma	68.5%	35.0%	2.78	
Leukemia	55.9%	30.5%	1.60	
Liver and Intrahepatic Bile Ducts	23.8%	4.9%	0.66	
Urinary Bladder	83.8%	60.4%	>5 years	
Esophagus	35.8%	5.9%	0.78	
Ovary	72.9%	32.8%	2.80	
Stomach	31.9%	6.7%	0.73	
Kidney and Renal Pelvis	71.4%	51.3%	>5 years	
Brain and Other Central Nervous System	47.2%	33.9%	0.95	
Skin	89.0%	40.9%	3.90	
Multiple Myeloma	64.7%	30.5%	1.89	
Lip, Oral Cavity and Pharynx	76.5%	31.0%	2.72	
Larynx	76.6%	43.3%	3.48	
Cervix Uteri	83.9%	62.2%	>5 years	
Corpus Uteri & Uterus NOS	92.0%	57.7%	>5 years	
Hodgkin's Lymphoma	84.8%	72.2%	>5 years	
Thyroid Gland	96.1%	91.9%	>5 years	
All Other Sites	59.4%	31.8%	1.78	
Total	66.6%	36.8%	2.51	

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 19. One- and Five-Year Survival Rates by Type of Cancer and Gender, Nevada Residents, 1996-2000 (Revised)

			Ge	nder		
Type of Cancer	Tot	tal	Ma	ale	Fen	nale
	1-Year	5-Year	1-Year	5-Year	1-Year	5-Year
Lung and Bronchus	37.0%	8.4%	34.4%	8.2%	40.3%	8.6%
Colorectal	72.6%	33.3%	71.6%	36.9%	73.6%	28.7%
Breast	94.2%	72.8%			94.2%	72.8%
Prostate	94.4%	67.1%	94.4%	67.1%		
Pancreas	21.9%	3.3%	21.7%	5.7%	22.1%	
Non-Hodgkin's Lymphoma	68.5%	35.0%	68.8%	37.9%	68.1%	30.7%
Leukemia	55.9%	30.5%	55.2%	33.3%	57.1%	27.3%
Liver and Intrahepatic Bile Ducts	23.8%	4.9%	22.1%	6.0%	27.3%	4.8%
Urinary Bladder	83.8%	60.4%	85.0%	60.4%	80.0%	59.2%
Esophagus	35.8%	5.9%	35.3%	11.5%	37.5%	0.0%
Ovary	72.9%	32.8%			72.9%	32.8%
Stomach	31.9%	6.7%	32.4%	5.9%	31.0%	10.4%
Kidney and Renal Pelvis	71.4%	51.3%	70.3%	50.0%	73.5%	55.0%
Brain and Other Central Nervous System	47.2%	33.9%	44.0%	26.9%	51.3%	42.3%
Skin	89.0%	40.9%	86.6%	46.0%	92.8%	32.5%
Multiple Myeloma	64.7%	30.5%	59.6%	25.6%	73.6%	38.3%
Lip, Oral Cavity and Pharynx	76.5%	31.0%	76.1%	33.6%	77.2%	28.5%
Larynx	76.6%	43.3%	76.8%	35.7%	75.9%	61.5%
Cervix Uteri	83.9%	62.2%			83.9%	62.2%
Corpus Uteri & Uterus NOS	92.0%	57.7%			92.0%	57.7%
Hodgkin's Lymphoma	84.8%	72.2%	81.0%	70.3%	89.7%	74.4%
Thyroid Gland	96.1%	91.9%	88.7%	82.3%	98.3%	94.8%
All Other Sites	59.4%	31.8%	63.3%	35.9%	52.8%	25.4%
Total	66.6%	36.8%	62.8%	33.6%	70.6%	40.1%

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 20. One- and Five-Year Survival Rates by Type of Cancer and Race/Ethnicity, Nevada Residents, 1996-2000 (Revised)

		Race/Ethnicity							
Type of Cance	er	Total	White	Black	Native American	Asian	Hispanic		
Lung and Bronchus	1-Year	37.0%	36.6%	38.5%		44.9%	42.9%		
	5-Year	8.4%	8.4%	3.5%		10.6%			
Colorectal	1-Year	72.6%	72.1%	75.6%		76.2%	75.0%		
	5-Year	33.3%	32.5%	39.6%			34.5%		
Breast	1-Year	94.2%	94.4%	86.5%		95.7%	96.7%		
	5-Year	72.8%	73.9%	47.5%		87.8%	62.8%		
Prostate	1-Year	94.4%	94.0%	96.6%			100.0%		
	5-Year	67.1%	65.7%	75.2%			91.3%		
Pancreas	1-Year	21.9%	21.9%	20.9%					
	5-Year	3.3%	2.7%						
Non-Hodgkin's Lymphoma	1-Year	68.5%	68.3%						
	5-Year	35.0%	34.7%						
Leukemia	1-Year	55.9%	53.5%				67.3%		
	5-Year	30.5%	28.3%				38.1%		
Liver and Intrahepatic Bile	1-Year	23.8%	22.8%						
Ducts	5-Year	4.9%	8.2%						
Urinary Bladder	1-Year	83.8%	83.9%						
,	5-Year	60.4%	60.9%						
Esophagus	1-Year	35.8%	34.5%						
3.1	5-Year	5.9%	6.3%						
Ovary	1-Year	72.9%	72.5%						
5 · a.· ,	5-Year	32.8%	31.8%						
Stomach	1-Year	31.9%	31.9%						
	5-Year	6.7%	4.9%						
Kidney and Renal Pelvis	1-Year	71.4%	70.4%						
radioy and radian conte	5-Year	51.3%	49.0%						
Brain and Other Central	1-Year	47.2%	45.8%						
Nervous System	5-Year	33.9%	31.2%						
Skin	1-Year	89.0%	88.9%						
OKIII	5-Year	40.9%	40.7%						
Multiple Myeloma	1-Year	64.7%	64.5%						
Walapie Wycioma	5-Year	30.5%	27.4%						
Lip, Oral Cavity and Pharynx		76.5%	76.4%						
Lip, Grai Gavity and Friarynx	5-Year	31.0%	31.3%						
Larynx	1-Year	76.6%	77.1%						
Lai yiix	5-Year	43.3%	42.5%						
Cervix Uteri	1-Year	83.9%	81.3%						
Cervix Oteri	5-Year	62.2%	60.7%						
Corpus Uteri & Uterus NOS	1-Year	92.0%	92.3%						
Corpus Oteri & Oterus NOS	5-Year	57.7%	58.7%						
Hodgkin's Lymphoma	1-Year	84.8%	85.7%						
Hougkin's Lymphoma	5-Year	72.2%	70.7%						
Thyroid Gland	1-Year	96.1%	96.0%						
Thyrold Glarid	5-Year	96.1%	96.0%						
All Other Sites			59.5%	49.1%			6E 00/		
All Other Sites	1-Year	59.4% 31.8%	59.5% 31.3%	49.1% 22.6%			65.8% 37.5%		
Total	5-Year				E 4 40/	67 30/	37.5%		
Total	1-Year 5-Year	66.6% 36.8%	66.4% 36.5%	63.5%	54.1% 41.8%	67.2% 48.9%	72.1% 43.0%		
	J- I Cal	30.0%	30.5%	28.4%	41.076	40.370	43.0%		

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

ALL CANCERS

ALL CANCERS

HIGHLIGHTS

- ➤ The ratio of the cancer age-adjusted incidence rate, 449.2, to the age-adjusted mortality rate, 207.6 (per 100,000 2000 US Standard population), was 2.16 during the 1996 to 2000 period, which means that for every 2.16 cancer cases there was one death due to Cancer in Nevada during this period.
- Nevadan females had a higher ratio than males when the cancer incidence and cancer mortality age-adjusted rates were compared. For every female death due to Cancer there was 2.35 female cases while there were 2.03 male cases for every male Cancer death in Nevada from 1996 to 2000.
- The median age at diagnosis of cancer was 66 years of age for Nevada residents from 1996 to 2000. The median age at time of death due to Cancer was 70 years. The median age at diagnosis for females was lower than the age for males, 65 and 67 years, respectively, while the median age at time of death was 71 years for females and 70 years for males.

INCIDENCE

- Nevada's lower cancer incidence rate (449.2) was statistically significant when compared to the 1995-1999 National rate of 483.4 (per 100,000 2000 US Standard population) from 1996 to 2000.
- ➤ There were 38,261 Resident Cancer cases reported in Nevada from 1996 to 2000. Statistical significance tests show that Washoe County had the highest age-adjusted incidence rate of cancer once regional comparisons were made, with a rate of 496.4. Clark County and All Other Counties, as a region, followed with rates of 441.1 and 433.6 (per 100,000 population 2000 US Standard population), respectively. Washoe County's rate showed slight statistical significance over the 1995-1999 National rate of 483.4, while Clark County and All Other Counties were lower than the National rate.
- Whites, as a racial/ethnic group, accounted for 88.7% of all reported cancer cases in Nevada during the 1996 to 2000 period. Their statistically significant higher age-adjusted incidence rate of 483.5 was 153.8%, 140.7%, 94.1%, and 14.8% greater than the rates for Native Americans (190.5), Hispanics (200.9), Asians (190.5) and Blacks (421.3), respectively, during this period.
- Males had a statistically significant higher age-adjusted cancer incidence rate, 497.4 (490.0-504.9) over the female rate of 414.0 (408.0-420.1) during the 1996 to 2000 period. However, both had statistically significant lower rates when compared to their national counterparts who had rates of 549.8 (548.0-551.5) and 443.1 (441.7-444.5), respectively.

INPATIENT HOSPITAL DISCHARGES

- ➤ There were 32,109 hospital inpatient discharges for a primary diagnosis of Cancer to Nevada Residents from 1996 to 2000. Clark County had the highest cancer age-adjusted inpatient discharge rate, 393.8 (388.6-399.1), once regional comparisons were made and showed statistical significance over the rates for Nevada overall, Washoe County, and All Other Counties who had rates of 372.2 (368.1-376.4), 356.3 (346.6-366.3), 301.6 (292.5-311.0) (per 100,000 2000 US Standard population), respectively, during this period.
- Total billed charges for hospital inpatient discharges due to a primary diagnosis for Cancer in Nevada totaled over 922.3 million dollars from 1996 to 2000. Nevadans in the 1-4 year age group had the highest median total billed amount at \$34,057 during this period. The overall average billed charge per day for a hospital inpatient discharge due to Cancer was approximately \$4,080 in Nevada from 1996 to 2000.

MORTALITY

- ➤ There were 16,806 resident deaths due to Cancer in Nevada from 1996 to 2000, which was the second leading cause of death during this period. Males had a 39.2% higher statistically significant age-adjusted mortality rate, 247.1 (241.6-252.7) than the female rate of 177.5 (173.5-181.6), per 100,000 2000 US Standard population, in Nevada during this period.
- Racial/ethnic comparisons showed that Blacks and Whites, as racial/ethnic groups, had the highest statistically significant cancer age-adjusted mortality rates of 233.3 (216.8-251.0) and 219.0 (215.4-222.7), respectively, of all racial/ethnic groups. They were followed by Native Americans, Asians and Hispanics who had age-adjusted mortality rates of 125.1 (100.6-154.7), 122.6 (106.3-141.9) and 98.6 (88.8-109.5), respectively from 1996 to 2000.


SURVIVAL RATE

- The one-year survival rate for Cancer in Nevada was 66.6% during the 1996 to 2000 period, while the five-year survival rate was 36.8% during this same time. The median survival rate in Nevada was 2.51 years.
- Females in Nevada had a higher one-year survival rate (70.6%) than males (62.8%) for all cancers during the 1996 to 2000 period. This trend was similar for the five-year survival rate and the median survival time with females and males at 40.1% and 33.6%, respectively, and 3.12 and 1.94 years, respectively.
- ➤ Hispanics, as a racial/ethnic group, had the highest One-Year Survival Rate for all cancers (72.1%) in the State, and were followed by Asians, Whites, Blacks, and Native Americans, with rates of 67.2%, 66.4%, 63.5%, and 54.1%, respectively, during the 1996 to 2000 period.

- ➤ While Native Americans had the lowest one-year survival rate for all cancers in Nevada at 54.1%, Blacks had the lowest five-year survival rate at 28.1% during the 1996-2000 period.
- The five-year survival rate for those diagnosed at the in situ stage was 94.2% for Nevada from 1996 to 2000. The rate for those at the localized stage was 69.6%, while those recorded at the regional, distant and unstaged stages had rates of 32.8%, 8.4% and 14.6%, respectively.
- ➤ While the Median Survival time for those diagnosed at the in situ or localized stages was over five years for all types of cancer, those diagnosed at the regional, distant and unstaged levels had median survival times of 2.59, 0.77 and 0.90 years, respectively, for Nevada during the 1996 to 2000 period.

INCIDENCE

Figure 24. Age-Adjusted (2000) Incidence Rates for All Cancers, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 25. All Cancers Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 26. All Cancers Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1996-2000




Table 21. All Cancers Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

	County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)			
Total									
Cases	38,261	24,899	7,248	6,099	15	815,121			
Rate*	449.2	441.1	496.4	433.6		483.4			
95% C.I.	(444.6-453.9)	(435.4-446.8)	(484.9-508.2)	(422.6-444.8)		(482.4-484.5)			
Gender									
Male	19,907	12,708	3,819	3,369	11	401,657			
Rate*	497.4	480.5	566.5	496.6		549.8			
95% C.I.	(490.0-504.9)	(471.5-489.8)	(547.7-586.0)	(479.3-514.6)		(548.0-551.5)			
Female	18,347	12,190	3,425	2,728	4	413,464			
Rate*	414.0	414.4	444.4	380.6		443.1			
95% C.I.	(408.0-420.1)	(407.0-421.9)	(429.6-459.6)	(366.3-395.2)		(441.7-444.5)			
Other/Unknown	7	1	4	2	0	0			
Race/Ethnicity									
White	33,946	21,370	6,737	5,827	12	670,866			
Rate*	483.5	479.0	529.3	455.1		488.0			
95% C.I.	(478.3-488.8)	(472.4-485.6)	(516.6-542.3)	(443.3-467.2)		(486.8-489.1)			
Black	1,723	1,568	116	39	0	75,145			
Rate*	421.3	417.7	484.1	489.6		529.9			
95% C.I.	(400.2-443.6)	(395.6-441.2)	(397.1-587.0)	(345.3-680.9)		(526.0-533.8)			
Native American	165	45	50	70	0	2,084			
Rate*	190.5	135.4	280.6	193.7		182.6			
95% C.I.	(160.8-225.1)	(95.7-191.0)	(201.2-387.3)	(149.9-247.9)		(174.4-174.4)			
Asian	837	663	140	32	2	56,521			
Rate*	249.1	247.3	253.4	249.4		359.3			
95% C.I.	(228.5-272.3)	(224.0-274.1)	(206.1-317.3)	(157.0-398.9)		(356.3-362.3)			
Hispanic	1,346	1,022	198	125	1	58,332			
Rate*	200.9	199.6	210.9	198.5		322.5			
95% C.I.	(188.2-214.6)	(185.0-215.5)	(177.4-252.1)	(160.2-245.1)		(319.7-325.3)			
Other/Unknown	244	231	7	6	0	10,505			

^{*} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing rates for racial/ethnic groups to the National (SEER) rates. See Technical Notes for more information.

Table 22. All Cancers Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

		County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)				
Total										
Cases	38,261	24,899	7,248	6,099	15	815,121				
Rate*	411.3	395.5	442.6	445.2		440.2				
95% C.I.	(407.2-415.4)	(390.6-400.4)	(432.4-452.8)	(434.0-456.3)		(439.2-441.1)				
Age Group										
<1	30	19	5	6	0	619				
Rate*	21.5	19.4				22.3				
95% C.I.	(13.8-29.2)	(10.7-28.1)				(20.6-24.1)				
1-4	89	62	12	15	0	2,248				
Rate*	16.3	16.3	12.7	20.5		20.2				
95% C.I.	(12.9-19.6)	(12.3-20.4)	(5.5-20.0)	(10.1-30.9)		(19.3-21.0)				
5-14	142	94	24	24	0	3,183				
Rate*	10.7	10.6	10.6	11.5		11.9				
95% C.I.	(9.0-12.5)	(8.4-12.7)	(6.4-14.8)	(6.9-16.1)		(11.5-12.3)				
15-24	254	162	45	45	2	6,785				
Rate*	19.9	18.6	19.8	24.8		26.3				
95% C.I.	(17.4-22.3)	(15.7-21.5)	(14.0-25.6)	(17.6-32.1)		(25.6-26.9)				
25-34	817	574	153	89	1	21,091				
Rate*	57.1	56.3	60.6	56.0		72.1				
95% C.I.	(53.2-61.0)	(51.7-60.9)	(51.0-70.2)	(44.4-67.6)		(71.1-73.0)				
35-44	2,103	1,371	459	273	0	53,676				
Rate*	140.8	138.4	165.3	120.9		171.8				
95% C.I.	(134.8-146.8)	(131.1-145.8)	(150.2-180.4)	(106.6-135.2)		(170.3-173.2)				
45-54	4,831	3,149	970	710	2	107,078				
Rate*	399.6	397.5	431.9	369.2		467.9				
95% C.I.	(388.3-410.8)	(383.6-411.4)	(404.8-459.1)	(342.0-396.3)		(465.1-470.7)				
55-64	8,567	5,696	1,527	1,342	2	155,741				
Rate*	995.2	979.6	1,079.5	972.8		1,112.3				
95% C.I.	(974.1-1,016.3)	(954.2-1,005.1)	(1,025.3-1,133.6)	(920.8-1,024.9)		(1,106.8-1,117.9)				
65-74	11,877	7,640	2,236	1,997	4	228,518				
Rate*	1,915.9	1,842.9	2,217.0	1,911.2		1,980.7				
95% C.I.	(1,881.4-1,950.4)	(1,801.6-1,884.2)	(2,125.2-2,308.9)	(1,827.3-1,995.0)		(1,972.6-1,988.9)				
75-84	7,723	4,979	1,458	1,282	4	179,105				
Rate*	2,356.3	2,302.4	2,649.5	2,269.9		2,464.1				
95% C.I.	(2,303.7-2,408.8)	(2,238.4-2,366.4)	(2,513.5-2,785.5)	(2,145.6-2,394.1)		(2,452.7-2,475.5)				
85+	1,822	1,147	359	316	0	57,077				
Rate*	2,586.2	2,677.4	2,490.3	2,395.0		2,301.4				
95% C.I.	(2,467.5-2,705.0)	(2,522.4-2,832.3)	(2,232.7-2,747.9)	(2,131.0-2,659.1)		(2,282.5-2,320.2)				
Unknown	6	6	0	0	0	0				

^{*}Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 23. All Cancers Cases by County of Residence at Diagnosis, Nevada Residents, 1996-2000

County of	1996-2000 Incidence						
Residence	Cases	Rat	te*	Age-Adjus	ted Rate**		
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	1,613	658.1	(625.9-690.2)	571.9	(544.1-600.9)		
Churchill	661	560.3	(517.5-603.0)	589.2	(544.8-636.6)		
Clark	24,899	395.5	(390.6-400.4)	441.1	(435.4-446.8)		
Douglas	862	431.3	(402.5-460.0)	373.1	(347.6-400.6)		
Elko	372	162.3	(145.8-178.8)	299.7	(267.0-335.8)		
Esmeralda	27	505.0	(314.5-695.5)	424.1	(270.4-672.3)		
Eureka	23	271.5	(160.5-382.5)	274.9	(172.5-443.3)		
Humboldt	222	264.4	(229.7-299.2)	358.6	(310.6-413.3)		
Lander	81	252.7	(197.7-307.7)	372.9	(291.8-472.1)		
Lincoln	81	397.5	(310.9-484.1)	322.1	(254.8-409.6)		
Lyon	955	590.2	(552.8-627.7)	518.0	(485.0-553.1)		
Mineral	167	606.7	(514.7-698.7)	469.7	(399.5-551.8)		
Nye	802	540.3	(502.9-577.7)	400.2	(371.1-431.9)		
Pershing	76	266.5	(206.6-326.5)	309.1	(242.9-389.7)		
Storey	38	212.8	(145.1-280.4)	182.1	(123.2-281.6)		
Washoe	7,248	442.6	(432.4-452.8)	496.6	(485.1-508.4)		
White Pine	119	272.8	(223.8-321.9)	240.5	(199.0-289.3)		
Unknown	15						
Total	38,261	411.3	(407.2-415.4)	449.2	(444.6-453.9)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 24. All Cancers Cases by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

			Gen	ider	
Race/Ethnicity		Male	Female	Other/ Unknown	Total
White	Incidence	17,756	16,183	7	33,946
	Rate*	529.2	450.5		483.5
	95% C.I.	(520.9-537.5)	(443.6-457.6)		(478.3-488.8)
Black	Incidence	910	813	0	1,723
	Rate*	494.5	367.1		421.3
	95% C.I.	(457.9-534.6)	(341.1-394.8)		(400.2-443.6)
Native	Incidence	77	88	0	165
American	Rate*	207.8	182.5		190.5
	95% C.I.	(157.4-274.8)	(144.9-227.6)		(160.8-225.1)
Asian	Incidence	357	480	0	837
	Rate*	270.6	232.2		249.1
	95% C.I.	(236.7-310.9)	(207.3-261.8)		(228.5-272.3)
Hispanic	Incidence	706	640	0	1,346
	Rate*	239.6	172.6		200.9
	95% C.I.	(217.6-264.5)	(157.4-189.4)		(188.2-214.6)
Other/Unkr	nown	101	143	0	244
Total	Incidence	19,907	18,347	7	38,261
	Rate*	497.4	414.0		449.2
	95% C.I.	(490.0-504.9)	(408.0-420.1)		(444.6-453.9)

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and age-adjusted to the 2000 US Standard population.

Table 25. All Cancers Cases by Age Group and Gender, Nevada Residents, 1996-2000

Section	Age		Gen	nder	
Rate* 23.8 19.0	_	Male	Female		Total
95% C.I. (12.5-35.2) (8.7-29.4) (13.8-29.2) 1-4 47 42 0 89 Rate* 16.8 15.7 16.3 95% C.I. (12.0-21.6) (10.9-20.4) (12.9-19.6) 5-14 78 64 0 142 Rate* 11.4 10.0 10.7 95% C.I. (8.9-14.0) (7.5-12.4) (9.0-12.5) 15-24 123 131 0 254 Rate* 18.5 21.3 19.9 95% C.I. (15.3-21.8) (17.6-24.9) (17.4-22.3) 25-34 311 505 1 817 8tate* 41.8 73.5 57.1 95% C.I. (37.1-46.4) (67.1-79.9) (134.8-146.8) 45-54 2.054 2.775 2 4.831 Rate* 335.4 465.1 39.6	<1	17	13	0	30
1-4 47 42 0 89 Rate* 16.8 15.7 11.6.3 95% C.I. (12.0-21.6) (10.9-20.4) (12.9-19.6) 5-14 78 64 0 142 Rate* 11.4 10.0 10.7 95% C.I. (8.9-14.0) (7.5-12.4) (9.0-12.5) 15-24 123 131 0 254 Rate* 18.5 21.3 19.9 95% C.I. (15.3-21.8) (17.6-24.9) (17.4-22.3) 25-34 311 505 1 817 Rate* 41.8 73.5 57.1 95% C.I. (37.1-46.4) (67.1-79.9) (53.2-61.0) 35-44 725 1,378 0 2,103 Rate* 93.9 190.9 (134.8-146.8) 45-54 2,054 2,775 2 2 4,831	Rate*	23.8	19.0		21.5
Rate* 16.8 15.7 — 16.3 95% C.I. (12.0-21.6) (10.9-20.4) — (12.9-19.6) 5-14 78 64 0 142 Rate* 11.4 10.0 — 10.7 95% C.I. (8.9-14.0) (7.5-12.4) — (9.0-12.5) 15-24 123 131 0 254 Rate* 18.5 21.3 — 19.9 95% C.I. (15.3-21.8) (17.6-24.9) — (17.4-22.3) 25-34 311 505 1 817 Rate* 41.8 73.5 — 57.1 95% C.I. (37.1-46.4) (67.1-79.9) — (53.2-61.0) 35-44 725 1,378 0 2,103 Rate* 93.9 190.9 — 140.8 95% C.I. (87.1-100.8) (180.8-200.9) — (134.8-146.8) 45-54 2,054 2,775 2 4,831 Ra	95% C.I.	(12.5-35.2)	(8.7-29.4)		(13.8-29.2)
95% C.I. (12.0-21.6) (10.9-20.4) — (12.9-19.6) 5-14 78 64 0 142 Rate* 11.4 10.0 — 10.7 95% C.I. (8.9-14.0) (7.5-12.4) — (9.0-12.5) 15-24 123 131 0 254 Rate* 18.5 21.3 — 19.9 95% C.I. (15.3-21.8) (17.6-24.9) — (17.4-22.3) 25-34 311 505 1 817 Rate* 41.8 73.5 — 57.1 95% C.I. (37.1-46.4) (67.1-79.9) — (53.2-61.0) 35-44 725 1,378 0 2,103 Rate* 93.9 190.9 — (134.8-146.8) 45-54 2,054 2,775 2 4,831 Rate* 335.4 465.1 — 399.6 95% C.I. (320.9-349.9) (447.8-482.4) — (388.3-410.8)	1-4	47	42	0	89
5-14 78 64 0 142 Rate* 11.4 10.0 10.7 95% C.I. (8.9-14.0) (7.5-12.4) (9.0-12.5) 15-24 123 131 0 254 Rate* 18.5 21.3 19.9 95% C.I. (15.3-21.8) (17.6-24.9) (17.4-22.3) 25-34 311 505 1 817 Rate* 41.8 73.5 57.1 95% C.I. (37.1-46.4) (67.1-79.9) (53.2-61.0) 35-44 725 1,378 0 2,103 Rate* 93.9 190.9 140.8 95% C.I. (87.1-100.8) (180.8-200.9) (134.8-146.8) 45-54 2,054 2,775 2 4,831 8ate* 3,35.4 465.1 (388.3-410.8) 55-64 4,750 3,816 1 8,567	Rate*	16.8	15.7		16.3
Rate* 11.4 10.0	95% C.I.	(12.0-21.6)	(10.9-20.4)		(12.9-19.6)
95% C.I. (8.9-14.0) (7.5-12.4) (9.0-12.5) 15-24 123 131 0 254 Rate* 18.5 21.3 19.9 95% C.I. (15.3-21.8) (17.6-24.9) (17.4-22.3) 25-34 311 505 1 817 Rate* 41.8 73.5 57.1 95% C.I. (37.1-46.4) (67.1-79.9) (53.2-61.0) 35-44 725 1,378 0 2,103 Rate* 93.9 190.9 (134.8-146.8) 95% C.I. (87.1-100.8) (180.8-200.9) 140.8 45-54 2,054 2,775 2 4,831 Rate* 335.4 465.1 (388.3-410.8) 55-64 4,750 3,816 1 8,567 Rate* 1,107.9 883.1 (974.1-1,016.3) 65-74 6,869 5,006 2 11,877	5-14	78	64	0	142
15-24 123 131 0 254 Rate* 18.5 21.3 19.9 95% C.I. (15.3-21.8) (17.6-24.9) (17.4-22.3) 25-34 311 505 1 817 Rate* 41.8 73.5 57.1 95% C.I. (37.1-46.4) (67.1-79.9) (53.2-61.0) 35-44 725 1,378 0 2,103 Rate* 93.9 190.9 (134.8-146.8) 95% C.I. (87.1-100.8) (180.8-200.9) (134.8-146.8) 45-54 2,054 2,775 2 4,831 Rate* 335.4 465.1 (388.3-410.8) 55-64 4,750 3,816 1 8,567 Rate* 1,107.9 883.1 (974.1-1,016.3) 65-74 6,869 5,006 2 11,877 Rate* 2,246.7 1,593.4 (1,881.4-1,950.4)	Rate*	11.4	10.0		10.7
Rate* 18.5 21.3 19.9 95% C.I. (15.3-21.8) (17.6-24.9) (17.4-22.3) 25-34 311 505 1 817 Rate* 41.8 73.5 57.1 95% C.I. (37.1-46.4) (67.1-79.9) (53.2-61.0) 35-44 725 1,378 0 2,103 Rate* 93.9 190.9 (134.8-146.8) 95% C.I. (87.1-100.8) (180.8-200.9) (134.8-146.8) 45-54 2,054 2,775 2 4,831 Rate* 335.4 465.1 399.6 95% C.I. (320.9-349.9) (447.8-482.4) (388.3-410.8) 55-64 4,750 3,816 1 8,567 Rate* 1,107.9 883.1 995.2 95% C.I. (1,076.4-1,139.4) (855.1-911.1) (974.1-1,016.3) 65-74 6,869 5,006	95% C.I.	(8.9-14.0)	(7.5-12.4)		(9.0-12.5)
95% C.I. (15.3-21.8) (17.6-24.9) (17.4-22.3) 25-34 311 505 1 817 Rate* 41.8 73.5 57.1 95% C.I. (37.1-46.4) (67.1-79.9) (53.2-61.0) 35-44 725 1,378 0 2,103 Rate* 93.9 190.9 140.8 95% C.I. (87.1-100.8) (180.8-200.9) (134.8-146.8) 45-54 2,054 2,775 2 4,831 Rate* 335.4 465.1 399.6 95% C.I. (320.9-349.9) (447.8-482.4) (388.3-410.8) 55-64 4,750 3,816 1 8,567 Rate* 1,107.9 883.1 995.2 95% C.I. (1,076.4-1,139.4) (855.1-911.1) (974.1-1,016.3) 65-74 6,869 5,006 2 11,877 Rate* 2,246.7 1,593.4	15-24	123	131	0	254
25-34 311 505 1 817 Rate* 41.8 73.5 57.1 95% C.I. (37.1-46.4) (67.1-79.9) (53.2-61.0) 35-44 725 1,378 0 2,103 Rate* 93.9 190.9 140.8 95% C.I. (87.1-100.8) (180.8-200.9) (134.8-146.8) 45-54 2,054 2,775 2 4,831 Rate* 335.4 465.1 399.6 95% C.I. (320.9-349.9) (447.8-482.4) (388.3-410.8) 55-64 4,750 3,816 1 8,567 Rate* 1,107.9 883.1 (974.1-1,016.3) 65-74 6,869 5,006 2 11,877 Rate* 2,246.7 1,593.4 1,915.9 95% C.I. (2,193.6-2,299.8) (1,549.2-1,637.5) (1,881.4-1,950.4) 75-84 4,121 3,602	Rate*	18.5	21.3		19.9
Rate* 41.8 73.5 57.1 95% C.I. (37.1-46.4) (67.1-79.9) (53.2-61.0) 35-44 725 1,378 0 2,103 Rate* 93.9 190.9 140.8 95% C.I. (87.1-100.8) (180.8-200.9) (134.8-146.8) 45-54 2,054 2,775 2 4,831 Rate* 335.4 465.1 (388.3-410.8) 55-64 (320.9-349.9) (447.8-482.4) (388.3-410.8) 55-64 4,750 3,816 1 8,567 Rate* 1,107.9 883.1 995.2 95% C.I. (1,076.4-1,139.4) (855.1-911.1) (974.1-1,016.3) 65-74 6,869 5,006 2 11,877 Rate* 2,246.7 1,593.4 (1,881.4-1,950.4) 75-84 4,121 3,602 0 7,723 Rate* 2,794.4 1,997.9	95% C.I.	(15.3-21.8)	(17.6-24.9)		(17.4-22.3)
95% C.I. (37.1-46.4) (67.1-79.9) (53.2-61.0) 35-44 725 1,378 0 2,103 Rate* 93.9 190.9 140.8 95% C.I. (87.1-100.8) (180.8-200.9) (134.8-146.8) 45-54 2,054 2,775 2 4,831 Rate* 335.4 465.1 399.6 95% C.I. (320.9-349.9) (447.8-482.4) (388.3-410.8) 55-64 4,750 3,816 1 8,567 Rate* 1,107.9 883.1 995.2 95% C.I. (1,076.4-1,139.4) (855.1-911.1) (974.1-1,016.3) 65-74 6,869 5,006 2 11,877 Rate* 2,246.7 1,593.4 1,915.9 95% C.I. (2,193.6-2,299.8) (1,549.2-1,637.5) (1,881.4-1,950.4) 75-84 4,121 3,602 0 7,723 Rate* 2,794.4 <td>25-34</td> <td>311</td> <td>505</td> <td>1</td> <td>817</td>	25-34	311	505	1	817
35-44 725 1,378 0 2,103 Rate* 93.9 190.9 140.8 95% C.I. (87.1-100.8) (180.8-200.9) (134.8-146.8) 45-54 2,054 2,775 2 4,831 Rate* 335.4 465.1 399.6 95% C.I. (320.9-349.9) (447.8-482.4) (388.3-410.8) 55-64 4,750 3,816 1 8,567 Rate* 1,107.9 883.1 995.2 95% C.I. (1,076.4-1,139.4) (855.1-911.1) (974.1-1,016.3) 65-74 6,869 5,006 2 11,877 Rate* 2,246.7 1,593.4 (1,915.9 95% C.I. (2,193.6-2,299.8) (1,549.2-1,637.5) (1,881.4-1,950.4) 75-84 4,121 3,602 0 7,723 Rate* 2,794.4 1,997.9 2,356.3 95% C.I. (2,709.1-2,879.7) <td>Rate*</td> <td>41.8</td> <td>73.5</td> <td></td> <td>57.1</td>	Rate*	41.8	73.5		57.1
Rate* 93.9 190.9 140.8 95% C.I. (87.1-100.8) (180.8-200.9) (134.8-146.8) 45-54 2,054 2,775 2 4,831 Rate* 335.4 465.1 399.6 95% C.I. (320.9-349.9) (447.8-482.4) (388.3-410.8) 55-64 4,750 3,816 1 8,567 Rate* 1,107.9 883.1 995.2 95% C.I. (1,076.4-1,139.4) (855.1-911.1) (974.1-1,016.3) 65-74 6,869 5,006 2 11,877 Rate* 2,246.7 1,593.4 1,915.9 95% C.I. (2,193.6-2,299.8) (1,549.2-1,637.5) (1,881.4-1,950.4) 75-84 4,121 3,602 0 7,723 Rate* 2,794.4 1,997.9 2,356.3 95% C.I. (2,709.1-2,879.7) (1,932.7-2,063.2) (2,303.7-2,408.8) 85+ </td <td>95% C.I.</td> <td>(37.1-46.4)</td> <td>(67.1-79.9)</td> <td></td> <td>(53.2-61.0)</td>	95% C.I.	(37.1-46.4)	(67.1-79.9)		(53.2-61.0)
Rate* 93.9 190.9 140.8 95% C.I. (87.1-100.8) (180.8-200.9) (134.8-146.8) 45-54 2,054 2,775 2 4,831 Rate* 335.4 465.1 399.6 95% C.I. (320.9-349.9) (447.8-482.4) (388.3-410.8) 55-64 4,750 3,816 1 8,567 Rate* 1,107.9 883.1 995.2 95% C.I. (1,076.4-1,139.4) (855.1-911.1) (974.1-1,016.3) 65-74 6,869 5,006 2 11,877 Rate* 2,246.7 1,593.4 1,915.9 95% C.I. (2,193.6-2,299.8) (1,549.2-1,637.5) (1,881.4-1,950.4) 75-84 4,121 3,602 0 7,723 Rate* 2,794.4 1,997.9 2,356.3 95% C.I. (2,709.1-2,879.7) (1,932.7-2,063.2) (2,303.7-2,408.8) 85+ </td <td>35-44</td> <td>725</td> <td>1,378</td> <td>0</td> <td>2,103</td>	35-44	725	1,378	0	2,103
45-54 2,054 2,775 2 4,831 Rate* 335.4 465.1 399.6 95% C.I. (320.9-349.9) (447.8-482.4) (388.3-410.8) 55-64 4,750 3,816 1 8,567 Rate* 1,107.9 883.1 995.2 95% C.I. (1,076.4-1,139.4) (855.1-911.1) (974.1-1,016.3) 65-74 6,869 5,006 2 11,877 Rate* 2,246.7 1,593.4 (1,915.9 95% C.I. (2,193.6-2,299.8) (1,549.2-1,637.5) (1,881.4-1,950.4) 75-84 4,121 3,602 0 7,723 Rate* 2,794.4 1,997.9 2,356.3 95% C.I. (2,709.1-2,879.7) (1,932.7-2,063.2) (2,303.7-2,408.8) 85+ 808 1,013 1 1,822 Rate* 3,563.7 2,120.3 (2,467.5-2,705.0) Unknown	Rate*				
Rate* 335.4 465.1 399.6 95% C.I. (320.9-349.9) (447.8-482.4) (388.3-410.8) 55-64 4,750 3,816 1 8,567 Rate* 1,107.9 883.1 995.2 95% C.I. (1,076.4-1,139.4) (855.1-911.1) (974.1-1,016.3) 65-74 6,869 5,006 2 11,877 Rate* 2,246.7 1,593.4 1,915.9 95% C.I. (2,193.6-2,299.8) (1,549.2-1,637.5) (1,881.4-1,950.4) 75-84 4,121 3,602 0 7,723 Rate* 2,794.4 1,997.9 2,356.3 95% C.I. (2,709.1-2,879.7) (1,932.7-2,063.2) (2,303.7-2,408.8) 85+ 808 1,013 1 1,822 Rate* 3,563.7 2,120.3 2,586.2 95% C.I. (3,317.9-3,809.4) (1,989.7-2,250.9) (2,467.5-2,705.0)	95% C.I.	(87.1-100.8)	(180.8-200.9)		(134.8-146.8)
Rate* 335.4 465.1 399.6 95% C.I. (320.9-349.9) (447.8-482.4) (388.3-410.8) 55-64 4,750 3,816 1 8,567 Rate* 1,107.9 883.1 995.2 95% C.I. (1,076.4-1,139.4) (855.1-911.1) (974.1-1,016.3) 65-74 6,869 5,006 2 11,877 Rate* 2,246.7 1,593.4 1,915.9 95% C.I. (2,193.6-2,299.8) (1,549.2-1,637.5) (1,881.4-1,950.4) 75-84 4,121 3,602 0 7,723 Rate* 2,794.4 1,997.9 2,356.3 95% C.I. (2,709.1-2,879.7) (1,932.7-2,063.2) (2,303.7-2,408.8) 85+ 808 1,013 1 1,822 Rate* 3,563.7 2,120.3 2,586.2 95% C.I. (3,317.9-3,809.4) (1,989.7-2,250.9) (2,467.5-2,705.0)	45-54	2,054	2,775	2	4,831
55-64 4,750 3,816 1 8,567 Rate* 1,107.9 883.1 995.2 95% C.I. (1,076.4-1,139.4) (855.1-911.1) (974.1-1,016.3) 65-74 6,869 5,006 2 11,877 Rate* 2,246.7 1,593.4 1,915.9 95% C.I. (2,193.6-2,299.8) (1,549.2-1,637.5) (1,881.4-1,950.4) 75-84 4,121 3,602 0 7,723 Rate* 2,794.4 1,997.9 2,356.3 95% C.I. (2,709.1-2,879.7) (1,932.7-2,063.2) (2,303.7-2,408.8) 85+ 808 1,013 1 1,822 85* C.I. (3,317.9-3,809.4) (1,989.7-2,250.9) (2,467.5-2,705.0) Unknown 4 2 0 6 Total 19,907 18,347 7 38,261 Rate* 420.9 401.2 411.3	Rate*				
55-64 4,750 3,816 1 8,567 Rate* 1,107.9 883.1 995.2 95% C.I. (1,076.4-1,139.4) (855.1-911.1) (974.1-1,016.3) 65-74 6,869 5,006 2 11,877 Rate* 2,246.7 1,593.4 1,915.9 95% C.I. (2,193.6-2,299.8) (1,549.2-1,637.5) (1,881.4-1,950.4) 75-84 4,121 3,602 0 7,723 Rate* 2,794.4 1,997.9 2,356.3 95% C.I. (2,709.1-2,879.7) (1,932.7-2,063.2) (2,303.7-2,408.8) 85+ 808 1,013 1 1,822 85* C.I. (3,317.9-3,809.4) (1,989.7-2,250.9) (2,467.5-2,705.0) Unknown 4 2 0 6 Total 19,907 18,347 7 38,261 Rate* 420.9 401.2 411.3	95% C.I.	(320.9-349.9)	(447.8-482.4)		(388.3-410.8)
Rate* 1,107.9 883.1 995.2 95% C.I. (1,076.4-1,139.4) (855.1-911.1) (974.1-1,016.3) 65-74 6,869 5,006 2 11,877 Rate* 2,246.7 1,593.4 1,915.9 95% C.I. (2,193.6-2,299.8) (1,549.2-1,637.5) (1,881.4-1,950.4) 75-84 4,121 3,602 0 7,723 Rate* 2,794.4 1,997.9 2,356.3 95% C.I. (2,709.1-2,879.7) (1,932.7-2,063.2) (2,303.7-2,408.8) 85+ 808 1,013 1 1,822 Rate* 3,563.7 2,120.3 2,586.2 95% C.I. (3,317.9-3,809.4) (1,989.7-2,250.9) (2,467.5-2,705.0) Unknown 4 2 0 6 Total 19,907 18,347 7 38,261 Rate* 420.9 401.2 411.3	55-64	4,750	3,816	1	
65-74 6,869 5,006 2 11,877 Rate* 2,246.7 1,593.4 1,915.9 95% C.I. (2,193.6-2,299.8) (1,549.2-1,637.5) (1,881.4-1,950.4) 75-84 4,121 3,602 0 7,723 Rate* 2,794.4 1,997.9 2,356.3 95% C.I. (2,709.1-2,879.7) (1,932.7-2,063.2) (2,303.7-2,408.8) 85+ 808 1,013 1 1,822 Rate* 3,563.7 2,120.3 2,586.2 95% C.I. (3,317.9-3,809.4) (1,989.7-2,250.9) (2,467.5-2,705.0) Unknown 4 2 0 6 Total 19,907 18,347 7 38,261 Rate* 420.9 401.2 411.3					
65-74 6,869 5,006 2 11,877 Rate* 2,246.7 1,593.4 1,915.9 95% C.I. (2,193.6-2,299.8) (1,549.2-1,637.5) (1,881.4-1,950.4) 75-84 4,121 3,602 0 7,723 Rate* 2,794.4 1,997.9 2,356.3 95% C.I. (2,709.1-2,879.7) (1,932.7-2,063.2) (2,303.7-2,408.8) 85+ 808 1,013 1 1,822 Rate* 3,563.7 2,120.3 2,586.2 95% C.I. (3,317.9-3,809.4) (1,989.7-2,250.9) (2,467.5-2,705.0) Unknown 4 2 0 6 Total 19,907 18,347 7 38,261 Rate* 420.9 401.2 411.3	95% C.I.	(1,076.4-1,139.4)	(855.1-911.1)		(974.1-1,016.3)
Rate* 2,246.7 1,593.4 1,915.9 95% C.I. (2,193.6-2,299.8) (1,549.2-1,637.5) (1,881.4-1,950.4) 75-84 4,121 3,602 0 7,723 Rate* 2,794.4 1,997.9 2,356.3 95% C.I. (2,709.1-2,879.7) (1,932.7-2,063.2) (2,303.7-2,408.8) 85+ 808 1,013 1 1,822 Rate* 3,563.7 2,120.3 2,586.2 95% C.I. (3,317.9-3,809.4) (1,989.7-2,250.9) (2,467.5-2,705.0) Unknown 4 2 0 6 Total 19,907 18,347 7 38,261 Rate* 420.9 401.2 411.3	65-74	6,869	5,006	2	
95% C.I. (2,193.6-2,299.8) (1,549.2-1,637.5) (1,881.4-1,950.4) 75-84 4,121 3,602 0 7,723 Rate* 2,794.4 1,997.9 2,356.3 95% C.I. (2,709.1-2,879.7) (1,932.7-2,063.2) (2,303.7-2,408.8) 85+ 808 1,013 1 1,822 Rate* 3,563.7 2,120.3 2,586.2 95% C.I. (3,317.9-3,809.4) (1,989.7-2,250.9) (2,467.5-2,705.0) Unknown 4 2 0 6 Total 19,907 18,347 7 38,261 Rate* 420.9 401.2 411.3	Rate*	•	•		
Rate* 2,794.4 1,997.9 2,356.3 95% C.I. (2,709.1-2,879.7) (1,932.7-2,063.2) (2,303.7-2,408.8) 85+ 808 1,013 1 1,822 Rate* 3,563.7 2,120.3 2,586.2 95% C.I. (3,317.9-3,809.4) (1,989.7-2,250.9) (2,467.5-2,705.0) Unknown 4 2 0 6 Total 19,907 18,347 7 38,261 Rate* 420.9 401.2 411.3	95% C.I.	(2,193.6-2,299.8)			
Rate* 2,794.4 1,997.9 2,356.3 95% C.I. (2,709.1-2,879.7) (1,932.7-2,063.2) (2,303.7-2,408.8) 85+ 808 1,013 1 1,822 Rate* 3,563.7 2,120.3 2,586.2 95% C.I. (3,317.9-3,809.4) (1,989.7-2,250.9) (2,467.5-2,705.0) Unknown 4 2 0 6 Total 19,907 18,347 7 38,261 Rate* 420.9 401.2 411.3	75-84	4,121	3,602	0	7,723
95% C.I. (2,709.1-2,879.7) (1,932.7-2,063.2) (2,303.7-2,408.8) 85+ 808 1,013 1 1,822 Rate* 3,563.7 2,120.3 2,586.2 95% C.I. (3,317.9-3,809.4) (1,989.7-2,250.9) (2,467.5-2,705.0) Unknown 4 2 0 6 Total 19,907 18,347 7 38,261 Rate* 420.9 401.2 411.3		•	•		
85+ 808 1,013 1 1,822 Rate* 3,563.7 2,120.3 2,586.2 95% C.I. (3,317.9-3,809.4) (1,989.7-2,250.9) (2,467.5-2,705.0) Unknown 4 2 0 6 Total 19,907 18,347 7 38,261 Rate* 420.9 401.2 411.3	95% C.I.	•	· ·		
Rate* 3,563.7 2,120.3 2,586.2 95% C.I. (3,317.9-3,809.4) (1,989.7-2,250.9) (2,467.5-2,705.0) Unknown 4 2 0 6 Total 19,907 18,347 7 38,261 Rate* 420.9 401.2 411.3				1	
95% C.I. (3,317.9-3,809.4) (1,989.7-2,250.9) (2,467.5-2,705.0) Unknown 4 2 0 6 Total 19,907 18,347 7 38,261 Rate* 420.9 401.2 411.3					
Unknown 4 2 0 6 Total 19,907 18,347 7 38,261 Rate* 420.9 401.2 411.3					
Total 19,907 18,347 7 38,261 Rate* 420.9 401.2 411.3		4	2	0	
Rate* 420.9 401.2 411.3		19,907	18,347	7	38,261

Rates are per 100,000 age-specific population. Note: The "---" is used for rates calculated on numbers less than ten.

Table 26. All Cancers Cases by Age Group and Stage, Nevada Residents, 1996-2000

0 212	0			St	age		
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total
<1	Number	0	6	2	12	10	30
	Percent		20.0%	6.7%	40.0%	33.3%	100.0%
1-4	Number	0	26	4	42	17	89
	Percent		29.2%	4.5%	47.2%	19.1%	100.0%
5-14	Number	0	42	8	70	22	142
	Percent		29.6%	5.6%	49.3%	15.5%	100.0%
15-24	Number	2	119	32	66	35	254
	Percent	0.8%	46.9%	12.6%	26.0%	13.8%	100.0%
25-34	Number	11	409	155	128	114	817
	Percent	1.3%	50.1%	19.0%	15.7%	14.0%	100.0%
35-44	Number	82	968	455	338	260	2,103
	Percent	3.9%	46.0%	21.6%	16.1%	12.4%	100.0%
45-54	Number	259	1,924	988	888	772	4,831
	Percent	5.4%	39.8%	20.5%	18.4%	16.0%	100.0%
55-64	Number	264	3,254	1,781	1,700	1,568	8,567
	Percent	3.1%	38.0%	20.8%	19.8%	18.3%	100.0%
65-74	Number	333	4,518	2,167	2,292	2,567	11,877
	Percent	2.8%	38.0%	18.2%	19.3%	21.6%	100.0%
75-84	Number	188	2,585	1,226	1,469	2,255	7,723
	Percent	2.4%	33.5%	15.9%	19.0%	29.2%	100.0%
85+	Number	26	469	255	291	781	1,822
	Percent	1.4%	25.7%	14.0%	16.0%	42.9%	100.0%
Unknown	Number	0	0	1	2	3	6
	Percent			16.7%	33.3%	50.0%	100.0%
Total	Number Percent	1,165 3.0%	14,320 37.4%	7,074 18.5%	7,298 19.1%	8,404 22.0%	38,261 100.0%

Table 27. Cancer Incidence by Stage and Race/Ethnicity, Nevada Residents, 1996-2000

			Race/Ethnicity					
8	Stage	White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total
In situ	Number	1,039	31	3	27	36	29	1,165
	Percent	3.1%	1.8%	1.8%	3.2%	2.7%	11.9%	3.0%
Localized	Number	12,864	545	42	264	470	135	14,320
	Percent	37.9%	31.6%	25.5%	31.5%	34.9%	55.3%	37.4%
Regional	Number	6,240	340	27	181	248	38	7,074
	Percent	18.4%	19.7%	16.4%	21.6%	18.4%	15.6%	18.5%
Distant	Number	6,351	383	38	188	321	17	7,298
	Percent	18.7%	22.2%	23.0%	22.5%	23.8%	7.0%	19.1%
Unstaged	Number	7,452	424	55	177	271	25	8,404
	Percent	22.0%	24.6%	33.3%	21.1%	20.1%	10.2%	22.0%
Total	Number	33,946	1,723	165	837	1,346	244	38,261
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%


Table 28. Median Age at Diagnosis of All Cancers by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

		Gender								
Race/Ethnicity	Male		Fem	nale	То	Total				
	Incidence	Median Age	Incidence	Median Age	Incidence	Median Age				
White	17,752	68.0	16,181	66.0	33,933	67.0				
Black	910	64.0	813	62.0	1,723	63.0				
Native American	77	65.0	88	65.0	165	65.0				
Asian	357	65.0	480	59.0	837	62.0				
Hispanic	706	61.0	640	54.0	1,346	59.0				
Other/Unknown	101	64.0	143	57.0	244	61.0				
Total	19,903	67.0	18,345	65.0	38,248	66.0				

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

Figure 27. All Cancers Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical notes for more information.

Figure 28. All Cancers Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 29. Median Charges for All Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000




Figure 30. Average Length of Stay for All Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000




Table 29. All Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

		Cour	ity/Region of Resid	lence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	32,109	22,597	5,220	4,280	12
Rate*	372.2	393.8	356.3	301.6	
95% C.I.	(368.1-376.4)	(388.6-399.1)	(346.6-366.3)	(292.5-311.0)	
Gender					
Male	15,724	11,096	2,379	2,241	8
Rate*	384.3	409.5	348.9	322.4	
95% C.I.	(378.0-390.8)	(401.3-417.9)	(334.3-364.2)	(308.7-336.8)	
Female	16,385	11,501	2,841	2,039	4
Rate*	367.2	387.0	368.4	283.8	
95% C.I.	(361.6-372.9)	(379.9-394.3)	(355.0-382.3)	(271.5-296.5)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	narges (\$)				
Total Charges	\$922,372,294	\$682,410,648	\$142,104,479	\$96,970,002	\$887,165
Average Charges	\$28,726	\$30,199	\$27,223	\$22,657	\$73,930
Median Charges	\$19,220	\$19,723	\$20,250	\$14,739	\$13,855
Discharge Length of S	tay (LOS) (Days)				
Total LOS	225,968	163,442	36,495	25,901	130
Average LOS	7.0	7.2	7.0	6.1	10.8
Median LOS	5.0	5.0	5.0	4.0	4.5

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 30. Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		Cour	nty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	32,109	22,597	5,220	4,280	12
Rate*	345.2	359.0	318.8	312.4	
95% C.I.	(341.4-348.9)	(354.3-363.6)	(310.1-327.4)	(303.0-321.7)	
Age Group					
<1	30	27	0	3	0
Rate*	21.5	27.6			
95% C.I.	(13.8-29.2)	(17.2-38.0)			
1-4	132	118	3	11	0
Rate*	24.1	31.0		11.7	
95% C.I.	(20.0-28.2)	(25.4-36.7)		(4.8-18.6)	
5-14	266	234	17	15	0
Rate*	20.1	26.3	7.5	6.6	
95% C.I.	(17.7-22.5)	(23.0-29.7)	(3.9-11.1)	(3.3-10.0)	
15-24	246	181	39	26	0
Rate*	19.2	20.8	17.2	11.5	
95% C.I.	(16.8-21.6)	(17.8-23.8)	(11.8-22.6)	(7.1-15.9)	
25-34	770	586	115	69	0
Rate*	53.8	57.4	45.6	27.3	
95% C.I.	(50.0-57.6)	(52.8-62.1)	(37.2-53.9)	(20.9-33.8)	
35-44	1,952	1,413	341	197	1
Rate*	130.7	142.7	122.8	71.0	
95% C.I.	(124.9-136.5)	(135.2-150.1)	(109.8-135.8)	(61.0-80.9)	
45-54	4,120	2,951	668	501	0
Rate*	340.8	372.5	297.5	223.1	
95% C.I.	(330.4-351.2)	(359.1-386.0)	(274.9-320.0)	(203.6-242.6)	
55-64	7,587	5,436	1,168	979	4
Rate*	881.3	934.9	825.7	692.1	
95% C.I.	(861.5-901.2)	(910.1-959.8)	(778.3-873.1)	(648.7-735.4)	
65-74	9,726	6,631	1,609	1,483	3
Rate*	1,568.9	1,599.5	1,595.4	1,470.4	
95% C.I.	(1,537.7-1,600.1)	(1,561.0-1,638.0)	(1,517.4-1,673.3)	(1,395.6-1,545.3)	
75-84	6,028	4,212	1,016	797	3
Rate*	1,839.1	1,947.7	1,846.3	1,448.3	
95% C.I.	(1,792.7-1,885.6)	(1,888.9-2,006.5)	(1,732.8-1,959.8)	(1,347.8-1,548.9)	
85+	1,251	808	243	199	1
Rate*	1,775.7	1,886.1	1,685.6	1,380.4	
95% C.I.	(1,677.3-1,874.1)	(1,756.0-2,016.1)	(1,473.7-1,897.6)	(1,188.6-1,572.2)	
Unknown	1	0	1	0	0

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 31. All Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1996-2000

Age		Gender	
Group	Male	Female	Total
<1	11	19	30
Rate*	15.4	27.8	21.5
95% C.I.	(6.3-24.5)	(15.3-40.4)	(13.8-29.2)
1-4	76	56	132
Rate*	27.2	20.9	24.1
95% C.I.	(21.1-33.3)	(15.4-26.4)	(20.0-28.2)
5-14	136	130	266
Rate*	19.9	20.3	20.1
95% C.I.	(16.6-23.3)	(16.8-23.7)	(17.7-22.5)
15-24	107	139	246
Rate*	16.1	22.6	19.2
95% C.I.	(13.1-19.2)	(18.8-26.3)	(16.8-21.6)
25-34	255	515	770
Rate*	34.2	75.0	53.8
95% C.I.	(30.0-38.4)	(68.5-81.4)	(50.0-57.6)
35-44	633	1,319	1,952
Rate*	82.0	182.7	130.7
95% C.I.	(75.6-88.4)	(172.8-192.6)	(124.9-136.5)
45-54	1,745	2,375	4,120
Rate*	285.0	398.0	340.8
95% C.I.	(271.6-298.3)	(382.0-414.0)	(330.4-351.2)
55-64	4,072	3,515	7,587
Rate*	949.8	813.5	881.3
95% C.I.	(920.6-978.9)	(786.6-840.3)	(861.5-901.2)
65-74	5,251	4,475	9,726
Rate*	1,717.5	1,424.4	1,568.9
95% C.I.	(1,671.0-1,763.9)	(1,382.6-1,466.1)	(1,537.7-1,600.1)
75-84	2,905	3,123	6,028
Rate*	1,969.8	1,732.3	1,839.1
95% C.I.	(1,898.2-2,041.5)	(1,671.5-1,793.0)	(1,792.7-1,885.6)
85+	533	718	1,251
Rate*	2,350.8	1,502.8	1,775.7
95% C.I.	(2,151.2-2,550.4)	(1,392.9-1,612.8)	(1,677.3-1,874.1)
Unknown	0	1	1
Total	15,724	16,385	32,109
Rate*	332.4	358.3	345.2
95% C.I.	(327.2-337.6)	(352.8-363.8)	(341.4-348.9)

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 32. All Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000

Country of	1996-2000 Inpatient Hospital Discharges						
County of Residence	Number	Rat	e*	Age-Adjust	ed Rate**		
	Number	Rate	95% C.I.	Rate	95% C.I.		
Carson City	752	306.8	(284.9-328.7)	265.5	(246.7-285.4)		
Churchill	404	342.4	(309.0-375.8)	358.0	(323.7-395.3)		
Clark	22,597	359.0	(354.3-363.6)	393.8	(388.6-399.1)		
Douglas	567	283.7	(260.3-307.0)	244.2	(223.6-266.7)		
Elko	235	102.6	(89.4-115.7)	193.4	(167.2-223.1)		
Esmeralda	39	729.5	(500.6-958.5)	592.5	(412.6-862.3)		
Eureka	18	212.5	(114.3-310.7)	203.8	(119.6-355.5)		
Humboldt	186	221.6	(189.7-253.4)	296.4	(253.4-346.0)		
Lander	77	240.2	(186.6-293.9)	348.3	(270.6-443.9)		
Lincoln	44	215.9	(152.1-279.7)	179.6	(129.4-251.0)		
Lyon	968	598.3	(560.6-635.9)	526.6	(493.3-562.0)		
Mineral	121	439.6	(361.2-517.9)	344.3	(284.2-416.5)		
Nye	697	469.5	(434.7-504.4)	346.6	(319.7-376.0)		
Pershing	63	221.0	(166.4-275.5)	254.7	(195.2-328.8)		
Storey	18	100.8	(54.2-147.4)	98.1	(52.8-188.9)		
Washoe	5,220	318.8	(310.1-327.4)	356.3	(346.6-366.3)		
White Pine	91	208.6	(165.8-251.5)	184.7	(148.5-228.4)		
Unknown	12						
Total	32,109	345.2	(341.4-348.9)	372.2	(368.1-376.4)		


Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 33. All Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1996-2000

Age	Diocharges	(Charges (\$)		Len	gth of Stay (Da	ıys)
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	30	1,335,664	44,522	28,650	337	11.2	8.0
1-4	132	7,416,845	56,188	34,057	1,705	12.9	8.0
5-14	266	12,529,596	47,104	31,535	2,464	9.3	6.0
15-24	246	10,560,148	42,927	23,683	2,206	9.0	5.0
25-34	770	21,782,306	28,289	15,643	4,763	6.2	3.5
35-44	1,952	51,391,338	26,328	16,720	11,875	6.1	4.0
45-54	4,120	114,426,252	27,773	18,732	27,027	6.6	4.0
55-64	7,587	229,041,353	30,189	20,014	54,588	7.2	5.0
65-74	9,726	273,548,238	28,125	19,735	66,733	6.9	5.0
75-84	6,028	170,090,873	28,217	18,639	45,013	7.5	6.0
85+	1,251	30,129,714	24,085	16,306	9,237	7.4	6.0
Unknown	1						
Total	32,109	922,372,294	28,726	19,220	225,968	7.0	5.0

MORTALITY

Figure 31. Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 32. Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 33. Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1996-2000




Table 34. All Cancers Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	16,806	11,300	2,878	2,628
Rate*	207.6	210.9	208.9	193.6
95% C.I.	(204.4-210.9)	(206.9-215.1)	(201.2-216.9)	(186.1-201.3)
Gender				
Male	9,173	6,161	1,525	1,487
Rate*	247.1	251.5	248.6	230.6
95% C.I.	(241.6-252.7)	(244.5-258.7)	(235.4-262.6)	(218.3-243.5)
Female	7,633	5,139	1,353	1,141
Rate*	177.5	180.6	180.8	161.6
95% C.I.	(173.5-181.6)	(175.7-185.8)	(171.2-190.7)	(152.3-171.4)
Other/Unknown	0	0	0	0
Race/Ethnicity				
White	14,954	9,762	2,686	2,506
Rate*	219.0	224.5	219.4	200.4
95% C.I.	(215.4-222.7)	(219.9-229.2)	(211.0-228.0)	(192.5-208.7)
Black	867	821	40	6
Rate*	233.3	240.2	185.0	
95% C.I.	(216.8-251.0)	(222.6-259.2)	(130.3-257.1)	
Native American	101	30	27	44
Rate*	125.1	83.8	177.2	130.1
95% C.I.	(100.6-154.7)	(54.9-128.7)	(112.5-271.3)	(93.6-177.3)
Asian	353	299	43	11
Rate*	122.6	129.0	98.2	106.6
95% C.I.	(106.3-141.9)	(110.1-151.9)	(65.0-151.0)	(46.7-231.7)
Hispanic	515	379	77	59
Rate*	98.6	95.7	102.2	115.0
95% C.I.	(88.8-109.5)	(84.5-108.4)	(77.2-135.6)	(84.3-154.6)
Other/Unknown	16	9	5	2

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 35. All Cancers Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region	of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	16,806	11,300	2,878	2,628
Rate*	180.7	179.5	175.7	191.8
95% C.I.	(177.9-183.4)	(176.2-182.8)	(169.3-182.2)	(184.5-199.1)
Age Group				
<1	3	2	0	1
Rate*				
95% C.I.				
1-4	10	6	1	3
Rate*	1.8			
95% C.I.	(0.7-3.0)			
5-14	27	19	5	3
Rate*	2.0	2.1		
95% C.I.	(1.3-2.8)	(1.2-3.1)		
15-24	42	28	4	10
Rate*	3.3	3.2		5.5
95% C.I.	(2.3-4.3)	(2.0-4.4)		(2.1-8.9)
25-34	104	86	11	7
Rate*	7.3	8.4	4.4	
95% C.I.	(5.9-8.7)	(6.6-10.2)	(1.8-6.9)	
35-44	479	335	93	51
Rate*	32.1	33.8	33.5	22.6
95% C.I.	(29.2-34.9)	(30.2-37.4)	(26.7-40.3)	(16.4-28.8)
45-54	1,494	1,054	240	200
Rate*	123.6	133.1	106.9	104.0
95% C.I.	(117.3-129.8)	(125.0-141.1)	(93.3-120.4)	(89.6-118.4)
55-64	3,262	2,224	527	511
Rate*	378.9	382.5	372.6	370.4
95% C.I.	(365.9-391.9)	(366.6-398.4)	(340.7-404.4)	(338.3-402.5)
65-74	5,493	3,679	926	888
Rate*	886.1	887.4	918.2	849.8
95% C.I.	(862.7-909.5)	(858.8-916.1)	(859.0-977.3)	(793.9-905.7)
75-84	4,487	3,004	786	697
Rate*	1,369.0	1,389.1	1,428.4	1,234.1
95% C.I.	(1,328.9-1,409.0)	(1,339.4-1,438.8)	(1,328.5-1,528.2)	(1,142.5-1,325.7)
85+	1,404	862	285	257
Rate*	1,992.9	2,012.1	1,977.0	1,947.9
95% C.I.	(1,888.7-2,097.2)	(1,877.8-2,146.5)	(1,747.5-2,206.5)	(1,709.7-2,186.0)
Unknown	1	1	0	0

Note: The "---" is used for rates calculated on numbers less than ten. * Rates are per 100,000 age-specific population.

Table 36. Cancer Mortality by County of Residence, Nevada Residents, 1996-2000

Country of			1996-2000 Morta	ality	
County of Residence	Cases	Rat	te*	Age-Adjus	ted Rate**
	Cases	Rate	95% C.I.	Rate	95% C.I.
Carson City	651	265.6	(245.2-286.0)	228.7	(211.3-247.2)
Churchill	194	164.4	(141.3-187.6)	175.5	(151.4-202.6)
Clark	11,300	179.5	(176.2-182.8)	210.9	(206.9-215.1)
Douglas	361	180.6	(162.0-199.2)	160.9	(143.9-179.8)
Elko	222	96.9	(84.1-109.6)	200.9	(173.1-232.3)
Esmeralda	10	187.1	(71.1-303.0)	138.2	(65.4-315.2)
Eureka	7				
Humboldt	104	123.9	(100.1-147.7)	184.1	(148.8-226.3)
Lander	45	140.4	(99.4-181.4)	225.0	(161.2-307.9)
Lincoln	44	215.9	(152.1-279.7)	176.9	(127.8-247.1)
Lyon	403	249.1	(224.8-273.4)	227.1	(204.9-251.6)
Mineral	75	272.5	(210.8-334.1)	221.2	(172.9-281.9)
Nye	371	249.9	(224.5-275.4)	192.1	(171.3-215.6)
Pershing	31	108.7	(70.4-147.0)	133.7	(90.5-192.4)
Storey	28	156.8	(98.7-214.9)	146.9	(91.2-245.3)
Washoe	2,878	175.7	(169.3-182.2)	208.9	(201.2-216.9)
White Pine	82	188.0	(147.3-228.7)	163.4	(129.9-204.4)
Unknown	0				
Total	16,806	180.7	(177.9-183.4)	207.6	(204.4-210.9)

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 37. Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

Race/Ethnicity		Gender		
		Male	Female	Total
White	Mortality	8,187	6,767	14,954
	Rate* 95% C.I.	258.8 (252.7-264.9)	188.6 (184.1-193.2)	219.0 (215.4-222.7)
Black	Mortality Rate*	469 285.3	398 195.6	867 233.3
	95% C.I.	(255.7-318.7)	(175.9-217.1)	(216.8-251.0)
Native	Mortality	52	49	101
American	Rate*	147.8	110.9	125.1
	95% C.I.	(104.7-208.2)	(81.2-148.6)	(100.6-154.7)
Asian	Mortality	166	187	353
	Rate*	134.5	113.5	122.6
	95% C.I.	(109.5-166.3)	(92.5-139.9)	(106.3-141.9)
Hispanic	Mortality	288	227	515
	Rate*	124.1	79.3	98.6
	95% C.I.	(106.7-144.8)	(68.0-92.4)	(88.8-109.5)
Other/Unknown		11	5	16
Total	Mortality	9,173	7,633	16,806
	Rate*	247.1	177.5	207.6
	95% C.I.	(241.6-252.7)	(173.5-181.6)	(204.4-210.9)

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 38. Cancer Mortality by Age Group and Gender, Nevada Residents, 1996-2000

Age	Gender			
Group	Male	Female	Total	
<1	2	1	3	
Rate*				
95% C.I.				
1-4	5	5	10	
Rate*			1.8	
95% C.I.			(0.7-3.0)	
5-14	13	14	27	
Rate*	1.9	2.2	2.0	
95% C.I.	(0.9-2.9)	(1.0-3.3)	(1.3-2.8)	
15-24	24	18	42	
Rate*	3.6	2.9	3.3	
95% C.I.	(2.2-5.1)	(1.6-4.3)	(2.3-4.3)	
25-34	46	58	104	
Rate*	6.2	8.4	7.3	
95% C.I.	(4.4-8.0)	(6.3-10.6)	(5.9-8.7)	
35-44	213	266	479	
Rate*	27.6	36.8	32.1	
95% C.I.	(23.9-31.3)	(32.4-41.3)	(29.2-34.9)	
45-54	717	777	1,494	
Rate*	117.1	130.2	123.6	
95% C.I.	(108.5-125.7)	(121.1-139.4)	(117.3-129.8)	
55-64	1,885	1,377	3,262	
Rate*	439.7	318.7	378.9	
95% C.I.	(419.8-459.5)	(301.8-335.5)	(365.9-391.9)	
65-74	3,182	2,311	5,493	
Rate*	1,040.8	735.6	886.1	
95% C.I.	(1,004.6-1,076.9)	(705.6-765.6)	(862.7-909.5)	
75-84 Data*	2,450	2,037	4,487	
Rate*	1,661.3 (1,595.5-1,727.1)	1,129.9 (1,080.8-1,178.9)	1,369.0	
95% C.I.			(1,328.9-1,409.0)	
85+	635	769 1 600 6	1,404	
Rate* 95% C.I.	2,800.7 (2,582.8-3,018.5)	1,609.6 (1,495.8-1,723.3)	1,992.9 (1,888.7-2,097.2)	
Unknown	(2,302.0-3,010.3)	(1,495.6-1,725.5)	(1,000.1-2,091.2)	
Total	9,173	7,633	16,806	
Rate*	193.9	166.9	180.7	
95% C.I.	(190.0-197.9)	(163.2-170.7)	(177.9-183.4)	
3570 0.1.	(130.0-137.9)	(100.2-110.1)	(177.5-105.4)	

Note: The "---" is used for rates calculated on numbers less than ten. * Rates are per 100,000 age-specific population.

Table 39. Median Age at Death from All Cancers by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

	Gender							
Race/Ethnicity	Ма	le	Fem	nale	То	tal		
	Deaths	Median Age	Deaths	Median Age	Deaths	Median Age		
White	8,186	70.0	6,767	71.0	14,953	71.0		
Black	469	67.0	398	66.0	867	66.0		
Native American	52	67.0	49	73.0	101	68.0		
Asian	166	65.0	187	64.0	353	65.0		
Hispanic	288	66.0	227	65.0	515	65.0		
Other/Unknown	11	64.0	5	77.0	16	66.0		
Total	9,172	70.0	7,633	71.0	16,805	70.0		

Note: Those deaths of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE

Figure 34. Survival Rates for All Cancers by Race/Ethnicity, Nevada Residents, 1996-2000




Figure 35. Survival Rates for All Cancers by Stage of Cancer at Diagnosis, Nevada Residents, 1996-2000




Table 40. Cause-Specific Survival Rates for All Cancers by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

Race/	Name		Cause Specific Survival Rate					
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)	
Total	25,079	66.6%	53.9%	46.3%	40.5%	36.8%	2.51	
Male	12,712	62.8%	49.2%	41.7%	36.9%	33.6%	1.94	
Female	12,362	70.6%	58.6%	50.8%	44.1%	40.1%	3.12	
Race/Ethnicity								
White	22,130	66.4%	53.4%	45.8%	40.0%	36.5%	2.44	
Male	11,271	62.7%	48.7%	41.3%	36.4%	33.0%	1.91	
Female	10,854	70.2%	58.1%	50.3%	43.6%	40.0%	3.05	
Black	1,148	63.5%	47.9%	40.4%	33.3%	28.4%	1.86	
Male	593	61.6%	48.1%	39.2%	32.9%	32.9%	1.86	
Female	555	65.5%	47.7%	41.6%	33.6%	23.0%	1.87	
Native American	89	54.1%	52.3%	41.8%	41.8%	41.8%	2.22	
Male	41	44.0%	40.3%	30.8%	30.8%	30.8%	0.89	
Female	48	63.4%	63.4%	52.4%	52.4%	52.4%	>5 years	
i ciliale	40	03.4 /0	03.4 /0	32.4 /0	32.4 /0	J2.4 /0	~5 years	
Asian	577	67.2%	56.7%	50.9%	48.9%	48.9%	3.45	
Male	241	61.7%	47.5%	40.2%	40.2%	40.2%	1.82	
Female	336	71.3%	63.3%	58.9%	54.9%	54.9%	>5 years	
Hispanic	967	72.1%	64.0%	53.8%	49.6%	43.0%	3.90	
Male	496	65.0%	56.7%	49.8%	48.0%	39.3%	2.97	
Female	471	79.6%	71.8%	58.4%	51.9%	47.4%	4.42	

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 41. Cause-Specific Survival Rates for All Cancers by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1996-2000


Surviv	/al Rate of Stage		Gender	
	nt Diagnosis	Total	Male	Female
Total	Cases	25,079	12,712	12,362
	One Year	66.6%	62.8%	70.6%
	5 Years	36.8%	33.6%	40.1%
	Median Survival	2.51	1.94	3.12
Stage at D	iagnosis			
In situ	Cases	890	235	655
	One Year	100.0%	100.0%	100.0%
	5 Years	94.2%	87.2%	97.0%
	Median Survival	>5 years	>5 years	>5 years
Localized	Cases	9,922	5,073	4,846
	One Year	91.8%	90.2%	93.4%
	5 Years	69.6%	67.6%	71.5%
	Median Survival	>5 years	>5 years	>5 years
Regional	Cases	4,997	2,287	2,710
	One Year	73.8%	69.3%	77.7%
	5 Years	32.8%	26.7%	38.2%
	Median Survival	2.59	1.93	3.22
Distant	Cases	5,357	2,922	2,434
	One Year	35.2%	32.0%	39.1%
	5 Years	8.4%	8.4%	8.4%
	Median Survival	0.77	0.73	0.82
Unstaged	Cases	3,913	2,195	1,717
	One Year	44.4%	44.4%	44.5%
	5 Years	14.6%	17.4%	11.2%
	Median Survival	0.90	0.90	0.90

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

LUNG AND BRONCHUS CANCER

LUNG AND BRONCHUS CANCER GENERAL PROFILE⁴

Figure 36. Anatomy of the Respiratory Tract⁵



General Anatomy: The lungs, a pair of sponge-like, cone-shaped organs, are part of the respiratory system. The right lung has three sections, called lobes; it is a little larger than the left lung, which has two lobes. When we breathe in, the lungs take in oxygen, which our cells need to live and carry out their normal functions. When we breathe out, the lungs get rid of carbon dioxide, which is a waste product of the body's cells.

Risk Factors: Smoking is the most prevalent risk factor in determining risk for Lung and Bronchus Cancer. Exposure to radon, asbestos, pollution, certain lung diseases, such as tuberculosis, and personal family history are all also important risk factors.

Signs and Symptoms: Common signs and symptoms include: a cough that doesn't go away and gets worse over time, constant chest pain, coughing up blood, shortness of breath, wheezing or hoarseness, repeated problems with pneumonia or bronchitis, swelling of the neck and face, loss of appetite or weight loss, and fatigue.

Diagnosing the Cancer: The most common ways of diagnosing Lung and Bronchus Cancer are: brochoscopy, needle aspiration, thoracentesis, thoracotomy.

Treatment: Treatment options include: surgery, chemotherapy, radiation therapy, and photodynamic therapy.

HIGHLIGHTS

- Nevadan females had a higher ratio than males when the incidence and mortality ageadjusted rates for Lung and Bronchus Cancer were compared. Females had a ratio of 1.36 while the ratio for males was 1.27. This means that for every death due to Lung and Bronchus Cancer there would be 1.36 female cases while only 1.27 cases for every male death.
- The median age at diagnosis of Lung and Bronchus Cancer for Nevada residents and females was 69 years of age from 1996 to 2000 while the median age for males was 68 years. The median age at time of death due to Lung and Bronchus Cancer was 70 years for Nevada overall and females and 69 years of age for males.

INCIDENCE

- ➤ There were 7,162 cases of Lung and Bronchus Cancer reported in Nevada from 1996 to 2000, which was the highest of any type of cancer during this period. Clark County had a statistically significant higher incidence rate of Lung and Bronchus Cancer (87.5) during this period, with both Washoe County and All Other Counties, as a region, slightly lower at rates of 78.1 and 77.3, respectively. However Nevada, as a whole, as well as the three regions had statistically significant higher rates than the National rate of 62.8 (per 100,000 2000 US Standard population).
- ➤ Whites and Blacks, as racial/ethnic groups, accounted for 95.6% of all reported Lung and Bronchus Cancer cases during the 1996 to 2000 period. Their higher age-adjusted incidence rates, 91.0 and 82.3 respectively, showed statistical significance over Asians, Native Americans and Hispanics who had age-adjusted incidence rates of 45.0, 33.6 and 25.0 (per 100,000 2000 US Standard population), respectively, during this same period.
- The higher age-adjusted incidence rate for males was statistically significant at 98.8 (95.6-102.2) over the rate for females (72.2, 69.7-74.7) during the 1996 to 2000 period. However, both had statistically significant higher rates when compared to their national counterparts. The difference was considerably more for females who were 46.2% greater than the National rate, while the rate difference for Males was still a considerable 21.3% over the National rate during this period.

INPATIENT HOSPITAL DISCHARGES

- ➤ Billed charges from Lung and Bronchus Cancer inpatient discharges accounted for nearly 150 million dollars from 1996 to 2000. Nevadans in the 55-64 and 65-74 age groups accounted for 65.8% of the total charges during this period. The overall daily billed amount for these discharges was approximately \$3,822 in Nevada during this period.
- ➤ There were 4,895 Inpatient Discharges for Lung and Bronchus Cancer to Nevada residents in Nevada from 1996 to 2000. Clark County (61.4) had the highest age-adjusted inpatient discharge rate for Lung and Bronchus Cancer in Nevada, and showed statistical

- significance over the rates for Nevada overall, Washoe County, and All Other Counties who had rates of 56.5, 49.0 and 44.8 (per 100,000 2000 US Standard population), respectively.
- ➤ The median total billed charges in Nevada for inpatient discharges due to Lung and Bronchus Cancer from 1996 to 2000 was \$24,201. Clark County had the highest median total billed charge, \$25,913, when compared to the amounts for Washoe County and All Other Counties of \$20,627 and \$17,074.

MORTALITY


- ➤ There were 5,385 resident deaths due to Lung and Bronchus Cancer from 1996 to 2000. Clark County had a higher age-adjusted mortality rate (66.9) than Washoe County (61.4) and All Other Counties, as a region, (58.1) during the 1996 to 2000 period.
- Nevadan males had a 46.1% higher statistically significant age-adjusted mortality rate (78.1) for Lung and Bronchus Cancer when compared to the female rate of 53.4 (per 100,000 2000 US Standard population) for the 1996 to 2000 period.
- ➤ Whites and Blacks, as racial/ethnic groups, accounted for 96.4% of all reported Lung and Bronchus Cancer cases during the 1996 to 2000 period. Their higher age-adjusted mortality rates, 69.6 and 68.3 respectively, showed statistical significance over Asians, Native Americans and Hispanics who had age-adjusted incidence rates of 34.7, 30.3 and 16.3 (per 100,000 2000 US Standard population), respectively, during this same period.

SURVIVAL RATE

- Females had a higher one-year survival rate (40.3%) than males (34.4%) for Lung and Bronchus Cancer in Nevada from 1996 to 2000. This trend was similar for the median survival time with females and males at 0.84 and 0.76 years, respectively. However, the difference decreased by the five-year survival rate where females only had a slightly higher rate at 8.6% with males at 8.2% during this period.
- Asians, as a racial/ethnic group, had the highest one-year survival rate for Lung and Bronchus Cancer (44.9%) as well as the highest five-year survival rate (10.6%) of those groups that had a rate calculated for Nevada from 1996 to 2000.
- ➤ The Lung and Bronchus Cancer Survival Rate varies greatly by the stage of the cancer at time of diagnosis. Those diagnosed at the localized stage had the highest one- and five-year survival rates with 76.1% and 38.3%, respectively. This was followed by those with Regional and then Distant diagnoses with rates of 52.1% and 18.5% for the one year period and 9.2% and 2.2% for the five year period.

INCIDENCE

Figure 37. Lung and Bronchus Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 38. Lung and Bronchus Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 39. Lung and Bronchus Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1996-2000




Table 42. Lung and Bronchus Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

			County/Region	n of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)
Total						
Cases	7,162	4,930	1,122	1,108	2	104,761
Rate*	84.1	87.5	78.2	77.1		62.8
95% C.I.	(82.1-86.1)	(85.0-90.1)	(73.7-83.0)	(72.5-81.9)		(62.5-63.2)
Gender						
Male	3,947	2,712	603	630	2	58,573
Rate*	98.8	103.3	91.1	90.8		81.5
95% C.I.	(95.6-102.2)	(99.1-107.7)	(83.6-99.2)	(83.6-98.7)		(80.8-82.2)
Female	3,214	2,218	519	477	0	46,188
Rate*	72.2	75.1	68.2	64.9		49.3
95% C.I.	(69.7-74.7)	(71.9-78.3)	(62.4-74.3)	(59.2-71.1)		(48.9-49.8)
Other/Unknown	1	0	0	1	0	0
Race/Ethnicity						
White	6,522	4,386	1,053	1,081	2	86,528
Rate*	91.0	96.1	82.8	81.7		63.2
95% C.I.	(88.7-93.3)	(93.2-99.0)	(77.9-88.1)	(76.8-86.8)		(62.8-63.6)
Black	325	300	21	4	0	11,170
Rate*	82.3	81.8	93.6			81.1
95% C.I.	(73.2-92.7)	(72.3-92.6)	(56.7-148.3)			(79.6-82.7)
Native American	28	11	6	11	0	206
Rate*	33.6	31.4		33.5		20.5
95% C.I.	(21.9-50.6)	(14.9-65.7)		(16.4-62.2)		(17.7-17.7)
Asian	134	104	28	2	0	6,564
Rate*	45.0	44.6	56.9			43.6
95% C.I.	(36.1-56.9)	(34.2-59.0)	(36.0-97.5)			(42.5-44.7)
Hispanic	140	116	14	10	0	4,648
Rate*	25.0	27.1	21.3	15.9		29.8
95% C.I.	(20.5-30.6)	(21.6-34.1)	(10.9-41.4)	(7.1-34.0)		(28.9-30.7)
Other/Unknown	13	13	0	0	0	293

^{*} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing rates for racial/ethnic groups to the National (SEER) rates. See Technical Notes for more information.

Table 43. Lung and Bronchus Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

			County/Regio	on of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)
Total						
Cases	7,162	4,930	1,122	1,108	2	104,761
Rate*	77.0	78.3	68.5	80.9		56.6
95% C.I.	(75.2-78.8)	(76.1-80.5)	(64.5-72.5)	(76.1-85.6)		(56.2-56.9)
Age Group						
<1	0	0	0	0	0	
Rate*						
95% C.I.						
1-4	0	0	0	0	0	
Rate*						
95% C.I.						
5-14	0	0	0	0	0	6
Rate*						
95% C.I.						
15-24	1	1	0	0	0	43
Rate*						0.2
95% C.I.						(0.1-0.2)
25-34	18	14	2	2	0	275
Rate*	1.3	1.4				0.9
95% C.I.	(0.7-1.8)	(0.7-2.1)				(0.8-1.1)
35-44	127	94	18	15	0	2,331
Rate*	8.5	9.5	6.5	6.6		7.5
95% C.I.	(7.0-10.0)	(7.6-11.4)	(3.5-9.5)	(3.3-10.0)		(7.2-7.8)
45-54	630	440	106	84	0	9,336
Rate*	52.1	55.5	47.2	43.7		40.8
95% C.I.	(48.0-56.2)	(50.4-60.7)	(38.2-56.2)	(34.3-53.0)		(40.0-41.6)
55-64	1,695	1,182	244	268	1	21,460
Rate*	196.9	203.3	172.5	194.3		153.3
95% C.I.	(187.5-206.3)	(191.7-214.9)	(150.8-194.1)	(171.0-217.5)		(151.2-155.3)
65-74	2,739	1,862	431	445	1	37,267
Rate*	441.8	449.1	427.3	425.9		323.0
95% C.I.	(425.3-458.4)	(428.7-469.5)	(387.0-467.7)	(386.3-465.4)		(319.7-326.3)
75-84	1,658	1,132	272	254	0	27,729
Rate*	505.9	523.5	494.3	449.7		381.5
95% C.I.	(481.5-530.2)	(493.0-554.0)	(435.5-553.0)	(394.4-505.0)		(377.0-386.0)
85+	293	204	49	40	0	6,312
Rate*	415.9	476.2	339.9	303.2		254.5
95% C.I.	(368.3-463.5)	(410.8-541.5)	(244.7-435.1)	(209.2-397.1)		(248.2-260.8)
Unknown	1	1	0	0	0	0

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 44. Lung and Bronchus Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1996-2000

County of			1996-2000 Incidence					
Residence	Cases	Rat	te*	Age-Adjust	ed Rate**			
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	260	106.1	(93.2-119.0)	89.2	(78.6-101.0)			
Churchill	105	89.0	(72.0-106.0)	93.3	(76.2-113.5)			
Clark	4,930	78.3	(76.1-80.5)	87.5	(85.0-90.1)			
Douglas	128	64.0	(52.9-75.1)	54.6	(45.1-66.0)			
Elko	74	32.3	(24.9-39.7)	58.5	(44.9-75.6)			
Esmeralda	4							
Eureka	5							
Humboldt	37	44.1	(29.9-58.3)	60.7	(42.0-86.5)			
Lander	19	59.3	(32.6-85.9)	100.0	(58.6-161.5)			
Lincoln	18	88.3	(47.5-129.1)	67.7	(40.0-118.3)			
Lyon	186	115.0	(98.4-131.5)	96.7	(83.2-112.4)			
Mineral	35	127.1	(85.0-169.3)	94.3	(65.1-136.1)			
Nye	204	137.4	(118.6-156.3)	96.2	(82.6-112.3)			
Pershing	12	42.1	(18.3-65.9)	51.9	(26.7-93.4)			
Storey	5							
Washoe	1,122	68.5	(64.5-72.5)	78.2	(73.7-83.0)			
White Pine	16	36.7	(18.7-54.7)	31.2	(17.8-52.6)			
Unknown	2							
Total	7,162	77.0	(75.2-78.8)	84.1	(82.1-86.1)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 45. Lung and Bronchus Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

			Ger	nder	
Rac	Race/Ethnicity		Female	Other/ Unknown	Total
White	Incidence	3,569	2,952	1	6,522
	Rate*	105.0	79.6		91.0
	95% C.I.	(101.4-108.8)	(76.7-82.5)		(88.7-93.3)
Black	Incidence	185	140	0	325
	Rate*	102.2	66.8		82.3
	95% C.I.	(86.4-121.8)	(55.8-79.6)		(73.2-92.7)
Native	Incidence	15	13	0	28
American	Rate*	40.5	29.9		33.6
	95% C.I.	(20.6-79.4)	(15.6-52.7)		(21.9-50.6)
Asian	Incidence	71	63	0	134
	Rate*	59.7	33.7		45.0
	95% C.I.	(43.8-83.0)	(24.5-48.7)		(36.1-56.9)
Hispanic	Incidence	99	41	0	140
	Rate*	36.5	14.7		25.0
	95% C.I.	(28.5-47.7)	(10.1-21.2)		(20.5-30.6)
Other/Unkn	own	8	5	0	13
Total	Incidence	3,947	3,214	1	7,162
	Rate*	98.8	72.2		84.1
	95% C.I.	(95.6-102.2)	(69.7-74.7)		(82.1-86.1)

Note: The "---" is used for rates calculated on numbers less than ten.

^{*}Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 46. Lung and Bronchus Cancer Cases by Age Group and Gender, Nevada Residents, 1996-2000

Age		Gen	ıder	
Group	Male	Female	Other/ Unknown	Total
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	0	0	0
Rate*				
95% C.I.				
15-24	0	1	0	1
Rate*				
95% C.I.				
25-34	13	5	0	18
Rate*	1.7			1.3
95% C.I.	(0.8-2.7)			(0.7-1.8)
35-44	63	64	0	127
Rate*	8.2	8.9		8.5
95% C.I.	(6.1-10.2)	(6.7-11.0)		(7.0-10.0)
45-54	327	303	0	630
Rate*	53.4	50.8		52.1
95% C.I.	(47.6-59.2)	(45.1-56.5)		(48.0-56.2)
55-64	969	725	1	1,695
Rate*	226.0	167.8		196.9
95% C.I.	(211.8-240.2)	(155.6-180.0)		(187.5-206.3)
65-74	1,547	1,192	0	2,739
Rate*	506.0	379.4		441.8
95% C.I.	(480.8-531.2)	(357.9-400.9)		(425.3-458.4)
75-84	877	781	0	1,658
Rate*	594.7	433.2		505.9
95% C.I.	(555.3-634.0)	(402.8-463.6)		(481.5-530.2)
85+	150	143	0	293
Rate*	661.6	299.3		415.9
95% C.I.	(555.7-767.4)	(250.3-348.4)		(368.3-463.5)
Unknown	1	0	0	1
Total	3,947	3,214	1	7,162
Rate*	83.4	70.3		77.0
95% C.I.	(80.8-86.1)	(67.9-72.7)		(75.2-78.8)

Note: The "---" is used for rates calculated on numbers less than ten.

^{*} Rates are per 100,000 age-specific population.

Table 47. Lung and Bronchus Cancer Cases by Age Group and Stage, Nevada Residents, 1996-2000

				Si	tage		
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total
<1	Number	0	0	0	0	0	0
	Percent						
1-4	Number	0	0	0	0	0	0
	Percent						
5-14	Number	0	0	0	0	0	0
	Percent						
15-24	Number	0	0	1	0	0	1
	Percent			100.0%			100.0%
25-34	Number	0	5	3	7	3	18
	Percent		27.8%	16.7%	38.9%	16.7%	100.0%
35-44	Number	0	10	32	69	16	127
	Percent		7.9%	25.2%	54.3%	12.6%	100.0%
45-54	Number	0	75	115	302	138	630
	Percent		11.9%	18.3%	47.9%	21.9%	100.0%
55-64	Number	0	251	347	669	428	1,695
	Percent		14.8%	20.5%	39.5%	25.3%	100.0%
65-74	Number	0	460	548	907	824	2,739
	Percent		16.8%	20.0%	33.1%	30.1%	100.0%
75-84	Number	0	274	257	509	618	1,658
	Percent		16.5%	15.5%	30.7%	37.3%	100.0%
85+	Number	0	31	34	59	169	293
	Percent		10.6%	11.6%	20.1%	57.7%	100.0%
Unknown	Number	0	0	0	0	1	1
	Percent					100.0%	100.0%
Total	Number Percent	0	1,106 15.4%	1,337 18.7%	2,522 35.2%	2,197 30.7%	7,162 100.0%

Table 48. Lung and Bronchus Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1996-2000

			Race/Ethnicity							
Stage		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total		
In situ	Number	0	0	0	0	0	0	0		
	Percent									
Localized	Number	1,019	43	0	22	14	8	1,106		
	Percent	15.6%	13.2%		16.4%	10.0%	61.5%	15.4%		
Regional	Number	1,212	64	6	23	30	2	1,337		
	Percent	18.6%	19.7%	21.4%	17.2%	21.4%	15.4%	18.7%		
Distant	Number	2,296	105	10	51	58	2	2,522		
	Percent	35.2%	32.3%	35.7%	38.1%	41.4%	15.4%	35.2%		
Unstaged	Number	1,995	113	12	38	38	1	2,197		
	Percent	30.6%	34.8%	42.9%	28.4%	27.1%	7.7%	30.7%		
Total	Number	6,522	325	28	134	140	13	7,162		
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%		


Table 49. Median Age at Diagnosis of Lung and Bronchus Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

	Gender							
Race/Ethnicity	Ма	ile	Female		То	tal		
	Incidence	Median Age	Incidence	Median Age	Incidence	Median Age		
White	3,568	69.0	2,952	69.0	6,520	69.0		
Black	185	65.0	140	66.0	325	66.0		
Native American	15	68.0	13	70.0	28	68.5		
Asian	71	69.0	63	66.0	134	66.0		
Hispanic	99	64.0	41	65.0	140	64.0		
Other/Unknown	8	69.0	5	69.0	13	69.0		
Total	3,946	68.0	3,214	69.0	7,160	69.0		

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

Figure 40. Lung and Bronchus Cancer Age-Adjusted (2000) Inpatient Hospital Discharge Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical notes for more information.

Figure 41. Lung and Bronchus Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 42. Median Charges for Lung and Bronchus Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000




Figure 43. Average Length of Stay for Lung and Bronchus Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000




Table 50. Lung and Bronchus Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

		Coun	ty/Region of Resid	ence				
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Discharges	4,895	3,532	709	651	3			
Rate*	56.5	61.4	49.0	44.8				
95% C.I.	(54.9-58.2)	(59.3-63.5)	(45.4-52.9)	(41.4-48.5)				
Gender								
Male	2,592	1,908	333	349	2			
Rate*	63.3	70.5	49.3	49.7				
95% C.I.	(60.8-66.0)	(67.1-74.0)	(43.9-55.4)	(44.4-55.6)				
Female	2,303	1,624	376	302	1			
Rate*	51.2	54.2	49.2	40.8				
95% C.I.	(49.1-53.3)	(51.5-56.9)	(44.3-54.5)	(36.3-45.7)				
Other/Unknown	0	0	0	0	0			
Inpatient Discharge Ch	narges (\$)							
Total Charges	\$149,204,005	\$115,506,592	\$18,390,109	\$15,220,766	\$86,538			
Average Charges	\$30,481	\$32,703	\$25,938	\$23,381	\$28,846			
Median Charges	\$24,201	\$25,913	\$20,627	\$17,074	\$5,794			
Discharge Length of S	Discharge Length of Stay (LOS) (Days)							
Total LOS	39,033	29,376	5,302	4,343	12			
Average LOS	8.0	8.3	7.5	6.7	4.0			
Median LOS	6.0	7.0	6.0	5.0	1.0			

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 51. Lung and Bronchus Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown				
Total									
Discharges	4,895	3,532	709	651	3				
Rate*	52.6	56.1	43.3	47.5					
95% C.I.	(51.1-54.1)	(54.3-58.0)	(40.1-46.5)	(43.9-51.2)					
Age Group									
<1	0	0	0	0	0				
Rate*									
95% C.I.									
1-4	0	0	0	0	0				
Rate*									
95% C.I.									
5-14	0	0	0	0	0				
Rate*									
95% C.I.									
15-24	1	1	0	0	0				
Rate*									
95% C.I.									
25-34	10	9	0	1	0				
Rate*	0.7								
95% C.I.	(0.3-1.1)								
35-44	123	95	12	16	0				
Rate*	8.2	9.6	4.3	5.8					
95% C.I.	(6.8-9.7)	(7.7-11.5)	(1.9-6.8)	(2.9-8.6)					
45-54	480	357	70	53	0				
Rate*	39.7	45.1	31.2	23.6					
95% C.I.	(36.1-43.3)	(40.4-49.7)	(23.9-38.5)	(17.2-30.0)					
55-64	1,277	947	174	156	0				
Rate*	148.3	162.9	123.0	110.3					
95% C.I.	(140.2-156.5)	(152.5-173.2)	(104.7-141.3)	(93.0-127.6)					
65-74	1,837	1,294	263	279	1				
Rate*	296.3	312.1	260.8	276.6					
95% C.I.	(282.8-309.9)	(295.1-329.1)	(229.3-292.3)	(244.2-309.1)					
75-84	1,016	725	164	126	1				
Rate*	310.0	335.3	298.0	229.0					
95% C.I.	(290.9-329.0)	(310.9-359.7)	(252.4-343.6)	(189.0-269.0)					
85+	151	104	26	20	1				
Rate*	214.3	242.8	180.4	138.7					
95% C.I.	(180.1-248.5)	(196.1-289.4)	(111.0-249.7)	(77.9-199.5)					
Unknown	0	o o	0	0	0				

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 52. Lung and Bronchus Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1996-2000

Age	Gender						
Group	Male	Female	Total				
<1	0	0	0				
Rate*							
95% C.I.							
1-4	0	0	0				
Rate*							
95% C.I.							
5-14	0	0	0				
Rate*							
95% C.I.							
15-24	0	1	1				
Rate*							
95% C.I.							
25-34	7	3	10				
Rate*			0.7				
95% C.I.			(0.3-1.1)				
35-44	55	68	123				
Rate*	7.1	9.4	8.2				
95% C.I.	(5.2-9.0)	(7.2-11.7)	(6.8-9.7)				
45-54	241	239	480				
Rate* 95% C.I.	39.4 (34.4-44.3)	40.1 (35.0-45.1)	39.7 (36.1-43.3)				
55-64	702	575	1,277				
Rate*	163.7	133.1	148.3				
95% C.I.	(151.6-175.8)	(122.2-143.9)	(140.2-156.5)				
65-74	990	847	1,837				
Rate*	323.8	269.6	296.3				
95% C.I.	(303.6-344.0)	(251.4-287.8)	(282.8-309.9)				
75-84	520	496	1,016				
Rate*	352.6	275.1	310.0				
95% C.I.	(322.3-382.9)	(250.9-299.3)	(290.9-329.0)				
85+	77	74	151				
Rate*	339.6	154.9	214.3				
95% C.I.	(263.8-415.5)	(119.6-190.2)	(180.1-248.5)				
Unknown	0	0	0				
Total	2,592	2,303	4,895				
Rate*	54.8	50.4	52.6				
95% C.I.	(52.7-56.9)	(48.3-52.4)	(51.1-54.1)				

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 53. Lung and Bronchus Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000

Onweter of	1996-2000 Inpatient Hospital Discharges						
County of Residence	Number	Rat	te*	Age-Adjus	ted Rate**		
	Number	Rate	95% C.I.	Rate	95% C.I.		
Carson City	93	37.9	(30.2-45.7)	31.4	(25.3-38.6)		
Churchill	49	41.5	(29.9-53.2)	42.1	(31.1-56.2)		
Clark	3,532	56.1	(54.3-58.0)	61.4	(59.3-63.5)		
Douglas	75	37.5	(29.0-46.0)	33.2	(25.7-42.8)		
Elko	35	15.3	(10.2-20.3)	28.1	(19.1-40.7)		
Esmeralda	8						
Eureka	5						
Humboldt	28	33.4	(21.0-45.7)	43.0	(28.1-65.1)		
Lander	14	43.7	(20.8-66.6)	76.0	(40.0-133.0)		
Lincoln	14	68.7	(32.7-104.7)	52.2	(28.4-99.6)		
Lyon	153	94.6	(79.6-109.5)	81.1	(68.5-95.7)		
Mineral	22	79.9	(46.5-113.3)	65.3	(40.3-103.7)		
Nye	139	93.6	(78.1-109.2)	60.8	(50.8-73.3)		
Pershing	7						
Storey	2						
Washoe	709	43.3	(40.1-46.5)	49.0	(45.4-52.9)		
White Pine	7						
Unknown	3						
Total	4,895	52.6	(51.1-54.1)	56.5	(54.9-58.2)		


Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 54. Lung and Bronchus Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1996-2000

Age	Discharges		Charges (\$)		Len	gth of Stay (Da	ays)
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	0						
1-4	0						
5-14	0						
15-24	1						
25-34	10	716,742	71,674	29,282	84	8.4	7.0
35-44	123	3,304,320	26,864	22,913	962	7.8	6.0
45-54	480	14,204,815	29,593	24,894	3,861	8.0	6.0
55-64	1,277	41,924,255	32,830	25,431	10,741	8.4	6.0
65-74	1,837	56,394,156	30,699	24,939	14,210	7.7	6.0
75-84	1,016	28,949,516	28,494	22,091	7,946	7.8	7.0
85+	151	3,686,000	24,411	18,730	1,225	8.1	7.0
Unknown	0						
Total	4,895	149,204,005	30,481	24,201	39,033	8.0	6.0

MORTALITY

Figure 44. Lung and Bronchus Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 45. Lung and Bronchus Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 46. Lung and Bronchus Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1996-2000




Table 55. Lung and Bronchus Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties					
Total									
Mortality	5,385	3,692	864	829					
Rate*	64.4	66.9	61.4	58.1					
95% C.I.	(62.6-66.2)	(64.7-69.2)	(57.3-65.8)	(54.1-62.3)					
Gender									
Male	3,032	2,082	466	484					
Rate*	78.1	82.0	72.5	70.6					
95% C.I.	(75.1-81.2)	(78.1-86.0)	(65.7-80.0)	(64.2-77.6)					
Female	2,353	1,610	398	345					
Rate*	53.4	55.3	52.8	47.0					
95% C.I.	(51.3-55.7)	(52.6-58.1)	(47.7-58.3)	(42.1-52.3)					
Other/Unknown	0	0	0	0					
Race/Ethnicity									
White	4,926	3,296	821	809					
Rate*	69.6	73.2	65.5	61.4					
95% C.I.	(67.6-71.6)	(70.7-75.9)	(61.0-70.2)	(57.2-65.9)					
Black	263	249	12	2					
Rate*	68.3	69.8	56.2						
95% C.I.	(59.8-78.0)	(60.8-80.0)	(28.2-102.8)						
Native American	25	9	8	8					
Rate*	30.3								
95% C.I.	(19.1-46.8)								
Asian	86	71	13	2					
Rate*	34.7	37.6	29.8						
95% C.I.	(25.6-47.2)	(26.5-53.4)	(14.6-67.0)						
Hispanic	80	65	8	7					
Rate*	16.3	17.1							
95% C.I.	(12.4-21.3)	(12.7-23.2)							
Other/Unknown	5	2	2	1					

Note: The "---" is used for rates calculated on numbers less than ten.

^{*}Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 56. Lung and Bronchus Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties					
Total									
Mortality	5,385	3,692	864	829					
Rate*	57.9	58.6	52.8	60.5					
95% C.I.	(56.3-59.4)	(56.8-60.5)	(49.2-56.3)	(56.4-64.6)					
Age Group									
<1	0	0	0	0					
Rate*									
95% C.I.									
1-4	0	0	0	0					
Rate*									
95% C.I.									
5-14	0	0	0	0					
Rate*									
95% C.I.									
15-24	1	1	0	0					
Rate*									
95% C.I.									
25-34	7	7	0	0					
Rate*									
95% C.I.									
35-44	77	54	13	10					
Rate*	5.2	5.5	4.7	4.4					
95% C.I.	(4.0-6.3)	(4.0-6.9)	(2.1-7.2)	(1.7-7.2)					
45-54	430	313	64	53					
Rate*	35.6	39.5	28.5	27.6					
95% C.I.	(32.2-38.9)	(35.1-43.9)	(21.5-35.5)	(20.1-35.0)					
55-64	1,174	804	181	189					
Rate*	136.4	138.3	128.0	137.0					
95% C.I.	(128.6-144.2)	(128.7-147.8)	(109.3-146.6)	(117.5-156.5)					
65-74	2,036	1,387	314	335					
Rate*	328.4	334.6	311.3	320.6					
95% C.I.	(314.2-342.7)	(317.0-352.2)	(276.9-345.8)	(286.3-354.9)					
75-84	1,377	927	242	208					
Rate*	420.1	428.7	439.8	368.3					
95% C.I.	(397.9-442.3)	(401.1-456.3)	(384.4-495.2)	(318.2-418.3)					
85+	282	198	50	34					
Rate*	400.3	462.2	346.8	257.7					
95% C.I.	(353.6-447.0)	(397.8-526.6)	(250.7-443.0)	(171.1-344.3)					
Unknown	1	1	0	0					

Note: The "---" is used for rates calculated on numbers less than ten. * Rates are per 100,000 age-specific population.

Table 57. Lung and Bronchus Cancer Mortality by County of Residence, Nevada Residents, 1996-2000

Country of	1996-2000 Mortality							
County of Residence	Rate*			Age-Adjusted Rate**				
	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	207	84.4	(72.9-96.0)	71.0	(61.6-81.5)			
Churchill	56	47.5	(35.0-59.9)	49.8	(37.5-65.3)			
Clark	3,692	58.6	(56.8-60.5)	66.9	(64.7-69.2)			
Douglas	115	57.5	(47.0-68.0)	50.1	(40.9-61.2)			
Elko	61	26.6	(19.9-33.3)	50.2	(37.4-66.6)			
Esmeralda	4							
Eureka	3							
Humboldt	34	40.5	(26.9-54.1)	59.6	(40.7-85.8)			
Lander	10	31.2	(11.9-50.5)	51.2	(23.3-100.1)			
Lincoln	9							
Lyon	133	82.2	(68.2-96.2)	68.1	(56.9-81.4)			
Mineral	19	69.0	(38.0-100.1)	52.7	(31.3-87.5)			
Nye	144	97.0	(81.2-112.9)	67.8	(56.5-81.7)			
Pershing	9							
Storey	9							
Washoe	864	52.8	(49.2-56.3)	61.4	(57.3-65.8)			
White Pine	16	36.7	(18.7-54.7)	31.9	(18.2-53.7)			
Unknown	0							
Total	5,385	57.9	(56.3-59.4)	64.4	(62.6-66.2)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 58. Lung and Bronchus Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

		Gender						
Rac	ce/Ethnicity	Male	Female	Total				
White	Mortality	2,757	2,169	4,926				
	Rate* 95% C.I.	82.9 (79.6-86.3)	58.8 (56.3-61.4)	69.6 (67.6-71.6)				
Black	Mortality	164	99	263				
	Rate* 95% C.I.	95.9 (79.8-115.9)	47.5 (38.3-58.6)	68.3 (59.8-78.0)				
Native	Mortality	14	11	25				
American	Rate*	42.2	24.7	30.3				
	95% C.I.	(20.2-84.1)	(12.1-45.9)	(19.1-46.8)				
Asian	Mortality	41	45	86				
	Rate*	40.4	30.3	34.7				
	95% C.I.	(25.7-63.3)	(19.6-47.3)	(25.6-47.2)				
Hispanic	Mortality	54	26	80				
	Rate*	23.2	10.5	16.3				
	95% C.I.	(16.2-33.8)	(6.5-16.4)	(12.4-21.3)				
Other/Unkr	nown	2	3	5				
Total	Mortality	3,032	2,353	5,385				
	Rate*	78.1	53.4	64.4				
	95% C.I.	(75.1-81.2)	(51.3-55.7)	(62.6-66.2)				

Note: The "---" is used for rates calculated on numbers less than ten.

^{*}Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 59. Lung and Bronchus Cancer Mortality by Age Group and Gender, Nevada Residents, 1996-2000

Age	Gender						
Group	Male	Female	Total				
<1	0	0	0				
Rate*							
95% C.I.							
1-4	0	0	0				
Rate*							
95% C.I.							
5-14	0	0	0				
Rate*							
95% C.I.							
15-24	0	1	1				
Rate*							
95% C.I.							
25-34	5	2	7				
Rate*							
95% C.I.							
35-44	34	43	77				
Rate*	4.4	6.0	5.2				
95% C.I.	(2.9-5.9)	(4.2-7.7)	(4.0-6.3)				
45-54	232	198	430				
Rate*	37.9	33.2	35.6				
95% C.I.	(33.0-42.8)	(28.6-37.8)	(32.2-38.9)				
55-64	707	467	1,174				
Rate*	164.9	108.1	136.4				
95% C.I.	(152.7-177.1)	(98.3-117.9)	(128.6-144.2)				
65-74	1,164	872	2,036				
Rate*	380.7	277.6	328.4				
95% C.I.	(358.8-402.6)	(259.1-296.0)	(314.2-342.7)				
75-84	742	635	1,377				
Rate*	503.1	352.2	420.1				
95% C.I.	(466.9-539.3)	(324.8-379.6)	(397.9-442.3)				
85+	147	135	282				
Rate*	648.3	282.6	400.3				
95% C.I.	(543.5-753.1)	(234.9-330.2)	(353.6-447.0)				
Unknown	1	0	1				
Total	3,032	2,353	5,385				
Rate*	64.1	51.5	57.9 (56.3.50.4)				
95% C.I.	(61.8-66.4)	(49.4-53.5)	(56.3-59.4)				

Note: The "---" is used for rates calculated on numbers less than ten.

^{*} Rates are per 100,000 age-specific population.


Table 60. Median Age at Death from Lung and Bronchus Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

	Gender								
Race/Ethnicity	Ма	ile	Fem	nale	Total				
	Deaths	Median Age	Deaths	Median Age	Deaths	Median Age			
White	2,756	70.0	2,169	70.0	4,925	70.0			
Black	164	66.0	99	66.0	263	66.0			
Native American	14	67.0	11	69.0	25	68.0			
Asian	41	69.0	45	68.0	86	68.5			
Hispanic	54	66.0	26	67.5	80	66.0			
Other/Unknown	2		3		5	70.0			
Total	3,031	69.0	2,353	70.0	5,384	70.0			

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE

Figure 47. Survival Rates for Lung and Bronchus Cancer by Race/Ethnicity, Nevada Residents, 1996-2000



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 48. Survival Rates for Lung and Bronchus Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 1996-2000




Table 61. Cause-Specific Survival Rates for Lung and Bronchus Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

Race/			Median				
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)
Total	4,702	37.0%	19.5%	14.2%	10.2%	8.4%	0.79
Male	2,575	34.4%	18.2%	13.5%	9.5%	8.2%	0.76
Female	2,127	40.3%	21.2%	15.1%	11.1%	8.6%	0.84
Race/Ethnicity							
White	4,276	36.6%	19.1%	13.9%	10.0%	8.4%	0.79
Male	2,331	34.0%	17.6%	13.1%	9.1%	7.7%	0.76
Female	1,945	39.8%	20.9%	14.9%	11.1%	9.3%	0.83
Black	213	38.5%	19.7%	15.0%	10.4%	3.5%	0.81
Male	119	31.2%	15.6%	11.4%	11.4%	11.4%	0.73
Female	94	48.2%	25.0%	19.7%	9.9%	0.0%	0.97
Native American	16						
Male	9						
Female	7						
Asian	90	44.9%	21.3%	10.6%	10.6%	10.6%	0.91
Male	46						
Female	44						
Hispanic	97	42.9%	34.1%	23.3%	14.0%		0.88
Male	64	41.4%	32.8%	27.8%	16.7%		0.85
Female	33						

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 62. Cause-Specific Survival Rates for Lung and Bronchus Cancer by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1996-2000


Survival Rate of Stage at Diagnosis			Gender					
		Total	Male	Female				
Total	Cases	4,702	2,575	2,127				
	One Year	37.0%	34.4%	40.3%				
	5 Years	8.4%	8.2%	8.6%				
	Median Survival	0.79	0.76	0.84				
Stage at D	iagnosis							
In situ	Cases	0	0	0				
	One Year							
	5 Years							
	Median Survival							
Localized	Cases	751	392	359				
	One Year	76.1%	73.5%	79.2%				
	5 Years	38.3%	37.8%	38.9%				
	Median Survival	2.84	2.74	2.95				
Regional	Cases	987	522	465				
	One Year	52.1%	54.5%	49.4%				
	5 Years	9.2%	9.5%	8.9%				
	Median Survival	1.08	1.15	0.99				
Distant	Cases	1,954	1,115	839				
	One Year	18.5%	15.8%	22.2%				
	5 Years	2.2%	1.8%	2.7%				
	Median Survival	0.61	0.59	0.64				
Unstaged	Cases	1,010	546	464				
	One Year	34.6%	30.6%	39.4%				
	5 Years	2.6%	3.6%	2.9%				
	Median Survival	0.76	0.72	0.83				

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

BREAST CANCER

BREAST CANCER GENERAL PROFILE⁴

Figure 49. Anatomy of the Breast⁵



General Anatomy: Each breast has 15 to 20 sections called lobes. Within each lobe are many smaller lobules, which end in dozens of tiny bulbs that can produce milk. The lobes, lobules, and bulbs are all linked by thin tubes called ducts. These ducts lead to the nipple in the center of a dark area of skin called the areola. Fat surrounds the lobules and ducts. Each breast also contains blood vessels and lymph vessels. The lymph vessels carry colorless fluid called lymph, and lead to small bean-shaped organs called lymph nodes. Clusters of lymph nodes are found near the breast in the axilla (under the arm), above the collarbone, and in the chest. Lymph nodes are also found in many other parts of the body.

Risk Factors: Personal, and/or family, history of Breast Cancer, atypical hyperplasia, lobular carcinoma in situ, prolonged levels of estrogen, later childbearing, breast density, radiation therapy, and alcohol use are all important risk factors.

Signs and Symptoms: Common signs and symptoms include: A lump or thickening in or near the breast or in the underarm area, change in the size or shape of the breast, nipple discharge or tenderness, nipple inverted into breast, ridges or pitting of the breast, and a change in the way the skin of the breast, areola, or nipple looks or feels (for example, warm, swollen, red, or scaly).

Diagnosing the Cancer: The most common ways of diagnosing Breast Cancer are: clinical breast exam, mammography, ultrasonography, fine-needle aspiration, and needle or surgical biopsy.

Treatment: Treatment options include: surgery (Lumpectomy, Segmental Mastectomy, Simple Mastectomy, and Radical Mastectomy), radiation therapy, chemotherapy, hormonal therapy, and biological therapy.

HIGHLIGHTS

- ➤ The ratio of the age-adjusted incidence rate, 124.3, to the age-adjusted mortality rate, 26.1 (per 100,000 2000 US Standard female population), for Female Breast Cancer was 4.76 during the 1996 to 2000 period, which means that for every 4.76 Female Breast Cancer cases there was one female death due to Breast Cancer in Nevada during this period.
- ➤ The median age at diagnosis of Breast Cancer for Nevada females was 61 years of age from 1996 to 2000. The median age at time of death due to Breast Cancer for females was 67 years.

CANCER SCREENING

- From 1996 to 2000, 93.9% of the 5,593 Nevadan females who responded had ever had a mammogram and/or a clinical breast exam to try and detect early signs of Breast Cancer.
- The percentage of women who stated their education level at less than high school, 89.8% (87.1%-92.5%), or high school, 91.3% (90.0%-92.6%), had a statistically significant lower rate of ever having had a mammogram and/or clinical breast exam than those who stated their education level at some post high school, 96.0% (95.1%-96.9%), or college graduate, 96.7% (95.7%-97.7%), during the 1996 to 2000 period.
- Those women whose age was 18 to 24 years, 80.7% (77.3%-84.1%), had the lowest statistically significant percentage of ever having a mammogram and/or a clinical breast exam of any age group surveyed from 1996 to 2000. However, those women 25 to 34 years of age also had a statistically significant lower percentage, 92.2% (90.6%-93.8%), than all other age groups surveyed.

INCIDENCE

- ➤ There were 5,582 cases of Female Breast Cancer reported in Nevada from 1996 to 2000. Regional comparisons showed that Washoe County's age-adjusted incidence rate, 148.1 (139.6-156.9), was statistically higher than the rate for Clark County, 119.6 (115.7-123.7), and the All Other Counties region, 117.8 (110.0-126.1), during this period. However, Nevada and all three regions had lower statistically significant rates than the National rate, 161.3 (160.4-162.1 per 100,000 2000 US Standard female population) during this period.
- Asian females were considerably lower than the statewide median age at time of diagnosis for Breast Cancer (61 years) with a median age of 52 years, the lowest of any racial/ethnic group. The racial/ethnic group with the highest median age at diagnosis was White females with a median age of 62 years for the 1996 to 2000 period.
- ➤ White females accounted for 88.9% of all reported Female Breast Cancer cases in Nevada from 1996 to 2000. They had a statistically significant higher rate, 137.7 (133.9-

141.6), than Black females, 96.0 (83.5-110.3), Asian females, 52.5 (42.6-67.6), Hispanic females, 42.8 (35.8-51.3), and Native American females, 38.8 (23.6-61.7), per 100,000 – 2000 US Standard population, during this period.

INPATIENT HOSPITAL DISCHARGES

- ➤ There were 2,524 female hospital inpatient discharges with a primary diagnosis of Breast Cancer from 1996 to 2000. Washoe County had the highest age-adjusted inpatient discharge rate, 62.4, for Female Breast Cancer, and was followed by Clark County and the All Other Counties region with rates of 55.9 and 50.8 (per 100,000 2000 US Standard female population), respectively.
- Total billed charges for hospital inpatient discharges from Breast Cancer in Nevada totaled nearly 35 million dollars from 1996 to 2000. Washoe County had the highest median total charge (\$12,108) and average length of stay (2.8 days) during this time; once regional comparisons were made.
- ➤ The overall average billed charge per day for a Breast Cancer inpatient hospital discharge in Nevada was over \$5,600 from 1996 to 2000.

MORTALITY

- ➤ There were 1,128 female deaths in Nevada due to Breast Cancer from 1996 to 2000. While Washoe County had a higher age-adjusted mortality rate for Female Breast Cancer (28.8) than Clark County (26.4) and All Other Counties (21.7), statistical analysis does not indicate a statistical difference between the three regions or the statewide rate of 26.1 (per 100,000 2000 US Standard female population) for this period.
- ➤ Racial/ethnic comparisons showed that Black and White females had higher age-adjusted mortality rates, 32.8 and 27.8, respectively, when compared to Asians and Hispanics who had rates of 13.0 and 11.8 (per 100,000 2000 US Standard female population), respectively, from 1996 to 2000.

SURVIVAL RATE

- ➤ Hispanic females in Nevada had the highest one-year survival rate (96.7%) of any racial/ethnic group for Female Breast Cancer during the 1996 to 2000 period. They were followed by Asian, White and Black females with rates of 95.7%, 94.4% and 86.4%, respectively. However, Asian females had the highest five-year survival rate (87.8%) for Female Breast Cancer during this time, while White, Hispanic and Black females followed with rates of 73.9%, 62.8% and 47.4%, respectively.
- The five-year survival rate for females diagnosed with Breast Cancer at the in situ stage was 96.7% for Nevada from 1996 to 2000. The rate for those at the localized stage was 86.4%, while those recorded at the regional, distant and unstaged stages had rates of 68.1%, 6.0% and 21.6%, respectively.

SCREENING (BRFSS)

Table 63. Female Breast Cancer Screening by County/Region of Residence, Education, Age Group, and Income, Nevada Residents, 1996-2000

	Answers									
Responses		Yes			No		_ , .			
	Number	Percent*	95% C.I.	Number	Percent*	95% C.I.	Total			
Total	Total									
Responses	5,248	93.9%	(93.3%-94.5%)	345	6.1%	(5.5%-6.7%)	5,593			
County/Region of Resid	lence									
Clark County	1,687	94.2%	(93.1%-95.3%)	110	5.8%	(4.7%-6.9%)	1,797			
Washoe County	1,745	94.6%	(93.6%-95.6%)	105	5.4%	(4.4%-6.4%)	1,850			
All Other Counties	1,816	92.0%	(90.8%-93.2%)	130	8.0%	(6.8%-9.2%)	1,946			
Education										
Less than High School	443	89.8%	(87.1%-92.5%)	56	10.2%	(7.5%-12.9%)	499			
High School	1,668	91.3%	(90.0%-92.6%)	146	8.7%	(7.4%-10.0%)	1,814			
Some Post High School	1,862	96.0%	(95.1%-96.9%)	104	4.0%	(3.1%-4.9%)	1,966			
College Graduate	1,264	96.7%	(95.7%-97.7%)	38	3.3%	(2.3%-4.3%)	1,302			
Age Group										
18-24 years old	398	80.7%	(77.3%-84.1%)	110	19.3%	(15.9%-22.7%)	508			
25-34 years old	973	92.2%	(90.6%-93.8%)	66	7.8%	(6.2%-9.4%)	1,039			
35-44 years old	1,248	95.5%	(94.4%-96.6%)	59	4.5%	(3.4%-5.6%)	1,307			
45-54 years old	1,031	97.8%	(96.9%-98.7%)	23	2.2%	(1.3%-3.1%)	1,054			
55-64 years old	671	96.9%	(95.6%-98.2%)	21	3.1%	(1.8%-4.4%)	692			
65+ years old	904	95.5%	(94.2%-96.8%)	63	4.5%	(3.2%-5.8%)	967			
Income										
Less than \$15,000	582	91.1%	(88.9%-93.3%)	69	8.9%	(6.7%-11.1%)	651			
\$15,000 - \$24,999	467	90.0%	(87.4%-92.6%)	59	10.0%	(7.4%-12.6%)	526			
\$25,000 - \$34,999	812	93.6%	(92.0%-95.2%)	52	6.4%	(4.8%-8.0%)	864			
\$35,000 - \$49,999	1,024	95.0%	(93.7%-96.3%)	40	5.0%	(3.7%-6.3%)	1,064			
\$50,000 or More	1,533	96.5%	(95.6%-97.4%)	36	3.5%	(2.6%-4.4%)	1,569			

^{*}Denominator is persons age 18-64 and excludes missing, don't know, and refused responses.


Note: This table includes those respondents who answered "Yes" or "No" to either of the following questions:

¹⁾ A mammogram is an x-ray of each breast to look for breast cancer. Have you ever had a mammogram?

²⁾ A clinical breast exam is when a doctor, nurse, or other health professional feels the breast for lumps. Have you ever had a clinical breast exam?

INCIDENCE

Figure 50. Female Breast Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 female population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 51. Female Breast Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 52. Female Breast Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1996-2000




Table 64. Breast Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)			
Total									
Cases	5,643	3,605	1,170	867	1	148,611			
Rate*	64.8	62.4	78.0	60.9		87.9			
95% C.I.	(63.1-66.6)	(60.3-64.5)	(73.5-82.7)	(56.8-65.2)		(87.5-88.4)			
Gender									
Male	59	33	12	14	0	923			
Rate*	1.5	1.3	1.8	2.0					
95% C.I.	(1.1-2.0)	(0.9-2.0)	(0.9-3.6)	(1.1-3.7)					
Female	5,582	3,572	1,156	853	1	147,688			
Rate*	124.3	119.6	148.1	117.8		161.3			
95% C.I.	(121.0-127.6)	(115.7-123.7)	(139.6-156.9)	(110.0-126.1)		(160.4-162.1)			
Other/Unknown	2	0	2	0	0	0			
Race/Ethnicity									
White	4,962	3,054	1,084	823	1	122,654			
Rate*	137.7	134.3	161.2	126.0		166.8			
95% C.I.	(133.9-141.6)	(129.5-139.2)	(151.8-171.2)	(117.5-135.1)		(165.9-167.8)			
Black	229	212	13	4	0	12,369			
Rate*	96.0	95.8	106.6			145.9			
95% C.I.	(83.5-110.3)	(82.7-110.8)	(56.2-188.2)			(143.4-148.6)			
Native American	21	4	7	10	0	324			
Rate*	38.8			46.4		46.7			
95% C.I.	(23.6-61.7)			(22.0-88.7)		(41.6-52.3)			
Asian	131	102	25	4	0	11,003			
Rate*	52.5	52.0	61.7			120.4			
95% C.I.	(42.6-67.6)	(40.8-70.0)	(38.4-128.1)			(118.1-122.7)			
Hispanic	164	127	26	11	0	9,833			
Rate*	42.8	41.7	53.7	38.1		95.2			
95% C.I.	(35.8-51.3)	(34.0-51.5)	(32.2-91.2)	(17.9-75.9)		(93.3-97.1)			
Other/Unknown	75	73	1	1	0	1,338			

^{*} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Rates for race/ethnicity groups are per 100,000 female population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the National (SEER) rates. See Technical Notes for more information.

Table 65. Female Breast Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

			County/Regio	on of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)
Total						
Cases	5,582	3,572	1,156	853	1	147,688
Rate*	122.1	115.5	143.2	126.7		157.0
95% C.I.	(118.9-125.3)	(111.7-119.3)	(135.0-151.5)	(118.2-135.2)		(156.2-157.8)
Age Group						
<1	0	0	0	0	0	
Rate*						
95% C.I.						
1-4	0	0	0	0	0	
Rate*						
95% C.I.						
5-14	0	0	0	0	0	
Rate*						
95% C.I.						
15-24	3	3	0	0	0	109
Rate*						0.9
95% C.I.						(0.7-1.0)
25-34	97	67	16	14	0	2,761
Rate*	14.1	13.7	13.2	18.0		19.0
95% C.I.	(11.3-16.9)	(10.5-17.0)	(6.7-19.6)	(8.6-27.4)		(18.3-19.7)
35-44	591	392	132	67	0	16,467
Rate*	81.9	82.7	97.0	59.9		104.9
95% C.I.	(75.3-88.5)	(74.5-90.9)	(80.4-113.5)	(45.5-74.2)		(103.3-106.5)
45-54	1,225	793	264	168	0	33,764
Rate*	205.3	201.8	240.7	178.6		290.6
95% C.I.	(193.8-216.8)	(187.7-215.8)	(211.7-269.8)	(151.6-205.6)		(287.5-293.7)
55-64	1,298	845	248	205	0	30,854
Rate*	300.4	286.3	356.1	304.4		423.6
95% C.I.	(284.0-316.7)	(267.0-305.6)	(311.8-400.4)	(262.7-346.1)		(418.9-428.3)
65-74	1,372	868	275	228	1	33,105
Rate*	436.7	413.6	528.6	436.2		518.7
95% C.I.	(413.6-459.8)	(386.1-441.1)	(466.1-591.1)	(379.6-492.8)		(513.1-524.3)
75-84	795	481	173	141	0	24,254
Rate*	441.0	406.7	549.9	461.6		555.0
95% C.I.	(410.3-471.6)	(370.3-443.0)	(468.0-631.9)	(385.4-537.8)		(548.0-561.9)
85+	200	122	48	30	0	7,294
Rate*	418.6	416.0	479.3	355.7		419.5
95% C.I.	(360.6-476.6)	(342.2-489.8)	(343.7-614.9)	(228.4-483.0)		(409.8-429.1)
Unknown	1	1	0	0	0	0

^{*}Rates are per 100,000 age-specific female population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 66. Female Breast Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1996-2000 (Revised)

County of		nce			
Residence	Cases	Rat	e*	Age-Adjust	ed Rate**
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.
Carson City	276	221.3	(195.2-247.4)	183.1	(161.9-206.6)
Churchill	82	139.5	(109.3-169.7)	142.5	(113.3-177.3)
Clark	3,572	115.5	(111.7-119.3)	119.6	(115.7-123.7)
Douglas	123	124.2	(102.2-146.1)	99.9	(82.8-120.7)
Elko	41	37.5	(26.0-49.0)	52.0	(36.6-72.9)
Esmeralda	3				
Eureka	4				
Humboldt	28	69.9	(44.0-95.8)	83.5	(54.6-123.5)
Lander	13	83.5	(38.1-128.9)	112.5	(58.4-200.5)
Lincoln	8				
Lyon	132	165.5	(137.3-193.8)	142.6	(119.1-170.0)
Mineral	20	146.9	(82.5-211.3)	124.0	(74.9-199.5)
Nye	83	115.5	(90.7-140.4)	81.1	(64.0-103.2)
Pershing	15	108.6	(53.6-163.6)	122.3	(68.3-203.3)
Storey	6				
Washoe	1,156	143.2	(135.0-151.5)	148.1	(139.6-156.9)
White Pine	19	87.8	(48.3-127.2)	76.7	(45.8-124.7)
Unknown	1				
Total	5,582	122.1	(118.9-125.3)	124.3	(121.0-127.6)

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 female population. **Rates are per 100,000 female population and are age-adjusted to the 2000 US Standard population.

Table 67. Breast Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

			Gender						
Rac	e/Ethnicity	Male	Female	Other/ Unknown	Total				
White	Incidence	51	4,962	2	5,015				
	Rate*	1.5	137.7		71.0				
	95% C.I.	(1.1-2.1)	(133.9-141.6)		(69.0-73.0)				
Black	Incidence	6	229	0	235				
	Rate*		96.0		53.0				
	95% C.I.		(83.5-110.3)		(45.9-61.4)				
Native	Incidence	0	21	0	21				
American	Rate*		38.8		21.0				
	95% C.I.		(23.6-61.7)		(12.6-34.5)				
Asian	Incidence	1	131	0	132				
	Rate*		52.5		30.5				
	95% C.I.		(42.6-67.6)		(24.8-39.0)				
Hispanic	Incidence	1	164	0	165				
	Rate*		42.8		22.2				
	95% C.I.		(35.8-51.3)		(18.4-27.1)				
Other/Unkr	iown	0	75	0	75				
Total	Incidence	59	5,582	2	5,643				
	Rate*	1.5	124.3		64.8				
	95% C.I.	(1.1-2.0)	(121.0-127.6)		(63.1-66.6)				

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 female population and are age-adjusted to the 2000 US Standard population.

Table 68. Breast Cancer Cases by Age Group and Gender, Nevada Residents, 1996-2000

Age	Gender						
Group	Male	Female	Other/ Unknown	Total			
<1	0	0	0	0			
Rate*							
95% C.I.							
1-4	0	0	0	0			
Rate*							
95% C.I.							
5-14	0	0	0	0			
Rate*							
95% C.I.							
15-24	0	3	0	3			
Rate*							
95% C.I.							
25-34	1	97	0	98			
Rate*		14.1		6.8			
95% C.I.		(11.3-16.9)		(5.5-8.2)			
35-44 Rate*	3	591 81.9	0	594 39.8			
95% C.I.		(75.3-88.5)		(36.6-43.0)			
45-54	7	1,225		1,233			
Rate*	,	205.3	· · · · · · · · · · · · · · · · · · ·	102.0			
95% C.I.		(193.8-216.8)		(96.3-107.7)			
55-64	15	1,298	0	1,313			
Rate*	3.5	300.4		152.5			
95% C.I.	(1.7-5.3)	(284.0-316.7)		(144.3-160.8)			
65-74	14	1,372	1	1,387			
Rate*	4.6	436.7		223.7			
95% C.I.	(2.2-7.0)	(413.6-459.8)		(212.0-235.5)			
75-84	17	795	0	812			
Rate*	11.5	441.0		247.7			
95% C.I.	(6.0-17.0)	(410.3-471.6)		(230.7-264.8)			
85+	2	200	0	202			
Rate*		418.6		286.7			
95% C.I.		(360.6-476.6)		(247.2-326.3)			
Unknown	0	1	0	1			
Total	59	5,582	2	5,643			
Rate*	1.2	122.1		60.7			
95% C.I.	(0.9-1.6)	(118.9-125.3)		(59.1-62.2)			

Note: The "---" is used for rates calculated on numbers less than ten.

^{*} Rates are per 100,000 age-specific population.

Table 69. Breast Cancer Cases by Age Group and Stage, Nevada Residents, 1996-2000

A = = 0	C	Stage						
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total	
<1	Number	0	0	0	0	0	0	
	Percent							
1-4	Number	0	0	0	0	0	0	
	Percent							
5-14	Number	0	0	0	0	0	0	
	Percent							
15-24	Number	0	1	1	0	1	3	
	Percent		33.3%	33.3%		33.3%	100.0%	
25-34	Number	9	39	36	5	9	98	
	Percent	9.2%	39.8%	36.7%	5.1%	9.2%	100.0%	
35-44	Number	72	256	201	37	28	594	
	Percent	12.1%	43.1%	33.8%	6.2%	4.7%	100.0%	
45-54	Number	208	566	316	50	93	1,233	
	Percent	16.9%	45.9%	25.6%	4.1%	7.5%	100.0%	
55-64	Number	179	642	349	60	83	1,313	
	Percent	13.6%	48.9%	26.6%	4.6%	6.3%	100.0%	
65-74	Number	191	705	288	71	132	1,387	
	Percent	13.8%	50.8%	20.8%	5.1%	9.5%	100.0%	
75-84	Number	75	459	154	51	73	812	
	Percent	9.2%	56.5%	19.0%	6.3%	9.0%	100.0%	
85+	Number	9	87	34	11	61	202	
	Percent	4.5%	43.1%	16.8%	5.4%	30.2%	100.0%	
Unknown	Number	0	0	1	0	0	1	
	Percent			100.0%			100.0%	
Total	Number	743	2,755	1,380	285	480	5,643	
	Percent	13.2%	48.8%	24.5%	5.1%	8.5%	100.0%	

Table 70. Breast Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1996-2000

		Race/Ethnicity						
	Stage		Black	Native American	Asian	Hispanic	Other/ Unknown	Total
In situ	Number	658	24	3	21	16	21	743
	Percent	13.1%	10.2%	14.3%	15.9%	9.7%	28.0%	13.2%
Localized	Number	2,467	98	9	67	75	39	2,755
	Percent	49.2%	41.7%	42.9%	50.8%	45.5%	52.0%	48.8%
Regional	Number	1,215	62	5	33	54	11	1,380
	Percent	24.2%	26.4%	23.8%	25.0%	32.7%	14.7%	24.5%
Distant	Number	245	25	2	3	8	2	285
	Percent	4.9%	10.6%	9.5%	2.3%	4.8%	2.7%	5.1%
Unstaged	Number	430	26	2	8	12	2	480
	Percent	8.6%	11.1%	9.5%	6.1%	7.3%	2.7%	8.5%
Total	Number	5,015	235	21	132	165	75	5,643
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%


Table 71. Median Age at Diagnosis of Breast Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

	Gender								
Race/Ethnicity	Ma	le	Fem	iale	То	Total			
	Incidence	Median Age	Incidence	Median Age	Incidence	Median Age			
White	51	67.0	4,961	62.0	5,012	62.0			
Black	6	70.0	229	55.0	235	56.0			
Native American	0		21	60.0	21	60.0			
Asian	1		131	52.0	132	52.0			
Hispanic	1		164	53.0	165	53.0			
Other/Unknown	0		75	56.0	75	56.0			
Total	59	66.0	5,581	61.0	5,640	61.0			

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

Figure 53. Female Breast Cancer Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 female population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical notes for more information.

Figure 54. Female Breast Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 55. Median Charges for Breast Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000




Figure 56. Average Length of Stay for Breast Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000




Table 72. Breast Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

		Coun	ty/Region of Resid	lence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	2,542	1,679	493	368	2
Rate*	29.2	29.1	32.6	26.1	
95% C.I.	(28.1-30.4)	(27.7-30.6)	(29.8-35.7)	(23.5-29.0)	
Gender					
Male	18	11	4	3	0
Rate*	0.5	0.5			
95% C.I.	(0.3-0.9)	(0.2-1.0)			
Female	2,524	1,668	489	365	2
Rate*	56.2	55.9	62.4	50.8	
95% C.I.	(54.0-58.5)	(53.2-58.7)	(57.0-68.3)	(45.7-56.3)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Cl	narges (\$)				
Total Charges	\$34,663,372	\$22,210,278	\$8,194,104	\$4,236,598	\$22,392
Average Charges	\$13,636	\$13,228	\$16,621	\$11,512	\$11,196
Median Charges	\$10,622	\$10,515	\$12,108	\$8,597	\$11,196
Discharge Length of S	stay (LOS) (Days)				
Total LOS	6,155	3,975	1,403	774	
Average LOS	2.4	2.4	2.8	2.1	
Median LOS	1.0	1.0	2.0	1.0	

^{*} Rates are per 100,000 female population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 73. Female Breast Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown		
Total							
Cases	2,524	1,668	489	365	2		
Rate*	55.2	53.9	60.6	54.2			
95% C.I.	(53.0-57.3)	(51.3-56.5)	(55.2-66.0)	(48.7-59.8)			
Age Group							
<1	0	0	0	0	0		
Rate*							
95% C.I.							
1-4	0	0	0	0	0		
Rate*							
95% C.I.							
5-14	0	0	0	0	0		
Rate*							
95% C.I.							
15-24	1	0	0	1	0		
Rate*							
95% C.I.							
25-34	56	38	11	7	0		
Rate*	8.2	7.8	9.0				
95% C.I.	(6.0-10.3)	(5.3-10.3)	(3.7-14.4)				
35-44	290	192	62	36	0		
Rate*	40.2	40.5	45.5	32.2			
95% C.I.	(35.5-44.8)	(34.8-46.2)	(34.2-56.9)	(21.7-42.7)			
45-54	511	348	94	69	0		
Rate*	85.6	88.6	85.7	73.4			
95% C.I.	(78.2-93.1)	(79.3-97.9)	(68.4-103.0)	(56.1-90.7)			
55-64	578	393	113	70	2		
Rate*	133.8	133.2	162.2	103.9			
95% C.I.	(122.9-144.7)	(120.0-146.3)	(132.3-192.2)	(79.6-128.3)			
65-74	615	394	121	100	0		
Rate*	195.8	187.7	232.6	191.3			
95% C.I.	(180.3-211.2)	(169.2-206.3)	(191.1-274.0)	(153.8-228.8)			
75-84	387	248	71	68	0		
Rate*	214.7	209.7	225.7	222.6			
95% C.I.	(193.3-236.0)	(183.6-235.8)	(173.2-278.2)	(169.7-275.6)			
85+	85	55	16	14	0		
Rate*	177.9	187.5	159.8	166.0			
95% C.I.	(140.1-215.7)	(138.0-237.1)	(81.5-238.0)	(79.0-253.0)			
Unknown	1	0	1	0	0		

^{*} Rates are per 100,000 female age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 74. Breast Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1996-2000

Age		Gender	
Group	Male	Female	Total
<1	0	0	0
Rate*			
95% C.I.			
1-4	0	0	0
Rate*			
95% C.I.			
5-14	0	0	0
Rate*			
95% C.I.			
15-24	0	1	1
Rate*			
95% C.I.			
25-34	1	56	57
Rate*		8.2	4.0
95% C.I.		(6.0-10.3)	(2.9-5.0)
35-44	1	290	291
Rate*		40.2	19.5
95% C.I.		(35.5-44.8)	(17.2-21.7)
45-54	1	511	512
Rate*		85.6	42.3
95% C.I.		(78.2-93.1)	(38.7-46.0)
55-64	4	578	582
Rate*		133.8	67.6
95% C.I.		(122.9-144.7)	(62.1-73.1)
65-74	3	615	618
Rate*		195.8	99.7
95% C.I.		(180.3-211.2)	(91.8-107.6)
75-84	7	387	394
Rate*		214.7	120.2
95% C.I.		(193.3-236.0)	(108.3-132.1)
85+	1	85	86
Rate*		177.9	122.1
95% C.I.		(140.1-215.7)	(96.3-147.9)
Unknown	0	1	1
Total	18	2,524	2,542
Rate*	0.4	55.2 (53.0.57.3)	27.3
95% C.I.	(0.2-0.6)	(53.0-57.3)	(26.3-28.4)

^{*} Rates are per 100,000 female age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 75. Female Breast Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000

Country of	1996-2000 Inpatient Hospital Admissions								
County of Residence	Cases	Ra	Age-Adjus	sted Rate**					
	Cases	Rate	95% C.I.	Rate	95% C.I.				
Carson City	56	44.9	(33.1-56.7)	37.3	(28.1-49.0)				
Churchill	41	69.7	(48.4-91.1)	70.9	(50.9-96.6)				
Clark	1,668	53.9	(51.3-56.5)	55.9	(53.2-58.7)				
Douglas	44	44.4	(31.3-57.5)	36.1	(26.1-50.2)				
Elko	32	29.3	(19.1-39.4)	42.9	(28.8-62.8)				
Esmeralda	2								
Eureka	3								
Humboldt	13	32.5	(14.8-50.1)	40.5	(21.1-71.8)				
Lander	12	77.1	(33.5-120.7)	105.7	(53.2-192.5)				
Lincoln	3								
Lyon	82	102.8	(80.6-125.1)	91.4	(72.5-114.2)				
Mineral	9								
Nye	46	64.0	(45.5-82.5)	47.9	(34.7-66.1)				
Pershing	8								
Storey	2								
Washoe	489	60.6	(55.2-66.0)	62.4	(57.0-68.3)				
White Pine	12	55.4	(24.1-86.8)	44.0	(22.6-82.6)				
Unknown	2								
Total	2,524	55.2	(53.0-57.3)	56.2	(54.0-58.5)				


Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 female population. **Rates are per 100,000 female population and are age-adjusted to the 2000 US Standard population.

Table 76. Breast Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1996-2000

Age	Discharges		Charges (\$)		Length of Stay (Days)		ays)
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	0						
1-4	0						
5-14	0						
15-24	1						
25-34	57	872,333	15,304	12,555	142	2.5	2.0
35-44	291	5,221,101	17,942	11,916	841	2.9	2.0
45-54	512	7,750,123	15,137	12,046	1,228	2.4	2.0
55-64	582	7,839,350	13,470	10,669	1,353	2.3	1.0
65-74	618	7,165,575	11,595	9,898	1,240	2.0	1.0
75-84	394	4,612,504	11,707	9,479	1,023	2.6	2.0
85+	86	1,079,458	12,552	9,977	307	3.6	2.0
Unknown	1						
Total	2,542	34,663,372	13,636	10,622	6,155	2.4	1.0

MORTALITY

Figure 57. Female Breast Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 female population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 58. Female Breast Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 59. Female Breast Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1996-2000




Table 77. Breast Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region	n of Residence		
Category	Nevada Total Clark		Washoe	All Other Counties	
Total					
Cases	1,139	767	219	153	
Rate*	14.1	14.3	15.8	11.6	
95% C.I.	(13.3-15.0)	(13.3-15.4)	(13.7-18.1)	(9.8-13.7)	
Gender					
Male	11	8	1	2	
Rate*	0.3				
95% C.I.	(0.1-0.6)				
Female	1,128	759	218	151	
Rate*	26.1	26.4	28.8	21.7	
95% C.I.	(24.6-27.7)	(24.6-28.4)	(25.1-32.9)	(18.4-25.6)	
Other/Unknown	0	0	0	0	
Race/Ethnicity					
White	987	632	206	149	
Rate*	27.8	27.9	31.1	23.7	
95% C.I.	(26.1-29.6)	(25.8-30.2)	(27.0-35.7)	(20.0-28.0)	
Black	69	65	3	1	
Rate*	32.8	33.5			
95% C.I.	(25.2-42.4)	(25.5-43.8)			
Native American	5	3	1	1	
Rate*					
95% C.I.					
Asian	26	24	2	0	
Rate*	13.0	14.7			
95% C.I.	(7.0-25.7)	(7.6-30.3)			
Hispanic	41	35	6	0	
Rate*	11.8	13.3			
95% C.I.	(8.1-17.3)	(8.8-20.3)			
Other/Unknown	0	0	0	0	

^{*} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Rates for race/ethnicity groups are per 100,000 female population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 78. Female Breast Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties					
Total									
Cases	1,128	759	218	151					
Rate*	24.7	24.5	27.0	22.4					
95% C.I.	(23.2-26.1)	(22.8-26.3)	(23.4-30.6)	(18.9-26.0)					
Age Group									
<1	0	0	0	0					
Rate*									
95% C.I.									
1-4	0	0	0	0					
Rate*									
95% C.I.									
5-14	0	0	0	0					
Rate*									
95% C.I.									
15-24	2	1	0	1					
Rate*									
95% C.I.									
25-34	8	7	0	1					
Rate*									
95% C.I.									
35-44	89	57	22	10					
Rate*	12.3	12.0	16.2	8.9					
95% C.I.	(9.8-14.9)	(8.9-15.1)	(9.4-22.9)	(3.4-14.5)					
45-54	173	106	36	31					
Rate*	29.0	27.0	32.8	33.0					
95% C.I.	(24.7-33.3)	(21.8-32.1)	(22.1-43.6)	(21.4-44.6)					
55-64	236	162	41	33					
Rate*	54.6	54.9	58.9	49.0					
95% C.I.	(47.6-61.6)	(46.4-63.3)	(40.8-76.9)	(32.3-65.7)					
65-74	276	209	42	25					
Rate*	87.8	99.6	80.7	47.8					
95% C.I.	(77.5-98.2)	(86.1-113.1)	(56.3-105.1)	(29.1-66.6)					
75-84	230	149	51	30					
Rate*	127.6	126.0	162.1	98.2					
95% C.I.	(111.1-144.1)	(105.7-146.2)	(117.6-206.6)	(63.1-133.4)					
85+	114	68	26	20					
Rate*	238.6	231.9	259.6	237.2					
95% C.I.	(194.8-282.4)	(176.7-287.0)	(159.8-359.4)	(133.2-341.1)					
Unknown	0	0	0	0					

^{*} Rates are per 100,000 female age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 79. Female Breast Cancer Mortality by County of Residence, Nevada Residents, 1996-2000

	1996-2000 Mortality								
County of Residence	Dootho	Rat	te*	Age-Adjus	ted Rate**				
	Deaths	Rate	95% C.I.	Rate	95% C.I.				
Carson City	35	28.1	(18.8-37.4)	23.5	(16.3-33.2)				
Churchill	8								
Clark	759	24.5	(22.8-26.3)	26.4	(24.6-28.4)				
Douglas	16	16.2	(8.2-24.1)	13.4	(7.7-23.6)				
Elko	14	12.8	(6.1-19.5)	19.3	(10.1-34.7)				
Esmeralda	1								
Eureka	1								
Humboldt	11	27.5	(11.2-43.7)	32.7	(16.1-61.0)				
Lander	3								
Lincoln	2								
Lyon	25	31.3	(19.1-43.6)	28.8	(18.5-43.3)				
Mineral	5								
Nye	19	26.4	(14.6-38.3)	20.1	(11.7-34.1)				
Pershing	2								
Storey	1								
Washoe	218	27.0	(23.4-30.6)	28.8	(25.1-32.9)				
White Pine	8								
Unknown	0								
Total	1,128	24.7	(23.2-26.1)	26.1	(24.6-27.7)				

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 female population. **Rates are per 100,000 female population and are age-adjusted to the 2000 US Standard population.

Table 80. Breast Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

			Gender						
Rad	ce/Ethnicity	Male	Female	Total					
White	Mortality	9	987	996					
	Rate*		27.8	14.9					
	95% C.I.		(26.1-29.6)	(14.0-15.9)					
Black	Mortality	1	69	70					
	Rate*		32.8	18.3					
·	95% C.I.		(25.2-42.4)	(13.9-24.0)					
Native	Mortality	1	5	6					
American	Rate*								
	95% C.I.								
Asian	Mortality	0	26	26					
	Rate*		13.0	7.4					
	95% C.I.		(7.0-25.7)	(4.1-14.5)					
Hispanic	Mortality	0	41	41					
	Rate*		11.8	6.2					
	95% C.I.		(8.1-17.3)	(4.2-9.4)					
Other/Unki	nown	0	0	0					
Total	Mortality	11	1,128	1,139					
	Rate*	0.3	26.1	14.1					
	95% C.I.	(0.1-0.6)	(24.6-27.7)	(13.3-15.0)					

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 81. Breast Cancer Mortality by Age Group and Gender, Nevada Residents, 1996-2000

Age		Gender	
Group	Male	Female	Total
<1	0	0	0
Rate*			
95% C.I.			
1-4	0	0	0
Rate*			
95% C.I.			
5-14	0	0	0
Rate*			
95% C.I.			
15-24	0	2	2
Rate*			
95% C.I.			
25-34 Rate*	0	8	8
95% C.I.			
35-44		89	90
Rate*	<u>'</u>	12.3	6.0
95% C.I.		(9.8-14.9)	(4.8-7.3)
45-54	1	173	174
Rate*	· 	29.0	14.4
95% C.I.		(24.7-33.3)	(12.3-16.5)
55-64	5	236	241
Rate*		54.6	28.0
95% C.I.		(47.6-61.6)	(24.5-31.5)
65-74	1	276	277
Rate*		87.8	44.7
95% C.I.		(77.5-98.2)	(39.4-49.9)
75-84	3	230	233
Rate*		127.6	71.1
95% C.I.		(111.1-144.1)	(62.0-80.2)
85+	0	114	114
Rate*		238.6	161.8
95% C.I.		(194.8-282.4)	(132.1-191.5)
Unknown	11	1 129	1 120
Total Rate*	0.2	1,128 24.7	1,139 12.2
95% C.I.	(0.1-0.4)	(23.2-26.1)	(11.5-13.0)
00 /0 O.I.	(0.1-0.4)	(20.2-20.1)	(11.5-15.0)

Note: The "---" is used for rates calculated on numbers less than ten.

^{*} Rates are per 100,000 age-specific population.


Table 82. Median Age at Death from Breast Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

	Gender									
Race/Ethnicity	Ма	ile	Fen	nale	То	Total				
	Deaths	Median Age	Deaths	Median Age	Deaths	Median Age				
White	9	64.0	987	68.0	996	68.0				
Black	1		69	63.0	70	62.5				
Native American	1		5	57.0	6	58.0				
Asian	0		26	54.5	26	54.5				
Hispanic	0		41	59.0	41	59.0				
Other/Unknown	0		0		0					
Total	11	61.0	1,128	67.0	1,139	67.0				

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE

Figure 60. Survival Rates for Breast Cancer by Race/Ethnicity, Nevada Residents, 1996-2000



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 61. Survival Rates for Breast Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 1996-2000




Table 83. Cause-Specific Survival Rates for Breast Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

Race/	Name		Cause Specific Survival Rate					
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)	
Total	3,910	94.2%	88.3%	81.8%	74.3%	72.8%	>5 years	
Male	41							
Female	3,868	94.2%	88.4%	81.8%	74.3%	72.8%	>5 years	
Race/Ethnicity								
White	3,462	94.4%	88.7%	82.4%	74.8%	73.9%	>5 years	
Male	38							
Female	3,423	94.4%	88.9%	82.5%	74.8%	73.9%	>5 years	
Black	170	86.5%	74.4%	69.8%	61.1%	47.5%	4.82	
Male	2							
Female	168	86.4%	74.3%	69.7%	61.0%	47.4%	4.81	
Native American	11							
Male	0							
Female	11							
Asian	96	95.7%	92.8%	87.8%	87.8%	87.8%	>5 years	
Male	1							
Female	95	95.7%	92.8%	87.8%	87.8%	87.8%	>5 years	
Hispanic	124	96.7%	86.8%	68.8%	62.8%	62.8%	>5 years	
Male	0							
Female	124	96.7%	86.8%	68.8%	62.8%	62.8%	>5 years	

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 84. Cause-Specific Survival Rates for Breast Cancer by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1996-2000


Survival Rate of Stage			Gender	
	nt Diagnosis	Total	Male	Female
Total	Cases	3,910	41	3,868
	One Year	94.2%	96.4%	94.2%
	5 Years	72.8%	71.3%	72.8%
	Median Survival	>5 years	>5 years	>5 years
Stage at D	iagnosis			
In situ	Cases	581	4	577
	One Year	100.0%	100.0%	100.0%
	5 Years	96.7%	0.0%	96.7%
	Median Survival	>5 years	0.00	>5 years
Localized	Cases	1,962	24	1,937
	One Year	99.1%	100.0%	99.1%
	5 Years	86.4%	0.0%	86.4%
	Median Survival	>5 years	0.00	>5 years
Regional	Cases	964	7	957
	One Year	97.0%	80.0%	97.1%
	5 Years	68.1%	0.0%	68.1%
	Median Survival	>5 years	0.00	>5 years
Distant	Cases	208	2	206
	One Year	52.6%	100.0%	52.4%
	5 Years	6.0%	0.0%	6.0%
	Median Survival	1.18	0.00	1.16
Unstaged	Cases	195	4	191
	One Year	71.8%	100.0%	71.0%
	5 Years	24.9%	50.0%	21.6%
	Median Survival	2.25	2.00	2.28

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

PROSTATE CANCER

PROSTATE CANCER GENERAL PROFILE⁴

Figure 62. Anatomy of the Male Urogenital System⁵



General Anatomy: The prostate is a gland in a man's reproductive system. It makes and stores seminal fluid, a milky fluid that nourishes sperm. This fluid is released to form part of semen. The prostate is about the size of a walnut. It is located below the bladder and in front of the rectum. It surrounds the upper part of the urethra, the tube that empties urine from the bladder. If the prostate grows too large, the flow of urine can be slowed or stopped. To work properly, the prostate needs male hormones (androgens), which are responsible for male sex characteristics. The main male hormone is testosterone, which is made mainly by the testicles. Some male hormones are produced in small amounts by the adrenal glands.

Risk Factors: Age, family history of Prostate Cancer, race, and diet and dietary factors are all important risk factors in being diagnosed with Prostate Cancer.

Signs and Symptoms: A need to urinate frequently, especially at night, difficulty starting urination or holding back urine, inability to urinate, weak or interrupted flow of urine, painful or burning urination, difficulty in having an erection, painful ejaculation, blood in urine or semen, or frequent pain or stiffness in the lower back, hips, or upper thighs.

Diagnosing the Cancer: Digital rectal exam, blood test for prostate-specific antigen (PSA test), transrectal ultrasonography, intravenous pyelogram, and cystoscopy.

Treatment: Treatment options include: watchful waiting, surgery (Prostatectomy, Orchiectomy), radiation therapy, and hormonal therapy.

HIGHLIGHTS

- ➤ The ratio of the age-adjusted incidence rate, 114.2, to the age-adjusted mortality rate, 29.2 (per 100,000 2000 US Standard male population) for Prostate Cancer, was 3.91 during the 1996 to 2000 period, which means that for every 3.91 cancer cases there was one death due to Prostate Cancer in Nevada during this period.
- The median age at diagnosis of Prostate Cancer was 68 years of age for Nevada residents from 1996 to 2000. The median age at time of death due to Prostate Cancer was 76 years. Black males had the lowest median age at time of diagnosis of Prostate Cancer (65 years) and the largest difference (10 years) between the median age at diagnosis and median age at time of death (75 years) during this period.
- Asian males had the highest median age at diagnosis of Prostate Cancer (71 years) and the smallest difference (3 years) between the median age at diagnosis and median age at time of death (74 years) during the 1996 to 2000 period.

CANCER SCREENING

- ➤ Of the 815 men in Nevada who were surveyed in 2001, 82.1% responded yes to ever having a Prostate-Specific Antigen (PSA) test and/or a digital rectal exam to try and detect early signs of Prostate Cancer.
- ➤ The percentage of men who stated their education level as high school had the lowest percentage (77.1%) of those ever having a PSA test and/or a digital rectal exam, while those who stated their education level as a college graduate had the highest percentage (90.3%) when the questions were asked in 2001.
- ➤ Those men whose income was either less than \$15,000 or \$50,000 or more a year had the highest percentage of respondents who stated that they had ever received a PSA test or a digital rectal exam with percentages of 80.8% and 84.8%, respectively.

INCIDENCE

- Nevada's Prostate Cancer age-adjusted incidence rate, 114.2 (110.6-117.8), showed statistically significance in being lower than the 1995-1999 National rate of 165.5 (164.6-166.5) (per 100,000 2000 US Standard male population) during this period.
- ➤ There were 4,572 resident Prostate Cancer cases reported in Nevada from 1996 to 2000. Statistical significance tests show that Washoe County had the highest age-adjusted incidence rate of cancer once regional comparisons were made, with a rate of 144.8 (135.4-154.9). The All Other Counties region and Clark County followed with rates of 122.7 (114.1-132.0) and 104.3 (100.1-108.7) (per 100,000 population 2000 US Standard population), respectively.

Racial/ethnic comparisons showed that Blacks and Whites, as racial/ethnic groups, had the highest statistically significant age-adjusted incidence rates for Prostate Cancer with rates of 63.8 (55.9-73.0) and 56.1 (54.4-57.9), respectively, of all racial/ethnic groups. Asians, Hispanics and Native Americans, followed with rates of 25.3 (17.6-36.5), 22.5 (18.5-27.6) and 17.5 (9.2-31.4), respectively from 1996 to 2000.

INPATIENT HOSPITAL DISCHARGES

- ➤ There were 2,450 hospital inpatient discharges for Prostate Cancer to Nevada Residents from 1996 to 2000, with an age-adjusted inpatient discharge rate of 57.3 (per 100,000 2000 US Standard male population). The All Other Counties region had the highest cancer age-adjusted inpatient discharge rate, 59.9, once regional comparisons were made, and was followed by Clark County and Washoe County with rates of 57.6 and 53.3, respectively.
- Total billed charges for hospital inpatient discharges due Prostate Cancer in Nevada totaled nearly 50 million dollars from 1996 to 2000. Nevadans in the 55-74 year age group accounted for 76.1% of the total number of inpatient discharges and 80.8% of the total billed charges.
- ➤ Washoe County had a considerably higher median total billed charge for Prostate Cancer inpatient discharges (\$22,276) than Clark County (\$17,094) and All Other Counties (\$13,568) from 1996 to 2000.
- ➤ The overall average billed charge per day for a hospital inpatient discharge due to Prostate Cancer was just over \$5,400 in Nevada from 1996 to 2000.

MORTALITY

- ➤ There were 883 resident deaths due to Prostate Cancer in Nevada from 1996 to 2000. While Washoe County had the highest age-adjusted mortality rate from Prostate Cancer, 33.4, statistical analysis does not show statistical significance over the rates for Nevada overall, Clark County or All Other Counties, who had rates of 29.2, 28.2 and 28.2, respectively.
- ➤ Racial/ethnic comparisons showed that Blacks and Whites, as racial/ethnic groups, had the highest cancer age-adjusted mortality rates of 17.5 and 12.6, respectively, of all racial/ethnic groups. They were followed by Asians and Hispanics who had age-adjusted mortality rates of 5.8 and 5.6 (per 100,000 2000 US Standard male population), respectively, from 1996 to 2000.

SURVIVAL RATE

➤ The one-year survival rate for Prostate Cancer in Nevada was 94.4% during the 1996 to 2000 period, while the five-year survival rate was 67.1% during this same time. The median survival rate for Prostate Cancer in Nevada was greater than five years.

- The one-year survival rate for those diagnosed with Prostate Cancer at the localized stage was 99.4%, while those diagnosed at the regional, distant and unstaged stages had rates of 98.0%, 71.1% and 76.3%, respectively.
- ➤ The five-year survival rate for those diagnosed with Prostate Cancer at the localized stage was 82.9%, while those recorded at the regional, distant and unstaged stages had rates of 80.2%, 8.3% and 33.3%, respectively.
- ➤ Those diagnosed with Prostate Cancer at the distant stage had a significantly lower median survival rate than those at all other stages with a rate of 1.76 years compared to over five years for the localized and regional stages.

SCREENING (BRFSS)

Table 85. Prostate Cancer Screening by County/Region of Residence, Education, Age Group, and Income, Nevada Residents, 2001 (Revised)

				Answers			
Responses		Yes			No		_,,,
	Number	Percent*	95% C.I.	Number	Percent*	95% C.I.	Total
Total							
Responses	686	82.1%	(79.5%-84.7%)	129	17.9%	(15.3%-20.5%)	815
County/Region of Resid	lence						
Clark County	216	79.7%	(74.9%-84.5%)	55	20.3%	(15.5%-25.1%)	271
Washoe County	213	85.7%	(81.4%-90.0%)	37	14.3%	(10.0%-18.6%)	250
All Other Counties	257	88.5%	(84.9%-92.1%)	37	11.5%	(7.9%-15.1%)	294
Education							
Less than High School	39	77.1%	(65.2%-89.0%)	9	22.9%	(11.0%-34.8%)	48
High School	173	69.2%	(63.2%-75.2%)	54	30.8%	(24.8%-36.8%)	227
Some Post High School	216	83.3%	(78.7%-87.9%)	38	16.7%	(12.1%-21.3%)	254
College Graduate	256	90.3%	(86.9%-93.7%)	37	9.7%	(6.3%-13.1%)	293
Age Group							
18-24 years old	0			0			0
25-34 years old	0			0			0
35-44 years old	103	61.3%	(53.4%-69.2%)	44	38.7%	(30.8%-46.6%)	147
45-54 years old	202	78.0%	(72.9%-83.1%)	54	22.0%	(16.9%-27.1%)	256
55-64 years old	175	90.8%	(86.8%-94.8%)	21	9.2%	(5.2%-13.2%)	196
65+ years old	206	94.0%	(90.8%-97.2%)	10	6.0%	(2.8%-9.2%)	216
Income							
Less than \$15,000	47	80.8%	(70.9%-90.7%)	14	19.2%	(9.3%-29.1%)	61
\$15,000 - \$24,999	40	74.0%	(62.0%-86.0%)	11	26.0%	(14.0%-38.0%)	51
\$25,000 - \$34,999	64	72.5%	(62.9%-82.1%)	19	27.5%	(17.9%-37.1%)	83
\$35,000 - \$49,999	120	74.8%	(67.8%-81.8%)	26	25.2%	(18.2%-32.2%)	146
\$50,000 or More	313	84.8%	(81.1%-88.5%)	41	15.2%	(11.5%-18.9%)	354

^{*}Denominator is persons age 18-64 and excludes missing, don't know, and refused responses.


Note: This table includes those respondents who answered "Yes" or "No" to either of the following questions:

¹⁾ A Prostate-Specific Antigen test, also called a PSA test, is a blood test used to check men for prostate cancer. Have you ever had a PSA test?

²⁾ A digital rectal exam is an exam in which a doctor, nurse, or other health professional places a gloved finger into the rectum to feel the size, and hardness of the prostate gland. Have you ever had a digital rectal exam?

INCIDENCE

Figure 63. Prostate Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 male population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 64. Prostate Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 65. Prostate Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1996-2000




Table 86. Prostate Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

		County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)				
Total										
Cases	4,572	2,771	969	830	2	119,272				
Rate*	53.1	48.3	66.7	58.3		71.6				
95% C.I.	(51.5-54.7)	(46.5-50.2)	(62.5-71.1)	(54.4-62.6)		(71.2-72.0)				
Gender										
Male	4,572	2,771	969	830	2	119,272				
Rate*	114.2	104.3	144.8	122.7		165.5				
95% C.I.	(110.6-117.8)	(100.1-108.7)	(135.4-154.9)	(114.1-132.0)		(164.6-166.5)				
Female	0	0	0	0	0	0				
Rate*										
95% C.I.										
Other/Unknown	0	0	0	0	0	0				
Race/Ethnicity										
White	4,076	2,365	912	797	2	94,367				
Rate*	119.3	108.0	153.4	127.4		158.7				
95% C.I.	(115.5-123.4)	(103.4-112.9)	(143.2-164.4)	(118.3-137.2)		(157.7-159.7)				
Black	257	227	20	10	0	14,572				
Rate*	140.8	136.5	172.2	236.9		257.3				
95% C.I.	(122.0-163.4)	(117.0-160.5)	(101.1-289.5)	(112.4-516.1)		(253.0-261.6)				
Native American	14	4	3	7	0	209				
Rate*	43.9					51.7				
95% C.I.	(21.1-86.5)					(44.7-59.7)				
Asian	59	43	14	2	0	6,450				
Rate*	58.6	58.0	55.5			100.9				
95% C.I.	(41.0-84.0)	(37.3-90.2)	(29.0-125.3)			(98.4-103.5)				
Hispanic	125	94	18	13	0	7,733				
Rate*	48.7	47.1	49.6	51.2		117.2				
95% C.I.	(39.6-60.8)	(37.4-62.0)	(28.3-92.8)	(25.2-98.2)		(114.5-119.9)				
Other/Unknown	41	38	2	1	0	0				

^{*}Rates are per 100,000 male population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the National (SEER) rates. See Technical Notes for more information.

Table 87. Prostate Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

			County/Regio	n of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)
Total						
Cases	4,572	2,771	969	830	2	119,272
Rate*	96.7	86.5	116.7	119.1		130.9
95% C.I.	(93.9-99.5)	(83.3-89.8)	(109.3-124.0)	(111.0-127.2)		(130.1-131.6)
Age Group						
<1	0	0	0	0	0	
Rate*						
95% C.I.						
1-4	0	0	0	0	0	
Rate*						
95% C.I.						
5-14	0	0	0	0	0	
Rate*						
95% C.I.						
15-24	1	1	0	0	0	7
Rate*						
95% C.I.						
25-34	1	1	0	0	0	11
Rate*						0.1
95% C.I.						(0.0-0.1)
35-44	13	8	3	2	0	421
Rate*	1.7					2.7
95% C.I.	(0.8-2.6)					(2.4-3.0)
45-54	291	183	56	51	1	7,828
Rate*	47.5	45.8	48.7	51.9		69.5
95% C.I.	(42.1-53.0)	(39.2-52.5)	(36.0-61.5)	(37.7-66.1)		(67.9-71.0)
55-64	1,271	811	257	203	0	28,440
Rate*	296.5	283.2	357.9	287.5		423.4
95% C.I.	(280.2-312.7)	(263.7-302.7)	(314.1-401.7)	(248.0-327.1)		(418.4-428.3)
65-74	1,918	1,144	431	343	0	48,387
Rate*	627.3	558.9	882.7	656.8		938.8
95% C.I.	(599.3-655.4)	(526.5-591.3)	(799.3-966.0)	(587.3-726.4)		(930.4-947.1)
75-84	882	512	184	185	1	28,206
Rate*	598.1	522.6	780.7	713.3		973.2
95% C.I.	(558.6-637.5)	(477.3-567.9)	(667.9-893.5)	(610.5-816.1)		(961.9-984.6)
85+	195	111	38	46	0	5,964
Rate*	860.0	821.5	863.5	966.3		804.7
95% C.I.	(739.3-980.8)	(668.7-974.3)	(588.9-1,138.0)	(687.0-1,245.5)		(784.2-825.1)
Unknown	0	0	0	0	0	0

^{*} Rates are per 100,000 age-specific male population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 88. Prostate Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1996-2000 (Revised)

County of			1996-2000 Incide	nce	
Residence	Cases	Rat	te*	Age-Adjus	ted Rate**
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.
Carson City	223	185.2	(160.9-209.5)	172.6	(150.4-197.7)
Churchill	75	126.7	(98.0-155.4)	146.6	(114.4-186.9)
Clark	2,771	86.5	(83.3-89.8)	104.3	(100.1-108.7)
Douglas	139	137.9	(114.9-160.8)	124.8	(103.0-151.6)
Elko	56	46.8	(34.5-59.0)	117.0	(84.0-160.7)
Esmeralda	3				
Eureka	3				
Humboldt	32	72.9	(47.6-98.2)	129.9	(84.8-199.3)
Lander	6				
Lincoln	16	151.8	(77.4-226.2)	121.2	(68.3-218.3)
Lyon	133	162.1	(134.5-189.6)	139.5	(116.0-168.0)
Mineral	27	194.0	(120.8-267.2)	152.7	(96.3-242.9)
Nye	86	112.3	(88.6-136.0)	78.1	(61.6-100.6)
Pershing	8				
Storey	4				
Washoe	969	116.7	(109.3-124.0)	144.8	(135.4-154.9)
White Pine	19	86.5	(47.6-125.4)	84.6	(50.6-135.5)
Unknown	2				
Total	4,572	96.7	(93.9-99.5)	114.2	(110.6-117.8)

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 male population. **Rates are per 100,000 male population and are age-adjusted to the 2000 US Standard population.

Table 89. Prostate Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

			Gender					
Race/Ethnicity		Male	Female	Other/ Unknown	Total			
White	Incidence	4,076	0	0	4,076			
	Rate*	119.3			56.1			
	95% C.I.	(115.5-123.4)			(54.4-57.9)			
Black	Incidence	257	0	0	257			
	Rate*	140.8			63.8			
	95% C.I.	(122.0-163.4)			(55.9-73.0)			
Native	Incidence	14	0	0	14			
American	Rate*	43.9			17.5			
	95% C.I.	(21.1-86.5)			(9.2-31.4)			
Asian	Incidence	59	0	0	59			
	Rate*	58.6			25.3			
	95% C.I.	(41.0-84.0)			(17.6-36.5)			
Hispanic	Incidence	125	0	0	125			
	Rate*	48.7			22.5			
	95% C.I.	(39.6-60.8)			(18.5-27.6)			
Other/Unkr	nown	41	0	0	41			
Total	Incidence	4,572	0	0	4,572			
	Rate*	114.2			53.1			
	95% C.I.	(110.6-117.8)			(51.5-54.7)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 male population and are age-adjusted to the 2000 US Standard population.

Table 90. Prostate Cancer Cases by Age Group and Gender, Nevada Residents, 1996-2000

Age	Gender						
Group	Male	Female	Other/ Unknown	Total			
<1	0	0	0	0			
Rate*							
95% C.I.							
1-4	0	0	0	0			
Rate*							
95% C.I.							
5-14	0	0	0	0			
Rate*							
95% C.I.							
15-24	1	0	0	1			
Rate*							
95% C.I.							
25-34	1	0	0	1			
Rate*							
95% C.I.							
35-44	13	0	0	13			
Rate*	1.7			0.9			
95% C.I.	(0.8-2.6)			(0.4-1.3)			
45-54	291	0	0	291			
Rate*	47.5			24.1			
95% C.I.	(42.1-53.0)			(21.3-26.8)			
55-64	1,271	0	0	1,271			
Rate*	296.5			147.6			
95% C.I.	(280.2-312.7)			(139.5-155.8)			
65-74	1,918	0	0	1,918			
Rate*	627.3			309.4			
95% C.I.	(599.3-655.4)			(295.6-323.2)			
75-84	882	0	0	882			
Rate*	598.1			269.1			
95% C.I.	(558.6-637.5)			(251.3-286.9)			
85+	195	0	0	195			
Rate*	860.0			276.8			
95% C.I.	(739.3-980.8)			(237.9-315.6)			
Unknown	0	0	0	0			
Total	4,572	0	0	4,572			
Rate*	96.7			49.1			
95% C.I.	(93.9-99.5)			(47.7-50.6)			

Note: The "---" is used for rates calculated on numbers less than ten.

^{*} Rates are per 100,000 age-specific population.

Table 91. Prostate Cancer Cases by Age Group and Stage, Nevada Residents, 1996-2000

A	C			Si	tage		
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total
<1	Number	0	0	0	0	0	0
	Percent						
1-4	Number	0	0	0	0	0	0
	Percent						
5-14	Number	0	0	0	0	0	0
	Percent						
15-24	Number	0	1	0	0	0	1
	Percent		100.0%				100.0%
25-34	Number	0	1	0	0	0	1
-	Percent		100.0%				100.0%
35-44	Number	0	9	3	0	1	13
	Percent		69.2%	23.1%		7.7%	100.0%
45-54	Number	0	206	50	6	29	291
	Percent		70.8%	17.2%	2.1%	10.0%	100.0%
55-64	Number	0	885	219	43	124	1,271
	Percent		69.6%	17.2%	3.4%	9.8%	100.0%
65-74	Number	0	1,327	212	107	272	1,918
	Percent		69.2%	11.1%	5.6%	14.2%	100.0%
75-84	Number	0	462	43	71	306	882
	Percent		52.4%	4.9%	8.0%	34.7%	100.0%
85+	Number	0	72	6	21	96	195
	Percent		36.9%	3.1%	10.8%	49.2%	100.0%
Unknown	Number	0	0	0	0	0	0
	Percent						
Total	Number	0	2,963	533	248	828	4,572
	Percent		64.8%	11.7%	5.4%	18.1%	100.0%

Table 92. Prostate Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1996-2000

				F	Race/Ethnicit	у		
Stage		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total
In situ	Number	0	0	0	0	0	0	0
	Percent							
Localized	Number	2,633	169	7	36	89	29	2,963
	Percent	64.6%	65.8%	50.0%	61.0%	71.2%	70.7%	64.8%
Regional	Number	486	27	1	3	12	4	533
	Percent	11.9%	10.5%	7.1%	5.1%	9.6%	9.8%	11.7%
Distant	Number	223	12	1	7	4	1	248
	Percent	5.5%	4.7%	7.1%	11.9%	3.2%	2.4%	5.4%
Unstaged	Number	734	49	5	13	20	7	828
	Percent	18.0%	19.1%	35.7%	22.0%	16.0%	17.1%	18.1%
Total	Number	4,076	257	14	59	125	41	4,572
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%


Table 93. Median Age at Diagnosis of Prostate Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

		Gender								
Race/Ethnicity	Male		Fem	ale	Total					
	Incidence	Median Age	Incidence		Incidence	Median Age				
White	4,076	68.0	0		4,076	68.0				
Black	257	65.0	0		257	65.0				
Native American	14	69.0	0		14	69.0				
Asian	59	71.0	0		59	71.0				
Hispanic	125	66.0	0		125	66.0				
Other/Unknown	41	65.0	0		41	65.0				
Total	4,572	68.0	0		4,572	68.0				

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

Figure 66. Prostate Cancer Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 male population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical notes for more information.

Figure 67. Prostate Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 68. Median Charges for Prostate Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000




Figure 69. Average Length of Stay for Prostate Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000




Table 94. Prostate Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

		Coun	ty/Region of Resid	lence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	2,450	1,631	383	436	0
Rate*	27.3	27.3	25.3	29.3	
95% C.I.	(26.2-28.4)	(26.0-28.7)	(22.8-28.1)	(26.6-32.3)	
Gender					
Male	2,450	1,631	383	436	0
Rate*	57.3	57.6	53.3	59.9	
95% C.I.	(54.9-59.7)	(54.7-60.8)	(47.9-59.4)	(54.2-66.2)	
Female	0	0	0	0	0
Rate*					
95% C.I.					
Other/Unknown	0	0	0	0	0
Inpatient Discharge Cl	harges (\$)				
Total Charges	\$49,678,772	\$34,466,293	\$8,499,386	\$6,713,093	
Average Charges	\$20,277	\$21,132	\$22,192	\$15,397	
Median Charges	\$17,164	\$17,094	\$22,276	\$13,568	
Discharge Length of S	stay (LOS) (Days)				
Total LOS	9,175	6,269	1,405	1,501	
Average LOS	3.7	3.8	3.7	3.4	
Median LOS	3.0	3.0	3.0	3.0	

^{*} Rates are per 100,000 male population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 95. Prostate Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		Coun	ty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Cases	2,450	1,631	383	436	0
Rate*	51.8	50.9	46.1	62.6	
95% C.I.	(49.7-53.8)	(48.5-53.4)	(41.5-50.7)	(56.7-68.4)	
Age Group					
<1	0	0	0	0	0
Rate*					
95% C.I.					
1-4	2	2	0	0	0
Rate*					
95% C.I.					
5-14	0	0	0	0	0
Rate*					
95% C.I.					
15-24	0	0	0	0	0
Rate*					
95% C.I.					
25-34	0	0	0	0	0
Rate*					
95% C.I.					
35-44	11	8	2	1	0
Rate*	1.4				
95% C.I.	(0.6-2.3)				
45-54	220	150	34	36	0
Rate*	35.9	37.6	29.6	36.6	
95% C.I.	(31.2-40.7)	(31.6-43.6)	(19.6-39.5)	(24.7-48.6)	
55-64	900	603	151	146	0
Rate*	209.9	210.6	210.3	206.8	
95% C.I.	(196.2-223.6)	(193.8-227.4)	(176.7-243.8)	(173.2-240.3)	
65-74	965	623	149	193	0
Rate*	315.6	304.4	305.1	369.6	
95% C.I.	(295.7-335.5)	(280.5-328.3)	(256.1-354.1)	(317.5-421.7)	
75-84	292	208	37	47	0
Rate*	198.0	212.3	157.0	181.2	
95% C.I.	(175.3-220.7)	(183.5-241.2)	(106.4-207.6)	(129.4-233.0)	
85+	60	37	10	13	0
Rate*	264.6	273.8	227.2	273.1	
95% C.I.	(197.7-331.6)	(185.6-362.1)	(86.4-368.1)	(124.6-421.5)	
Unknown	0	0	0	0	0

^{*} Rates are per 100,000 age-specific male population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 96. Prostate Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1996-2000

Age		Gender	
Group	Male	Female	Total
<1	0	0	0
Rate*			
95% C.I.			
1-4	2	0	2
Rate*			
95% C.I.			
5-14	0	0	0
Rate*			
95% C.I.			
15-24	0	0	0
Rate*			
95% C.I.			
25-34	0	0	0
Rate*			
95% C.I.			
35-44	11	0	11
Rate*	1.4		0.7
95% C.I.	(0.6-2.3)		(0.3-1.2)
45-54 Rate*	220 35.9	0	220 18.2
95% C.I.	(31.2-40.7)		(15.8-20.6)
55-64	900	0	900
Rate*	209.9		104.5
95% C.I.	(196.2-223.6)		(97.7-111.4)
65-74	965	0	965
Rate*	315.6		155.7
95% C.I.	(295.7-335.5)		(145.8-165.5)
75-84	292	0	292
Rate*	198.0		89.1
95% C.I.	(175.3-220.7)		(78.9-99.3)
85+	60	0	60
Rate*	264.6		85.2
95% C.I.	(197.7-331.6)		(63.6-106.7)
Unknown	0	0	0
Total	2,450	0	2,450
Rate*	51.8		26.3
95% C.I.	(49.7-53.8)		(25.3-27.4)

^{*} Rates are per 100,000 male age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 97. Prostate Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000

Onweter of		1996-2000	Inpatient Hospita	al Admissions	
County of Residence	Cases	Rat	e*	Age-Adjust	ted Rate**
	Cases	Rate	95% C.I.	Rate	95% C.I.
Carson City	88	73.1	(57.8-88.4)	67.9	(54.4-84.4)
Churchill	42	71.0	(49.5-92.4)	78.1	(55.8-108.5)
Clark	1,631	50.9	(48.5-53.4)	57.6	(54.7-60.8)
Douglas	77	76.4	(59.3-93.4)	65.3	(50.2-85.5)
Elko	26	21.7	(13.4-30.1)	41.5	(24.5-68.9)
Esmeralda	1				
Eureka	1				
Humboldt	17	38.7	(20.3-57.1)	60.8	(32.5-114.9)
Lander	1				
Lincoln	7				
Lyon	96	117.0	(93.6-140.4)	95.5	(77.1-118.9)
Mineral	12	86.2	(37.4-135.0)	60.7	(31.2-125.8)
Nye	55	71.8	(52.8-90.8)	49.9	(36.8-69.4)
Pershing	7				
Storey	2				
Washoe	383	46.1	(41.5-50.7)	53.3	(47.9-59.4)
White Pine	4				
Unknown	0				
Total	2,450	51.8	(49.7-53.8)	57.3	(54.9-59.7)


Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 male population. **Rates are per 100,000 male population and are age-adjusted to the 2000 US Standard population.

Table 98. Prostate Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1996-2000

Age	Discharges		Charges (\$)	Length of Stay (Days)			
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	0						
1-4	2						
5-14	0						
15-24	0						
25-34	0						
35-44	11	194,101	17,646	18,350	35	3.2	3.0
45-54	220	4,089,156	18,587	17,980	755	3.4	3.0
55-64	900	22,203,627	24,671	18,343	3,357	3.7	3.0
65-74	965	17,927,622	18,578	17,138	3,598	3.7	3.0
75-84	292	4,107,523	14,067	10,571	1,161	4.0	2.0
85+	60	1,129,456	18,824	10,371	264	4.4	3.0
Unknown	0						
Total	2,450	49,678,772	20,277	17,164	9,175	3.7	3.0

MORTALITY

Figure 70. Prostate Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 male population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 71. Prostate Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 72. Prostate Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1996-2000




Table 99. Prostate Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Cases	883	568	166	149
Rate*	12.2	11.8	13.4	12.2
95% C.I.	(11.4-13.1)	(10.8-12.9)	(11.4-15.6)	(10.3-14.4)
Gender				
Male	883	568	166	149
Rate*	29.2	28.2	33.4	28.2
95% C.I.	(27.1-31.5)	(25.6-31.0)	(28.2-39.5)	(23.6-33.7)
Female	0	0	0	0
Rate*				
95% C.I.				
Other/Unknown	0	0	0	0
Race/Ethnicity				
White	791	491	158	142
Rate*	30.0	28.8	35.1	29.1
95% C.I.	(27.8-32.5)	(26.0-31.9)	(29.4-41.6)	(24.2-34.9)
Black	54	52	2	0
Rate*	42.6	44.0		
95% C.I.	(30.4-59.5)	(31.0-62.3)		
Native American	3	1	1	1
Rate*				
95% C.I.				
Asian	13	12	0	1
Rate*	13.5	16.0		
95% C.I.	(6.0-30.0)	(6.5-38.6)		
Hispanic	22	12	5	5
Rate*	13.4	10.5		
95% C.I.	(7.7-23.1)	(4.6-23.4)		
Other/Unknown	0	0	0	0

Note: The "---" is used for rates calculated on numbers less than ten.

^{*}Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Rates for race/ethnicity groups are per 100,000 male population and age-adjusted to the 2000 US Standard population.

Table 100. Prostate Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties					
Total									
Cases	883	568	166	149					
Rate*	18.7	17.7	20.0	21.4					
95% C.I.	(17.4-19.9)	(16.3-19.2)	(16.9-23.0)	(17.9-24.8)					
Age Group									
<1	0	0	0	0					
Rate*									
95% C.I.									
1-4	0	0	0	0					
Rate*									
95% C.I.									
5-14	0	0	0	0					
Rate*									
95% C.I.									
15-24	0	0	0	0					
Rate*									
95% C.I.									
25-34	0	0	0	0					
Rate*									
95% C.I.									
35-44	0	0	0	0					
Rate*									
95% C.I.									
45-54	6	4	1	1					
Rate*									
95% C.I.									
55-64	73	50	16	7					
Rate*	17.0	17.5	22.3						
95% C.I.	(13.1-20.9)	(12.6-22.3)	(11.4-33.2)						
65-74 P-4-*	283	191	45	47					
Rate*	92.6	93.3	92.2	90.0					
95% C.I.	(81.8-103.3)	(80.1-106.5)	(65.2-119.1)	(64.3-115.7)					
75-84	373	242	70	61					
Rate*	252.9	247.0	297.0	235.2					
95% C.I.	(227.3-278.6)	(215.9-278.1)	(227.4-366.6)	(176.2-294.2)					
85+	148	81	34	33					
Rate*	652.8	599.5	772.6	693.2					
95% C.I.	(547.6-757.9)	(468.9-730.0)	(512.9-1,032.3)	(456.7-929.7)					
Unknown	0	0	0	0					

^{*} Rates are per 100,000 age-specific male population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 101. Prostate Cancer Mortality by County of Residence, Nevada Residents, 1996-2000

Operator of	1996-2000 Mortality								
County of Residence	Dootho	Rat	te*	Age-Adjus	Age-Adjusted Rate**				
	Deaths	Rate	95% C.I.	Rate	95% C.I.				
Carson City	40	33.2	(22.9-43.5)	31.6	(22.4-43.9)				
Churchill	18	30.4	(16.4-44.5)	37.2	(21.6-61.7)				
Clark	568	17.7	(16.3-19.2)	28.2	(25.6-31.0)				
Douglas	19	18.8	(10.4-27.3)	25.5	(14.2-43.2)				
Elko	15	12.5	(6.2-18.9)	48.7	(26.0-83.9)				
Esmeralda	1								
Eureka	0								
Humboldt	6								
Lander	2								
Lincoln	3								
Lyon	16	19.5	(9.9-29.1)	22.2	(12.0-38.7)				
Mineral	3								
Nye	17	22.2	(11.6-32.8)	24.3	(12.6-44.2)				
Pershing	3								
Storey	1								
Washoe	166	20.0	(16.9-23.0)	33.4	(28.2-39.5)				
White Pine	5								
Unknown	0								
Total	883	18.7	(17.4-19.9)	29.2	(27.1-31.5)				

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 male population. **Rates are per 100,000 male population and are age-adjusted to the 2000 US Standard population.

Table 102. Prostate Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

		Gender					
Rad	ce/Ethnicity	Male	Female	Total			
White	Mortality	791	0	791			
	Rate*	30.0		12.6			
	95% C.I.	(27.8-32.5)		(11.7-13.5)			
Black	Mortality	54	0	54			
	Rate*	42.6		17.5			
	95% C.I.	(30.4-59.5)		(12.9-23.5)			
Native	Mortality	3	0	3			
American	Rate*						
	95% C.I.						
Asian	Mortality	13	0	13			
	Rate*	13.5		5.8			
	95% C.I.	(6.0-30.0)		(2.6-13.1)			
Hispanic	Mortality	22	0	22			
	Rate*	13.4		5.6			
	95% C.I.	(7.7-23.1)		(3.4-9.2)			
Other/Unki	nown	0	0	0			
Total	Mortality	883	0	883			
	Rate*	29.2		12.2			
	95% C.I.	(27.1-31.5)		(11.4-13.1)			

Note: The "---" is used for rates calculated on numbers less than ten.*Rates are per 100,000 male population and are aga-adjusted to the 2000 US Standard population.

Table 103. Prostate Cancer Mortality by Age Group and Gender, Nevada Residents, 1996-2000

Age		Gender							
Group	Male	Female	Total						
<1	0	0	0						
Rate*									
95% C.I.									
1-4	0	0	0						
Rate*									
95% C.I.									
5-14	0	0	0						
Rate*									
95% C.I.									
15-24	0	0	0						
Rate*									
95% C.I.									
25-34	0	0	0						
Rate*									
95% C.I.									
35-44	0	0	0						
Rate*									
95% C.I.									
45-54	6	0	6						
Rate*									
95% C.I.									
55-64	73	0	73						
Rate*	17.0		8.5						
95% C.I.	(13.1-20.9)		(6.5-10.4)						
65-74	283	0	283						
Rate*	92.6		45.7						
95% C.I.	(81.8-103.3)		(40.3-51.0)						
75-84	373	0	373						
Rate*	252.9		113.8						
95% C.I.	(227.3-278.6)		(102.3-125.4)						
85+	148	0	148						
Rate*	652.8		210.1						
95% C.I.	(547.6-757.9)		(176.2-243.9)						
Unknown	0	0	0						
Total	883	0	883						
Rate*	18.7 (17.4.10.0)		9.5 (8.9-10.1)						
95% C.I.	(17.4-19.9)		(0.9-10.1)						

Note: The "---" is used for rates calculated on numbers less than ten.

^{*} Rates are per 100,000 age-specific population.


Table 104. Median Age at Death from Prostate Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

	Gender									
Race/Ethnicity	Ма	ile	Fem	nale	Total					
	Deaths	Median Age	Deaths	Median Age	Deaths	Median Age				
White	791	77.0	0		791	77.0				
Black	54	75.0	0		54	75.0				
Native American	3		0		3					
Asian	13	74.0	0		13	74.0				
Hispanic	22	74.0	0		22	74.0				
Other/Unknown	0		0		0					
Total	883	76.0	0		883	76.0				

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE

Figure 73. Survival Rates for Prostate Cancer by Race/Ethnicity, Nevada Residents, 1996-2000



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 74. Survival Rates for Prostate Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 1996-2000




Table 105. Cause-Specific Survival Rates for Prostate Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

Race/	Namel	Cause Specific Survival Rate					Median
Ethnicity and Gender			Two Years	Three Years	Four Years	Five Years	Survival Time (years)
Total	2,626	94.4%	87.1%	80.0%	73.1%	67.1%	>5 years
Male	2,626	94.4%	87.1%	80.0%	73.1%	67.1%	>5 years
Female	0						
Race/Ethnicity							
White	2,310	94.0%	86.5%	79.5%	72.6%	65.7%	>5 years
Male	2,310	94.0%	86.5%	79.5%	72.6%	65.7%	>5 years
Female	0						
Black	165	96.6%	89.1%	80.2%	75.2%	75.2%	>5 years
Male	165	96.6%	89.1%	80.2%	75.2%	75.2%	>5 years
Female	0						
Native American	3						
Male	3						
Female	0						
Asian	36						
Male	36						
Female	0						
Hispanic	80	100.0%	91.3%	91.3%	91.3%	91.3%	>5 years
Male	80	100.0%	91.3%	91.3%	91.3%	91.3%	>5 years
Female	0						

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 106. Cause-Specific Survival Rates for Prostate Cancer by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1996-2000


Survival Rate of Stage at Diagnosis			Gender	
		Total	Male	Female
Total	Cases	2,626	2,626	0
	One Year	94.4%	94.4%	
	5 Years	67.1%	67.1%	
	Median Survival	>5 years	>5 years	
Stage at Di	iagnosis			
In situ	Cases	0	0	0
	One Year			
	5 Years			
	Median Survival			
Localized	Cases	1,877	1,877	0
	One Year	99.4%	99.4%	
	5 Years	82.9%	82.9%	
	Median Survival	>5 years	>5 years	
Regional	Cases	312	312	0
	One Year	98.0%	98.0%	
	5 Years	80.2%	80.2%	
	Median Survival	>5 years	>5 years	
Distant	Cases	147	147	0
	One Year	71.1%	71.1%	
	5 Years	8.3%	8.3%	
	Median Survival	1.76	1.76	
Unstaged	Cases	290	290	0
	One Year	76.3%	76.3%	
	5 Years	33.3%	33.3%	
	Median Survival	3.02	3.02	

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

COLORECTAL CANCER

COLORECTAL CANCER GENERAL PROFILE⁴

Figure 75. Anatomy of the Digestive System⁵



General Anatomy: The colon and rectum are parts of the body's digestive system, which removes nutrients from food and stores waste until it passes out of the body. Together, the colon and rectum form a long, muscular tube called the large intestine (also called the large bowel). The colon is the first 6 feet of the large intestine, and the rectum is the last 8 to 10 inches.

Risk Factors: Age, diet, polyps (benign growths on the inner wall of the colon and rectum), personal medical history, family medical history, and ulcerative colitis (the lining of the colon becomes inflamed).

Signs and Symptoms: A change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood (either bright red or very dark) in the stool, stools that are narrower than usual, general abdominal discomfort (frequent gas pains, bloating, fullness, and/or cramps), weight loss with no known reason, constant tiredness, and vomiting.

Diagnosing the Cancer: Fecal occult blood test, sigmoidoscopy, colonscopy, double contrast barium enema (DCBE), polypectomy, biopsy, and a digital rectal exam.

Treatment: Treatment options include: surgery (Colostomy), chemotherapy, radiation therapy, biological therapy, and clinical trials.

HIGHLIGHTS

- ➤ The ratio of the age-adjusted incidence rate, 53.1, to the age-adjusted mortality rate, 22.9 (per 100,000 2000 US Standard population), for Colorectal Cancer was 2.32 during the 1996 to 2000 period, which means that for every 2.32 Colorectal Cancer cases during this period, there was one death due to Colorectal Cancer in Nevada.
- Nevadan females had a higher ratio than males when the age-adjusted incidence and age-adjusted mortality rates for Colorectal Cancer were compared. For every female death due to Colorectal Cancer there was 2.48 female cases while there were 2.17 male cases for every male Colorectal Cancer death in Nevada from 1996 to 2000.
- ➤ The median age at diagnosis of Colorectal Cancer was 70 years of age for Nevada residents from 1996 to 2000; the median age at time of death was 72 years.

CANCER SCREENING

- ➤ Of the 3,841 individuals in Nevada who were surveyed in 1997, 1999 and 2001, 51.9% responded no to ever having a blood stool test and/or a sigmoidoscopy or colonoscopy to try and detect early signs of Colorectal Cancer.
- Males had a lower percentage of respondents who said yes to ever having a blood stool test and/or a sigmoidoscopy or colonoscopy than females (49.3%) with a percentage of 46.9% when the questions were asked in 1997, 1999 and 2001.
- Each age group showed statistical significance over the next age group for those respondents who said that they had never had a blood stool test and/or a sigmoidoscopy or colonoscopy, with the 35 to 44 age group having the highest percentage at 85.1% (82.1%-88.1%); being followed by the 45 to 54, 55 to 64 and 65 and older age groups with percentages of 59.8% (57.0%-62.6%), 44.5% (41.3%-47.7%) and 34.6% (31.8%-37.4%), respectively, when these questions were included in the Behavorial Risk Factor Surveillance Survey.

INCIDENCE

- Nevada's Incidence rate for Colorectal Cancer (53.1) was only slightly lower than the National rate of 54.9 (per 100,000 2000 US Standard population) from 1996 to 2000.
- ➤ There were 4,345 cases of Colorectal Cancer reported in Nevada from 1996 to 2000. Regional comparisons of Colorectal Cancer incidence showed that Clark County had the highest age-adjusted incidence rate, 54.7, followed by Washoe County, 53.4, and the All Other Counties region, 46.5 (per 100,000 2000 US Standard population), during the 1996 to 2000 period.
- Males had a statistically significant higher age-adjusted cancer incidence rate for Colorectal Cancer 60.7 (58.1-63.5) than the female rate of 46.6 (44.5-48.7) during the

1996 to 2000 period.

➤ The Colorectal Cancer age-adjusted incidence rates for Blacks, 56.1 (48.5-65.0), and Whites, 56.1 (54.3-57.9), showed statistical significance over, and were nearly double, the rates for all other racial/ethnic groups from 1996 to 2000. They were followed by Asians, Native Americans and Hispanics with rates of 29.9 (23.5-39.2), 22.5 (13.0-37.4) and 21.7 (17.5-27.0), respectively.

INPATIENT HOSPITAL DISCHARGES

- There were 4,034 hospital inpatient discharges for a primary diagnosis of Colorectal Cancer to Nevada Residents from 1996 to 2000. Clark County had the highest cancer age-adjusted inpatient discharge rate, 52.2 (50.2-54.3), once regional comparisons were made. However, the rate was only statistically significant over the All Other Counties region who had the lowest age-adjusted discharge rate, 39.7 (36.4-43.3), during this same period.
- ➤ Total billed charges for Colorectal Cancer inpatient hospital discharges in Nevada totaled nearly 134.7 million dollars from 1996 to 2000. The overall average billed charge per day for a hospital inpatient discharge due to Colorectal Cancer was approximately \$3,900 in Nevada from 1996 to 2000.
- ➤ Washoe County had the highest median total billed amount (\$28,274) and average length of stay (8.9 days) during this time, once regional comparisons were made.

MORTALITY

- ➤ There were 1,792 resident deaths due to Colorectal Cancer in Nevada from 1996 to 2000. Males had a higher statistically significant age-adjusted mortality rate, 28.0 (26.1-30.0), than females who had a rate of 18.8 (17.5-20.2), per 100,000 2000 US Standard population, during this period.
- ➤ Blacks, as a racial/ethnic group, had the highest age-adjusted mortality rate for Colorectal Cancer of any racial/ethnic group, 30.0, and were followed by Whites, Asians, Native Americans, and Hispanics with rates of 23.7, 12.5, 12.0, and 11.3, (per 100,000 2000 US Standard population) respectively, from 1996 to 2000.

SURVIVAL RATE

- The one-year survival rate for Colorectal Cancer in Nevada was 72.6% during the 1996 to 2000 period, while the five-year survival rate was 33.3% during this same time. The median survival rate in Nevada was 2.64 years.
- Females in Nevada had a slightly higher one-year survival rate (73.6%) than males (71.6%) for Colorectal Cancer during the 1996 to 2000 period. This trend was similar for the median survival time with females and males at 2.81 and 2.54 years, respectively. However, males had a higher five-year survival rate (36.9%) for Colorectal Cancer than females who had a rate of 28.7% during this time.

- ➤ Hispanics had a considerably higher median survival time than other racial/ethnic groups with a period of 4.10 years, while Blacks and Whites had periods of 2.63 and 2.55 years, respectively.
- The five-year survival rate for those diagnosed at the localized stage for Colorectal Cancer was 69.2% for Nevada from 1996 to 2000, while those recorded at the regional, distant and unstaged stages had rates of 35.4%, 5.4% and 16.2%, respectively.
- ➤ While the median survival time for those diagnosed at the localized stage was over five years for Colorectal Cancer, those diagnosed at the regional, distant and unstaged levels had median survival times of 3.21, 0.84 and 0.97 years, respectively, for Nevada during the 1996 to 2000 period.

SCREENING (BRFSS)

Table 107. Colorectal Cancer Screening by County/Region of Residence, Gender, Education, Age Group, and Income, Nevada Residents, 1997, 1999 and 2001

				Answers					
Responses		Yes			No				
	Number	Percent*	95% C.I.	Number	Percent*	95% C.I.	Total		
Total									
Responses	1,828	48.1%	(46.5%-49.7%)	2,013	51.9%	(50.3%-53.5%)	3,841		
County/Region of Resid	dence								
Clark County	569	48.0%	(45.2%-50.8%)	662	52.0%	(49.2%-54.8%)	1,231		
Washoe County	581	49.2%	(46.4%-52.0%)	612	50.8%	(48.0%-53.6%)	1,193		
All Other Counties	678	47.7%	(45.1%-50.3%)	739	52.3%	(49.7%-54.9%)	1,417		
Gender									
Male	881	46.9%	(44.6%-49.2%)	989	53.1%	(50.8%-55.4%)	1,870		
Female	947	49.3%	(47.1%-51.5%)	1,024	50.7%	(48.5%-52.9%)	1,971		
Education									
Less than High School	169	51.7%	(46.4%-57.0%)	170	48.3%	(43.0%-53.6%)	339		
High School	483	41.9%	(39.0%-44.8%)	664	58.1%	(55.2%-61.0%)	1,147		
Some Post High School	600	50.1%	(47.3%-52.9%)	659	49.9%	(47.1%-52.7%)	1,259		
College Graduate	572	51.6%	(48.6%-54.6%)	513	48.4%	(45.4%-51.4%)	1,085		
Age Group									
18-24 years old	0			0			0		
25-34 years old	0			0			0		
35-44 years old	89	14.9%	(11.9%-17.9%)	468	85.1%	(82.1%-88.1%)	557		
45-54 years old	443	40.2%	(37.4%-43.0%)	740	59.8%	(57.0%-62.6%)	1,183		
55-64 years old	529	55.5%	(52.3%-58.7%)	422	44.5%	(41.3%-47.7%)	951		
65+ years old	762	65.4%	(62.6%-68.2%)	370	34.6%	(31.8%-37.4%)	1,132		
Income									
Less than \$15,000	179	40.0%	(35.1%-44.9%)	201	60.0%	(55.1%-64.9%)	380		
\$15,000 - \$24,999	172	50.6%	(45.3%-55.9%)	166	49.4%	(44.1%-54.7%)	338		
\$25,000 - \$34,999	228	41.9%	(37.7%-46.1%)	297	58.1%	(53.9%-62.3%)	525		
\$35,000 - \$49,999	317	46.4%	(42.7%-50.1%)	392	53.6%	(49.9%-57.3%)	709		
\$50,000 or More	606	48.1%	(45.4%-50.8%)	664	51.9%	(49.2%-54.6%)	1,270		

^{*}Denominator is persons age 18-64 and excludes missing, don't know, and refused responses.


Note: This table includes those respondents who answered "Yes" or "No" to either of the following questions:

¹⁾ A blood stool test is a test that may use a special kit at home to determine whether the stool contains blood. Have you ever had this test using a home kit?

²⁾ A sigmoidoscopy or colonoscopy is when a tube is inserted in the rectum to view the bowel for signs of cancer and other health problems. Have you ever had this exam?

INCIDENCE

Figure 76. Colorectal Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 77. Colorectal Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 78. Colorectal Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1996-2000




Table 108. Colorectal Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

		County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)				
Total										
Cases	4,345	2,965	746	634	0	91,312				
Rate*	53.1	54.7	53.4	46.5		54.9				
95% C.I.	(51.5-54.8)	(52.7-56.8)	(49.6-57.5)	(42.9-50.4)		(54.5-55.2)				
Gender										
Male	2,343	1,579	429	335	0	45,698				
Rate*	60.7	61.7	65.5	51.7		64.6				
95% C.I.	(58.1-63.5)	(58.4-65.2)	(59.1-72.7)	(46.0-58.1)		(64.0-65.2)				
Female	2,000	1,386	316	298	0	45,614				
Rate*	46.6	48.7	42.5	42.0		47.6				
95% C.I.	(44.5-48.7)	(46.2-51.4)	(37.9-47.5)	(37.3-47.1)		(47.1-48.0)				
Other/Unknown	2	0	1	1	0	0				
Race/Ethnicity										
White	3,853	2,548	699	606	0	74,892				
Rate*	56.1	58.2	56.6	48.3		54.5				
95% C.I.	(54.3-57.9)	(55.9-60.6)	(52.4-61.0)	(44.5-52.4)		(54.1-54.9)				
Black	224	203	15	6	0	8,436				
Rate*	56.1	55.0	63.5			62.7				
95% C.I.	(48.5-65.0)	(47.1-64.3)	(34.9-109.7)			(61.3-64.1)				
Native American	19	6	8	5	0	214				
Rate*	22.5					19.3				
95% C.I.	(13.0-37.4)					(16.7-16.7)				
Asian	100	81	14	5	0	7,269				
Rate*	29.9	30.9	24.1			48.3				
95% C.I.	(23.5-39.2)	(23.5-42.3)	(12.2-58.3)			(47.2-49.5)				
Hispanic	122	101	10	11	0	5,798				
Rate*	21.7	23.3	13.5	23.1		35.8				
95% C.I.	(17.5-27.0)	(18.3-29.8)	(6.1-31.1)	(10.8-45.4)		(34.8-36.8)				
Other/Unknown	27	26	0	1	0	501				

^{*} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the National (SEER) rates. See Technical Notes for more information.

Table 109. Colorectal Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

			County/Region	on of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)
Total						
Cases	4,345	2,965	746	634	0	91,312
Rate*	46.7	47.1	45.6	46.3		49.3
95% C.I.	(45.3-48.1)	(45.4-48.8)	(42.3-48.8)	(42.7-49.9)		(49.0-49.6)
Age Group						
<1	0	0	0	0	0	
Rate*						
95% C.I.						
1-4	0	0	0	0	0	
Rate*						
95% C.I.						
5-14	1	0	1	0	0	12
Rate*						0.0
95% C.I.						(0.0-0.1)
15-24	1	0	1	0	0	122
Rate*						0.5
95% C.I.						(0.4-0.6)
25-34	30	25	4	1	0	836
Rate*	2.1	2.5				2.9
95% C.I.	(1.3-2.8)	(1.5-3.4)				(2.7-3.0)
35-44	147	112	25	10	0	3,192
Rate*	9.8	11.3	9.0	4.4		10.2
95% C.I.	(8.2-11.4)	(9.2-13.4)	(5.5-12.5)	(1.7-7.2)		(9.9-10.6)
45-54	412	277	73	62	0	8,388
Rate*	34.1	35.0	32.5	32.2		36.7
95% C.I.	(30.8-37.4)	(30.9-39.1)	(25.0-40.0)	(24.2-40.3)		(35.9-37.4)
55-64	865	609	143	113	0	15,120
Rate*	100.5	104.7	101.1	81.9		108.0
95% C.I.	(93.8-107.2)	(96.4-113.1)	(84.5-117.7)	(66.8-97.0)		(106.3-109.7)
65-74	1,430	964	248	218	0	25,963
Rate*	230.7	232.5	245.9	208.6		225.0
95% C.I.	(218.7-242.6)	(217.9-247.2)	(215.3-276.5)	(180.9-236.3)		(222.3-227.8)
75-84	1,138	781	184	173	0	26,555
Rate*	347.2	361.2	334.4	306.3		365.3
95% C.I.	(327.0-367.4)	(335.8-386.5)	(286.1-382.7)	(260.7-352.0)		(360.9-369.7)
85+	320	196	67	57	0	11,123
Rate*	454.2	457.5	464.8	432.0		448.5
95% C.I.	(404.5-504.0)	(393.5-521.6)	(353.5-576.1)	(319.9-544.2)		(440.1-456.8)
Unknown	1	1	0	0	0	0

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 110. Colorectal Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1996-2000

County of	1996-2000 Incidence							
Residence	Casas	Rat	e*	Age-Adjus	ted Rate**			
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	157	64.1	(54.0-74.1)	55.9	(47.4-65.5)			
Churchill	76	64.4	(49.9-78.9)	69.7	(54.8-87.9)			
Clark	2,965	47.1	(45.4-48.8)	54.7	(52.7-56.8)			
Douglas	76	38.0	(29.5-46.6)	33.1	(25.8-42.5)			
Elko	47	20.5	(14.6-26.4)	45.1	(32.2-61.9)			
Esmeralda	2							
Eureka	1							
Humboldt	19	22.6	(12.5-32.8)	36.4	(21.5-59.2)			
Lander	7							
Lincoln	12	58.9	(25.6-92.2)	47.9	(24.3-95.6)			
Lyon	99	61.2	(49.1-73.2)	54.4	(44.0-67.1)			
Mineral	17	61.8	(32.4-91.1)	48.1	(27.5-82.3)			
Nye	96	64.7	(51.7-77.6)	49.4	(39.3-62.2)			
Pershing	4							
Storey	3							
Washoe	746	45.6	(42.3-48.8)	53.4	(49.6-57.5)			
White Pine	18	41.3	(22.2-60.3)	36.2	(21.4-59.1)			
Unknown	0							
Total	4,345	46.7	(45.3-48.1)	53.1	(51.5-54.8)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 111. Colorectal Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

			Gender						
Race/Ethnicity		Male	Female	Other/ Unknown	Total				
White	Incidence	2,082	1,769	2	3,853				
	Rate*	63.7	49.3		56.1				
	95% C.I.	(60.9-66.8)	(47.0-51.7)		(54.3-57.9)				
Black	Incidence	123	101	0	224				
	Rate*	67.6	47.3		56.1				
	95% C.I.	(54.4-84.9)	(38.1-58.4)		(48.5-65.0)				
Native	Incidence	12	7	0	19				
American	Rate*	30.9			22.5				
	95% C.I.	(13.8-67.7)			(13.0-37.4)				
Asian	Incidence	50	50	0	100				
	Rate*	37.1	24.4		29.9				
	95% C.I.	(25.9-55.7)	(17.6-37.0)		(23.5-39.2)				
Hispanic	Incidence	63	59	0	122				
	Rate*	22.5	20.7		21.7				
	95% C.I.	(16.4-32.1)	(15.2-27.9)		(17.5-27.0)				
Other/Unknown		13	14	0	27				
Total	Incidence	2,343	2,000	2	4,345				
	Rate*	60.7	46.6		53.1				
	95% C.I.	(58.1-63.5)	(44.5-48.7)		(51.5-54.8)				

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are aga-adjusted to the 2000 US Standard population.

Table 112. Colorectal Cancer Cases by Age Group and Gender, Nevada Residents, 1996-2000

Age	Gender							
Group	Male	Female	Other/ Unknown	Total				
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	0	1	0	1				
Rate*								
95% C.I.								
15-24	0	1	0	1				
Rate*								
95% C.I.								
25-34	12	18	0	30				
Rate*	1.6	2.6		2.1				
95% C.I.	(0.7-2.5)	(1.4-3.8)		(1.3-2.8)				
35-44	69	78	0	147				
Rate*	8.9	10.8		9.8				
95% C.I.	(6.8-11.0)	(8.4-13.2)		(8.2-11.4)				
45-54	231	181	0	412				
Rate*	37.7	30.3		34.1				
95% C.I.	(32.9-42.6)	(25.9-34.8)		(30.8-37.4)				
55-64	519	346	0	865				
Rate*	121.1	80.1		100.5				
95% C.I.	(110.6-131.5)	(71.6-88.5)		(93.8-107.2)				
65-74	812	617	1	1,430				
Rate*	265.6	196.4		230.7				
95% C.I.	(247.3-283.9)	(180.9-211.9)		(218.7-242.6)				
75-84	580	558	0	1,138				
Rate*	393.3	309.5		347.2				
95% C.I.	(361.3-425.3)	(283.8-335.2)		(327.0-367.4)				
85+	120	199	1	320				
Rate*	529.3	416.5		454.2				
95% C.I.	(434.6-624.0)	(358.6-474.4)		(404.5-504.0)				
Unknown	0	1	0	1				
Total	2,343	2,000	2	4,345				
Rate*	49.5	43.7		46.7				
95% C.I.	(47.5-51.5)	(41.8-45.7)		(45.3-48.1)				

Note: The "---" is used for rates calculated on numbers less than ten.

^{*} Rates are per 100,000 age-specific population.

Table 113. Colorectal Cancer Cases by Age Group and Stage, Nevada Residents, 1996-2000

		Stage							
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total		
<1	Number	0	0	0	0	0	0		
	Percent								
1-4	Number	0	0	0	0	0	0		
	Percent								
5-14	Number	0	0	1	0	0	1		
	Percent			100.0%			100.0%		
15-24	Number	0	0	0	1	0	1		
	Percent				100.0%		100.0%		
25-34	Number	0	10	13	2	5	30		
	Percent		33.3%	43.3%	6.7%	16.7%	100.0%		
35-44	Number	0	54	41	29	23	147		
	Percent		36.7%	27.9%	19.7%	15.6%	100.0%		
45-54	Number	0	116	157	93	46	412		
	Percent		28.2%	38.1%	22.6%	11.2%	100.0%		
55-64	Number	0	255	312	198	100	865		
	Percent		29.5%	36.1%	22.9%	11.6%	100.0%		
65-74	Number	0	442	544	268	176	1,430		
	Percent		30.9%	38.0%	18.7%	12.3%	100.0%		
75-84	Number	0	340	412	196	190	1,138		
	Percent		29.9%	36.2%	17.2%	16.7%	100.0%		
85+	Number	0	77	116	47	80	320		
	Percent		24.1%	36.3%	14.7%	25.0%	100.0%		
Unknown	Number	0	0	0	0	1	1		
	Percent					100.0%	100.0%		
Total	Number	0	1,294 29.8%	1,596	834 19.2%	621 14.3%	4,345		
	Percent		29.8%	36.7%	19.2%	14.5%	100.0%		

Table 114. Colorectal Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1996-2000

Stage		Race/Ethnicity							
		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total	
In situ	Number	0	0	0	0	0	0	0	
	Percent								
Localized	Number	1,163	57	2	20	37	15	1,294	
	Percent	30.2%	25.4%	10.5%	20.0%	30.3%	55.6%	29.8%	
Regional	Number	1,420	81	5	41	40	9	1,596	
	Percent	36.9%	36.2%	26.3%	41.0%	32.8%	33.3%	36.7%	
Distant	Number	719	52	5	23	34	1	834	
	Percent	18.7%	23.2%	26.3%	23.0%	27.9%	3.7%	19.2%	
Unstaged	Number	551	34	7	16	11	2	621	
	Percent	14.3%	15.2%	36.8%	16.0%	9.0%	7.4%	14.3%	
Total	Number	3,853	224	19	100	122	27	4,345	
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	


Table 115. Median Age at Diagnosis of Colorectal Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

	Gender								
Race/Ethnicity	Male		Female		Total				
	Incidence	Median Age	Incidence	Median Age	Incidence	Median Age			
White	2,082	69.0	1,768	72.0	3,850	70.0			
Black	123	64.0	101	64.0	224	64.0			
Native American	12	54.5	7	69.0	19	65.0			
Asian	50	64.0	50	65.5	100	64.5			
Hispanic	63	63.0	59	64.0	122	64.0			
Other/Unknown	13	63.0	14	70.5	27	64.0			
Total	2,343	68.0	1,999	71.0	4,342	70.0			

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

Figure 79. Colorectal Cancer Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical notes for more information.

Figure 80. Colorectal Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 81. Median Charges for Colorectal Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000




Figure 82. Average Length of Stay for Colorectal Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000




Table 116. Colorectal Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

		Coun	ty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	4,034	2,832	661	541	0
Rate*	49.4	52.2	47.9	39.7	
95% C.I.	(47.8-51.0)	(50.2-54.3)	(44.2-51.8)	(36.4-43.3)	
Gender					
Male	2,095	1,483	332	280	0
Rate*	54.0	58.1	51.1	41.9	
95% C.I.	(51.6-56.6)	(54.9-61.5)	(45.5-57.6)	(36.9-47.5)	
Female	1,939	1,349	329	261	0
Rate*	45.2	47.3	44.3	37.1	
95% C.I.	(43.2-47.3)	(44.8-50.0)	(39.7-49.4)	(32.7-42.0)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	narges (\$)				
Total Charges	\$134,658,129	\$97,330,793	\$22,445,648	\$14,881,688	
Average Charges	\$33,381	\$34,368	\$33,957	\$27,508	
Median Charges	\$25,540	\$25,469	\$28,274	\$22,069	
Discharge Length of S	tay (LOS) (Days)				
Total LOS	34,507	24,326	5,908	4,273	
Average LOS	8.6	8.6	8.9	7.9	
Median LOS	7.0	7.0	8.0	6.0	

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 117. Colorectal Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown				
Total									
Discharges	4,034	2,832	661	541	0				
Rate*	43.4	45.0	40.4	39.5					
95% C.I.	(42.0-44.7)	(43.3-46.6)	(37.3-43.4)	(36.2-42.8)					
Age Group									
<1	0	0	0	0	0				
Rate*									
95% C.I.									
1-4	0	0	0	0	0				
Rate*									
95% C.I.									
5-14	0	0	0	0	0				
Rate*									
95% C.I.									
15-24	2	2	0	0	0				
Rate*									
95% C.I.									
25-34	29	23	1	5	0				
Rate*	2.0	2.3							
95% C.I.	(1.3-2.8)	(1.3-3.2)							
35-44	117	93	18	6	0				
Rate*	7.8	9.4	6.5						
95% C.I.	(6.4-9.3)	(7.5-11.3)	(3.5-9.5)						
45-54	356	250	58	48	0				
Rate*	29.4	31.6	25.8	21.4					
95% C.I.	(26.4-32.5)	(27.6-35.5)	(19.2-32.5)	(15.3-27.4)					
55-64	807	599	120	88	0				
Rate*	93.7	103.0	84.8	62.2					
95% C.I.	(87.3-100.2)	(94.8-111.3)	(69.7-100.0)	(49.2-75.2)					
65-74	1,320	897	235	188	0				
Rate*	212.9	216.4	233.0	186.4					
95% C.I.	(201.4-224.4)	(202.2-230.5)	(203.2-262.8)	(159.8-213.1)					
75-84	1,112	791	159	162	0				
Rate*	339.3	365.8	288.9	294.4					
95% C.I.	(319.3-359.2)	(340.3-391.3)	(244.0-333.9)	(249.1-339.7)					
85+	291	177	70	44	0				
Rate*	413.1	413.2	485.6	305.2					
95% C.I.	(365.6-460.5)	(352.3-474.0)	(371.8-599.3)	(215.0-395.4)					
Unknown	0	0	0	0	0				

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 118. Colorectal Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1996-2000

Age	Gender						
Group	Male	Female	Total				
<1	0	0	0				
Rate*							
95% C.I.							
1-4	0	0	0				
Rate*							
95% C.I.							
5-14	0	0	0				
Rate*							
95% C.I.							
15-24	0	2	2				
Rate*							
95% C.I.							
25-34	13	16	29				
Rate*	1.7	2.3	2.0				
95% C.I.	(0.8-2.7)	(1.2-3.5)	(1.3-2.8)				
35-44	56	61	117				
Rate*	7.3	8.4	7.8				
95% C.I.	(5.4-9.2)	(6.3-10.6)	(6.4-9.3)				
45-54	206	150	356				
Rate*	33.6	25.1	29.4				
95% C.I.	(29.0-38.2)	(21.1-29.2)	(26.4-32.5)				
55-64	464	343	807				
Rate*	108.2	79.4	93.7				
95% C.I.	(98.4-118.1)	(71.0-87.8)	(87.3-100.2)				
65-74	731	589	1,320				
Rate*	239.1	187.5	212.9				
95% C.I.	(221.8-256.4)	(172.3-202.6)	(201.4-224.4)				
75-84	524	588	1,112				
Rate*	355.3	326.1	339.3				
95% C.I.	(324.9-385.7)	(299.8-352.5)	(319.3-359.2)				
85+	101	190	291				
Rate*	445.5	397.7	413.1				
95% C.I.	(358.6-532.3)	(341.1-454.2)	(365.6-460.5)				
Unknown	2.005	1,020	4 024				
Total	2,095	1,939	4,034				
Rate* 95% C.I.	44.3 (42.4-46.2)	42.4 (40.5-44.3)	43.4 (42.0-44.7)				
90 /0 O.I.	(42.4-40.2)	(40.5-44.3)	(42.0-44.7)				

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 119. Colorectal Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000

		1996-2000 Inpatient Hospital Discharges						
County of Residence	Neuralean	Rat	:e*	Age-Adjuste	Age-Adjusted Rate**			
	Number	Rate	95% C.I.	Rate	95% C.I.			
Carson City	82	33.5	(26.2-40.7)	28.7	(22.8-35.8)			
Churchill	59	50.0	(37.2-62.8)	54.3	(41.2-70.6)			
Clark	2,832	45.0	(43.3-46.6)	52.2	(50.2-54.3)			
Douglas	61	30.5	(22.9-38.2)	27.1	(20.5-35.8)			
Elko	45	19.6	(13.9-25.4)	46.3	(32.9-63.6)			
Esmeralda	2							
Eureka	2							
Humboldt	17	20.3	(10.6-29.9)	30.7	(17.6-51.4)			
Lander	11	34.3	(14.0-54.6)	36.9	(18.2-73.8)			
Lincoln	2							
Lyon	118	72.9	(59.8-86.1)	67.1	(55.2-81.2)			
Mineral	25	90.8	(55.2-126.4)	69.7	(44.5-107.9)			
Nye	89	60.0	(47.5-72.4)	43.9	(34.8-55.7)			
Pershing	8							
Storey	3							
Washoe	661	40.4	(37.3-43.4)	47.9	(44.2-51.8)			
White Pine	17	39.0	(20.4-57.5)	35.1	(20.4-58.1)			
Unknown	0							
Total	4,034	43.4	(42.0-44.7)	49.4	(47.8-51.0)			


Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 120. Colorectal Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1996-2000

Age	Discharges	Charges (\$)		Len	Length of Stay (Days)		
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	0						
1-4	0						
5-14	0						
15-24	2						
25-34	29	874,733	30,163	20,806	242	8.3	6.0
35-44	117	3,791,834	32,409	25,174	985	8.4	7.0
45-54	356	11,050,332	31,040	23,886	2,865	8.0	7.0
55-64	807	25,775,710	31,940	25,649	6,514	8.1	7.0
65-74	1,320	43,015,660	32,588	25,088	10,753	8.1	7.0
75-84	1,112	39,751,121	35,747	26,527	10,314	9.3	7.0
85+	291	10,183,528	34,995	27,007	2,798	9.6	8.0
Unknown	0						
Total	4,034	134,658,129	33,381	25,540	34,507	8.6	7.0

MORTALITY

Figure 83. Colorectal Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 84. Colorectal Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 85. Colorectal Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1996-2000




Table 121. Colorectal Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	1,792	1,223	294	275
Rate*	22.9	23.6	22.0	21.0
95% C.I.	(21.8-24.0)	(22.2-25.0)	(19.5-24.7)	(18.6-23.8)
Gender				
Male	1,011	692	177	142
Rate*	28.0	28.9	30.0	22.6
95% C.I.	(26.1-30.0)	(26.5-31.4)	(25.4-35.4)	(18.8-27.0)
Female	781	531	117	133
Rate*	18.8	19.3	16.0	19.4
95% C.I.	(17.5-20.2)	(17.7-21.1)	(13.2-19.2)	(16.2-23.1)
Other/Unknown	0	0	0	0
Race/Ethnicity				
White	1,572	1,038	274	260
Rate*	23.7	24.5	23.0	21.5
95% C.I.	(22.5-24.9)	(23.0-26.1)	(20.3-26.0)	(18.9-24.4)
Black	110	105	4	1
Rate*	30.0	31.2		
95% C.I.	(24.1-37.1)	(24.9-38.9)		
Native American	10	4	4	2
Rate*	12.0			
95% C.I.	(5.4-24.4)			
Asian	42	33	7	2
Rate*	12.5	12.3		
95% C.I.	(8.8-19.6)	(8.3-21.0)		
Hispanic	57	42	5	10
Rate*	11.3	10.8		18.5
95% C.I.	(8.3-15.5)	(7.4-15.8)		(8.2-38.5)
Other/Unknown	1	1	0	0

Note: The "---" is used for rates calculated on numbers less than ten.

^{*}Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 122. Colorectal Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Mortality	1,792	1,223	294	275				
Rate*	19.3	19.4	18.0	20.1				
95% C.I.	(18.4-20.2)	(18.3-20.5)	(15.9-20.0)	(17.7-22.4)				
Age Group								
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	0	0	0	0				
Rate*								
95% C.I.								
15-24	1	0	1	0				
Rate*								
95% C.I.								
25-34	8	7	0	1				
Rate*								
95% C.I.								
35-44	43	31	10	2				
Rate*	2.9	3.1	3.6					
95% C.I.	(2.0-3.7)	(2.0-4.2)	(1.4-5.8)					
45-54	117	85	18	14				
Rate*	9.7	10.7	8.0	7.3				
95% C.I.	(7.9-11.4)	(8.4-13.0)	(4.3-11.7)	(3.5-11.1)				
55-64	308	216	49	43				
Rate*	35.8	37.1	34.6	31.2				
95% C.I.	(31.8-39.8)	(32.2-42.1)	(24.9-44.3)	(21.9-40.5)				
65-74	579	401	96	82				
Rate*	93.4	96.7	95.2	78.5				
95% C.I.	(85.8-101.0)	(87.3-106.2)	(76.1-114.2)	(61.5-95.5)				
75-84	533	360	76	97				
Rate*	162.6	166.5	138.1	171.7				
95% C.I.	(148.8-176.4)	(149.3-183.7)	(107.1-169.2)	(137.6-205.9)				
85+	203	123	44	36				
Rate*	288.1	287.1	305.2	272.9				
95% C.I.	(248.5-327.8)	(236.4-337.9)	(215.0-395.4)	(183.7-362.0)				
Unknown	0	0	0	0				

Note: The "---" is used for rates calculated on numbers less than ten.

^{*} Rates are per 100,000 age-specific population.

Table 123. Colorectal Cancer Mortality by County of Residence, Nevada Residents, 1996-2000

	1996-2000 Mortality						
County of Residence	Rate*			Age-Adjus	Age-Adjusted Rate**		
	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	57	23.3	(17.2-29.3)	20.4	(15.4-26.7)		
Churchill	29	24.6	(15.6-33.5)	27.0	(18.0-39.3)		
Clark	1,223	19.4	(18.3-20.5)	23.6	(22.2-25.0)		
Douglas	29	14.5	(9.2-19.8)	12.9	(8.5-19.6)		
Elko	26	11.3	(7.0-15.7)	28.4	(18.0-42.8)		
Esmeralda	0						
Eureka	1						
Humboldt	12	14.3	(6.2-22.4)	22.9	(11.5-42.4)		
Lander	7						
Lincoln	7						
Lyon	42	26.0	(18.1-33.8)	24.2	(17.3-33.5)		
Mineral	14	50.9	(24.2-77.5)	44.1	(23.7-78.6)		
Nye	41	27.6	(19.2-36.1)	20.6	(14.5-29.7)		
Pershing	1						
Storey	1						
Washoe	294	18.0	(15.9-20.0)	22.0	(19.5-24.7)		
White Pine	8						
Unknown	0						
Total	1,792	19.3	(18.4-20.2)	22.9	(21.8-24.0)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 124. Colorectal Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

		Gender					
Race/Ethnicity		Male	Female	Total			
White	Mortality	876	696	1,572			
	Rate*	28.5	19.8	23.7			
	95% C.I.	(26.4-30.6)	(18.3-21.3)	(22.5-24.9)			
Black	Mortality	69	41	110			
	Rate*	43.4	20.1	30.0			
	95% C.I.	(31.9-59.2)	(14.1-28.2)	(24.1-37.1)			
Native	Mortality	7	3	10			
American	Rate*			12.0			
	95% C.I.			(5.4-24.4)			
Asian	Mortality	23	19	42			
	Rate*	16.9	9.2	12.5			
	95% C.I.	(10.4-31.6)	(5.3-20.0)	(8.8-19.6)			
Hispanic	Mortality	36	21	57			
	Rate*	15.3	7.8	11.3			
	95% C.I.	(10.2-23.9)	(4.6-13.0)	(8.3-15.5)			
Other/Unkr	nown	0	1	1			
Total	Mortality	1,011	781	1,792			
	Rate*	28.0	18.8	22.9			
	95% C.I.	(26.1-30.0)	(17.5-20.2)	(21.8-24.0)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 125. Colorectal Cancer Mortality by Age Group and Gender, Nevada Residents, 1996-2000

Age	Gender						
Group	Male	Female	Total				
<1	0	0	0				
Rate*							
95% C.I.							
1-4	0	0	0				
Rate*							
95% C.I.							
5-14	0	0	0				
Rate*							
95% C.I.							
15-24	0	1	1				
Rate*							
95% C.I.							
25-34	2	6	8				
Rate*							
95% C.I.							
35-44	23	20	43				
Rate*	3.0	2.8	2.9				
95% C.I.	(1.8-4.2)	(1.6-4.0)	(2.0-3.7)				
45-54	67	50	117				
Rate*	10.9	8.4	9.7				
95% C.I.	(8.3-13.6)	(6.1-10.7)	(7.9-11.4)				
55-64 Data*	198	110	308				
Rate*	46.2	25.5	35.8				
95% C.I.	(39.7-52.6)	(20.7-30.2)	(31.8-39.8)				
65-74 Rate*	361 118.1	218 69.4	579 93.4				
95% C.I.	(105.9-130.3)	(60.2-78.6)	(85.8-101.0)				
75-84	276	257	533				
Rate*	187.2	142.6	162.6				
95% C.I.	(165.1-209.2)	(125.1-160.0)	(148.8-176.4)				
85+	84	119	203				
Rate*	370.5	249.1	288.1				
95% C.I.	(291.3-449.7)	(204.3-293.8)	(248.5-327.8)				
Unknown	(=3::3::3)	0	0				
Total	1,011	781	1,792				
Rate*	21.4	17.1	19.3				
95% C.I.	(20.1-22.7)	(15.9-18.3)	(18.4-20.2)				

Note: The "---" is used for rates calculated on numbers less than ten.

^{*} Rates are per 100,000 age-specific population.


Table 126. Median Age at Death from Colorectal Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

	Gender								
Race/Ethnicity	Ма	ile	Fem	nale	Total				
	Deaths	Median Age	Deaths	Median Age	Deaths	Median Age			
White	876	71.0	696	75.0	1,572	72.0			
Black	69	65.0	41	65.0	110	65.0			
Native American	7	56.0	3		10	67.5			
Asian	23	67.0	19	68.0	42	67.5			
Hispanic	36	69.5	21	69.0	57	69.0			
Other/Unknown	0		1		1				
Total	1,011	71.0	781	74.0	1,792	72.0			

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE

Figure 86. Survival Rates for Colorectal Cancer by Race/Ethnicity, Nevada Residents, 1996-2000



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 87. Survival Rates for Colorectal Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 1996-2000




Table 127. Cause-Specific Survival Rates for Colorectal Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

Race/	Newskar		Cause Specific Survival Rate					
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)	
Total	2,864	72.6%	57.7%	45.7%	37.4%	33.3%	2.64	
Male	1,509	71.6%	57.7%	43.5%	38.4%	36.9%	2.54	
Female	1,353	73.6%	57.6%	48.2%	35.9%	28.7%	2.81	
Race/Ethnicity								
White	2,532	72.1%	56.5%	44.7%	36.0%	32.5%	2.55	
Male	1,340	71.5%	57.1%	43.1%	37.6%	37.6%	2.51	
Female	1,190	72.6%	55.7%	46.5%	34.0%	26.9%	2.62	
Black	151	75.6%	61.0%	43.6%	39.6%	39.6%	2.63	
Male	78	70.3%	57.3%	38.2%	31.3%	31.3%	2.38	
Female	73	81.4%	65.1%	49.3%	49.3%	49.3%	2.96	
Native American	11							
Male	9							
Female	2							
Asian	66	76.2%	68.4%	61.2%	61.2%			
Male	33							
Female	33							
Hispanic	88	75.0%	69.7%	59.8%	51.8%	34.5%	4.10	
Male	45							
Female	43							

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 128. Cause-Specific Survival Rates for Colorectal Cancer by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1996-2000


Surviv	/al Rate of Stage		Gender	
a	nt Diagnosis	Total	Male	Female
Total	Cases	2,864	1,509	1,353
	One Year	72.6%	71.6%	73.6%
	5 Years	33.3%	36.9%	28.7%
	Median Survival	2.64	2.54	2.81
Stage at D	iagnosis			
In situ	Cases	0	0	0
	One Year			
	5 Years			
	Median Survival			
Localized	Cases	871	463	406
	One Year	92.6%	91.9%	93.3%
	5 Years	69.2%	78.5%	57.9%
	Median Survival	>5 years	>5 years	>5 years
Regional	Cases	1,112	566	546
	One Year	85.4%	86.4%	84.3%
	5 Years	35.4%	42.8%	26.9%
	Median Survival	3.21	3.17	3.24
Distant	Cases	632	350	282
	One Year	40.4%	37.0%	44.7%
	5 Years	5.4%	4.6%	7.4%
	Median Survival	0.84	0.79	0.90
Unstaged	Cases	249	130	119
	One Year	48.5%	50.5%	46.5%
	5 Years	16.2%	0.0%	19.9%
	Median Survival	0.97	1.02	0.93

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

URINARY BLADDER CANCER

URINARY BLADDER CANCER GENERAL PROFILE⁴

Figure 88. Anatomy of the Urinary System⁵



General Anatomy: The bladder is a hollow organ in the lower abdomen. It stores urine, the liquid waste produced by the kidneys. Urine passes from each kidney into the bladder through a tube called a ureter. An outer layer of muscle surrounds the inner lining of the bladder. When the bladder is full, the muscles in the bladder wall can tighten to allow urination. Urine leaves the bladder through another tube, the urethra.

Risk Factors: Age, tobacco use, occupation (due to amount of carcinogens in the workplace), infection, treatment with cyclophosphamide or arsenic, race, being a man, family history, and personal history with Bladder Cancer.

Signs and Symptoms: Blood in the urine (making the urine slightly rusty to deep red), pain during urination, and frequent urination, or feeling the need to urinate without results.

Diagnosing the Cancer: Physical exams, urine tests, intravenous pyelogram, and cystoscopy.

Treatment: Treatment options include: surgery (Transurethral resection, Radical cystectomy, and Segmental cystectomy), radiation therapy (internal or external), chemotherapy, and biological therapy.

HIGHLIGHTS

- Nevadan males had a considerably higher ratio than females when the incidence and mortality age-adjusted rates for Urinary Bladder Cancer were compared. Males had a ratio of 4.69 while the ratio for females was 3.81. This means that for every death due to Urinary Bladder Cancer there would be 4.69 male cases while only 3.81 cases for every female death.
- ➤ The median age at diagnosis of Urinary Bladder Cancer for Nevada residents and males was 70 years of age for Nevada Residents from 1996 to 2000 while the median age for females was 71 years. However, the median age at time of death due to Urinary Bladder Cancer was 74 years for Nevada overall, 75 years for females and 73 years of age for males.

INCIDENCE

- ➤ There were 1,866 cases of Urinary Bladder Cancer reported in Nevada from 1996 to 2000. Nevada's age-adjusted incidence rate (22.6) for Urinary Bladder Cancer was only slightly higher than the National rate of 20.0 (per 100,000 2000 US Standard population).
- ➤ While there was little regional variation between Washoe County (23.2), All Other Counties (22.7) and Clark County (22.5) in the age-adjusted incidence rate for Urinary Bladder Cancer, the rate for Males (37.3) was more than three times as the rate for Nevada Females (10.4, per 100,000 2000 US Standard population) for the 1996 to 2000 period.
- ➤ Similar to the National rates, Nevada Whites, as a racial/ethnic group, had an ageadjusted incidence rate (25.3, per 100,000 – 2000 US Standard population) nearly double the rates for all other racial/ethnic groups from 1996 to 2000.

INPATIENT HOSPITAL DISCHARGES

- ➤ Billed charges from Urinary Bladder Cancer inpatient hospital discharges accounted for over 30.4 million dollars from 1996 to 2000. Nevadans in the 65-74 and 75-84 age groups accounted for 66.8% of the total inpatient discharges and 65.0% of the total billed charges during this period. The overall daily billed amount for these discharges was over \$4,600 in Nevada during this period.
- ➤ There were 989 Inpatient Discharges for Urinary Bladder Cancer to Nevada residents in Nevada from 1996 to 2000. Clark County had the highest age-adjusted inpatient discharge rate, 13.4 (12.4-14.5), for Urinary Bladder Cancer in Nevada, and showed statistical significance over the Washoe County rate of 9.4 (7.8-11.2) who had the lowest age-adjusted inpatient discharge rate during the 1996 to 2000 period.

➤ The median total billed charges in Nevada for inpatient discharges due to Urinary Bladder Cancer was \$16,433 from 1996 to 2000. Washoe County had the highest median total billed charge, \$17,504, when compared to the billed amounts for Clark County and All Other Counties of \$16,389 and \$13,033.

MORTALITY


- ➤ There were 379 resident deaths due to Urinary Bladder Cancer from 1996 to 2000. Regional comparisons were fairly similar between Clark, Washoe, and All Other Counties, as a region, with rates of 5.3, 4.7 and 4.2 (per 100,000 2000 US Standard population), respectively.
- Nevadan males had a 34.4% higher statistically significant age-adjusted mortality rate, 8.0 (6.9-9.1), for Urinary Bladder Cancer when compared to the female rate of 2.7 (2.2-3.3) (per 100,000 2000 US Standard population) for the 1996 to 2000 period.

SURVIVAL RATE

- Nevada's one-year survival rate for males with Urinary Bladder Cancer was higher than the rate for females during the 1996 to 2000 period, with rates of 85.0% and 80.0%, respectively. This difference lessened by the five-year rate where males had a rate of 60.4% and females had a rate of 59.2%.
- The one-year survival rate for those diagnosed with Urinary Bladder Cancer at the in situ stage was 100.0%, with those at the localized stage at 88.7%, and those recorded at the regional, distant and unstaged stages had rates of 61.4%, 20.0% and 74.4%, respectively.
- ➤ The Median Survival time for those diagnosed at the in situ, localized and unstaged stages was over five years, while those diagnosed at the regional, distant and unstaged levels had median survival times of 1.65 and 0.63 years, respectively.

INCIDENCE

Figure 89. Urinary Bladder Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 90. Urinary Bladder Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 91. Urinary Bladder Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1996-2000




Table 129. Urinary Bladder Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)			
Total									
Cases	1,866	1,221	327	318	0	33,284			
Rate*	22.6	22.5	23.2	22.7		20.0			
95% C.I.	(21.6-23.7)	(21.2-23.9)	(20.7-25.9)	(20.2-25.5)		(19.8-20.2)			
Gender									
Male	1,414	920	245	249	0	24,595			
Rate*	37.3	36.9	38.6	37.9		35.2			
95% C.I.	(35.3-39.6)	(34.3-39.7)	(33.6-44.3)	(33.1-43.4)		(34.7-35.6)			
Female	452	301	82	69	0	8,689			
Rate*	10.4	10.6	10.8	9.4		9.1			
95% C.I.	(9.5-11.5)	(9.4-11.9)	(8.6-13.5)	(7.3-12.0)		(8.9-9.3)			
Other/Unknown	0	0	0	0	0	0			
Race/Ethnicity									
White	1,763	1,129	320	314	0	29,914			
Rate*	25.3	25.5	25.6	24.4		21.8			
95% C.I.	(24.1-26.5)	(24.0-27.1)	(22.8-28.6)	(21.7-27.3)		(21.5-22.0)			
Black	35	34	0	1	0	1,598			
Rate*	11.4	12.2				12.3			
95% C.I.	(7.7-16.6)	(8.1-17.8)				(11.7-12.9)			
Native American	2	0	2	0	0	32			
Rate*						3.2			
95% C.I.						(2.1-2.1)			
Asian	13	9	4	0	0	1,438			
Rate*	5.3					9.8			
95% C.I.	(2.2-12.4)					(9.3-10.4)			
Hispanic	41	37	1	3	0	1,372			
Rate*	6.7	8.1				8.9			
95% C.I.	(4.5-10.0)	(5.3-12.5)				(8.4-9.4)			
Other/Unknown	12	12	0	0	0	302			

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the National (SEER) rates. See Technical Notes for more information.

Table 130. Urinary Bladder Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

		County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)				
Total										
Cases	1,866	1,221	327	318	0	33,284				
Rate*	20.1	19.4	20.0	23.2		18.0				
95% C.I.	(19.1-21.0)	(18.3-20.5)	(17.8-22.1)	(20.7-25.8)		(17.8-18.2)				
Age Group										
<1	1	0	1	0	0					
Rate*										
95% C.I.										
1-4	1	1	0	0	0					
Rate*										
95% C.I.										
5-14	0	0	0	0	0					
Rate*										
95% C.I.										
15-24	3	3	0	0	0	47				
Rate*						0.2				
95% C.I.						(0.1-0.2)				
25-34	8	5	3	0	0	190				
Rate*						0.6				
95% C.I.						(0.6-0.7)				
35-44	44	24	11	9	0	858				
Rate*	2.9	2.4	4.0			2.7				
95% C.I.	(2.1-3.8)	(1.5-3.4)	(1.6-6.3)			(2.6-2.9)				
45-54	148	101	29	18	0	2,648				
Rate*	12.2	12.8	12.9	9.4		11.6				
95% C.I.	(10.3-14.2)	(10.3-15.2)	(8.2-17.6)	(5.0-13.7)		(11.1-12.0)				
55-64	367	237	62	68	0	5,531				
Rate*	42.6	40.8	43.8	49.3		39.5				
95% C.I.	(38.3-47.0)	(35.6-46.0)	(32.9-54.7)	(37.6-61.0)		(38.5-40.5)				
65-74	663	426	116	121	0	10,517				
Rate*	107.0	102.8	115.0	115.8		91.2				
95% C.I.	(98.8-115.1)	(93.0-112.5)	(94.1-135.9)	(95.2-136.4)		(89.4-92.9)				
75-84	514	349	83	82	0	9,988				
Rate*	156.8	161.4	150.8	145.2		137.4				
95% C.I.	(143.3-170.4)	(144.5-178.3)	(118.4-183.3)	(113.8-176.6)		(134.7-140.1)				
85+	117	75	22	20	0	3,496				
Rate*	166.1	175.1	152.6	151.6		141.0				
95% C.I.	(136.0-196.2)	(135.4-214.7)	(88.8-216.4)	(85.1-218.0)		(136.3-145.6)				
Unknown	0	Ó	0	0	0	0				

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 131. Urinary Bladder Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1996-2000

County of		1996-2000 Incidence					
Residence	Casas	Rat	te*	Age-Adjus	Age-Adjusted Rate**		
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	89	36.3	(28.8-43.9)	30.5	(24.4-37.7)		
Churchill	28	23.7	(14.9-32.5)	24.4	(16.2-35.9)		
Clark	1,221	19.4	(18.3-20.5)	22.5	(21.2-23.9)		
Douglas	59	29.5	(22.0-37.0)	25.9	(19.4-34.5)		
Elko	11	4.8	(2.0-7.6)	7.7	(3.5-15.9)		
Esmeralda	0						
Eureka	0						
Humboldt	13	15.5	(7.1-23.9)	21.4	(10.8-39.7)		
Lander	3						
Lincoln	1						
Lyon	64	39.6	(29.9-49.2)	34.2	(26.1-44.4)		
Mineral	7						
Nye	35	23.6	(15.8-31.4)	18.1	(12.0-27.2)		
Pershing	2						
Storey	2						
Washoe	327	20.0	(17.8-22.1)	23.2	(20.7-25.9)		
White Pine	4						
Unknown	0						
Total	1,866	20.1	(19.1-21.0)	22.6	(21.6-23.7)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 132. Urinary Bladder Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

			Gei	nder	
Rac	e/Ethnicity	Male	Female	Other/ Unknown	Total
White	Incidence Rate* 95% C.I.	1,325 40.8 (38.5-43.3)	438 12.1 (11.0-13.3)	0	1,763 25.3 (24.1-26.5)
Black	Incidence Rate* 95% C.I.	31 24.8 (15.6-39.0)	4	0 	35 11.4 (7.7-16.6)
Native American	Incidence Rate* 95% C.I.	2	0	0 	2
Asian	Incidence Rate* 95% C.I.	9 	4	0 	13 5.3 (2.2-12.4)
Hispanic	Incidence Rate* 95% C.I.	36 12.3 (7.7-20.7)	5 	0 	41 6.7 (4.5-10.0)
Other/Unkn	iown	11	1	0	12
Total	Incidence Rate* 95% C.I.	1,414 37.3 (35.3-39.6)	452 10.4 (9.5-11.5)	0 	1,866 22.6 (21.6-23.7)

Note: The "---" is used for rates calculated on numbers less than ten.

^{*}Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 133. Urinary Bladder Cancer Cases by Age Group and Gender, Nevada Residents, 1996-2000

Age		Gen	ıder	
Group	Male	Female	Other/ Unknown	Total
<1	1	0	0	1
Rate*				
95% C.I.				
1-4	1	0	0	1
Rate*				
95% C.I.				
5-14	0	0	0	0
Rate*				
95% C.I.				
15-24	1	2	0	3
Rate*				
95% C.I.				
25-34	5	3	0	8
Rate*				
95% C.I.				
35-44	31	13	0	44
Rate*	4.0	1.8		2.9
95% C.I.	(2.6-5.4)	(0.8-2.8)		(2.1-3.8)
45-54	111	37	0	148
Rate*	18.1	6.2		12.2
95% C.I.	(14.8-21.5)	(4.2-8.2)		(10.3-14.2)
55-64	289	78	0	367
Rate*	67.4	18.1		42.6
95% C.I.	(59.6-75.2)	(14.0-22.1)		(38.3-47.0)
65-74	512	151	0	663
Rate*	167.5	48.1		107.0
95% C.I.	(153.0-182.0)	(40.4-55.7)		(98.8-115.1)
75-84	382	132	0	514
Rate*	259.0	73.2		156.8
95% C.I.	(233.1-285.0)	(60.7-85.7)		(143.3-170.4)
85+	81	36	0	117
Rate*	357.2	75.4		166.1
95% C.I.	(279.4-435.0)	(50.7-100.0)		(136.0-196.2)
Unknown	0	0	0	0
Total	1,414	452	0	1,866
Rate*	29.9	9.9		20.1
95% C.I.	(28.3-31.5)	(9.0-10.8)		(19.1-21.0)

Note: The "---" is used for rates calculated on numbers less than ten.

^{*} Rates are per 100,000 age-specific population.

Table 134. Urinary Bladder Cancer Cases by Age Group and Stage, Nevada Residents, 1996-2000

				Si	tage		
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total
<1	Number	0	1	0	0	0	1
	Percent		100.0%				100.0%
1-4	Number	0	0	0	0	1	1
	Percent					100.0%	100.0%
5-14	Number	0	0	0	0	0	0
	Percent						
15-24	Number	2	1	0	0	0	3
	Percent	66.7%	33.3%				100.0%
25-34	Number	2	4	0	1	1	8
	Percent	25.0%	50.0%		12.5%	12.5%	100.0%
35-44	Number	10	28	2	2	2	44
	Percent	22.7%	63.6%	4.5%	4.5%	4.5%	100.0%
45-54	Number	51	72	12	4	9	148
	Percent	34.5%	48.6%	8.1%	2.7%	6.1%	100.0%
55-64	Number	85	192	42	15	33	367
	Percent	23.2%	52.3%	11.4%	4.1%	9.0%	100.0%
65-74	Number	142	371	56	27	67	663
	Percent	21.4%	56.0%	8.4%	4.1%	10.1%	100.0%
75-84	Number	113	278	55	13	55	514
	Percent	22.0%	54.1%	10.7%	2.5%	10.7%	100.0%
85+	Number	17	60	10	4	26	117
	Percent	14.5%	51.3%	8.5%	3.4%	22.2%	100.0%
Unknown	Number	0	0	0	0	0	0
	Percent						
Total	Number	422	1,007	177	66	194	1,866
	Percent	22.6%	54.0%	9.5%	3.5%	10.4%	100.0%

Table 135. Urinary Bladder Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1996-2000

				у				
	Stage		Black	Native American	Asian	Hispanic	Other/ Unknown	Total
In situ	Number	381	7	0	6	20	8	422
	Percent	21.6%	20.0%		46.2%	48.8%	66.7%	22.6%
Localized	Number	974	12	1	3	13	4	1,007
	Percent	55.2%	34.3%	50.0%	23.1%	31.7%	33.3%	54.0%
Regional	Number	167	7	0	1	2	0	177
	Percent	9.5%	20.0%		7.7%	4.9%		9.5%
Distant	Number	61	3	0	0	2	0	66
	Percent	3.5%	8.6%			4.9%		3.5%
Unstaged	Number	180	6	1	3	4	0	194
	Percent	10.2%	17.1%	50.0%	23.1%	9.8%		10.4%
Total	Number	1,763	35	2	13	41	12	1,866
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%


Table 136. Median Age at Diagnosis of Urinary Bladder Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

	Gender								
Race/Ethnicity	Ма	ile	Fem	nale	То	Total			
	Incidence	Median Age	Incidence	Median Age	Incidence	Median Age			
White	1,325	70.0	438	71.0	1,763	70.0			
Black	31	75.0	4		35	75.0			
Native American	2		0		2				
Asian	9	71.0	4		13	71.0			
Hispanic	36	59.0	5	70.0	41	61.0			
Other/Unknown	11	67.0	1		12	67.5			
Total	1,414	70.0	452	71.0	1,866	70.0			

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

Figure 92. Urinary Bladder Cancer Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical notes for more information.

Figure 93. Urinary Bladder Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 94. Median Charges for Urinary Bladder Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000




Figure 95. Average Length of Stay for Urinary Bladder Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000




Table 137. Urinary Bladder Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

		Coun	ty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	989	710	129	149	1
Rate*	12.2	13.4	9.4	10.5	
95% C.I.	(11.4-13.0)	(12.4-14.5)	(7.8-11.2)	(8.8-12.4)	
Gender					
Male	740	540	87	112	1
Rate*	20.0	22.5	14.0	16.9	
95% C.I.	(18.5-21.7)	(20.4-24.8)	(11.1-17.7)	(13.7-20.7)	
Female	249	170	42	37	0
Rate*	5.8	6.1	5.6	4.9	
95% C.I.	(5.1-6.6)	(5.2-7.1)	(4.0-7.6)	(3.5-6.9)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	narges (\$)				
Total Charges	\$30,402,813	\$22,213,274	\$4,536,433	\$3,617,905	\$35,201
Average Charges	\$30,741	\$31,286	\$35,166	\$24,281	\$35,201
Median Charges	\$16,433	\$16,389	\$17,504	\$13,033	\$35,201
Discharge Length of S	tay (LOS) (Days)				
Total LOS	6,521	4,676	984	849	12
Average LOS	6.6	6.6	7.6	5.7	12.0
Median LOS	4.0	4.0	6.0	4.0	12.0

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 138. Urinary Bladder Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown				
Total									
Discharges	989	710	129	149	1				
Rate*	10.6	11.3	7.9	10.9					
95% C.I.	(10.0-11.3)	(10.4-12.1)	(6.5-9.2)	(9.1-12.6)					
Age Group									
<1	0	0	0	0	0				
Rate*									
95% C.I.									
1-4	2	2	0	0	0				
Rate*									
95% C.I.									
5-14	0	0	0	0	0				
Rate*									
95% C.I.									
15-24	0	0	0	0	0				
Rate*									
95% C.I.									
25-34	2	2	0	0	0				
Rate*									
95% C.I.									
35-44	13	9	2	2	0				
Rate*	0.9								
95% C.I.	(0.4-1.3)								
45-54	59	46	9	4	0				
Rate*	4.9	5.8							
95% C.I.	(3.6-6.1)	(4.1-7.5)							
55-64	182	131	26	25	0				
Rate*	21.1	22.5	18.4	17.7					
95% C.I.	(18.1-24.2)	(18.7-26.4)	(11.3-25.4)	(10.7-24.6)					
65-74	352	238	42	72	0				
Rate*	56.8	57.4	41.6	71.4					
95% C.I.	(50.9-62.7)	(50.1-64.7)	(29.0-54.2)	(54.9-87.9)					
75-84	309	230	39	39	1				
Rate*	94.3	106.4	70.9	70.9					
95% C.I.	(83.8-104.8)	(92.6-120.1)	(48.6-93.1)	(48.6-93.1)					
85+	70	52	11	7	0				
Rate*	99.4	121.4	76.3						
95% C.I.	(76.1-122.6)	(88.4-154.4)	(31.2-121.4)						
Unknown	0	0	0	0	0				

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 139. Urinary Bladder Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1996-2000

Age		Gender	
Group	Male	Female	Total
<1	0	0	0
Rate*			
95% C.I.			
1-4	2	0	2
Rate*			
95% C.I.			
5-14	0	0	0
Rate*			
95% C.I.			
15-24	0	0	0
Rate*			
95% C.I.			
25-34	2	0	2
Rate*			
95% C.I.			
35-44	10	3	13
Rate*	1.3		0.9
95% C.I.	(0.5-2.1)		(0.4-1.3)
45-54	36	23	59
Rate*	5.9	3.9	4.9
95% C.I.	(4.0-7.8)	(2.3-5.4)	(3.6-6.1)
55-64 Rate*	150	32	182
95% C.I.	35.0 (29.4-40.6)	7.4 (4.8-10.0)	21.1 (18.1-24.2)
65-74	267	85	352
Rate*	87.3	27.1	56.8
95% C.I.	(76.9-97.8)	(21.3-32.8)	(50.9-62.7)
75-84	225	84	309
Rate*	152.6	46.6	94.3
95% C.I.	(132.6-172.5)	(36.6-56.6)	(83.8-104.8)
85+	48	22	70
Rate*	211.7	46.0	99.4
95% C.I.	(151.8-271.6)	(26.8-65.3)	(76.1-122.6)
Unknown	0	0	0
Total	740	249	989
Rate*	15.6	5.4	10.6
95% C.I.	(14.5-16.8)	(4.8-6.1)	(10.0-11.3)

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 140. Urinary Bladder Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000

O sureture of	1996-2000 Inpatient Hospital Discharges							
County of Residence	Number	Ra	te*	Age-Adjusted Rate**				
		Rate	95% C.I.	Rate	95% C.I.			
Carson City	25	10.2	(6.2-14.2)	8.2	(5.3-12.3)			
Churchill	9							
Clark	710	11.3	(10.4-12.1)	13.4	(12.4-14.5)			
Douglas	20	10.0	(5.6-14.4)	7.9	(4.8-13.1)			
Elko	9							
Esmeralda	1							
Eureka	0							
Humboldt	4							
Lander	2							
Lincoln	1							
Lyon	38	23.5	(16.0-31.0)	18.8	(13.3-26.5)			
Mineral	4							
Nye	26	17.5	(10.8-24.2)	13.5	(8.2-22.0)			
Pershing	3							
Storey	0							
Washoe	129	7.9	(6.5-9.2)	9.4	(7.8-11.2)			
White Pine	7							
Unknown	1							
Total	989	10.6	(10.0-11.3)	12.2	(11.4-13.0)			


Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 141. Urinary Bladder Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1996-2000

Age Group	Discharges	Charges (\$)			Length of Stay (Days)		
		Total	Average	Median	Total	Average	Median
<1	0						
1-4	2						
5-14	0						
15-24	0						
25-34	2						
35-44	13	385,712	29,670	23,499	87	6.7	7.0
45-54	59	2,097,638	35,553	29,669	431	7.3	6.0
55-64	182	6,760,033	37,143	23,157	1,404	7.7	6.0
65-74	352	10,396,098	29,534	17,748	2,209	6.3	5.0
75-84	309	9,380,536	30,358	14,135	1,952	6.3	4.0
85+	70	1,206,108	17,230	12,319	392	5.6	3.0
Unknown	0						
Total	989	30,402,813	30,741	16,433	6,521	6.6	4.0

MORTALITY

Figure 96. Urinary Bladder Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 97. Urinary Bladder Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 98. Urinary Bladder Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1996-2000




Table 142. Urinary Bladder Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Mortality	379	260	64	55				
Rate*	5.0	5.3	4.7	4.2				
95% C.I.	(4.5-5.6)	(4.7-6.1)	(3.6-6.1)	(3.2-5.6)				
Gender								
Male	268	189	40	39				
Rate*	8.0	8.6	6.8	6.8				
95% C.I.	(6.9-9.1)	(7.3-10.2)	(4.7-9.7)	(4.7-9.7)				
Female	111	71	24	16				
Rate*	2.7	2.8	3.2	2.3				
95% C.I.	(2.2-3.3)	(2.2-3.5)	(2.0-4.8)	(1.3-3.8)				
Other/Unknown	0	0	0	0				
Race/Ethnicity								
White	350	237	59	54				
Rate*	5.3	5.8	4.8	4.5				
95% C.I.	(4.8-6.0)	(5.0-6.6)	(3.7-6.3)	(3.4-6.0)				
Black	13	13	0	0				
Rate*	4.6	5.0						
95% C.I.	(2.3-8.4)	(2.6-9.3)						
Native American	1	0	1	0				
Rate*								
95% C.I.								
Asian	5	4	1	0				
Rate*								
95% C.I.								
Hispanic	9	6	2	1				
Rate*								
95% C.I.								
Other/Unknown	1	0	1	0				

^{*}Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 143. Urinary Bladder Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Regio	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	379	260	64	55
Rate*	4.1	4.1	3.9	4.0
95% C.I.	(3.7-4.5)	(3.6-4.6)	(3.0-4.9)	(3.0-5.1)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	0	0	0
Rate*				
95% C.I.				
15-24	0	0	0	0
Rate*				
95% C.I.				
25-34	1	1	0	0
Rate*				
95% C.I.				
35-44	4	1	2	1
Rate*				
95% C.I.				
45-54	13	11	2	0
Rate*	1.1	1.4		
95% C.I.	(0.5-1.7)	(0.6-2.2)		
55-64	55	37	15	3
Rate*	6.4	6.4	10.6	
95% C.I.	(4.7-8.1)	(4.3-8.4)	(5.2-16.0)	
65-74	126	83	20	23
Rate*	20.3	20.0	19.8	22.0
95% C.I.	(16.8-23.9)	(15.7-24.3)	(11.1-28.5)	(13.0-31.0)
75-84 Rate*	126 38.4	88 40.7	18 32.7	20 35.4
95% C.I.	(31.7-45.2)	(32.2-49.2)	(17.6-47.8)	(19.9-50.9)
95% C.I.	(31.7-45.2)	(32.2-49.2)	(17.0-47.8)	(19.9-50.9)
Rate*	76.7	91.0		0
95% C.I.	(56.2-97.1)	(62.5-119.6)		
Unknown	(50.2-97.1)	(02.3-119.0)	0	0
CHAHOWH				0

^{*} Rates are per 100,000 age-specific population.

Table 144. Urinary Bladder Cancer Mortality by County of Residence, Nevada Residents, 1996-2000

Country of	1996-2000 Mortality							
County of Residence	Coooo	Rat	te*	Age-Adjusted Rate**				
	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	16	6.5	(3.3-9.7)	5.7	(3.2-9.4)			
Churchill	2				·			
Clark	260	4.1	(3.6-4.6)	5.3	(4.7-6.1)			
Douglas	13	6.5	(3.0-10.0)	6.0	(3.1-11.3)			
Elko	4							
Esmeralda	0							
Eureka	0							
Humboldt	3							
Lander	2							
Lincoln	0							
Lyon	3							
Mineral	1							
Nye	8							
Pershing	0							
Storey	0							
Washoe	64	3.9	(3.0-4.9)	4.7	(3.6-6.1)			
White Pine	3							
Unknown	0							
Total	379	4.1	(3.7-4.5)	5.0	(4.5-5.6)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 145. Urinary Bladder Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

		Gender					
Rac	ce/Ethnicity	Male	Female	Total			
White	Mortality	245	105	350			
	Rate*	8.4	3.0	5.3			
	95% C.I.	(7.3-9.7)	(2.4-3.6)	(4.8-6.0)			
Black	Mortality	9	4	13			
	Rate*			4.6			
	95% C.I.			(2.3-8.4)			
Native	Mortality	1	0	1			
American	Rate*						
	95% C.I.						
Asian	Mortality	4	1	5			
	Rate*						
	95% C.I.						
Hispanic	Mortality	8	1	9			
	Rate*						
	95% C.I.						
Other/Unkr	nown	1	0	1			
Total	Mortality	268	111	379			
	Rate*	8.0	2.7	5.0			
	95% C.I.	(6.9-9.1)	(2.2-3.3)	(4.5-5.6)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 146. Urinary Bladder Cancer Mortality by Age Group and Gender, Nevada Residents, 1996-2000

Age		Gender	
Group	Male	Female	Total
<1	0		
Rate*			
95% C.I.			
1-4	0	0	0
Rate*			
95% C.I.			
5-14	0	0	0
Rate*			
95% C.I.			
15-24	0	0	0
Rate*			
95% C.I.			
25-34	1	0	1
Rate*			
95% C.I.			
35-44	1	3	4
Rate*			
95% C.I.			
45-54	9	4	13
Rate*			1.1
95% C.I.			(0.5-1.7)
55-64	45	10	55
Rate*	10.5	2.3	6.4
95% C.I.	(7.4-13.6)	(0.9-3.7)	(4.7-8.1)
65-74	92	34	126
Rate*	30.1	10.8	20.3
95% C.I.	(23.9-36.2)	(7.2-14.5)	(16.8-23.9)
75-84	89	37	126
Rate*	60.3	20.5	38.4
95% C.I.	(47.8-72.9)	(13.9-27.1)	(31.7-45.2)
85+	31	23	54
Rate*	136.7	48.1	76.7 (56.2-97.1)
95% C.I. Unknown	(88.6-184.9)	(28.5-67.8)	(56.2-97.1)
	268	111	379
Total Rate*	5.7	2.4	4.1
95% C.I.	(5.0-6.3)	(2.0-2.9)	(3.7-4.5)
55 /0 O.I.	(5.5-6.5)	(2.0-2.9)	(3.7-4.3)

^{*} Rates are per 100,000 age-specific population.


Table 147. Median Age at Death from Urinary Bladder Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

	Gender								
Race/Ethnicity	Ма	ile	Fem	nale	То	Total			
	Deaths	Median Age	Deaths	Median Age	Deaths	Median Age			
White	245	73.0	105	75.0	350	74.0			
Black	9	72.0	4		13	77.0			
Native American	1		0		1				
Asian	4		1		5	69.0			
Hispanic	8	70.0	1		9	70.0			
Other/Unknown	1		0		1				
Total	268	73.0	111	75.0	379	74.0			

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE

Figure 99. Survival Rates for Urinary Bladder Cancer by Race/Ethnicity, Nevada Residents, 1996-2000



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 100. Survival Rates for Urinary Bladder Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 1996-2000




Table 148. Cause-Specific Survival Rates for Urinary Bladder Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

Race/	Newska	Cause Specific Survival Rate					Median
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)
Total	1,285	83.8%	75.5%	69.2%	65.9%	60.4%	>5 years
Male	974	85.0%	76.5%	70.5%	68.2%	60.4%	>5 years
Female	311	80.0%	72.1%	65.3%	59.2%	59.2%	>5 years
Race/Ethnicity							
White	1,212	83.9%	75.9%	69.3%	66.7%	60.9%	>5 years
Male	909	85.2%	77.2%	70.7%	69.5%	61.4%	>5 years
Female	303	79.9%	71.8%	64.8%	58.5%	58.5%	>5 years
Black	21						
Male	20						
Female	1						
Native American	1						
Male	1						
Female	0						
Asian	10						
Male	7						
Female	3						
Hispanic	34						
Male	31						
Female	3						

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 149. Cause-Specific Survival Rates for Urinary Bladder Cancer by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1996-2000

Survival Rate of Stage at Diagnosis			Gender	
		Total	Male	Female
Total	Cases	1,285	974	311
	One Year	83.8%	85.0%	80.0%
	5 Years	60.4%	60.4%	59.2%
	Median Survival	>5 years	>5 years	>5 years
Stage at D	iagnosis			
In situ	Cases	309	231	78
	One Year	100.0%	100.0%	100.0%
	5 Years	89.7%	87.2%	0.0%
	Median Survival	>5 years	>5 years	0.00
Localized	Cases	706	546	160
	One Year	88.7%	90.3%	83.2%
	5 Years	68.9%	69.5%	64.4%
	Median Survival	>5 years	>5 years	>5 years
Regional	Cases	127	95	32
	One Year	61.4%	62.3%	58.3%
	5 Years	0.0%	0.0%	0.0%
	Median Survival	1.65	1.65	1.71
Distant	Cases	51	37	14
	One Year	20.0%	18.8%	23.1%
	5 Years	0.0%	0.0%	0.0%
	Median Survival	0.63	0.62	0.65
Unstaged	Cases	92	65	27
	One Year	74.4%	75.0%	73.0%
	5 Years	56.8%	0.0%	58.4%
	Median Survival	>5 years	0.00	>5 years


Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

NON-HODGKIN'S LYMPHOMA

NON-HODGKIN'S LYMPHOMA

GENERAL PROFILE⁴

Figure 101. Anatomy of the Lymphatic System



General Anatomy: Lymphoma is a general term for cancers that develop in the lymphatic system. The lymphatic system is part of the body's immune system that helps the body fight disease and infection and includes a network of thin tubes (lymphatic vessels) that branch, like blood vessels, into tissues throughout the body. Lymphatic vessels carry lymph, a colorless, watery fluid that contains infection-fighting cells called lymphocytes. Along this network of vessels are small organs called lymph nodes that are found in the underarms, groin, neck, chest, and abdomen. Other parts of the lymphatic system are the spleen, thymus, tonsils, and bone marrow. Lymphatic tissue is also found in other parts of the body, including the stomach, intestines, and skin.

In non-Hodgkin's lymphoma, cells in the lymphatic system become abnormal. They divide and grow without any order or control, or old cells do not die as cells normally do. Non-Hodgkin's lymphoma can start almost anywhere in the body and may occur in a single lymph node, a group of lymph nodes, or in another organ. This type of cancer can spread to almost any part of the body, including the liver, bone marrow, and spleen.

Risk Factors: Age, male gender, weakened immune system, viruses (Human T-lymphotropic virus type I (HTLV-1) and Epstein-Barr virus), and environment (chemical exposure).

Signs and Symptoms: Unexplained fever, night sweats, constant fatigue, unexplained weight loss, itchy skin, and reddened patches on the skin.

Diagnosing the Cancer: X-rays, computed tomography (CAT) scan, magnetic resonance imaging (MRI), and lymphangiogram.

Treatment: Treatment options include: chemotherapy, radiation therapy, bone marrow transplantation (BMT), biological therapy, surgery, and clinical trials.

HIGHLIGHTS

- ➤ The ratio of the age-adjusted incidence rate, 14.8, to the age-adjusted mortality rate, 7.4 (per 100,000 2000 US Standard population), for Non-Hodgkin's Lymphoma was 2.01 during the 1996 to 2000 period, which means that for every 2.01 Non-Hodgkin's Lymphoma cases during this period, there was one death due to Non-Hodgkin's Lymphoma in Nevada.
- Nevadan females had a higher ratio than males when the age-adjusted incidence and age-adjusted mortality rates for Non-Hodgkin's Lymphoma were compared. For every female death due to Non-Hodgkin's Lymphoma there was 2.10 female cases while there were 1.89 male cases for every male Non-Hodgkin's Lymphoma death in Nevada from 1996 to 2000.
- ➤ The median age at diagnosis of Non-Hodgkin's Lymphoma was 65 years of age for Nevada residents from 1996 to 2000; the median age at time of death was 72 years.

INCIDENCE

- ➤ There were 1,252 cases of Non-Hodgkin's Lymphoma in Nevada from 1996 to 2000. Nevada's lower incidence rate, 14.8 (13.9-15.6), for Non-Hodgkin's Lymphoma showed statistical significance when compared to the National rate, 19.1 (18.9-19.3), per 100,000 2000 US Standard population.
- ➤ While regional comparisons showed that Washoe County's age-adjusted incidence rate, 17.0, was higher than the rate for All Other Counties and Clark County who had rates of 16.3 and 13.9 (per 100,000 2000 US Standard population) from 1996 to 2000, these differences were not statistically significant.
- ➤ Males had a higher statistically significant age-adjusted incidence rate, 17.6 (16.2-19.1), than Females from 1996 to 2000 who had a rate of 12.2 (11.2-13.3), per 100,000 2000 US Standard population.
- ➤ Whites had the highest age-adjusted incidence rate, 16.2, for Non-Hodgkin's Lymphoma of all racial/ethnic groups and were followed by Asians, Blacks and Hispanics with rates of 13.2, 8.7 and 8.1 (per 100,000 2000 US Standard population), respectively, during this period.

INPATIENT HOSPITAL DISCHARGES

➤ There were 966 Inpatient Discharges for Non-Hodgkin's Lymphoma to Nevada residents from 1996 to 2000. Regional comparisons showed little difference between the ageadjusted inpatient discharge rates and average length of stay in days between Clark County, Washoe County and All Other Counties, as a region.

- ➤ Total billed charges for hospital inpatient discharges from Non-Hodgkin's Lymphoma in Nevada totaled just over 35 million dollars from 1996 to 2000. Clark County had the highest median total billed charge (\$23,570) once regional comparisons were made.
- The overall average billed charge per day for an inpatient hospital discharge for Non-Hodgkin's Lymphoma was approximately \$4,000 in Nevada from 1996 to 2000.

MORTALITY


- There were 587 deaths in Nevada due to Non-Hodgkin's Lymphoma from 1996 to 2000. Regional comparisons showed little difference between the age-adjusted mortality rates for Clark County, Washoe County, and All Other Counties, as a region, with rates of 7.6, 7.1 and 6.8 (per 100,000 2000 US Standard population), respectively.
- ➤ While racial/ethnic comparisons showed that Whites had highest age-adjusted mortality rate (7.9) for Non-Hodgkin's Lymphoma, and were followed by Asians, Hispanics and Blacks with rates of 6.5, 4.5 and 4.1 (per 100,000 2000 US Standard population), respectively; statistical analysis does not show any statistical significance between any of the racial/ethnic groups during the 1996 to 2000 period.

SURVIVAL RATE

- Males in Nevada had a slightly higher one-year survival rate (68.8%) than females (68.1%) for Non-Hodgkin's Lymphoma during the 1996 to 2000 period. However, this difference grew by the five-year survival period where males had a survival rate of 37.9% and females had a rate of 30.7%.
- ➤ The Non-Hodgkin's Lymphoma survival rate varies greatly by the stage of the cancer at time of diagnosis. Those diagnosed at the localized stage had the highest one- and five-year survival rates with 83.6% and 43.6%, respectively. This was followed by those with regional and then distant diagnoses with rates of 61.8% and 61.1% for the one year period and 39.6% and 21.0% for the five year period.

INCIDENCE

Figure 102. Non-Hodgkin's Lymphoma Age-Adjusted (2000) Incidence Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 103. Non-Hodgkin's Lymphoma Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 104. Non-Hodgkin's Lymphoma Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1996-2000




Table 150. Non-Hodgkin's Lymphoma Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)		
Total								
Cases	1,252	773	253	226	0	32,597		
Rate*	14.8	13.9	17.0	16.3		19.1		
95% C.I.	(13.9-15.6)	(12.9-14.9)	(14.9-19.3)	(14.2-18.7)		(18.9-19.3)		
Gender								
Male	716	432	152	132	0	18,057		
Rate*	17.6	16.1	21.8	19.3		23.7		
95% C.I.	(16.2-19.1)	(14.5-17.9)	(18.2-26.1)	(16.1-23.3)		(23.3-24.0)		
Female	535	341	100	94	0	14,540		
Rate*	12.2	11.8	13.0	13.4		15.4		
95% C.I.	(11.2-13.3)	(10.6-13.2)	(10.6-15.8)	(10.8-16.5)		(15.2-15.7)		
Other/Unknown	1	0	1	0	0	0		
Race/Ethnicity								
White	1,109	668	229	212	0	27,505		
Rate*	16.2	15.4	17.9	17.1		19.9		
95% C.I.	(15.2-17.2)	(14.2-16.7)	(15.7-20.5)	(14.8-19.6)		(19.7-20.1)		
Black	37	33	3	1	0	2,332		
Rate*	8.7	8.7				14.7		
95% C.I.	(5.9-12.9)	(5.7-13.2)				(14.1-15.3)		
Native American	4	0	2	2	0	73		
Rate*						5.9		
95% C.I.						(4.5-4.5)		
Asian	40	33	5	2	0	2,178		
Rate*	13.2	13.8				13.8		
95% C.I.	(8.7-21.1)	(8.5-23.8)				(13.2-14.4)		
Hispanic	56	34	13	9	0	2,826		
Rate*	8.1	6.8	14.4			14.4		
95% C.I.	(5.8-11.6)	(4.4-10.9)	(6.2-32.9)			(13.8-15.0)		
Other/Unknown	6	5	1	0	0	509		

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the National (SEER) rates. See Technical Notes for more information.

Table 151. Non-Hodgkin's Lymphoma Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)			
Total									
Cases	1,252	773	253	226	0	32,597			
Rate*	13.5	12.3	15.4	16.5		17.6			
95% C.I.	(12.7-14.2)	(11.4-13.1)	(13.5-17.4)	(14.3-18.6)		(17.4-17.8)			
Age Group									
<1	1	1	0	0	0				
Rate*									
95% C.I.									
1-4	7	3	2	2	0	69			
Rate*						0.6			
95% C.I.						(0.5-0.8)			
5-14	11	6	3	2	0	261			
Rate*	0.8					1.0			
95% C.I.	(0.3-1.3)					(0.9-1.1)			
15-24	20	13	3	4	0	493			
Rate*	1.6	1.5				1.9			
95% C.I.	(0.9-2.2)	(0.7-2.3)				(1.7-2.1)			
25-34	62	39	12	11	0	1,663			
Rate*	4.3	3.8	4.8	6.9		5.7			
95% C.I.	(3.3-5.4)	(2.6-5.0)	(2.1-7.4)	(2.8-11.0)		(5.4-6.0)			
35-44	103	56	33	14	0	3,234			
Rate*	6.9	5.7	11.9	6.2		10.4			
95% C.I.	(5.6-8.2)	(4.2-7.1)	(7.8-15.9)	(3.0-9.4)		(10.0-10.7)			
45-54	163	102	30	31	0	4,410			
Rate*	13.5	12.9	13.4	16.1		19.3			
95% C.I.	(11.4-15.6)	(10.4-15.4)	(8.6-18.1)	(10.4-21.8)		(18.7-19.8)			
55-64	235	141	54	40	0	5,288			
Rate*	27.3	24.3	38.2	29.0		37.8			
95% C.I.	(23.8-30.8)	(20.2-28.3)	(28.0-48.4)	(20.0-38.0)		(36.8-38.8)			
65-74	316	197	57	62	0	7,764			
Rate*	51.0	47.5	56.5	59.3		67.3			
95% C.I.	(45.4-56.6)	(40.9-54.2)	(41.8-71.2)	(44.6-74.1)		(65.8-68.8)			
75-84	275	176	49	50	0	7,086			
Rate*	83.9	81.4	89.0	88.5		97.5			
95% C.I.	(74.0-93.8)	(69.4-93.4)	(64.1-114.0)	(64.0-113.1)		(95.2-99.8)			
85+	59	39	10	10	0	2,325			
Rate*	83.7	91.0	69.4	75.8		93.7			
95% C.I.	(62.4-105.1)	(62.5-119.6)	(26.4-112.4)	(28.8-122.8)		(89.9-97.6)			
Unknown	0	0	0	0	0	0			

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 152. Non-Hodgkin's Lymphoma Cases by County of Residence at Diagnosis, Nevada Residents, 1996-2000

County of	1996-2000 Incidence							
Residence	Casas	Rat	e*	Age-Adjus	Age-Adjusted Rate**			
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	67	27.3	(20.8-33.9)	24.4	(18.9-31.2)			
Churchill	28	23.7	(14.9-32.5)	24.3	(16.1-35.7)			
Clark	773	12.3	(11.4-13.1)	13.9	(12.9-14.9)			
Douglas	43	21.5	(15.1-27.9)	19.5	(13.9-27.3)			
Elko	12	5.2	(2.3-8.2)	9.4	(4.5-18.1)			
Esmeralda	0							
Eureka	0							
Humboldt	9							
Lander	1							
Lincoln	1							
Lyon	28	17.3	(10.9-23.7)	15.7	(10.4-23.4)			
Mineral	2							
Nye	28	18.9	(11.9-25.8)	15.1	(9.7-23.6)			
Pershing	3							
Storey	1							
Washoe	253	15.4	(13.5-17.4)	17.0	(14.9-19.3)			
White Pine	3							
Unknown	0							
Total	1,252	13.5	(12.7-14.2)	14.8	(13.9-15.6)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 153. Non-Hodgkin's Lymphoma Cases by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

			Ger	nder	
Rac	e/Ethnicity	Male	Female	Other/ Unknown	Total
White	Incidence	632	476	1	1,109
	Rate*	19.2	13.5		16.2
	95% C.I.	(17.6-20.8)	(12.3-14.8)		(15.2-17.2)
Black	Incidence	18	19	0	37
	Rate*	7.7	9.0		8.7
	95% C.I.	(4.4-15.9)	(5.2-14.9)		(5.9-12.9)
Native	Incidence	2	2	0	4
American	Rate*				
	95% C.I.				
Asian	Incidence	22	18	0	40
	Rate*	14.3	12.4		13.2
	95% C.I.	(8.6-28.4)	(6.1-25.6)		(8.7-21.1)
Hispanic	Incidence	39	17	0	56
	Rate*	11.4	5.0		8.1
	95% C.I.	(7.4-18.9)	(2.6-9.5)		(5.8-11.6)
Other/Unkr	iown	3	3	0	6
Total	Incidence	716	535	1	1,252
	Rate*	17.6	12.2		14.8
	95% C.I.	(16.2-19.1)	(11.2-13.3)		(13.9-15.6)

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 154. Non-Hodgkin's Lymphoma Cases by Age Group and Gender, Nevada **Residents, 1996-2000**

Age	Gender						
Group	Male	Female	Other/ Unknown	Total			
<1	0	1	0				
Rate*							
95% C.I.							
1-4	3	4	0	7			
Rate*							
95% C.I.							
5-14	7	4	0	11			
Rate*				0.8			
95% C.I.				(0.3-1.3)			
15-24	9	11	0	20			
Rate*		1.8		1.6			
95% C.I.		(0.7-2.8)		(0.9-2.2)			
25-34	34	27	1	62			
Rate*	4.6	3.9		4.3			
95% C.I.	(3.0-6.1)	(2.4-5.4)		(3.3-5.4)			
35-44	69	34	0	103			
Rate*	8.9	4.7		6.9			
95% C.I.	(6.8-11.0)	(3.1-6.3)		(5.6-8.2)			
45-54	100	63	0	163			
Rate*	16.3	10.6		13.5			
95% C.I.	(13.1-19.5)	(8.0-13.2)		(11.4-15.6)			
55-64	149	86	0	235			
Rate*	34.8	19.9		27.3			
95% C.I.	(29.2-40.3)	(15.7-24.1)		(23.8-30.8)			
65-74	180	136	0	316			
Rate*	58.9	43.3		51.0			
95% C.I.	(50.3-67.5)	(36.0-50.6)		(45.4-56.6)			
75-84	139	136	0	275			
Rate*	94.3	75.4		83.9			
95% C.I.	(78.6-109.9)	(62.8-88.1)		(74.0-93.8)			
85+	26	33	0	59			
Rate*	114.7	69.1		83.7			
95% C.I.	(70.6-158.8)	(45.5-92.6)		(62.4-105.1)			
Unknown	0	0	0	0			
Total	716	535	1	1,252			
Rate*	15.1	11.7		13.5			
95% C.I.	(14.0-16.2)	(10.7-12.7)		(12.7-14.2)			

* Rates are per 100,000 age-specific population. Note: The "---" is used for rates calculated on numbers less than ten.

Table 155. Non-Hodgkin's Lymphoma Cases by Age Group and Stage, Nevada Residents, 1996-2000

A	0	Stage						
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total	
<1	Number	0	0	0	0	1	1	
	Percent					100.0%	100.0%	
1-4	Number	0	2	1	2	2	7	
	Percent		28.6%	14.3%	28.6%	28.6%	100.0%	
5-14	Number	0	1	0	6	4	11	
	Percent		9.1%		54.5%	36.4%	100.0%	
15-24	Number	0	9	0	5	6	20	
	Percent		45.0%		25.0%	30.0%	100.0%	
25-34	Number	0	18	8	20	16	62	
	Percent		29.0%	12.9%	32.3%	25.8%	100.0%	
35-44	Number	0	35	7	32	29	103	
	Percent		34.0%	6.8%	31.1%	28.2%	100.0%	
45-54	Number	0	47	13	58	45	163	
	Percent		28.8%	8.0%	35.6%	27.6%	100.0%	
55-64	Number	0	68	26	78	63	235	
	Percent		28.9%	11.1%	33.2%	26.8%	100.0%	
65-74	Number	0	85	28	97	106	316	
	Percent		26.9%	8.9%	30.7%	33.5%	100.0%	
75-84	Number	0	61	22	81	111	275	
	Percent		22.2%	8.0%	29.5%	40.4%	100.0%	
85+	Number	0	10	5	22	22	59	
	Percent		16.9%	8.5%	37.3%	37.3%	100.0%	
Unknown	Number	0	0	0	0	0	0	
	Percent							
Total	Number	0	336	110	401	405	1,252	
	Percent		26.8%	8.8%	32.0%	32.3%	100.0%	

Table 156. Non-Hodgkin's Lymphoma Cases by Stage and Race/Ethnicity, Nevada Residents, 1996-2000

		Race/Ethnicity						
Stage		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total
In situ	Number	0	0	0	0	0	0	0
	Percent							
Localized	Number	297	8	2	10	16	3	336
	Percent	26.8%	21.6%	50.0%	25.0%	28.6%	50.0%	26.8%
Regional	Number	92	5	0	4	8	1	110
	Percent	8.3%	13.5%		10.0%	14.3%	16.7%	8.8%
Distant	Number	359	16	1	14	10	1	401
	Percent	32.4%	43.2%	25.0%	35.0%	17.9%	16.7%	32.0%
Unstaged	Number	361	8	1	12	22	1	405
	Percent	32.6%	21.6%	25.0%	30.0%	39.3%	16.7%	32.3%
Total	Number	1,109	37	4	40	56	6	1,252
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%


Table 157. Median Age at Diagnosis of Non-Hodgkin's Lymphoma by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

		Gender								
Race/Ethnicity	Ма	Male		nale	Total					
	Incidence	Median Age	Incidence	Median Age	Incidence	Median Age				
White	632	65.0	476	67.0	1,108	66.0				
Black	18	51.0	19	65.0	37	58.0				
Native American	2		2		4					
Asian	22	63.0	18	68.5	40	64.0				
Hispanic	39	55.0	17	61.0	56	58.0				
Other/Unknown	3		3		6	56.5				
Total	716	64.0	535	67.0	1,251	65.0				

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

Figure 105. Non-Hodgkin's Lymphoma Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical notes for more information.

Figure 106. Non-Hodgkin's Lymphoma Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 107. Median Charges for Non-Hodgkin's Lymphoma Discharges by County/Region of Residence, Nevada Residents, 1996-2000




Figure 108. Average Length of Stay for Non-Hodgkin's Lymphoma Discharges by County/Region of Residence, Nevada Residents, 1996-2000




Table 158. Non-Hodgkin's Lymphoma Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Discharges	966	662	164	140	0			
Rate*	11.3	11.7	11.2	10.0				
95% C.I.	(10.6-12.1)	(10.8-12.6)	(9.5-13.1)	(8.4-11.9)				
Gender								
Male	553	373	99	81	0			
Rate*	13.2	13.5	14.2	11.3				
95% C.I.	(12.1-14.5)	(12.1-15.1)	(11.3-17.8)	(8.9-14.3)				
Female	413	289	65	59	0			
Rate*	9.4	9.9	8.6	8.5				
95% C.I.	(8.5-10.4)	(8.8-11.2)	(6.6-11.0)	(6.5-11.1)				
Other/Unknown	0	0	0	0	0			
Inpatient Discharge Cl	narges (\$)							
Total Charges	\$35,296,828	\$24,713,117	\$5,762,200	\$4,821,511				
Average Charges	\$36,539	\$37,331	\$35,135	\$34,439				
Median Charges	\$21,406	\$23,570	\$20,192	\$17,496				
Discharge Length of S	stay (LOS) (Days)							
Total LOS	8,789	6,040	1,481	1,268				
Average LOS	9.1	9.1	9.0	9.1				
Median LOS	6.0	7.0	6.0	6.0				

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 159. Non-Hodgkin's Lymphoma Discharges by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Discharges	966	662	164	140	0			
Rate*	10.4	10.5	10.0	10.2				
95% C.I.	(9.7-11.0)	(9.7-11.3)	(8.5-11.5)	(8.5-11.9)				
Age Group								
<1	1	1	0	0	0			
Rate*								
95% C.I.								
1-4	6	4	0	2	0			
Rate*								
95% C.I.								
5-14	15	12	2	1	0			
Rate*	1.1	1.4						
95% C.I.	(0.6-1.7)	(0.6-2.1)						
15-24	20	15	2	3	0			
Rate*	1.6	1.7						
95% C.I.	(0.9-2.2)	(0.9-2.6)						
25-34	54	37	12	5	0			
Rate*	3.8	3.6	4.8					
95% C.I.	(2.8-4.8)	(2.5-4.8)	(2.1-7.4)					
35-44	61	43	14	4	0			
Rate*	4.1	4.3	5.0					
95% C.I.	(3.1-5.1)	(3.0-5.6)	(2.4-7.7)					
45-54	122	91	13	18	0			
Rate*	10.1	11.5	5.8	8.0				
95% C.I.	(8.3-11.9)	(9.1-13.8)	(2.6-8.9)	(4.3-11.7)				
55-64	178	112	42	24	0			
Rate*	20.7	19.3	29.7	17.0				
95% C.I.	(17.6-23.7)	(15.7-22.8)	(20.7-38.7)	(10.2-23.8)				
65-74	264	177	38	49	0			
Rate*	42.6	42.7	37.7	48.6				
95% C.I.	(37.4-47.7)	(36.4-49.0)	(25.7-49.7)	(35.0-62.2)				
75-84	203	146	31	26	0			
Rate*	61.9	67.5	56.3	47.2				
95% C.I.	(53.4-70.5)	(56.6-78.5)	(36.5-76.2)	(29.1-65.4)				
85+	42	24	10	8	0			
Rate*	59.6	56.0	69.4					
95% C.I.	(41.6-77.6)	(33.6-78.4)	(26.4-112.4)					
Unknown	0	0	0	0	0			

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 160. Non-Hodgkin's Lymphoma Discharges by Age Group and Gender, Nevada Residents, 1996-2000

Group Male Female <1 0 1 Rate* 95% C.I. 1-4 3 3	Total 1 6
Rate* 95% C.I	
Rate* 95% C.I	6
	6
1-4 3 3	6
Rate*	
95% C.I	
5-14 5 10	15
Rate* 1.6	1.1
95% C.I (0.6-2.5)	(0.6-1.7)
15-24 11 9	20
Rate* 1.7	1.6
95% C.I. (0.7-2.6)	(0.9-2.2)
25-34 33 21	54
Rate* 4.4 3.1	3.8
95% C.I. (2.9-5.9) (1.7-4.4)	(2.8-4.8)
35-44 49 12	61
Rate* 6.3 1.7	4.1
95% C.I. (4.6-8.1) (0.7-2.6)	(3.1-5.1)
45-54 69 53	122
Rate* 11.3 8.9	10.1
95% C.I. (8.6-13.9) (6.5-11.3)	(8.3-11.9)
55-64 109 69	178
Rate* 25.4 16.0 95% C.I. (20.7-30.2) (12.2-19.7)	20.7 (17.6-23.7)
	264
65-74 161 103 Rate* 52.7 32.8	42.6
95% C.I. (44.5-60.8) (26.5-39.1)	(37.4-47.7)
75-84 98 105	203
Rate* 66.5 58.2	61.9
95% C.I. (53.3-79.6) (47.1-69.4)	(53.4-70.5)
85+ 15 27	42
Rate* 66.2 56.5	59.6
95% C.I. (32.7-99.6) (35.2-77.8)	(41.6-77.6)
Unknown 0 0	0
Total 553 413	966
Rate* 11.7 9.0	10.4
95% C.I. (10.7-12.7) (8.2-9.9)	(9.7-11.0)

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 161. Non-Hodgkin's Lymphoma Discharges by County/Region of Residence, Nevada Residents, 1996-2000

Country of	1996-2000 Inpatient Hospital Discharges						
County of Residence	Number	Rate	e*	Age-Adjusted Rate**			
	Number	Rate	95% C.I.	Rate	95% C.I.		
Carson City	29	11.8	(7.5-16.1)	10.0	(6.7-14.6)		
Churchill	23	19.5	(11.5-27.5)	20.2	(12.8-30.9)		
Clark	662	10.5	(9.7-11.3)	11.7	(10.8-12.6)		
Douglas	14	7.0	(3.3-10.7)	6.5	(3.4-11.9)		
Elko	4						
Esmeralda	0						
Eureka	0						
Humboldt	7						
Lander	0						
Lincoln	1						
Lyon	28	17.3	(10.9-23.7)	15.6	(10.3-23.2)		
Mineral	3						
Nye	27	18.2	(11.3-25.1)	14.8	(9.4-23.3)		
Pershing	3						
Storey	0						
Washoe	164	10.0	(8.5-11.5)	11.2	(9.5-13.1)		
White Pine	1						
Unknown	0						
Total	966	10.4	(9.7-11.0)	11.3	(10.6-12.1)		


Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 162. Non-Hodgkin's Lymphoma Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1996-2000

Age	Discharges	Charges (\$)			Len	gth of Stay (Da	ays)
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	1						
1-4	6	365,693	60,949	33,537	64	10.7	7.0
5-14	15	768,799	51,253	46,479	155	10.3	8.0
15-24	20	2,087,493	104,375	36,043	332	16.6	9.5
25-34	54	2,520,021	46,667	32,897	648	12.0	7.0
35-44	61	2,988,784	48,996	21,100	638	10.5	6.0
45-54	122	4,361,742	35,752	25,295	1,067	8.7	6.0
55-64	178	6,195,907	34,808	20,935	1,559	8.8	6.0
65-74	264	8,977,281	34,005	21,095	2,337	8.9	6.0
75-84	203	6,047,647	29,791	20,039	1,674	8.2	7.0
85+	42	976,664	23,254	15,266	313	7.5	5.5
Unknown	0						
Total	966	35,296,828	36,539	21,406	8,789	9.1	6.0

MORTALITY

Figure 109. Non-Hodgkin's Lymphoma Age-Adjusted (2000) Mortality Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 110. Non-Hodgkin's Lymphoma Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 111. Non-Hodgkin's Lymphoma Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1996-2000




Table 163. Non-Hodgkin's Lymphoma Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	587	395	100	92
Rate*	7.4	7.6	7.1	6.8
95% C.I.	(6.8-8.0)	(6.8-8.4)	(5.7-8.7)	(5.4-8.4)
Gender				
Male	340	223	56	61
Rate*	9.3	9.4	8.9	9.4
95% C.I.	(8.3-10.5)	(8.1-10.9)	(6.5-12.1)	(7.1-12.5)
Female	247	172	44	31
Rate*	5.8	6.2	5.9	4.4
95% C.I.	(5.1-6.6)	(5.3-7.2)	(4.2-7.9)	(3.0-6.3)
Other/Unknown	0	0	0	0
Race/Ethnicity				
White	526	348	92	86
Rate*	7.9	8.3	7.4	6.9
95% C.I.	(7.2-8.6)	(7.4-9.3)	(5.9-9.1)	(5.5-8.6)
Black	16	15	1	0
Rate*	4.1	4.1		
95% C.I.	(2.2-7.3)	(2.2-7.7)		
Native American	3	0	1	2
Rate*				
95% C.I.				
Asian	19	17	1	1
Rate*	6.5	7.0		
95% C.I.	(3.7-12.9)	(3.9-15.2)		
Hispanic	22	14	5	3
Rate*	4.5	4.1		
95% C.I.	(2.6-7.8)	(2.0-8.2)		
Other/Unknown	1	1	0	0

^{*}Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 164. Non-Hodgkin's Lymphoma Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	587	395	100	92
Rate*	6.3	6.3	6.1	6.7
95% C.I.	(5.8-6.8)	(5.7-6.9)	(4.9-7.3)	(5.3-8.1)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	1	1	0	0
Rate*				
95% C.I.				
15-24	3	3	0	0
Rate*				
95% C.I.				
25-34	12	9	2	1
Rate*	0.8			
95% C.I.	(0.4-1.3)			
35-44	22	14	6	2
Rate*	1.5	1.4		
95% C.I.	(0.9-2.1)	(0.7-2.2)		
45-54	59	39	7	13
Rate*	4.9	4.9		6.8
95% C.I.	(3.6-6.1)	(3.4-6.5)		(3.1-10.4)
55-64	91	51	22	18
Rate*	10.6	8.8	15.6	13.0
95% C.I.	(8.4-12.7)	(6.4-11.2)	(9.1-22.1)	(7.0-19.1)
65-74	167	107	32	28
Rate*	26.9	25.8	31.7	26.8
95% C.I.	(22.9-31.0)	(20.9-30.7)	(20.7-42.7)	(16.9-36.7)
75-84	181	138	22	21
Rate*	55.2	63.8	40.0	37.2
95% C.I.	(47.2-63.3)	(53.2-74.5)	(23.3-56.7)	(21.3-53.1)
85+	51	33	9	9
Rate*	72.4	77.0		
95% C.I.	(52.5-92.3)	(50.7-103.3)		
Unknown	0	0	0	0

^{*} Rates are per 100,000 age-specific population.

Table 165. Non-Hodgkin's Lymphoma Mortality by County of Residence, Nevada Residents, 1996-2000

Country of	1996-2000 Mortality						
County of Residence	Casas	Rat	te*	Age-Adjus	ted Rate**		
	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	24	9.8	(5.9-13.7)	8.7	(5.6-13.2)		
Churchill	9						
Clark	395	6.3	(5.7-6.9)	7.6	(6.8-8.4)		
Douglas	13	6.5	(3.0-10.0)	6.7	(3.4-12.6)		
Elko	11	4.8	(2.0-7.6)	9.3	(4.3-18.4)		
Esmeralda	0						
Eureka	0						
Humboldt	4						
Lander	0						
Lincoln	0						
Lyon	14	8.7	(4.1-13.2)	7.2	(3.9-12.9)		
Mineral	2						
Nye	12	8.1	(3.5-12.7)	6.7	(3.2-13.6)		
Pershing	1						
Storey	0						
Washoe	100	6.1	(4.9-7.3)	7.1	(5.7-8.7)		
White Pine	2						
Unknown	0						
Total	587	6.3	(5.8-6.8)	7.4	(6.8-8.0)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 166. Non-Hodgkin's Lymphoma Mortality by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

Race/Ethnicity		Gender				
		Male	Female	Total		
White	Mortality	309	217	526		
	Rate*	10.1	6.1	7.9		
	95% C.I.	(8.9-11.4)	(5.3-6.9)	(7.2-8.6)		
Black	Mortality	7	9	16		
	Rate*			4.1		
	95% C.I.	<u> </u>		(2.2-7.3)		
Native	Mortality	1	2	3		
American	Rate*					
	95% C.I.					
Asian	Mortality	11	8	19		
	Rate*	8.0		6.5		
	95% C.I.	(3.7-21.5)		(3.7-12.9)		
Hispanic	Mortality	11	11	22		
	Rate*	2.9	5.3	4.5		
	95% C.I.	(1.2-9.1)	(2.5-10.4)	(2.6-7.8)		
Other/Unknown		1	0	1		
Total	Mortality	340	247	587		
	Rate*	9.3	5.8	7.4		
	95% C.I.	(8.3-10.5)	(5.1-6.6)	(6.8-8.0)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 167. Non-Hodgkin's Lymphoma Mortality by Age Group and Gender, Nevada Residents, 1996-2000

Age	Gender					
Group	Male	Female	Total			
<1	0	0	0			
Rate*						
95% C.I.						
1-4	0	0	0			
Rate*						
95% C.I.						
5-14	1	0	1			
Rate*						
95% C.I.						
15-24	3	0	3			
Rate*						
95% C.I.	<u> </u>					
25-34	9	3	12			
Rate*			0.8			
95% C.I.			(0.4-1.3)			
35-44	16	6	22			
Rate*	2.1		1.5			
95% C.I.	(1.1-3.1)		(0.9-2.1)			
45-54	35	24	59			
Rate*	5.7	4.0	4.9			
95% C.I.	(3.8-7.6)	(2.4-5.6)	(3.6-6.1)			
55-64 D-4-*	52	39	91			
Rate*	12.1	9.0	10.6			
95% C.I.	(8.8-15.4)	(6.2-11.9)	(8.4-12.7)			
65-74 Rate*	98 32.1	69 22.0	167 26.9			
95% C.I.	(25.7-38.4)	(16.8-27.1)	(22.9-31.0)			
75-84	101	80	181			
Rate*	68.5	44.4	55.2			
95% C.I.	(55.1-81.8)	(34.7-54.1)	(47.2-63.3)			
85+	25	26	51			
Rate*	110.3	54.4	72.4			
95% C.I.	(67.0-153.5)	(33.5-75.3)	(52.5-92.3)			
Unknown	0	0	0			
Total	340	247	587			
Rate*	7.2	5.4	6.3			
95% C.I.	(6.4-8.0)	(4.7-6.1)	(5.8-6.8)			

^{*} Rates are per 100,000 age-specific population.


Table 168. Median Age at Death from Non-Hodgkin's Lymphoma by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

	Gender						
Race/Ethnicity	Male		Female		Total		
	Deaths	Median Age	Deaths	Median Age	Deaths	Median Age	
White	309	71.0	217	72.0	526	72.0	
Black	7	70.0	9	63.0	16	66.5	
Native American	1		2		3		
Asian	11	69.0	8	74.5	19	73.0	
Hispanic	11	54.0	11	77.0	22	66.5	
Other/Unknown	1		0		1		
Total	340	70.0	247	72.0	587	72.0	

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE

Figure 112. Survival Rates for Non-Hodgkin's Lymphoma by Race/Ethnicity, Nevada Residents, 1996-2000



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 113. Survival Rates for Non-Hodgkin's Lymphoma by Stage of Cancer at Diagnosis, Nevada Residents, 1996-2000




Table 169. Cause-Specific Survival Rates for Non-Hodgkin's Lymphoma by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

Race/	Newskar		Cause Specific Survival Rate						
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)		
Total	845	68.5%	58.7%	47.6%	42.1%	35.0%	2.78		
Male	482	68.8%	57.6%	49.2%	43.9%	37.9%	2.90		
Female	362	68.1%	60.2%	45.3%	39.5%	30.7%	2.68		
Race/Ethnicity									
White	744	68.3%	57.8%	46.6%	40.7%	34.7%	2.70		
Male	420	67.5%	55.7%	47.3%	41.5%	34.9%	2.68		
Female	323	69.1%	60.5%	45.5%	39.3%	34.4%	2.70		
Black	28								
Male	15								
Female	13								
Native American	3								
Male	2								
Female	1								
Asian	26								
Male	15								
Female	11								
Hispanic	40								
Male	27								
Female	13								

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 170. Cause-Specific Survival Rates for Non-Hodgkin's Lymphoma by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1996-2000


Surviv	/al Rate of Stage		Gender	
	at Diagnosis	Total	Male	Female
Total	Cases	845	482	362
	One Year	68.5%	68.8%	68.1%
	5 Years	35.0%	37.9%	30.7%
	Median Survival	2.78	2.90	2.68
Stage at D	iagnosis			
In situ	Cases	0	0	0
	One Year			
	5 Years			
	Median Survival			
Localized	Cases	248	127	121
	One Year	83.6%	84.2%	83.0%
	5 Years	43.6%	42.2%	44.9%
	Median Survival	4.48	4.35	4.60
Regional	Cases	84	57	27
	One Year	61.8%	62.2%	60.9%
	5 Years	39.6%	46.3%	31.6%
	Median Survival	2.41	2.68	1.85
Distant	Cases	312	180	131
	One Year	61.1%	62.7%	58.5%
	5 Years	21.0%	28.3%	8.1%
	Median Survival	2.03	1.93	2.09
Unstaged	Cases	201	118	83
	One Year	66.1%	66.0%	66.4%
	5 Years	42.6%	43.1%	42.9%
	Median Survival	2.95	3.27	2.51

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

KIDNEY AND RENAL PELVIS CANCER

KIDNEY AND RENAL PELVIS CANCER GENERAL PROFILE⁴

Figure 114. Anatomy of the Urinary System⁵



General Anatomy: The kidneys are two reddish-brown, bean-shaped organs located just above the waist, one on each side of the spine. They are part of the urinary system. Their main function is to filter blood and produce urine to rid the body of waste. As blood flows through the kidneys, they remove waste products and unneeded water. The resulting liquid, urine, collects in the middle of each kidney in an area called the renal pelvis. Urine drains from each kidney through a long tube, the ureter, into the bladder, where it is stored. Urine leaves the body through another tube, called the urethra. The kidneys also produce substances that help control blood pressure and regulate the formation of red blood cells.

Risk Factors: Tobacco use, obesity, occupational exposure, radiation, phenacetin (prolonged heavy use of this painkiller), dialysis, and Von Hippel-Lindau (VHL) disease.

Signs and Symptoms: Blood in the urine, a lump or mass in the kidney area, and other less common symptoms may include: fatigue, loss of appetite, weight loss, recurrent fevers, a pain in the side that doesn't go away, or a general feeling of poor health.

Diagnosing the Cancer: Health exams, intravenous pyelogram (IVP), arteriography, computed tomography (CAT) scan, magnetic resonance imaging (MRI), and ultrasonography.

Treatment: Surgery (Simple or Radical Nephrectomy), arterial embolization, radiation therapy, biological therapy, chemotherapy, and hormone therapy.

HIGHLIGHTS

- ➤ The ratio of the age-adjusted incidence rate, 11.4, to the age-adjusted mortality rate, 3.9 (per 100,000 2000 US Standard population), for Kidney and Renal Pelvis Cancer was 2.90 during the 1996 to 2000 period, which means that for every 2.90 Kidney and Renal Pelvis Cancer cases during this period, there was one death caused by this type of cancer in Nevada.
- Nevadan females had a higher ratio than males when the age-adjusted incidence and age-adjusted mortality rates for Kidney and Renal Pelvis Cancer were compared. For every female death due to this type of cancer there was 3.43 female cases while there were 2.64 male cases for every male Kidney and Renal Pelvis Cancer death in Nevada from 1996 to 2000.
- The median age at diagnosis of Kidney and Renal Pelvis Cancer for Nevada residents and females was 65 years of age from 1996 to 2000 while the median age for males was 64 years. The median age at time of death due to Kidney and Renal Pelvis Cancer was 70 years for Nevada overall, 68 years of age for males and 73 years of age for females.

INCIDENCE

- ➤ There were 995 cases of Kidney and Renal Pelvis Cancer in Nevada from 1996 to 2000. Nevada's Incidence rate for Kidney and Renal Pelvis Cancer (11.4) was only slightly higher than the National rate of 10.8 (per 100,000 2000 US Standard population) from 1996 to 2000. Regional comparisons showed little variation between Washoe County (12.3), All Other Counties (12.1) and Clark County (11.0) from 1996 to 2000. None of these differences were found to be statistically significant different from the National rate of 10.8 (per 100,000 2000 US Standard population).
- The higher age-adjusted incidence rate for male Kidney and Renal Pelvis Cancer, 15.1 (13.9-16.5), was statistically significant over the female rate of 8.0 (7.1-8.8), per 100,000 2000 US Standard population, during the 1996 to 2000 period.
- ➤ Blacks had the highest age-adjusted incidence rate, 13.0, for Kidney and Renal Pelvis Cancer of all racial/ethnic groups and were followed by Whites, Hispanics and Asians with rates of 12.1, 7.4 and 3.8 (per 100,000 2000 US Standard population), respectively, during the 1996 to 2000 period.
- ➤ The median age at diagnosis for Hispanics (56 years) was the lowest of any racial/ethnic group and was significantly lower than the statewide median age of 65 years for the 1996 to 2000 period.

INPATIENT HOSPITAL DISCHARGES

➤ There were 842 hospital inpatient discharges for a primary diagnosis of Kidney and Renal Pelvis Cancer to Nevada Residents from 1996 to 2000. Regional comparisons

- showed little difference between the age-adjusted inpatient discharge rates between All Other Counties (9.8), Clark County (9.7) and Washoe County (8.7, per 100,000 2000 US Standard population).
- ➤ Total billed charges for Kidney and Renal Pelvis Cancer inpatient hospital discharges in Nevada totaled nearly 24 million dollars from 1996 to 2000. The overall average billed charge per day for a hospital inpatient discharge due to this type of cancer was approximately \$4,300 in Nevada from 1996 to 2000.
- ➤ Washoe County had the highest median total billed amount (\$26,792), while the statewide median billed amount was \$21,442 from 1996 to 2000; with Clark County and All Other Counties with median billed amounts of \$21,482 and \$17,839.

MORTALITY


- ➤ There were 326 resident deaths due to Kidney and Renal Pelvis Cancer from 1996 to 2000. Males had a statistically significant age-adjusted mortality rate, 5.7 (5.0-6.6), more than double the female rate of 2.3 (1.9-2.8), per 100,000 2000 US Standard population, during this period.
- ➤ Blacks, as a racial/ethnic group, had the highest age-adjusted mortality rate for Kidney and Renal Pelvis Cancer of any racial/ethnic group, 30.0, and were followed by Whites, Asians, Native Americans, and Hispanics with rates of 23.7, 12.5, 12.0, and 11.3, (per 100,000 2000 US Standard population) respectively, from 1996 to 2000.
- ➤ Males had a median age at death from Kidney and Renal Pelvis Cancer five years earlier than females in Nevada from 1996 to 2000 with a median age at death of 68 and 73 years, respectively.

SURVIVAL RATE

- ➤ The one-year survival rate for Kidney and Renal Pelvis Cancer in Nevada was 71.4% during the 1996 to 2000 period, while the five-year survival rate was 51.3% during this same time. The median survival rate in Nevada was greater than five years for Kidney and Renal Pelvis Cancer.
- Females in Nevada had a slightly higher one-year survival rate (73.5%) than males (70.3%) for Kidney and Renal Pelvis Cancer during the 1996 to 2000 period. This trend continued for the five-year survival rate with females and males at 55.0% and 50.0%, respectively. Both males and females had median survival times of over five years.
- The Kidney and Renal Pelvis Cancer Survival rate varies greatly by the stage of the cancer at time of diagnosis. Those diagnosed at the localized stage had the highest one-and five-year survival rates with 95.3% and 86.8%, respectively. This was followed by those with regional and then distant diagnoses with rates of 66.7% and 24.9% for the one year period and 25.3% and 5.2% for the five year period.

INCIDENCE

Figure 115. Kidney and Renal Pelvis Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 116. Kidney and Renal Pelvis Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 117. Kidney and Renal Pelvis Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1996-2000




Table 171. Kidney and Renal Pelvis Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

		County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)				
Total										
Cases	995	637	182	175	1	18,150				
Rate*	11.4	11.0	12.3	12.1		10.8				
95% C.I.	(10.7-12.2)	(10.1-11.9)	(10.6-14.3)	(10.4-14.1)		(10.6-10.9)				
Gender										
Male	641	408	117	115	1	11,142				
Rate*	15.1	14.4	16.9	15.9		14.9				
95% C.I.	(13.9-16.5)	(13.0-16.0)	(13.8-20.8)	(13.1-19.4)		(14.7-15.2)				
Female	354	229	65	60	0	7,008				
Rate*	8.0	7.8	8.5	8.3		7.5				
95% C.I.	(7.1-8.8)	(6.8-8.9)	(6.6-10.9)	(6.4-10.8)		(7.3-7.7)				
Other/Unknown	0	0	0	0	0	0				
Race/Ethnicity										
White	862	529	171	161	1	15,107				
Rate*	12.1	11.6	13.3	12.3		11.0				
95% C.I.	(11.3-12.9)	(10.6-12.7)	(11.4-15.5)	(10.5-14.5)		(10.9-11.2)				
Black	59	55	2	2	0	1,838				
Rate*	13.0	13.2				12.6				
95% C.I.	(9.7-17.5)	(9.7-18.0)				(12.0-13.2)				
Native American	8	1	3	4	0	92				
Rate*						7.9				
95% C.I.						(6.3-6.3)				
Asian	15	13	2	0	0	1,017				
Rate*	3.8	4.1				6.5				
95% C.I.	(2.0-9.6)	(2.1-11.6)				(6.1-6.9)				
Hispanic	49	37	4	8	0	1,717				
Rate*	7.4	8.0				9.7				
95% C.I.	(5.2-10.7)	(5.3-12.5)				(9.2-10.2)				
Other/Unknown	2	2	0	0	0	96				

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the National (SEER) rates. See Technical Notes for more information.

Table 172. Kidney and Renal Pelvis Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

		County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)				
Total										
Cases	995	637	182	175	1	18,150				
Rate*	10.7	10.1	11.1	12.8		9.8				
95% C.I.	(10.0-11.4)	(9.3-10.9)	(9.5-12.7)	(10.9-14.7)		(9.7-9.9)				
Age Group										
<1	0	0	0	0	0	52				
Rate*						1.9				
95% C.I.						(1.4-2.4)				
1-4	9	7	2	0	0	227				
Rate*						2.0				
95% C.I.						(1.8-2.3)				
5-14	2	1	1	0	0	84				
Rate*						0.3				
95% C.I.						(0.2-0.4)				
15-24	3	2	0	0	1	47				
Rate*						0.2				
95% C.I.						(0.1-0.2)				
25-34	11	9	0	2	0	225				
Rate*	0.8					0.8				
95% C.I.	(0.3-1.2)					(0.7-0.9)				
35-44	56	32	13	11	0	1,115				
Rate*	3.7	3.2	4.7	4.9		3.6				
95% C.I.	(2.8-4.7)	(2.1-4.4)	(2.1-7.2)	(2.0-7.8)		(3.4-3.8)				
45-54	156	91	35	30	0	2,709				
Rate*	12.9	11.5	15.6	15.6		11.8				
95% C.I.	(10.9-14.9)	(9.1-13.8)	(10.4-20.7)	(10.0-21.2)		(11.4-12.3)				
55-64	260	173	36	51	0	3,939				
Rate*	30.2	29.8	25.4	37.0		28.1				
95% C.I.	(26.5-33.9)	(25.3-34.2)	(17.1-33.8)	(26.8-47.1)		(27.3-29.0)				
65-74	292	194	52	46	0	5,032				
Rate*	47.1	46.8	51.6	44.0		43.6				
95% C.I.	(41.7-52.5)	(40.2-53.4)	(37.5-65.6)	(31.3-56.7)		(42.4-44.8)				
75-84	177	109	37	31	0	3,687				
Rate*	54.0	50.4	67.2	54.9		50.7				
95% C.I.	(46.0-62.0)	(40.9-59.9)	(45.6-88.9)	(35.6-74.2)		(49.1-52.4)				
85+	29	19	6	4	0	1,033				
Rate*	41.2	44.4				41.7				
95% C.I.	(26.2-56.1)	(24.4-64.3)				(39.1-44.2)				
Unknown	0	0	0	0	0	0				

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 173. Kidney and Renal Pelvis Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1996-2000

County of	1996-2000 Incidence						
Residence	Casas	Rat	te*	Age-Adjus	Age-Adjusted Rate**		
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	37	15.1	(10.2-20.0)	13.3	(9.3-18.5)		
Churchill	18	15.3	(8.2-22.3)	15.9	(9.4-25.7)		
Clark	637	10.1	(9.3-10.9)	11.0	(10.1-11.9)		
Douglas	26	13.0	(8.0-18.0)	10.4	(6.8-16.2)		
Elko	16	7.0	(3.6-10.4)	11.8	(6.4-20.9)		
Esmeralda	3						
Eureka	1						
Humboldt	5						
Lander	3						
Lincoln	2						
Lyon	28	17.3	(10.9-23.7)	15.4	(10.2-22.9)		
Mineral	1						
Nye	29	19.5	(12.4-26.6)	13.7	(9.0-21.4)		
Pershing	4						
Storey	1						
Washoe	182	11.1	(9.5-12.7)	12.3	(10.6-14.3)		
White Pine	1						
Unknown	1						
Total	995	10.7	(10.0-11.4)	11.4	(10.7-12.2)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 174. Kidney and Renal Pelvis Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

			Ger	nder	
Rac	Race/Ethnicity		Female	Other/ Unknown	Total
White	Incidence	556	306	0	862
	Rate*	15.9	8.5		12.1
	95% C.I.	(14.5-17.4)	(7.5-9.5)		(11.3-12.9)
Black	Incidence	40	19	0	59
	Rate*	18.0	8.2		13.0
	95% C.I.	(12.6-27.6)	(4.8-13.6)		(9.7-17.5)
Native	Incidence	2	6	0	8
American	Rate*				
	95% C.I.				
Asian	Incidence	8	7	0	15
	Rate*				3.8
	95% C.I.				(2.0-9.6)
Hispanic	Incidence	33	16	0	49
	Rate*	9.9	4.8		7.4
	95% C.I.	(6.5-17.0)	(2.4-9.2)		(5.2-10.7)
Other/Unkn	iown	2	0	0	2
Total	Incidence	641	354	0	995
	Rate*	15.1	8.0		11.4
	95% C.I.	(13.9-16.5)	(7.1-8.8)		(10.7-12.2)
		()10 1010)	(111 515)		(::: :=:=/

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 175. Kidney and Renal Pelvis Cancer Cases by Age Group and Gender, Nevada Residents, 1996-2000

Age	Gender							
Group	Male	Female	Other/ Unknown	Total				
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	4	5	0	9				
Rate*								
95% C.I.								
5-14	0	2	0	2				
Rate*								
95% C.I.								
15-24	2	1	0	3				
Rate*								
95% C.I.								
25-34	6	5	0	11				
Rate*				0.8				
95% C.I.				(0.3-1.2)				
35-44	35	21	0	56				
Rate*	4.5	2.9		3.7				
95% C.I.	(3.0-6.0)	(1.7-4.2)		(2.8-4.7)				
45-54	104	52	0	156				
Rate*	17.0	8.7		12.9				
95% C.I.	(13.7-20.2)	(6.3-11.1)		(10.9-14.9)				
55-64	174	86	0	260				
Rate*	40.6	19.9		30.2				
95% C.I.	(34.6-46.6)	(15.7-24.1)		(26.5-33.9)				
65-74	201	91	0	292				
Rate*	65.7	29.0		47.1				
95% C.I.	(56.7-74.8)	(23.0-34.9)		(41.7-52.5)				
75-84	102	75	0	177				
Rate*	69.2	41.6		54.0				
95% C.I.	(55.7-82.6)	(32.2-51.0)		(46.0-62.0)				
85+	13	16	0	29				
Rate*	57.3	33.5		41.2				
95% C.I.	(26.2-88.5)	(17.1-49.9)		(26.2-56.1)				
Unknown	0	0	0	0				
Total	641	354	0	995				
Rate*	13.6	7.7		10.7				
95% C.I.	(12.5-14.6)	(6.9-8.5)		(10.0-11.4)				

* Rates are per 100,000 age-specific population. Note: The "---" is used for rates calculated on numbers less than ten.

Table 176. Kidney and Renal Pelvis Cancer Cases by Age Group and Stage, Nevada Residents, 1996-2000

				Si	tage		
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total
<1	Number	0	0	0	0	0	0
	Percent						
1-4	Number	0	6	1	0	2	9
	Percent		66.7%	11.1%		22.2%	100.0%
5-14	Number	0	1	0	1	0	2
	Percent		50.0%		50.0%		100.0%
15-24	Number	0	1	1	0	1	3
	Percent		33.3%	33.3%		33.3%	100.0%
25-34	Number	0	9	0	1	1	11
	Percent		81.8%		9.1%	9.1%	100.0%
35-44	Number	0	39	3	7	7	56
	Percent		69.6%	5.4%	12.5%	12.5%	100.0%
45-54	Number	0	91	22	26	17	156
	Percent		58.3%	14.1%	16.7%	10.9%	100.0%
55-64	Number	0	138	39	49	34	260
	Percent		53.1%	15.0%	18.8%	13.1%	100.0%
65-74	Number	0	162	30	52	48	292
	Percent		55.5%	10.3%	17.8%	16.4%	100.0%
75-84	Number	0	76	20	33	48	177
	Percent		42.9%	11.3%	18.6%	27.1%	100.0%
85+	Number	0	7	3	4	15	29
	Percent		24.1%	10.3%	13.8%	51.7%	100.0%
Unknown	Number	0	0	0	0	0	0
	Percent						
Total	Number	0	530	119	173	173	995
	Percent		53.3%	12.0%	17.4%	17.4%	100.0%

Table 177. Kidney and Renal Pelvis Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1996-2000

			Race/Ethnicity							
	Stage		Black	Native American	Asian	Hispanic	Other/ Unknown	Total		
In situ	Number	0	0	0	0	0	0	0		
	Percent									
Localized	Number	455	36	2	6	30	1	530		
	Percent	52.8%	61.0%	25.0%	40.0%	61.2%	50.0%	53.3%		
Regional	Number	107	5	1	4	1	1	119		
	Percent	12.4%	8.5%	12.5%	26.7%	2.0%	50.0%	12.0%		
Distant	Number	152	5	1	4	11	0	173		
	Percent	17.6%	8.5%	12.5%	26.7%	22.4%		17.4%		
Unstaged	Number	148	13	4	1	7	0	173		
	Percent	17.2%	22.0%	50.0%	6.7%	14.3%		17.4%		
Total	Number	862	59	8	15	49	2	995		
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%		


Table 178. Median Age at Diagnosis of Kidney and Renal Pelvis Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

	Gender								
Race/Ethnicity	Male		Fem	nale	То	Total			
	Incidence	Median Age	Incidence	Median Age	Incidence	Median Age			
White	556	65.0	306	66.0	862	65.0			
Black	40	62.5	19	61.0	59	62.0			
Native American	2		6	70.5	8	68.5			
Asian	8	60.0	7	47.0	15	60.0			
Hispanic	33	57.0	16	50.0	49	56.0			
Other/Unknown	2		0		2				
Total	641	64.0	354	65.0	995	65.0			

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

Figure 118. Kidney and Renal Pelvis Cancer Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical notes for more information.

Figure 119. Kidney and Renal Pelvis Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 120. Median Charges for Kidney and Renal Pelvis Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000




Figure 121. Average Length of Stay for Kidney and Renal Pelvis Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000




Table 179. Kidney and Renal Pelvis Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

		Coun	ty/Region of Resid	lence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	842	569	129	144	0
Rate*	9.5	9.7	8.7	9.8	
95% C.I.	(8.9-10.2)	(8.9-10.5)	(7.2-10.4)	(8.3-11.6)	
Gender					
Male	540	358	82	100	0
Rate*	12.5	12.4	11.6	13.7	
95% C.I.	(11.5-13.7)	(11.1-13.9)	(9.1-14.8)	(11.1-17.0)	
Female	302	211	47	44	0
Rate*	6.7	7.0	6.1	6.0	
95% C.I.	(6.0-7.5)	(6.1-8.1)	(4.5-8.2)	(4.4-8.2)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Cl	harges (\$)				
Total Charges	\$23,358,873	\$16,428,706	\$3,976,738	\$2,953,429	
Average Charges	\$27,742	\$28,873	\$30,827	\$20,510	
Median Charges	\$21,442	\$21,482	\$26,792	\$17,839	
Discharge Length of S	stay (LOS) (Days)				
Total LOS	5,402	3,746	887	769	
Average LOS	6.4	6.6	6.9	5.3	
Median LOS	5.0	5.0	6.0	4.0	

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 180. Kidney and Renal Pelvis Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown				
Total									
Discharges	842	569	129	144	0				
Rate*	9.1	9.0	7.9	10.5					
95% C.I.	(8.4-9.7)	(8.3-9.8)	(6.5-9.2)	(8.8-12.2)					
Age Group									
<1	2	1	0	1	0				
Rate*									
95% C.I.									
1-4	11	11	0	0	0				
Rate*	2.0	2.9							
95% C.I.	(0.8-3.2)	(1.2-4.6)							
5-14	8	8	0	0	0				
Rate*									
95% C.I.									
15-24	3	2	1	0	0				
Rate*									
95% C.I.									
25-34	9	8	0	1	0				
Rate*									
95% C.I.									
35-44	46	32	9	5	0				
Rate*	3.1	3.2							
95% C.I.	(2.2-4.0)	(2.1-4.4)							
45-54	131	84	25	22	0				
Rate*	10.8	10.6	11.1	9.8					
95% C.I.	(9.0-12.7)	(8.3-12.9)	(6.8-15.5)	(5.7-13.9)					
55-64	224	149	26	49	0				
Rate*	26.0	25.6	18.4	34.6					
95% C.I.	(22.6-29.4)	(21.5-29.7)	(11.3-25.4)	(24.9-44.3)					
65-74	262	178	41	43	0				
Rate*	42.3	42.9	40.7	42.6					
95% C.I.	(37.1-47.4)	(36.6-49.2)	(28.2-53.1)	(29.9-55.4)					
75-84	127	83	24	20	0				
Rate*	38.7	38.4	43.6	36.3					
95% C.I.	(32.0-45.5)	(30.1-46.6)	(26.2-61.1)	(20.4-52.3)					
85+	19	13	3	3	0				
Rate*	27.0	30.3							
95% C.I.	(14.8-39.1)	(13.8-46.8)							
Unknown	0	0	0	0	0				

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 181. Kidney and Renal Pelvis Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1996-2000

Age	Gender					
Group	Male	Female	Total			
<1 =	0	2	2			
Rate*						
95% C.I.	<u></u>					
1-4	8	3	11			
Rate*			2.0			
95% C.I.			(0.8-3.2)			
5-14	2	6	8			
Rate*						
95% C.I.						
15-24	2	1	3			
Rate*						
95% C.I.	 -					
25-34 Rate*	5	4	9			
95% C.I.						
35-44	31	15	46			
Rate*	4.0	2.1	3.1			
95% C.I.	(2.6-5.4)	(1.0-3.1)	(2.2-4.0)			
45-54	86	45	131			
Rate*	14.0	7.5	10.8			
95% C.I.	(11.1-17.0)	(5.3-9.7)	(9.0-12.7)			
55-64	148	76	224			
Rate*	34.5	17.6	26.0			
95% C.I.	(29.0-40.1)	(13.6-21.5)	(22.6-29.4)			
65-74	172	90	262			
Rate*	56.3	28.6	42.3			
95% C.I.	(47.8-64.7)	(22.7-34.6)	(37.1-47.4)			
75-84	78	49	127			
Rate*	52.9	27.2	38.7			
95% C.I.	(41.2-64.6)	(19.6-34.8)	(32.0-45.5)			
85+	8	11	19			
Rate*		23.0	27.0			
95% C.I. Unknown		(9.4-36.6)	(14.8-39.1)			
Total	540	302	842			
Rate*	11.4	6.6	9.1			
95% C.I.	(10.5-12.4)	(5.9-7.3)	(8.4-9.7)			
1370 0	(10.0 12.1)	(5.5 7.6)	(3.1 3.1)			

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 182. Kidney and Renal Pelvis Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000

O sure transfer	1996-2000 Inpatient Hospital Discharges						
County of Residence	Number	Rat	Rate* Age-Adjusted		ted Rate**		
	Number	Rate	95% C.I.	Rate	95% C.I.		
Carson City	25	10.2	(6.2-14.2)	9.0	(5.8-13.4)		
Churchill	9						
Clark	569	9.0	(8.3-9.8)	9.7	(8.9-10.5)		
Douglas	14	7.0	(3.3-10.7)	5.5	(3.0-10.3)		
Elko	7						
Esmeralda	2						
Eureka	2						
Humboldt	5						
Lander	6						
Lincoln	2						
Lyon	36	22.2	(15.0-29.5)	19.6	(13.7-27.8)		
Mineral	1						
Nye	28	18.9	(11.9-25.8)	13.2	(8.6-20.7)		
Pershing	4						
Storey	1						
Washoe	129	7.9	(6.5-9.2)	8.7	(7.2-10.4)		
White Pine	2						
Unknown	0						
Total	842	9.1	(8.4-9.7)	9.5	(8.9-10.2)		


Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 183. Kidney and Renal Pelvis Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1996-2000

Age	Diocharges	(Charges (\$)		Length of Stay (Days)		ays)
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	2						
1-4	11	358,191	32,563	39,144	87	7.9	10.0
5-14	8	922,920	115,365	61,678	148	18.5	10.5
15-24	3						
25-34	9	167,246	18,583	18,502	42	4.7	4.0
35-44	46	1,198,213	26,048	18,662	258	5.6	4.5
45-54	131	3,023,520	23,080	19,739	683	5.2	4.0
55-64	224	6,161,874	27,508	21,953	1,466	6.5	5.0
65-74	262	6,513,425	24,860	21,544	1,500	5.7	5.0
75-84	127	4,350,314	34,254	23,399	1,026	8.1	6.0
85+	19	537,180	28,273	20,081	156	8.2	7.0
Unknown	0						
Total	842	23,358,873	27,742	21,442	5,402	6.4	5.0

MORTALITY

Figure 122. Kidney and Renal Pelvis Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 123. Kidney and Renal Pelvis Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 124. Kidney and Renal Pelvis Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1996-2000




Table 184. Kidney and Renal Pelvis Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1996-2000

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Mortality	326	217	52	57			
Rate*	3.9	4.0	3.7	4.1			
95% C.I.	(3.5-4.4)	(3.4-4.6)	(2.7-4.9)	(3.1-5.4)			
Gender							
Male	227	151	36	40			
Rate*	5.7	5.8	5.6	5.7			
95% C.I.	(5.0-6.6)	(4.8-7.0)	(3.8-8.2)	(4.0-8.1)			
Female	99	66	16	17			
Rate*	2.3	2.3	2.1	2.4			
95% C.I.	(1.9-2.8)	(1.8-3.0)	(1.2-3.5)	(1.4-4.0)			
Other/Unknown	0	0	0	0			
Race/Ethnicity							
White	292	193	48	51			
Rate*	4.2	4.3	3.8	4.0			
95% C.I.	(3.7-4.7)	(3.7-5.0)	(2.8-5.1)	(3.0-5.4)			
Black	13	12	1	0			
Rate*	3.7	3.8					
95% C.I.	(1.9-7.1)	(1.8-7.5)					
Native American	3	0	2	1			
Rate*							
95% C.I.							
Asian	4	3	1	0			
Rate*							
95% C.I.							
Hispanic	12	8	0	4			
Rate*	2.3						
95% C.I.	(1.0-5.0)						
Other/Unknown	2	1	0	1			

^{*}Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 185. Kidney and Renal Pelvis Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Mortality	326	217	52	57				
Rate*	3.5	3.4	3.2	4.2				
95% C.I.	(3.1-3.9)	(3.0-3.9)	(2.3-4.0)	(3.1-5.2)				
Age Group								
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	0	0	0	0				
Rate*								
95% C.I.								
15-24	0	0	0	0				
Rate*								
95% C.I.								
25-34	0	0	0	0				
Rate*								
95% C.I.								
35-44	5	5	0	0				
Rate*								
95% C.I.								
45-54	28	19	6	3				
Rate*	2.3	2.4						
95% C.I.	(1.5-3.2)	(1.3-3.5)						
55-64	81	56	8	17				
Rate*	9.4	9.6		12.3				
95% C.I.	(7.4-11.5)	(7.1-12.2)		(6.5-18.2)				
65-74	105	63	22	20				
Rate*	16.9	15.2	21.8	19.1				
95% C.I.	(13.7-20.2)	(11.4-18.9)	(12.7-30.9)	(10.8-27.5)				
75-84	88	63	13	12				
Rate*	26.8	29.1	23.6	21.2				
95% C.I.	(21.2-32.5)	(21.9-36.3)	(10.8-36.5)	(9.2-33.3)				
85+	19	11	3	5				
Rate*	27.0	25.7						
95% C.I.	(14.8-39.1)	(10.5-40.9)						
Unknown	0	0	0	0				

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 186. Kidney and Renal Pelvis Cancer Mortality by County of Residence, Nevada Residents, 1996-2000

	1996-2000 Mortality						
County of Residence	Conne	Ra	te*	Age-Adjus	Age-Adjusted Rate**		
	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	14	5.7	(2.7-8.7)	5.0	(2.7-8.7)		
Churchill	1						
Clark	217	3.4	(3.0-3.9)	4.0	(3.4-4.6)		
Douglas	14	7.0	(3.3-10.7)	5.6	(3.1-10.5)		
Elko	5						
Esmeralda	0						
Eureka	0						
Humboldt	1						
Lander	2						
Lincoln	2						
Lyon	8						
Mineral	0						
Nye	8						
Pershing	0						
Storey	1						
Washoe	52	3.2	(2.3-4.0)	3.7	(2.7-4.9)		
White Pine	1						
Unknown	0						
Total	326	3.5	(3.1-3.9)	3.9	(3.5-4.4)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 187. Kidney and Renal Pelvis Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

		Gender				
Race/Ethnicity		Male	Female	Total		
White	Mortality	207	85	292		
	Rate*	6.2	2.3	4.2		
	95% C.I.	(5.3-7.2)	(1.9-2.9)	(3.7-4.7)		
Black	Mortality	8	5	13		
	Rate*			3.7		
	95% C.I.			(1.9-7.1)		
Native	Mortality	0	3	3		
American	Rate*					
	95% C.I.					
Asian	Mortality	4	0	4		
	Rate*					
	95% C.I.					
Hispanic	Mortality	7	5	12		
	Rate*			2.3		
	95% C.I.			(1.0-5.0)		
Other/Unkr	nown	1	1	2		
Total	Mortality	227	99	326		
	Rate*	5.7	2.3	3.9		
	95% C.I.	(5.0-6.6)	(1.9-2.8)	(3.5-4.4)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 188. Kidney and Renal Pelvis Cancer Mortality by Age Group and Gender, Nevada Residents, 1996-2000

Age	Gender						
Group	Male	Female	Total				
<1	0	0	0				
Rate*							
95% C.I.							
1-4	0	0	0				
Rate*							
95% C.I.							
5-14	0	0	0				
Rate*							
95% C.I.							
15-24	0	0	0				
Rate*							
95% C.I.							
25-34	0	0	0				
Rate*							
95% C.I.							
35-44	4	1	5				
Rate*							
95% C.I.							
45-54	23	5	28				
Rate*	3.8		2.3				
95% C.I.	(2.2-5.3)		(1.5-3.2)				
55-64	62	19	81				
Rate*	14.5	4.4	9.4				
95% C.I.	(10.9-18.1)	(2.4-6.4)	(7.4-11.5)				
65-74 Rate*	74 24.2	31 9.9	105 16.9				
95% C.I.	(18.7-29.7)	(6.4-13.3)	(13.7-20.2)				
75-84	55	33	88				
Rate*	37.3	18.3	26.8				
95% C.I.	(27.4-47.2)	(12.1-24.5)	(21.2-32.5)				
85+	9	10	19				
Rate*		20.9	27.0				
95% C.I.		(8.0-33.9)	(14.8-39.1)				
Unknown	0	0	0				
Total	227	99	326				
Rate*	4.8	2.2	3.5				
95% C.I.	(4.2-5.4)	(1.7-2.6)	(3.1-3.9)				

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.


Table 189. Median Age at Death from Kidney and Renal Pelvis Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

Race/Ethnicity	Ma	ile	Fem	nale	Total	
	Deaths	Median Age	Deaths	Median Age	Deaths	Median Age
White	207	68.0	85	73.0	292	70.0
Black	8	70.0	5	74.0	13	72.0
Native American	0		3		3	
Asian	4		0		4	
Hispanic	7	65.0	5	67.0	12	65.5
Other/Unknown	1		1		2	
Total	227	68.0	99	73.0	326	70.0

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE

Figure 125. Survival Rates for Kidney and Renal Pelvis Cancer by Race/Ethnicity, Nevada Residents, 1996-2000



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 126. Survival Rates for Kidney and Renal Pelvis Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 1996-2000




Table 190. Cause-Specific Survival Rates for Kidney and Renal Pelvis Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

Race/	Number	Cause Specific Survival Rate					Median
Ethnicity and Gender	Ethnicity of Casos	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)
Total	667	71.4%	63.8%	56.3%	55.0%	51.3%	>5 years
Male	430	70.3%	61.5%	56.9%	55.0%	50.0%	>5 years
Female	237	73.5%	68.0%	55.0%	55.0%	55.0%	>5 years
Race/Ethnicity							
White	575	70.4%	62.1%	54.6%	53.1%	49.0%	4.76
Male	370	68.2%	58.2%	54.3%	52.1%	46.3%	4.37
Female	205	74.4%	69.6%	55.2%	55.2%	55.2%	>5 years
Black	36						
Male	23						
Female	13						
Native American	4						
Male	2						
Female	2						
Asian	12						
Male	8						
Female	4						
Hispanic	39						
Male	26						
Female	13						

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 191. Cause-Specific Survival Rates for Kidney and Renal Pelvis Cancer by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1996-2000

Surviv	/al Rate of Stage		Gender	
at Diagnosis		Total	Male	Female
Total	Cases	667	430	237
	One Year	71.4%	70.3%	73.5%
	5 Years	51.3%	50.0%	55.0%
	Median Survival	>5 years	>5 years	>5 years
Stage at D	iagnosis			
In situ	Cases	0	0	0
	One Year			
	5 Years			
	Median Survival			
Localized	Cases	378	237	141
	One Year	95.3%	95.6%	94.8%
	5 Years	86.8%	92.5%	77.7%
	Median Survival	>5 years	>5 years	>5 years
Regional	Cases	89	56	33
	One Year	66.7%	67.4%	65.4%
	5 Years	25.3%	13.1%	47.2%
	Median Survival	2.69	2.62	2.73
Distant	Cases	135	96	39
	One Year	24.9%	25.9%	22.4%
	5 Years	5.2%	4.8%	0.0%
	Median Survival	0.67	0.67	0.64
Unstaged	Cases	65	41	24
	One Year	65.3%	65.6%	64.7%
	5 Years	0.0%	0.0%	0.0%
	Median Survival	2.38	2.74	1.91


Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

LEUKEMIA

LEUKEMIA

GENERAL PROFILE⁴

Figure 127. Anatomy of Stem Cell Maturation



General Anatomy: Blood cells form in the bone marrow, which is the soft material in the center of most bones. Immature blood cells are called stem cells and blasts. Most blood cells mature in the bone marrow and then move into the blood vessels. The bone marrow makes different types of blood cells; each with a special function: White blood cells fight infection, red blood cells carry oxygen to body tissues, and platelets help form blood clots to speed healing. In people with leukemia, the bone marrow produces abnormal white blood cells. At first, leukemia cells function almost normally. In time, they may crowd out normal white blood cells, red blood cells, and platelets.

Risk Factors: Very high levels of radiation, working with certain chemicals (e.g. Benzene, Formaldehyde), chemotherapy, down syndrome, human T-cell leukemia virus-I (HTLV-I), and myelodysplastic syndrome.

Signs and Symptoms: Fevers or night sweats, frequent infections, feeling weak or tired, headache, bleeding and bruising easily (bleeding gums, purplish patches in the skin, or tiny red spots under the skin), pain in the bones or joints, swelling or discomfort in the abdomen (from an enlarged spleen), swollen lymph nodes, especially in the neck or armpit, and weight loss.

Diagnosing the Cancer: Health exams, blood tests (High level of white blood cells, low levels of red blood cells and platelets), bone marrow aspiration, bone marrow biopsy, cytogenetics, spinal tap, and chest x-ray.

Treatment: chemotherapy (intrathecal), biological therapy, radiation therapy, or stem cell transplantation (Bone Marrow, Peripheral stem cell and Umbilical cord blood transplantations).

HIGHLIGHTS

- ➤ The ratio of the age-adjusted incidence rate, 11.7, to the age-adjusted mortality rate, 7.2 (per 100,000 2000 US Standard population), for Leukemia was 1.63 during the 1996 to 2000 period, which means that for every 1.63 Leukemia cases during this period, there was one Leukemia death in Nevada.
- Nevadan females had a slighlty higher ratio than males when the age-adjusted incidence and age-adjusted mortality rates for Leukemia were compared. For every female death due to Leukemia there were 1.65 female cases while only 1.59 male cases for every male Leukemia death in Nevada from 1996 to 2000.
- The median age at diagnosis of Leukemia was 66 years of age for Nevada residents from 1996 to 2000; the median age at time of death was 71 years.

INCIDENCE

- ➤ There were 973 cases of Leukemia in Nevada from 1996 to 2000. Regional comparisons showed little variation between All Other Counties (11.8), Clark County (11.7) and Washoe County (11.5) from 1996 to 2000. While the age-adjusted incidence rates were slightly lower than the National rate of 12.1 (per 100,000 2000 US Standard population) statistical analysis does not show a significant difference between any of the areas.
- ➤ While regional comparisons showed that Washoe County's age-adjusted incidence rate, 17.0, was higher than the rate for All Other Counties and Clark County who had rates of 16.3 and 13.9 (per 100,000 2000 US Standard population) from 1996 to 2000, these differences were not statistically significant.
- The age-adjusted incidence rate for male Leukemia, 14.2 (13.0-15.5), was statistically significant over the rate for females, 9.4 (8.5-10.4), during the 1996 to 2000 period.
- ➤ Whites, as a racial/ethnic group, had the highest age-adjusted incidence rate from Leukemia during the 1996 to 2000 period. They were followed by Blacks, Hispanics and Asians, who had rates of 10.5, 7.8 and 6.4, (per 100,000 2000 US Standard population), respectively.

INPATIENT HOSPITAL DISCHARGES

➤ Statistical regional comparisons indicate that Clark County had the highest age-adjusted inpatient discharge rate for Leukemia, 13.3 (12.4-14.3), and was followed by All Other Counties, 10.1 (8.4-12.0), and Washoe County, 8.7 (7.3-10.4), per 100,000 – 2000 US Standard population) from 1996 to 2000.

- ➤ Clark County had the highest median total charge (\$30,364) that was nearly double that of Washoe County (\$16,087) and All Other Counties (\$15,159), as a region, during the 1996 to 2000 period.
- Total billed charges for hospital inpatient discharges from Leukemia in Nevada totaled approximately 55.4 million dollars from 1996 to 2000. The overall average billed charge per day for an inpatient hospital discharge for Leukemia was approximately \$4,300 in Nevada during this time.

MORTALITY


- ➤ There were 568 Leukemia deaths from 1996 to 2000. While All Other Counties, as a region, had a higher age-adjusted mortality rate, 7.5, than Clark County, 7.2 and Washoe County, 7.1 (per 100,000 2000 US Standard population), none of the rates show that any statistically significant difference exists between the three regions.
- Males had a statistically higher age-adjusted mortality rate due to Leukemia, 8.9 (7.9-10.0), than their Female counterparts' rate, 5.7 (5.0-6.5), in Nevada from 1996 to 2000.

SURVIVAL RATE

- The one-year survival rate for Leukemia in Nevada was 55.9% during the 1996 to 2000 period, while the five-year survival rate was 30.5% during this same time. The median survival rate in Nevada for Leukemia was 1.60 years.
- ➤ While Females in Nevada diagnosed with Leukemia had a higher one-year survival rate (57.1%) than males (55.2%), their five-year survival rate (27.3%) was lower than the rate for males (33.3%) during the 1996 to 2000 period.
- Nevadan females had a slightly higher median survival time than their male counterparts with median survival times of 1.65 and 1.58 years, respectively, during the 1996 to 2000 period.

INCIDENCE

Figure 128. Leukemia Age-Adjusted (2000) Incidence Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 129. Leukemia Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 130. Leukemia Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1996-2000




Table 192. Leukemia Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

			County/Region	n of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)
Total						
Cases	973	649	165	158	1	20,646
Rate*	11.7	11.7	11.5	11.8		12.1
95% C.I.	(11.0-12.5)	(10.8-12.7)	(9.8-13.5)	(10.0-13.8)		(11.9-12.2)
Gender						
Male	568	392	86	89	1	11,811
Rate*	14.2	15.1	12.3	13.2		15.8
95% C.I.	(13.0-15.5)	(13.5-16.9)	(9.8-15.6)	(10.5-16.5)		(15.5-16.1)
Female	405	257	79	69	0	8,835
Rate*	9.4	9.0	10.4	10.0		9.3
95% C.I.	(8.5-10.4)	(7.9-10.2)	(8.2-13.0)	(7.8-12.8)		(9.1-9.5)
Other/Unknown	0	0	0	0	0	0
Race/Ethnicity						
White	818	532	145	141	0	17,549
Rate*	12.3	12.7	11.8	11.6		12.6
95% C.I.	(11.4-13.2)	(11.6-13.8)	(10.0-14.0)	(9.7-13.8)		(12.4-12.8)
Black	40	35	4	1	0	1,438
Rate*	10.5	10.3				9.6
95% C.I.	(7.2-15.3)	(6.8-15.4)				(9.1-10.2)
Native American	9	2	2	5	0	56
Rate*						4.0
95% C.I.						(2.9-2.9)
Asian	27	20	4	3	0	1,335
Rate*	6.4	6.1				8.1
95% C.I.	(4.1-12.3)	(3.6-13.7)				(7.6-8.6)
Hispanic	75	58	9	7	1	2,161
Rate*	7.8	7.4				8.7
95% C.I.	(5.6-11.0)	(5.1-11.3)				(8.3-9.2)
Other/Unknown	4	2	1	1	0	268

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the National (SEER) rates. See Technical Notes for more information.

Table 193. Leukemia Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

			County/Region	on of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)
Total						
Cases	973	649	165	158	1	20,646
Rate*	10.5	10.3	10.1	11.5		11.1
95% C.I.	(9.8-11.1)	(9.5-11.1)	(8.5-11.6)	(9.7-13.3)		(11.0-11.3)
Age Group						
<1	7	5	1	1	0	104
Rate*						3.8
95% C.I.						(3.0-4.5)
1-4	34	24	3	7	0	983
Rate*	6.2	6.3				8.8
95% C.I.	(4.1-8.3)	(3.8-8.8)				(8.3-9.4)
5-14	53	38	7	8	0	958
Rate*	4.0	4.3				3.6
95% C.I.	(2.9-5.1)	(2.9-5.6)				(3.4-3.8)
15-24	30	24	2	4	0	651
Rate*	2.3	2.8				2.5
95% C.I.	(1.5-3.2)	(1.7-3.9)				(2.3-2.7)
25-34	37	28	7	1	1	801
Rate*	2.6	2.7				2.7
95% C.I.	(1.8-3.4)	(1.7-3.8)				(2.5-2.9)
35-44	48	31	13	4	0	1,264
Rate*	3.2	3.1	4.7			4.0
95% C.I.	(2.3-4.1)	(2.0-4.2)	(2.1-7.2)			(3.8-4.3)
45-54	92	65	12	15	0	2,006
Rate*	7.6	8.2	5.3	7.8		8.8
95% C.I.	(6.1-9.2)	(6.2-10.2)	(2.3-8.4)	(3.9-11.7)		(8.4-9.1)
55-64	147	99	25	23	0	2,707
Rate*	17.1	17.0	17.7	16.7		19.3
95% C.I.	(14.3-19.8)	(13.7-20.4)	(10.7-24.6)	(9.9-23.5)		(18.6-20.1)
65-74	251	165	42	44	0	4,567
Rate*	40.5	39.8	41.6	42.1		39.6
95% C.I.	(35.5-45.5)	(33.7-45.9)	(29.0-54.2)	(29.7-54.6)		(38.4-40.7)
75-84	205	124	45	36	0	4,603
Rate*	62.5	57.3	81.8	63.7		63.3
95% C.I.	(54.0-71.1)	(47.2-67.4)	(57.9-105.7)	(42.9-84.6)		(61.5-65.2)
85+	68	45	8	15	0	2,002
Rate*	96.5	105.0		113.7		80.7
95% C.I.	(73.6-119.5)	(74.4-135.7)		(56.2-171.2)		(77.2-84.3)
Unknown	, , , , , , , , , , , , , , , , , , ,	1	0	Ò	0	Ó

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 194. Leukemia Cases by County of Residence at Diagnosis, Nevada Residents, 1996-2000

County of	1996-2000 Incidence					
Residence	Cases	Rat	te*	Age-Adjusted Rate**		
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.	
Carson City	47	19.2	(13.7-24.7)	17.0	(12.5-22.9)	
Churchill	19	16.1	(8.9-23.3)	16.1	(9.6-25.9)	
Clark	649	10.3	(9.5-11.1)	11.7	(10.8-12.7)	
Douglas	25	12.5	(7.6-17.4)	11.6	(7.3-18.1)	
Elko	12	5.2	(2.3-8.2)	10.3	(5.0-19.6)	
Esmeralda	0					
Eureka	1					
Humboldt	2					
Lander	4					
Lincoln	2					
Lyon	16	9.9	(5.0-14.7)	8.6	(4.9-14.7)	
Mineral	6					
Nye	18	12.1	(6.5-17.7)	9.9	(5.6-17.5)	
Pershing	1					
Storey	2					
Washoe	165	10.1	(8.5-11.6)	11.5	(9.8-13.5)	
White Pine	3					
Unknown	1					
Total	973	10.5	(9.8-11.1)	11.7	(11.0-12.5)	

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 195. Leukemia Cases by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

			Ger	nder	
Rac	e/Ethnicity	Male	Female	Other/ Unknown	Total
White	Incidence	485	333	0	818
	Rate*	15.0	9.7		12.3
	95% C.I.	(13.6-16.5)	(8.7-10.8)		(11.4-13.2)
Black	Incidence	21	19	0	40
	Rate*	14.3	8.9		10.5
	95% C.I.	(7.4-26.4)	(5.2-14.8)		(7.2-15.3)
Native	Incidence	3	6	0	9
American	Rate*				
	95% C.I.				
Asian	Incidence	13	14	0	27
	Rate*	7.2	5.8		6.4
	95% C.I.	(3.6-20.2)	(3.1-15.8)		(4.1-12.3)
Hispanic	Incidence	44	31	0	75
	Rate*	8.8	6.8		7.8
	95% C.I.	(5.5-15.9)	(4.2-11.3)		(5.6-11.0)
Other/Unkn	iown	2	2	0	4
Total	Incidence	568	405	0	973
	Rate*	14.2	9.4		11.7
	95% C.I.	(13.0-15.5)	(8.5-10.4)		(11.0-12.5)

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 196. Leukemia Cases by Age Group and Gender, Nevada Residents, 1996-2000

Age	Gender						
Group	Male	Female	Other/ Unknown	Total			
<1	5	2	0	7			
Rate*							
95% C.I.							
1-4	19	15	0	34			
Rate*	6.8	5.6		6.2			
95% C.I.	(3.7-9.9)	(2.8-8.4)		(4.1-8.3)			
5-14	34	19	0	53			
Rate*	5.0	3.0		4.0			
95% C.I.	(3.3-6.7)	(1.6-4.3)		(2.9-5.1)			
15-24	16	14	0	30			
Rate*	2.4	2.3		2.3			
95% C.I.	(1.2-3.6)	(1.1-3.5)		(1.5-3.2)			
25-34	19	18	0	37			
Rate*	2.6	2.6		2.6			
95% C.I.	(1.4-3.7)	(1.4-3.8)		(1.8-3.4)			
35-44	29	19	0	48			
Rate*	3.8	2.6		3.2			
95% C.I.	(2.4-5.1)	(1.4-3.8)		(2.3-4.1)			
45-54	56	36	0	92			
Rate*	9.1	6.0		7.6			
95% C.I.	(6.7-11.5)	(4.1-8.0)		(6.1-9.2)			
55-64	91	56	0	147			
Rate*	21.2	13.0		17.1			
95% C.I.	(16.9-25.6)	(9.6-16.4)		(14.3-19.8)			
65-74	153	98	0	251			
Rate*	50.0	31.2		40.5			
95% C.I.	(42.1-58.0)	(25.0-37.4)		(35.5-45.5)			
75-84	122	83	0	205			
Rate*	82.7	46.0		62.5			
95% C.I.	(68.0-97.4)	(36.1-55.9)		(54.0-71.1)			
85+	23	45	0	68			
Rate*	101.4	94.2		96.5			
95% C.I.	(60.0-142.9)	(66.7-121.7)		(73.6-119.5)			
Unknown	1	0	0	1			
Total	568	405	0	973			
Rate*	12.0	8.9		10.5			
95% C.I.	(11.0-13.0)	(8.0-9.7)		(9.8-11.1)			

* Rates are per 100,000 age-specific population. Note: The "---" is used for rates calculated on numbers less than ten.

Table 197. Leukemia Incidence by Age Group and Stage, Nevada Residents, 1996-2000

A	0	Stage					
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total
<1	Number	0	0	0	6	1	7
	Percent				85.7%	14.3%	100.0%
1-4	Number	0	0	0	34	0	34
	Percent				100.0%		100.0%
5-14	Number	0	0	0	52	1	53
	Percent				98.1%	1.9%	100.0%
15-24	Number	0	0	0	29	1	30
	Percent				96.7%	3.3%	100.0%
25-34	Number	0	0	0	36	1	37
	Percent				97.3%	2.7%	100.0%
35-44	Number	0	0	0	44	4	48
	Percent				91.7%	8.3%	100.0%
45-54	Number	0	0	0	82	10	92
	Percent				89.1%	10.9%	100.0%
55-64	Number	0	0	0	138	9	147
	Percent				93.9%	6.1%	100.0%
65-74	Number	0	0	0	218	33	251
	Percent				86.9%	13.1%	100.0%
75-84	Number	0	0	0	169	36	205
	Percent				82.4%	17.6%	100.0%
85+	Number	0	0	0	49	19	68
	Percent				72.1%	27.9%	100.0%
Unknown	Number	0	0	0	1	0	1
	Percent				100.0%		100.0%
Total	Number Percent	0	0	0	858 88.2%	115 11.8%	973 100.0%
	i GIUCIII				JU.Z /0	11.0/0	100.0 /0

Table 198. Leukemia Cases by Stage and Race/Ethnicity, Nevada Residents, 1996-2000

			Race/Ethnicity						
Stage		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total	
In situ	Number	0	0	0	0	0	0	0	
	Percent								
Localized	Number	0	0	0	0	0	0	0	
	Percent								
Regional	Number	0	0	0	0	0	0	0	
	Percent								
Distant	Number	722	31	6	25	70	4	858	
	Percent	88.3%	77.5%	66.7%	92.6%	93.3%	100.0%	88.2%	
Unstaged	Number	96	9	3	2	5	0	115	
	Percent	11.7%	22.5%	33.3%	7.4%	6.7%		11.8%	
Total	Number	818	40	9	27	75	4	973	
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	


Table 199. Median Age at Diagnosis of Leukemia by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

	Gender								
Race/Ethnicity	Male		Fem	nale	Total				
	Incidence	Median Age	Incidence	Median Age	Incidence	Median Age			
White	484	68.0	333	70.0	817	68.0			
Black	21	65.0	19	68.0	40	66.5			
Native American	3		6	43.0	9	42.0			
Asian	13	33.0	14	11.5	27	15.0			
Hispanic	44	25.0	31	41.0	75	35.0			
Other/Unknown	2		2		4				
Total	567	66.0	405	67.0	972	66.0			

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

Figure 131. Leukemia Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical notes for more information.

Figure 132. Leukemia Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 133. Median Charges for Leukemia Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000




Figure 134. Average Length of Stay for Leukemia Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000




Table 200. Leukemia Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

		Cour	ty/Region of Resid	lence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	1,040	771	132	136	1
Rate*	12.0	13.3	8.7	10.1	
95% C.I.	(11.3-12.8)	(12.4-14.3)	(7.3-10.4)	(8.4-12.0)	
Gender					
Male	609	463	69	76	1
Rate*	14.7	16.9	9.4	11.3	
95% C.I.	(13.5-16.0)	(15.3-18.8)	(7.2-12.2)	(8.8-14.5)	
Female	431	308	63	60	0
Rate*	9.7	10.3	8.1	8.8	
95% C.I.	(8.8-10.6)	(9.2-11.6)	(6.2-10.4)	(6.7-11.4)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Cl	harges (\$)				
Total Charges	\$55,395,907	\$44,450,955	\$5,231,348	\$5,668,727	\$44,877
Average Charges	\$53,265	\$57,654	\$39,631	\$41,682	\$44,877
Median Charges	\$25,696	\$30,364	\$16,087	\$15,159	\$44,877
Discharge Length of S	stay (LOS) (Days)				
Total LOS	12,818	10,108	1,275	1,426	9
Average LOS	12.3	13.1	9.7	10.5	9.0
Median LOS	7.0	8.0	6.0	5.5	9.0

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 201. Leukemia Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		Coun	ty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	1,040	771	132	136	1
Rate*	11.2	12.2	8.1	9.9	
95% C.I.	(10.5-11.9)	(11.4-13.1)	(6.7-9.4)	(8.3-11.6)	
Age Group					
<1	6	6	0	0	0
Rate*					
95% C.I.					
1-4	57	47	2	8	0
Rate*	10.4	12.4			
95% C.I.	(7.7-13.1)	(8.8-15.9)			
5-14	131	117	7	7	0
Rate*	9.9	13.2			
95% C.I.	(8.2-11.6)	(10.8-15.5)			
15-24	58	42	9	7	0
Rate*	4.5	4.8			
95% C.I.	(3.4-5.7)	(3.4-6.3)			
25-34	57	40	8	9	0
Rate*	4.0	3.9			
95% C.I.	(2.9-5.0)	(2.7-5.1)			
35-44	54	40	9	5	0
Rate*	3.6	4.0			
95% C.I.	(2.7-4.6)	(2.8-5.3)			
45-54	91	63	17	11	0
Rate*	7.5	8.0	7.6	4.9	
95% C.I.	(6.0-9.1)	(6.0-9.9)	(4.0-11.2)	(2.0-7.8)	
55-64	171	124	24	22	1
Rate*	19.9	21.3	17.0	15.6	
95% C.I.	(16.9-22.8)	(17.6-25.1)	(10.2-23.8)	(9.1-22.1)	
65-74	213	146	31	36	0
Rate*	34.4	35.2	30.7	35.7	
95% C.I.	(29.7-39.0)	(29.5-40.9)	(19.9-41.6)	(24.0-47.4)	
75-84	157	114	23	20	0
Rate*	47.9	52.7	41.8	36.3	
95% C.I.	(40.4-55.4)	(43.0-62.4)	(24.7-58.9)	(20.4-52.3)	
85+	45	32	2	11	0
Rate*	63.9	74.7		76.3	
95% C.I.	(45.2-82.5)	(48.8-100.6)		(31.2-121.4)	
Unknown	0	0	0	0	0

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 202. Leukemia Inpatient Discharges by Age Group and Gender, Nevada Residents, 1996-2000

Age		Gender	
Group	Male	Female	Total
<1	4	2	6
Rate*			
95% C.I.			
1-4	31	26	57
Rate*	11.1	9.7	10.4
95% C.I.	(7.2-15.0)	(6.0-13.4)	(7.7-13.1)
5-14	80	51	131
Rate*	11.7	8.0	9.9
95% C.I.	(9.2-14.3)	(5.8-10.1)	(8.2-11.6)
15-24	34	24	58
Rate*	5.1	3.9	4.5
95% C.I.	(3.4-6.8)	(2.3-5.5)	(3.4-5.7)
25-34	27	30	57
Rate*	3.6	4.4	4.0
95% C.I.	(2.3-5.0)	(2.8-5.9)	(2.9-5.0)
35-44	41	13	54
Rate*	5.3	1.8	3.6
95% C.I.	(3.7-6.9)	(0.8-2.8)	(2.7-4.6)
45-54	51	40	91
Rate*	8.3	6.7	7.5
95% C.I.	(6.0-10.6)	(4.6-8.8)	(6.0-9.1)
55-64	104	67	171
Rate*	24.3	15.5	19.9
95% C.I.	(19.6-28.9)	(11.8-19.2)	(16.9-22.8)
65-74	117	96	213
Rate*	38.3	30.6	34.4
95% C.I.	(31.3-45.2)	(24.4-36.7)	(29.7-39.0)
75-84	99	58	157
Rate*	67.1	32.2	47.9
95% C.I.	(53.9-80.4)	(23.9-40.5)	(40.4-55.4)
85+	21	24	45
Rate*	92.6	50.2	63.9
95% C.I.	(53.0-132.2)	(30.1-70.3)	(45.2-82.5)
Unknown	000	424	1040
Total	609	431	1,040
Rate* 95% C.I.	12.9 (11.9-13.9)	9.4 (8.5-10.3)	11.2 (10.5-11.9)
₹50 /0 U.I.	(11.9-13.9)	(0.5-10.3)	(10.5-11.9)

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 203. Leukemia Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000

On water of	1996-2000 Inpatient Hospital Discharges					
County of Residence	Number	Rat	te*	Age-Adjus	ted Rate**	
	Number	Rate	95% C.I.	Rate	95% C.I.	
Carson City	18	7.3	(4.0-10.7)	7.0	(4.1-11.2)	
Churchill	17	14.4	(7.6-21.3)	14.2	(8.2-23.6)	
Clark	771	12.2	(11.4-13.1)	13.3	(12.4-14.3)	
Douglas	21	10.5	(6.0-15.0)	11.0	(6.7-17.5)	
Elko	5					
Esmeralda	3					
Eureka	1					
Humboldt	1					
Lander	4					
Lincoln	0					
Lyon	30	18.5	(11.9-25.2)	17.4	(11.6-25.7)	
Mineral	3					
Nye	27	18.2	(11.3-25.1)	14.8	(9.4-23.2)	
Pershing	1					
Storey	1					
Washoe	132	8.1	(6.7-9.4)	8.7	(7.3-10.4)	
White Pine	4					
Unknown	1					
Total	1,040	11.2	(10.5-11.9)	12.0	(11.3-12.8)	


Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 204. Leukemia Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1996-2000

Age	Diocharges	(Charges (\$)			gth of Stay (Da	ıys)
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	6	462,625	77,104	52,804	107	17.8	17.0
1-4	57	2,115,287	37,110	32,614	524	9.2	8.0
5-14	131	6,112,104	46,657	35,211	1,219	9.3	7.0
15-24	58	3,301,419	56,921	29,708	811	14.0	7.0
25-34	57	4,217,996	74,000	50,516	908	15.9	10.0
35-44	54	3,602,168	66,707	37,395	932	17.3	14.5
45-54	91	6,650,048	73,077	33,212	1,465	16.1	10.0
55-64	171	10,282,850	60,134	27,660	2,348	13.7	8.0
65-74	213	12,258,013	57,549	27,986	2,767	13.0	7.0
75-84	157	5,621,392	35,805	15,479	1,451	9.2	6.0
85+	45	772,005	17,156	15,154	286	6.4	5.0
Unknown	0						
Total	1,040	55,395,907	53,265	25,696	12,818	12.3	7.0

MORTALITY

Figure 135. Leukemia Age-Adjusted (2000) Mortality Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 136. Leukemia Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 137. Leukemia Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1996-2000




Table 205. Leukemia Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1996-2000

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Mortality	568	372	100	96				
Rate*	7.2	7.2	7.1	7.5				
95% C.I.	(6.6-7.8)	(6.4-8.0)	(5.8-8.7)	(6.0-9.3)				
Gender								
Male	330	224	57	49				
Rate*	8.9	9.4	8.6	7.8				
95% C.I.	(7.9-10.0)	(8.1-10.9)	(6.4-11.5)	(5.7-10.7)				
Female	238	148	43	47				
Rate*	5.7	5.4	5.7	7.0				
95% C.I.	(5.0-6.5)	(4.5-6.3)	(4.1-7.7)	(5.1-9.4)				
Other/Unknown	0	0	0	0				
Race/Ethnicity								
White	502	323	92	87				
Rate*	7.6	7.8	7.4	7.5				
95% C.I.	(6.9-8.3)	(6.9-8.7)	(6.0-9.2)	(5.9-9.3)				
Black	19	19	0	0				
Rate*	5.4	5.9						
95% C.I.	(3.1-9.2)	(3.3-10.2)						
Native American	6	2	0	4				
Rate*								
95% C.I.								
Asian	9	8	1	0				
Rate*								
95% C.I.								
Hispanic	30	20	5	5				
Rate*	4.5	4.0						
95% C.I.	(2.8-7.5)	(2.2-7.6)						
Other/Unknown	2	0	2	0				

^{*}Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten.

Table 206. Leukemia Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties					
Total									
Mortality	568	372	100	96					
Rate*	6.1	5.9	6.1	7.0					
95% C.I.	(5.6-6.6)	(5.3-6.5)	(4.9-7.3)	(5.6-8.4)					
Age Group									
<1	1	0	0	1					
Rate*									
95% C.I.									
1-4	3	1	1	1					
Rate*									
95% C.I.									
5-14	7	7	0	0					
Rate*									
95% C.I.									
15-24	15	11	1	3					
Rate*	1.2	1.3							
95% C.I.	(0.6-1.8)	(0.5-2.0)							
25-34	6	4	0	2					
Rate*									
95% C.I.									
35-44	21	13	6	2					
Rate*	1.4	1.3							
95% C.I.	(0.8-2.0)	(0.6-2.0)							
45-54	48	34	8	6					
Rate*	4.0	4.3							
95% C.I.	(2.8-5.1)	(2.8-5.7)							
55-64	86	57	15	14					
Rate*	10.0	9.8	10.6	10.1					
95% C.I.	(7.9-12.1)	(7.3-12.3)	(5.2-16.0)	(4.8-15.5)					
65-74	155	96	35	24					
Rate*	25.0	23.2	34.7	23.0					
95% C.I.	(21.1-28.9)	(18.5-27.8)	(23.2-46.2)	(13.8-32.2)					
75-84	170	114	28	28					
Rate*	51.9	52.7	50.9	49.6					
95% C.I.	(44.1-59.7)	(43.0-62.4)	(32.0-69.7)	(31.2-67.9)					
85+	56	35	6	15					
Rate*	79.5	81.7		113.7					
95% C.I.	(58.7-100.3)	(54.6-108.8)		(56.2-171.2)					
Unknown	0	0	0	0					

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 207. Leukemia Mortality by County of Residence, Nevada Residents, 1996-2000

	1996-2000 Mortality							
County of Residence	Conne	Ra	te*	Age-Adjus	ted Rate**			
	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	20	8.2	(4.6-11.7)	7.2	(4.3-11.3)			
Churchill	7							
Clark	372	5.9	(5.3-6.5)	7.2	(6.4-8.0)			
Douglas	14	7.0	(3.3-10.7)	6.2	(3.3-11.3)			
Elko	9							
Esmeralda	1							
Eureka	0							
Humboldt	1							
Lander	5							
Lincoln	3							
Lyon	12	7.4	(3.2-11.6)	7.3	(3.7-13.5)			
Mineral	3							
Nye	15	10.1	(5.0-15.2)	9.3	(4.8-17.3)			
Pershing	0							
Storey	1							
Washoe	100	6.1	(4.9-7.3)	7.1	(5.8-8.7)			
White Pine	5							
Unknown	0							
Total	568	6.1	(5.6-6.6)	7.2	(6.6-7.8)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 208. Leukemia Mortality by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

			Gender						
Rac	e/Ethnicity	Male	Female	Total					
White	Mortality Rate* 95% C.I.	293 9.4 (8.3-10.7)	209 6.0 (5.2-6.9)	502 7.6 (6.9-8.3)					
Black	Mortality Rate* 95% C.I.	10 6.6 (2.5-16.1)	9	19 5.4 (3.1-9.2)					
Native American	Mortality Rate* 95% C.I.		4 	6 					
Asian	Mortality Rate* 95% C.I.	7 		9 					
Hispanic	Mortality Rate* 95% C.I.	16 5.2 (2.6-12.0)	14 4.0 (2.0-8.0)	30 4.5 (2.8-7.5)					
Other/Unkr	nown	2	0	2					
Total	Mortality Rate* 95% C.I.	330 8.9 (7.9-10.0)	238 5.7 (5.0-6.5)	568 7.2 (6.6-7.8)					

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 209. Leukemia Mortality by Age Group and Gender, Nevada Residents, 1996-2000

Age	Gender						
Group	Male	Female	Total				
<1	1	0					
Rate*	' 						
95% C.I.							
1-4	1	2	3				
Rate*							
95% C.I.							
5-14	4	3	7				
Rate*							
95% C.I.							
15-24	10	5	15				
Rate*	1.5		1.2				
95% C.I.	(0.6-2.4)		(0.6-1.8)				
25-34	1	5	6				
Rate*							
95% C.I.							
35-44	12	9	21				
Rate*	1.6		1.4				
95% C.I.	(0.7-2.4)		(0.8-2.0)				
45-54	31	17	48				
Rate*	5.1	2.8	4.0				
95% C.I.	(3.3-6.8)	(1.5-4.2)	(2.8-5.1)				
55-64	58	28	86				
Rate*	13.5	6.5	10.0				
95% C.I.	(10.0-17.0)	(4.1-8.9)	(7.9-12.1)				
65-74	88	67	155				
Rate* 95% C.I.	28.8 (22.8-34.8)	21.3 (16.2-26.4)	25.0 (21.1-28.9)				
75-84	104	66	170				
Rate*	70.5	36.6	51.9				
95% C.I.	(57.0-84.1)	(27.8-45.4)	(44.1-59.7)				
85+	20	36	56				
Rate*	88.2	75.4	79.5				
95% C.I.	(49.5-126.9)	(50.7-100.0)	(58.7-100.3)				
Unknown	(40.0 120.0)	0	0				
Total	330	238	568				
Rate*	7.0	5.2	6.1				
95% C.I.	(6.2-7.7)	(4.5-5.9)	(5.6-6.6)				

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.


Table 210. Median Age at Death from Leukemia by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

	Gender									
Race/Ethnicity	Ma	Male		nale	Total					
	Deaths	Median Age	Deaths	Median Age	Deaths	Median Age				
White	293	71.0	209	73.0	502	72.0				
Black	10	72.5	9	73.0	19	73.0				
Native American	2		4		6	46.5				
Asian	7	63.0	2		9	63.0				
Hispanic	16	62.0	14	60.5	30	61.0				
Other/Unknown	2		0		2					
Total	330	71.0	238	73.0	568	71.0				

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE

Figure 138. Survival Rates for Leukemia by Race/Ethnicity, Nevada Residents, 1996-2000



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 139. Survival Rates for Leukemia by Stage of Cancer at Diagnosis, Nevada Residents, 1996-2000




Table 211. Cause-Specific Survival Rates for Leukemia by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

Race/			Cause Specific Survival Rate						
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)		
Total	560	55.9%	46.1%	41.1%	36.3%	30.5%	1.60		
Male	338	55.2%	46.2%	41.0%	38.8%	33.3%	1.58		
Female	222	57.1%	46.1%	41.4%	33.4%	27.3%	1.65		
Race/Ethnicity									
White	461	53.5%	43.3%	37.9%	33.0%	28.3%	1.34		
Male	282	52.9%	44.9%	38.7%	35.7%	35.7%	1.36		
Female	179	54.4%	41.3%	37.1%	29.7%	21.2%	1.34		
Black	15								
Male	9								
Female	6								
Native American	5								
Male	1								
Female	4								
Asian	18								
Male	9								
Female	9								
Hispanic	58	67.3%	63.8%	58.0%	50.8%	38.1%	4.06		
Male	36								
Female	22								

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 212. Cause-Specific Survival Rates for Leukemia by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1996-2000


Surviv	/al Rate of Stage		Gender					
a	nt Diagnosis	Total	Male	Female				
Total	Cases	560	338	222				
	One Year	55.9%	55.2%	57.1%				
	5 Years	30.5%	33.3%	27.3%				
	Median Survival	1.60	1.58	1.65				
Stage at D	iagnosis							
In situ	Cases	0	0	0				
	One Year							
	5 Years							
	Median Survival							
Localized	Cases	0	0	0				
	One Year							
	5 Years							
	Median Survival							
Regional	Cases	0	0	0				
	One Year							
	5 Years							
	Median Survival							
Distant	Cases	560	338	222				
	One Year	55.9%	55.2%	57.1%				
	5 Years	30.5%	33.3%	27.3%				
	Median Survival	1.60	1.58	1.65				
Unstaged	Cases	0	0	0				
	One Year							
	5 Years							
	Median Survival							

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

LIP, ORAL CAVITY AND PHARYNYX CANCER

LIP, ORAL CAVITY AND PHARYNX CANCER GENERAL PROFILE⁴

Figure 140. Anatomy of the Oral Cavity⁵



General Anatomy: The oral cavity includes many parts: the lips; the lining inside the lips and cheeks, called the buccal mucosa; the teeth; the bottom (floor) of the mouth under the tongue; the front two-thirds of the tongue; the bony top of the mouth (hard palate); the gums; and the small area behind the wisdom teeth. The oropharynx includes the back one-third of the tongue, the soft palate, the tonsils, and the part of the throat behind the mouth. Salivary glands throughout the oral cavity make saliva, which keeps the mouth moist and helps digest food.

Risk Factors: Tobacco use (especially smokeless tobacco), chronic and/or heavy alcohol use, sun exposure (Lip), history of leukoplakia (whitish patch inside the mouth associated with tobacco use), and erythroplakia (reddish patches usually in those over 60 years old)

Signs and Symptoms: Oral cancer usually occurs in people over the age of 45 but can develop at any age. These are some symptoms to watch for: A sore on the lip or in the mouth that does not heal, a lump on the lip or in the mouth or throat, a white or red patch on the gums, tongue, or lining of the mouth, unusual bleeding, pain, or numbness in the mouth, a sore throat that does not go away, or a feeling that something is caught in the throat, difficulty or pain with chewing or swallowing, swelling of the jaw that causes dentures to fit poorly or become uncomfortable, a change in the voice, and/or, pain in the ear.

Diagnosing the Cancer: Health exam, dental x-rays, head and chest x-rays, computed tomography (CAT) scan, ultrasonography, magnetic resonance imaging (MRI).

Treatment: Surgery, radiation therapy, chemotherapy, and clinical trials.

HIGHLIGHTS

- ➤ The ratio of the age-adjusted incidence rate, 10.4, to the age-adjusted mortality rate, 2.5 (per 100,000 2000 US Standard population), for Lip, Oral Cavity and Pharynx Cancer was 4.12 during the 1996 to 2000 period, which means that for every 4.12 cases of Lip, Oral Cavity and Pharynx Cancer there was one death for this type of cancer in Nevada during this period.
- Nevadan males had a higher ratio than females when the age-adjusted incidence and age-adjusted mortality rates for Lip, Oral Cavity and Pharynx Cancer were compared. For every male death due to this type of cancer there were 4.49 male cases while there were only 3.68 female cases for every female from 1996 to 2000.
- The median age at diagnosis of Lip, Oral Cavity and Pharynx Cancer for Nevada residents was 62 years of age from 1996 to 2000 while the median age for males and females was 60 and 65.5 years, respectively. The median age at time of death due to Lip, Oral Cavity and Pharynx Cancer was 67 years statewide, 65 years of age for males and 72 years of age for females.

INCIDENCE

- ➤ Nevada's age-adjusted incidence rate for Lip, Oral Cavity and Pharynx Cancer (10.4) was only slightly lower than the National rate of 11.0 (per 100,000 2000 US Standard population) from 1996 to 2000.
- ➤ The statistically significant age-adjusted incidence rate for male Lip, Oral Cavity and Pharynx Cancer, 14.5 (13.3-15.8), was more than double the rate for Females, 6.6 (5.9-7.4), per 100,000 2000 US Standard population, during the 1996 to 2000 period.
- ➤ While regional comparisons showed that Washoe County's age-adjusted incidence rate for Lip, Oral Cavity and Pharynx Cancer, 11.8, was higher than the rate for All Other Counties and Clark County who had rates of 10.3 and 10.1 (per 100,000 2000 US Standard population) from 1996 to 2000, these differences were not statistically significant.
- ➤ Whites, as a racial/ethnic group, had the highest age-adjusted incidence rate, 11.5 and were followed by Blacks, Asians and Hispanics with rates of 7.7, 5.8 and 4.3 (per 100,000 2000 US Standard population), respectively.

INPATIENT HOSPITAL DISCHARGES

➤ There were 505 Lip, Oral Cavity and Pharynx Cancer inpatient discharges in Nevada from 1996 to 2000. The statistically significant age-adjusted inpatient discharge rate for males, 7.6 (6.8-8.6), was twice the inpatient discharge rate for females, 3.8 (3.3-4.4), per 100,000 – 2000 US Standard population, in Nevada during this period.

- Total billed charges for hospital inpatient discharges from Lip, Oral Cavity and Pharynx Cancer in Nevada totaled over 17 million dollars from 1996 to 2000. Washoe County had the highest median total charge (\$22,090), while Clark County had the longest average length of stay (7.7 days) during this time; once regional comparisons were made.
- The overall average billed charge per day for a inpatient hospital discharge for Leukemia in Nevada was nearly \$4,500 from 1996 to 2000.

MORTALITY


- There were 213 deaths due to Lip, Oral Cavity and Pharynx Cancer in Nevada from 1996 to 2000. While All Other Counties and Washoe County had a higher age-adjusted mortality rate, 3.0, than Clark County, 2.2, statistical analysis shows that there is not a statistically significant difference between the three regions.
- Males had a statistically significant higher age-adjusted mortality rate due to Lip, Oral Cavity and Pharynx Cancer, 3.2 (2.7-3.9), than their female counterparts who had an age-adjusted mortality rate of 1.8 (1.4-2.3), per 100,000 2000 US Standard population, during the 1996 to 2000 period.

SURVIVAL RATE

- While females in Nevada had a slightly higher one-year survival rate (77.2%) than males (76.1%) for Lip, Oral Cavity and Pharynx Cancer during the 1996 to 2000 period, their five-year survival rate was lower (28.5%) than the five-year rate for males (33.6%). However, their median survival time was slightly greater than the time for males at 2.89 and 2.64 years, respectively.
- The one-year survival rate for those diagnosed with Lip, Oral Cavity and Pharynx Cancer at the localized stage was 91.2%, while those diagnosed at the regional, distant and unstaged stages had rates of 78.4%, 51.3% and 61.6%, respectively.
- The five-year survival rate for Lip, Oral Cavity and Pharynx Cancer with those at the localized stage was 49.9%, and was followed by those at the regional and distant stages with rates of 25.0% and 16.1%, respectively.
- ➤ The Median Survival time for those diagnosed with Lip, Oral Cavity and Pharynx Cancer at the localized stage was 4.00 years, while those diagnosed at the regional, distant and unstaged levels had median survival times of 2.71, 1.09 and 1.46 years, respectively.

INCIDENCE

Figure 141. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 142. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 143. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1996-2000




Table 213. Lip, Oral Cavity and Pharynx Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

	County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)			
Total									
Cases	921	593	180	147	1	18,648			
Rate*	10.4	10.1	11.8	10.3		11.0			
95% C.I.	(9.7-11.1)	(9.3-11.0)	(10.1-13.8)	(8.6-12.1)		(10.9-11.2)			
Gender									
Male	625	393	125	107	0	12,431			
Rate*	14.5	14.0	16.4	15.0		16.4			
95% C.I.	(13.3-15.8)	(12.5-15.7)	(13.6-19.9)	(12.2-18.5)		(16.1-16.7)			
Female	296	200	55	40	1	6,217			
Rate*	6.6	6.7	7.2	5.6		6.7			
95% C.I.	(5.9-7.4)	(5.8-7.7)	(5.4-9.4)	(4.0-7.7)		(6.5-6.8)			
Other/Unknown	0	0	0	0	0	0			
Race/Ethnicity									
White	829	522	162	144	1	14,911			
Rate*	11.5	11.3	12.3	11.2		10.9			
95% C.I.	(10.7-12.3)	(10.4-12.4)	(10.5-14.4)	(9.4-13.3)		(10.7-11.1)			
Black	33	32	1	0	0	1,942			
Rate*	7.7	8.2				12.8			
95% C.I.	(5.2-11.6)	(5.4-12.5)				(12.3-13.4)			
Native American	3	0	3	0	0	48			
Rate*						4.0			
95% C.I.						(2.9-2.9)			
Asian	18	13	5	0	0	1,537			
Rate*	5.8	6.0				9.2			
95% C.I.	(2.7-12.8)	(2.3-15.2)				(8.7-9.7)			
Hispanic	30	19	8	3	0	1,148			
Rate*	4.3	3.7				6.3			
95% C.I.	(2.7-7.1)	(2.0-7.1)				(5.9-6.7)			
Other/Unknown	8	7	1	0	0	210			

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the National (SEER) rates. See Technical Notes for more information.

Table 214. Lip, Oral Cavity and Pharynx Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

		County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)				
Total										
Cases	921	593	180	147	1	18,648				
Rate*	9.9	9.4	11.0	10.7		10.1				
95% C.I.	(9.3-10.5)	(8.7-10.2)	(9.4-12.6)	(9.0-12.5)		(9.9-10.2)				
Age Group										
<1	0	0	0	0	0					
Rate*										
95% C.I.										
1-4	0	0	0	0	0	8				
Rate*										
95% C.I.										
5-14	3	3	0	0	0	50				
Rate*						0.2				
95% C.I.						(0.1-0.2)				
15-24	5	2	2	1	0	148				
Rate*						0.6				
95% C.I.						(0.5-0.7)				
25-34	16	7	3	6	0	494				
Rate*	1.1					1.7				
95% C.I.	(0.6-1.7)					(1.5-1.8)				
35-44	63	42	12	9	0	1,503				
Rate*	4.2	4.2	4.3			4.8				
95% C.I.	(3.2-5.3)	(3.0-5.5)	(1.9-6.8)			(4.6-5.1)				
45-54	175	104	39	32	0	3,388				
Rate*	14.5	13.1	17.4	16.6		14.8				
95% C.I.	(12.3-16.6)	(10.6-15.7)	(11.9-22.8)	(10.9-22.4)		(14.3-15.3)				
55-64	271	179	53	39	0	4,100				
Rate*	31.5	30.8	37.5	28.3		29.3				
95% C.I.	(27.7-35.2)	(26.3-35.3)	(27.4-47.6)	(19.4-37.1)		(28.4-30.2)				
65-74	252	167	44	40	1	4,785				
Rate*	40.7	40.3	43.6	38.3		41.5				
95% C.I.	(35.6-45.7)	(34.2-46.4)	(30.7-56.5)	(26.4-50.1)		(40.3-42.7)				
75-84	108	72	21	15	0	3,177				
Rate*	33.0	33.3	38.2	26.6		43.7				
95% C.I.	(26.7-39.2)	(25.6-41.0)	(21.8-54.5)	(13.1-40.0)		(42.2-45.2)				
85+	28	17	6	5	0	992				
Rate*	39.7	39.7				40.0				
95% C.I.	(25.0-54.5)	(20.8-58.5)				(37.5-42.5)				
Unknown	0	0	0	0	0	0				

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 215. Lip, Oral Cavity and Pharynx Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1996-2000

County of	1996-2000 Incidence							
Residence	Cases	Rat	e*	Age-Adjusted Rate**				
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	34	13.9	(9.2-18.5)	12.3	(8.5-17.4)			
Churchill	20	17.0	(9.5-24.4)	17.8	(10.8-28.1)			
Clark	593	9.4	(8.7-10.2)	10.1	(9.3-11.0)			
Douglas	21	10.5	(6.0-15.0)	8.2	(5.1-13.5)			
Elko	10	4.4	(1.7-7.1)	6.9	(2.9-14.9)			
Esmeralda	0							
Eureka	1							
Humboldt	5							
Lander	3							
Lincoln	0							
Lyon	23	14.2	(8.4-20.0)	12.1	(7.6-18.9)			
Mineral	4							
Nye	20	13.5	(7.6-19.4)	10.6	(6.2-18.2)			
Pershing	2							
Storey	0							
Washoe	180	11.0	(9.4-12.6)	11.8	(10.1-13.8)			
White Pine	4							
Unknown	1							
Total	921	9.9	(9.3-10.5)	10.4	(9.7-11.1)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 216. Lip, Oral Cavity and Pharynx Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

Race/Ethnicity			Gender					
		Male	Female	Other/ Unknown	Total			
White	Incidence	567	262	0	829			
	Rate*	15.9	7.2		11.5			
	95% C.I.	(14.6-17.4)	(6.3-8.1)		(10.7-12.3)			
Black	Incidence	21	12	0	33			
	Rate*	11.3	5.3		7.7			
	95% C.I.	(6.2-21.2)	(2.7-10.1)		(5.2-11.6)			
Native	Incidence	2	1	0	3			
American	Rate*							
	95% C.I.							
Asian	Incidence	14	4	0	18			
	Rate*	11.3			5.8			
	95% C.I.	(4.7-27.2)			(2.7-12.8)			
Hispanic	Incidence	16	14	0	30			
	Rate*	5.1	3.7		4.3			
	95% C.I.	(2.6-11.7)	(1.8-7.6)		(2.7-7.1)			
Other/Unknown		5	3	0	8			
Total	Incidence	625	296	0	921			
	Rate*	14.5	6.6		10.4			
	95% C.I.	(13.3-15.8)	(5.9-7.4)		(9.7-11.1)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 217. Lip, Oral Cavity and Pharynx Cancer Cases by Age Group and Gender, Nevada Residents, 1996-2000

Age	Gender						
Group	Male	Female	Other/ Unknown	Total			
<1	0	0	0	0			
Rate*							
95% C.I.							
1-4	0	0	0	0			
Rate*							
95% C.I.							
5-14	2	1	0	3			
Rate*							
95% C.I.							
15-24	1	4	0	5			
Rate*							
95% C.I.							
25-34	10	6	0	16			
Rate*	1.3			1.1			
95% C.I.	(0.5-2.2)			(0.6-1.7)			
35-44	41	22	0	63			
Rate*	5.3	3.0		4.2			
95% C.I.	(3.7-6.9)	(1.8-4.3)		(3.2-5.3)			
45-54	132	43	0	175			
Rate*	21.6	7.2		14.5			
95% C.I.	(17.9-25.2)	(5.1-9.4)		(12.3-16.6)			
55-64	209	62	0	271			
Rate*	48.7	14.3		31.5			
95% C.I.	(42.1-55.4)	(10.8-17.9)		(27.7-35.2)			
65-74	155	97	0	252			
Rate*	50.7	30.9		40.7			
95% C.I.	(42.7-58.7)	(24.7-37.0)		(35.6-45.7)			
75-84	59	49	0	108			
Rate*	40.0	27.2		33.0			
95% C.I.	(29.8-50.2)	(19.6-34.8)		(26.7-39.2)			
85+	16	12	0	28			
Rate*	70.6	25.1		39.7			
95% C.I.	(36.0-105.1)	(10.9-39.3)		(25.0-54.5)			
Unknown	0	0	0	0			
Total	625	296	0	921			
Rate*	13.2	6.5		9.9			
95% C.I.	(12.2-14.2)	(5.7-7.2)		(9.3-10.5)			

* Rates are per 100,000 age-specific population. Note: The "---" is used for rates calculated on numbers less than ten.

Table 218. Lip, Oral Cavity and Pharynx Cancer Cases by Age Group and Stage, Nevada Residents, 1996-2000

Age Group		Stage						
		In situ	Localized	Regional	Distant	Unstaged	Total	
<1	Number	0	0	0	0	0	0	
	Percent							
1-4	Number	0	0	0	0	0	0	
	Percent							
5-14	Number	0	1	1	0	1	3	
	Percent		33.3%	33.3%		33.3%	100.0%	
15-24	Number	0	2	2	1	0	5	
-	Percent		40.0%	40.0%	20.0%		100.0%	
25-34	Number	0	7	4	3	2	16	
	Percent		43.8%	25.0%	18.8%	12.5%	100.0%	
35-44	Number	0	26	25	4	8	63	
	Percent		41.3%	39.7%	6.3%	12.7%	100.0%	
45-54	Number	0	46	78	16	35	175	
	Percent		26.3%	44.6%	9.1%	20.0%	100.0%	
55-64	Number	0	74	107	35	55	271	
	Percent		27.3%	39.5%	12.9%	20.3%	100.0%	
65-74	Number	0	97	90	15	50	252	
	Percent		38.5%	35.7%	6.0%	19.8%	100.0%	
75-84	Number	0	36	30	12	30	108	
	Percent		33.3%	27.8%	11.1%	27.8%	100.0%	
85+	Number	0	7	9	2	10	28	
	Percent		25.0%	32.1%	7.1%	35.7%	100.0%	
Unknown	Number	0	0	0	0	0	0	
	Percent							
Total	Number	0	296	346	88	191	921	
	Percent		32.1%	37.6%	9.6%	20.7%	100.0%	

Table 219. Lip, Oral Cavity and Pharynx Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1996-2000

			Race/Ethnicity							
•	Stage	White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total		
In situ	Number	0	0	0	0	0	0	0		
	Percent									
Localized	Number	270	5	1	3	13	4	296		
	Percent	32.6%	15.2%	33.3%	16.7%	43.3%	50.0%	32.1%		
Regional	Number	311	15	1	8	10	1	346		
	Percent	37.5%	45.5%	33.3%	44.4%	33.3%	12.5%	37.6%		
Distant	Number	76	4	1	4	3	0	88		
	Percent	9.2%	12.1%	33.3%	22.2%	10.0%		9.6%		
Unstaged	Number	172	9	0	3	4	3	191		
	Percent	20.7%	27.3%		16.7%	13.3%	37.5%	20.7%		
Total	Number	829	33	3	18	30	8	921		
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%		


Table 220. Median Age at Diagnosis of Lip, Oral Cavity and Pharynx Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

	Gender								
Race/Ethnicity	Male		Fem	nale	Total				
	Incidence	Median Age	Incidence	Median Age	Incidence	Median Age			
White	567	61.0	262	66.0	829	62.0			
Black	21	57.0	12	63.5	33	58.0			
Native American	2		1		3				
Asian	14	59.0	4		18	54.5			
Hispanic	16	60.5	14	49.5	30	59.0			
Other/Unknown	5	62.0	3		8	61.5			
Total	625	60.0	296	65.5	921	62.0			

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

Figure 144. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical notes for more information.

Figure 145. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 146. Median Charges for Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000




Figure 147. Average Length of Stay for Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000




Table 221. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Discharges	505	370	84	50	1			
Rate*	5.6	6.2	5.5	3.4				
95% C.I.	(5.2-6.2)	(5.6-6.9)	(4.4-6.9)	(2.5-4.6)				
Gender								
Male	332	241	55	35	1			
Rate*	7.6	8.4	7.1	5.0				
95% C.I.	(6.8-8.6)	(7.3-9.7)	(5.3-9.6)	(3.4-7.3)				
Female	173	129	29	15	0			
Rate*	3.8	4.3	3.8	2.0				
95% C.I.	(3.3-4.4)	(3.6-5.1)	(2.5-5.5)	(1.1-3.4)				
Other/Unknown	0	0	0	0	0			
Inpatient Discharge Ch	narges (\$)							
Total Charges	\$17,063,904	\$12,358,596	\$2,692,616	\$1,446,305	\$566,387			
Average Charges	\$33,790	\$33,402	\$32,055	\$28,926	\$566,387			
Median Charges	\$19,429	\$19,917	\$22,090	\$15,451	\$566,387			
Discharge Length of S	tay (LOS) (Days)							
Total LOS	3,826	2,835	633	292	66			
Average LOS	7.6	7.7	7.5	5.8	66.0			
Median LOS	4.0	4.0	5.0	3.5	66.0			

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 222. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown		
Total							
Discharges	505	370	84	50	1		
Rate*	5.4	5.9	5.1	3.6			
95% C.I.	(5.0-5.9)	(5.3-6.5)	(4.0-6.2)	(2.6-4.7)			
Age Group							
<1	0	0	0	0	0		
Rate*							
95% C.I.							
1-4	0	0	0	0	0		
Rate*							
95% C.I.							
5-14	1	1	0	0	0		
Rate*							
95% C.I.							
15-24	0	0	0	0	0		
Rate*							
95% C.I.							
25-34	3	3	0	0	0		
Rate*							
95% C.I.							
35-44	29	23	4	2	0		
Rate*	1.9	2.3					
95% C.I.	(1.2-2.6)	(1.4-3.3)					
45-54	98	71	19	8	0		
Rate*	8.1	9.0	8.5				
95% C.I.	(6.5-9.7)	(6.9-11.0)	(4.7-12.3)				
55-64	154	113	22	18	1		
Rate*	17.9	19.4	15.6	12.7			
95% C.I.	(15.1-20.7)	(15.9-23.0)	(9.1-22.1)	(6.8-18.6)			
65-74	156	112	27	17	0		
Rate*	25.2	27.0	26.8	16.9			
95% C.I.	(21.2-29.1)	(22.0-32.0)	(16.7-36.9)	(8.8-24.9)			
75-84	52	38	11	3	0		
Rate*	15.9	17.6	20.0				
95% C.I.	(11.6-20.2)	(12.0-23.2)	(8.2-31.8)				
85+	12	9	1	2	0		
Rate*	17.0						
95% C.I.	(7.4-26.7)						
Unknown	0	0	0	0	0		

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 223. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1996-2000

Age	Gender					
Group	Male	Female	Total			
<1	0	0	0			
Rate*						
95% C.I.						
1-4	0	0	0			
Rate*						
95% C.I.						
5-14	1	0	1			
Rate*						
95% C.I.						
15-24 Data*	0	0	0			
Rate* 95% C.I.						
25-34						
25-34 Rate*	0	3	3			
95% C.I.						
35-44	21	8	29			
Rate*	2.7		1.9			
95% C.I.	(1.6-3.9)		(1.2-2.6)			
45-54	77	21	98			
Rate*	12.6	3.5	8.1			
95% C.I.	(9.8-15.4)	(2.0-5.0)	(6.5-9.7)			
55-64	117	37	154			
Rate*	27.3	8.6	17.9			
95% C.I.	(22.3-32.2)	(5.8-11.3)	(15.1-20.7)			
65-74	86	70	156			
Rate*	28.1	22.3	25.2			
95% C.I.	(22.2-34.1)	(17.1-27.5)	(21.2-29.1)			
75-84 D-4-*	22	30	52			
Rate*	14.9	16.6	15.9			
95% C.I.	(8.7-21.2)	(10.7-22.6)	(11.6-20.2)			
85+ Rate*	8	4	12 17.0			
95% C.I.			(7.4-26.7)			
Unknown		0	(1.4-20.1)			
Total	332	173	505			
Rate*	7.0	3.8	5.4			
95% C.I.	(6.3-7.8)	(3.2-4.3)	(5.0-5.9)			

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 224. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000

	1996-2000 Inpatient Hospital Discharges						
County of Residence	Number Rate*			Age-Adjus	ted Rate**		
	Number	Rate	95% C.I.	Rate	95% C.I.		
Carson City	8						
Churchill	4						
Clark	370	5.9	(5.3-6.5)	6.2	(5.6-6.9)		
Douglas	5						
Elko	3						
Esmeralda	0						
Eureka	0						
Humboldt	1						
Lander	0						
Lincoln	0						
Lyon	13	8.0	(3.7-12.4)	6.5	(3.4-11.9)		
Mineral	2						
Nye	13	8.8	(4.0-13.5)	7.1	(3.5-14.0)		
Pershing	1						
Storey	0						
Washoe	84	5.1	(4.0-6.2)	5.5	(4.4-6.9)		
White Pine	0						
Unknown	1						
Total	505	5.4	(5.0-5.9)	5.6	(5.2-6.2)		


Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 225. Lip, Oral Cavity and Pharynx Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1996-2000

Age	Discharges		Charges (\$)			Length of Stay (Days)		
Group	Discharges	Total	Average	Median	Total	Average	Median	
<1	0							
1-4	0							
5-14	1							
15-24	0							
25-34	3							
35-44	29	712,962	24,585	16,824	132	4.6	3.0	
45-54	98	3,147,401	32,116	21,083	710	7.2	4.5	
55-64	154	6,393,399	41,516	21,721	1,570	10.2	5.0	
65-74	156	4,865,737	31,191	19,028	993	6.4	4.0	
75-84	52	1,399,378	26,911	16,386	304	5.8	3.0	
85+	12	322,482	26,874	21,204	69	5.8	4.5	
Unknown	0							
Total	505	17,063,904	33,790	19,429	3,826	7.6	4.0	

MORTALITY

Figure 148. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 149. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 150. Lip, Oral Cavity and Pharynx Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1996-2000




Table 226. Lip, Oral Cavity and Pharynx Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1996-2000

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Mortality	213	128	42	43			
Rate*	2.5	2.2	3.0	3.0			
95% C.I.	(2.2-2.9)	(1.9-2.7)	(2.1-4.1)	(2.2-4.2)			
Gender							
Male	137	80	23	34			
Rate*	3.2	2.9	3.0	4.8			
95% C.I.	(2.7-3.9)	(2.2-3.7)	(1.9-5.0)	(3.3-7.0)			
Female	76	48	19	9			
Rate*	1.8	1.7	2.6				
95% C.I.	(1.4-2.3)	(1.2-2.2)	(1.6-4.1)				
Other/Unknown	0	0	0	0			
Race/Ethnicity							
White	191	110	39	42			
Rate*	2.7	2.4	3.1	3.2			
95% C.I.	(2.3-3.1)	(2.0-2.9)	(2.2-4.4)	(2.3-4.5)			
Black	12	11	1	0			
Rate*	3.1	3.1					
95% C.I.	(1.6-6.2)	(1.5-6.5)					
Native American	1	0	1	0			
Rate*							
95% C.I.							
Asian	3	2	1	0			
Rate*							
95% C.I.							
Hispanic	6	5	0	1			
Rate*							
95% C.I.							
Other/Unknown	0	0	0	0			

^{*}Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten.

Table 227. Lip, Oral Cavity and Pharynx Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Regio	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	213	128	42	43
Rate*	2.3	2.0	2.6	3.1
95% C.I.	(2.0-2.6)	(1.7-2.4)	(1.8-3.3)	(2.2-4.1)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	0	0	0
Rate*				
95% C.I.				
15-24	1	1	0	0
Rate*				
95% C.I.				
25-34	1	1	0	0
Rate*				
95% C.I.				
35-44	6	4	1	1
Rate*				
95% C.I.				
45-54	28	13	9	6
Rate*	2.3	1.6		
95% C.I.	(1.5-3.2)	(0.7-2.5)		
55-64	51	32	9	10
Rate*	5.9	5.5		7.2
95% C.I.	(4.3-7.6)	(3.6-7.4)		(2.8-11.7)
65-74	68	40	12	16
Rate*	11.0	9.6	11.9	15.3
95% C.I.	(8.4-13.6)	(6.7-12.6)	(5.2-18.6)	(7.8-22.8)
75-84	47	34	6	7
Rate*	14.3	15.7		
95% C.I.	(10.2-18.4)	(10.4-21.0)		
85+	11	3	5	3
Rate*	15.6			
95% C.I.	(6.4-24.8)			
Unknown	0	0	0	0

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.

Table 228. Lip, Oral Cavity and Pharynx Cancer Mortality by County of Residence, Nevada Residents, 1996-2000

Country of	1996-2000 Mortality						
County of Residence	Casas	Rat	te*	Age-Adjusted Rate**			
	Cases	Rate	95% C.I.	Rate	95% C.I.		
Carson City	12	4.9	(2.1-7.7)	4.4	(2.2-7.9)		
Churchill	1		·		·		
Clark	128	2.0	(1.7-2.4)	2.2	(1.9-2.7)		
Douglas	6						
Elko	4						
Esmeralda	0						
Eureka	0						
Humboldt	0						
Lander	0						
Lincoln	1						
Lyon	4						
Mineral	1						
Nye	10	6.7	(2.6-10.9)	5.6	(2.4-12.2)		
Pershing	1						
Storey	2						
Washoe	42	2.6	(1.8-3.3)	3.0	(2.1-4.1)		
White Pine	1						
Unknown	0						
Total	213	2.3	(2.0-2.6)	2.5	(2.2-2.9)		

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 229. Lip, Oral Cavity and Pharynx Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

		Gender					
Rad	ce/Ethnicity	Male	Female	Total			
White	Mortality	126	65	191			
	Rate*	3.5	1.9	2.7			
	95% C.I.	(2.9-4.3)	(1.4-2.4)	(2.3-3.1)			
Black	Mortality	6	6	12			
	Rate*			3.1			
	95% C.I.			(1.6-6.2)			
Native	Mortality	0	1	1			
American	Rate*						
	95% C.I.						
Asian	Mortality	2	1	3			
	Rate*						
	95% C.I.						
Hispanic	Mortality	3	3	6			
	Rate*						
	95% C.I.						
Other/Unki	nown	0	0	0			
Total	Mortality	137	76	213			
	Rate*	3.2	1.8	2.5			
	95% C.I.	(2.7-3.9)	(1.4-2.3)	(2.2-2.9)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 230. Lip, Oral Cavity and Pharynx Cancer Mortality by Age Group and Gender, Nevada Residents, 1996-2000

Age		Gender	
Group	Male	Female	Total
<1	0	0	0
Rate*			
95% C.I.	<u></u>		
1-4	0	0	0
Rate*			
95% C.I.			
5-14	0	0	0
Rate*			
95% C.I.			
15-24	0	1	1
Rate*			
95% C.I.			
25-34	0	1	1
Rate*			
95% C.I.			
35-44	2	4	6
Rate*			
95% C.I.			
45-54	20	8	28
Rate*	3.3		2.3
95% C.I.	(1.8-4.7)		(1.5-3.2)
55-64 Rate*	40	11 2.5	51
95% C.I.	9.3 (6.4-12.2)	2.5 (1.0-4.1)	5.9 (4.3-7.6)
65-74	48	20	68
Rate*	15.7	6.4	11.0
95% C.I.	(11.3-20.1)	(3.6-9.2)	(8.4-13.6)
75-84	25	22	47
Rate*	17.0	12.2	14.3
95% C.I.	(10.3-23.6)	(7.1-17.3)	(10.2-18.4)
85+	2	9	11
Rate*			15.6
95% C.I.			(6.4-24.8)
Unknown	0	0	0
Total	137	76	213
Rate*	2.9	1.7	2.3
95% C.I.	(2.4-3.4)	(1.3-2.0)	(2.0-2.6)

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten.


Table 231. Median Age at Death from Lip, Oral Cavity and Pharynx Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

		Gender							
Race/Ethnicity	Ma	ile	Fem	nale	То	tal			
	Deaths	Median Age	Deaths	Median Age	Deaths	Median Age			
White	126	66.0	65	72.0	191	67.0			
Black	6	57.0	6	69.0	12	66.0			
Native American	0		1		1				
Asian	2		1		3				
Hispanic	3		3		6	73.5			
Other/Unknown	0		0		0				
Total	137	65.0	76	72.0	213	67.0			

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE

Figure 151. Survival Rates for Lip, Oral Cavity and Pharynx Cancer by Race/Ethnicity, Nevada Residents, 1996-2000



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 152. Survival Rates for Lip, Oral Cavity and Pharynx Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 1996-2000




Table 232. Cause-Specific Survival Rates for Lip, Oral Cavity and Pharynx Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

Race/	Number		Cause Specific Survival Rate						
Ethnicity and Gender	of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)		
Total	597	76.5%	58.6%	46.6%	35.4%	31.0%	2.72		
Male	413	76.1%	57.8%	45.6%	33.6%	33.6%	2.64		
Female	184	77.2%	60.4%	48.8%	39.9%	28.5%	2.89		
Race/Ethnicity									
White	532	76.4%	57.7%	45.8%	36.1%	31.3%	2.65		
Male	372	75.4%	56.8%	45.4%	34.0%	34.0%	2.60		
Female	160	78.6%	59.7%	46.7%	41.5%	29.6%	2.74		
Black	23								
Male	16								
Female	7								
Native American	1								
Male	0								
Female	1								
Asian	11								
Male	8								
Female	3								
Hispanic	22								
Male	12								
Female	10								

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 233. Cause-Specific Survival Rates for Lip, Oral Cavity and Pharynx Cancer by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1996-2000


Surviv	/al Rate of Stage		Gender					
	nt Diagnosis	Total	Male	Female				
Total	Cases	597	413	184				
	One Year	76.5%	76.1%	77.2%				
	5 Years	31.0%	33.6%	28.5%				
	Median Survival	2.72	2.64	2.89				
Stage at D	iagnosis							
In situ	Cases	0	0	0				
	One Year							
	5 Years							
	Median Survival							
Localized	Cases	200	120	80				
	One Year	91.2%	89.8%	93.3%				
	5 Years	49.9%	39.4%	67.5%				
	Median Survival	4.00	3.51	>5 years				
Regional	Cases	236	173	63				
	One Year	78.4%	78.4%	78.2%				
	5 Years	25.0%	36.1%	0.0%				
	Median Survival	2.71	3.04	2.35				
Distant	Cases	66	56	10				
	One Year	51.3%	52.6%	44.4%				
	5 Years	16.1%	23.7%	0.0%				
	Median Survival	1.09	1.20	0.90				
Unstaged	Cases	95	64	31				
	One Year	61.6%	68.1%	50.0%				
	5 Years	24.9%	28.4%	21.4%				
	Median Survival	1.46	1.80	1.00				

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

PANCREATIC CANCER

PANCREATIC CANCER GENERAL PROFILE⁴

Figure 153. Anatomy of the Endocrine System⁵



General Anatomy: The pancreas is a gland located deep in the abdomen between the stomach and the spine (backbone). The pancreas is about 6 inches long and is shaped like a flat pear. The pancreas makes insulin and other hormones that travel throughout the body to help the body use or store the energy that comes from food.

Risk Factors: Age, smoking, diabetes, being male, being African American, family history of pancreatic cancer, and Chronic pancreatitis.

Signs and Symptoms: Pancreatic cancer is sometimes called a "silent disease" because early pancreatic cancer often does not cause symptoms. But, as the cancer grows, symptoms may include: Pain in the upper abdomen or upper back, yellow skin and eyes, and dark urine from jaundice, weakness, loss of appetite, nausea and vomiting, and weight loss.

Diagnosing the Cancer: Physical exam, blood, stool and urine tests (Bilirubin levels), computed tomography (CAT) scan, ultrasonography (Transabdominal, Endoscopic), endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography (PTC), and fineneedle aspiration.

Treatment: Surgery (Whipple procedure, Distal pancreatectomy, Total pancreatectomy, bypass), radiation therapy, and chemotherapy.

HIGHLIGHTS

- ➤ The ratio of the age-adjusted incidence rate, 11.1, to the age-adjusted mortality rate, 10.0 (per 100,000 2000 US Standard population), for Pancreatic Cancer was 1.12 during the 1996 to 2000 period, which means that for every 1.12 Pancreatic Cancer cases there was one death due to this type of cancer in Nevada. Both females and males were similar with ratios of 1.13 and 1.12 during this period.
- The median age at diagnosis of Pancreatic Cancer for Nevada residents was 69.0 years of age, while the median age for males and females was 68 and 71 years during the 1996 to 2000 period. The median age at time of death due to Cancer of the Pancreas was 70 years for Nevada overall, 69 years for males and 71 years of age for females.

INCIDENCE

- ➤ There were 917 cases of Pancreatic Cancer reported in Nevada from 1996 to 2000. Nevada's age-adjusted incidence rate for Pancreatic Cancer (11.1) was only slightly higher than the National rate of 10.9 (per 100,000 2000 US Standard population) from 1996 to 2000.
- ➤ While regional comparisons showed only slight variations between the age-adjusted incidence rates of Pancreatic Cancer for Clark County (11.3), All Other Counties (11.2) and Washoe County (10.2) from 1996 to 2000, statistical analysis shows no statistically significant difference between the three regions. This was the same for Males and Females in Nevada who had rates of 12.3 and 10.3 (per 100,000 2000 US Standard population), respectively.
- ➤ Blacks, as a racial/ethnic group, had the highest statistically significant age-adjusted incidence rate for Pancreatic Cancer, 17.7 (13.5-23.2), of any racial/ethnic group from 1996 to 2000. Whites, Hispanics and Asians followed with rates of 11.4 (10.6-12.2), 8.0 (5.1-12.2) and 5.9 (3.4-12.1), per 100,000 2000 US Standard population, respectively, during this time.

INPATIENT HOSPITAL DISCHARGES

- ➤ Billed charges from Pancreatic Cancer inpatient hospital discharges accounted for greater than 26.7 million dollars from 1996 to 2000. Nevadans in the 55-64 and 65-74 age groups accounted for 56.9% of the total inpatient discharges and 56.6% of the total billed charges during this period. The overall daily billed amount for Pancreatic Cancer inpatient hospital discharges was approximately \$4,000 in Nevada during this period.
- ➤ There were 708 inpatient hospital discharges for Pancreatic Cancer to residents in Nevada from 1996 to 2000. Clark County had the highest age-adjusted inpatient discharge rate, 9.3 (8.5-10.2), for Pancreatic Cancer and showed statistical significance over the All Other Counties region's rate of 6.2 (4.9-7.7), which was the lowest age-adjusted inpatient discharge rate of any region in Nevada during the 1996 to 2000 period.

The median total billed charges in Nevada for inpatient discharges due to Cancer of the Pancreas were \$23,371 from 1996 to 2000. Clark and Washoe County had the highest median total billed charges, \$26,167 and \$23,196, which were more than double the All Other Counties' median billed amount of \$10,024.

MORTALITY


- ➤ There were 810 resident Pancreatic Cancer deaths from 1996 to 2000. Regional comparisons were fairly similar between Clark County, All Other Counties and Washoe County with rates of 10.3, 9.3 and 9.1 (per 100,000 2000 US Standard population), respectively.
- ➤ Blacks, as a racial/ethnic group, had the highest age-adjusted Pancreatic Cancer mortality rate, (13.3); followed by Whites, Hispanics and Asians with rates of 10.1, 8.4 and 5.2 (per 100,000 2000 US Standard population), respectively. However, statistical analysis does not show any statistical significance between any of the racial/ethnic groups.

SURVIVAL RATE

- ➤ While the one-year survival rate for Nevada females with Pancreatic Cancer (22.1%) was slightly higher than the rate for males (21.7%) during the 1996 to 2000 period, the five-year survival rate decreased to 0.0% for females and 5.7% for males from 1996 to 2000.
- The one-year survival rate for those diagnosed with Pancreatic Cancer at the localized stage was 36.1%, while those diagnosed at the regional, distant and unstaged stages had rates of 27.1%, 12.5% and 21.5%, respectively, during the 1996 to 2000 period.
- From 1996 to 2000, the median survival time for Pancreatic Cancer diagnosed at the localized stage was 0.78 years, while those diagnosed at the regional, distant and unstaged levels had median survival times of 0.69, 0.57 and 0.64 years, respectively.

INCIDENCE

Figure 154. Pancreatic Cancer Age-Adjusted (2000) Incidence Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 155. Pancreatic Cancer Age-Adjusted Incidence Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 156. Pancreatic Cancer Age-Adjusted Incidence Rates by Race/Ethnicity, Nevada Residents, 1996-2000




Table 234. Pancreatic Cancer Cases by Gender, Race/Ethnicity and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

			County/Region	n of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)
Total						
Cases	917	614	144	154	5	18,152
Rate*	11.1	11.3	10.2	11.2		10.9
95% C.I.	(10.4-11.9)	(10.4-12.3)	(8.6-12.1)	(9.5-13.2)		(10.8-11.1)
Gender						
Male	471	311	75	82	3	8,778
Rate*	12.3	12.4	11.5	12.5		12.4
95% C.I.	(11.1-13.6)	(10.9-14.2)	(8.9-14.8)	(9.8-15.9)		(12.1-12.7)
Female	446	303	69	72	2	9,374
Rate*	10.3	10.5	9.2	10.1		9.7
95% C.I.	(9.3-11.3)	(9.4-11.8)	(7.1-11.7)	(7.9-12.7)		(9.6-9.9)
Other/Unknown	0	0	0	0	0	0
Race/Ethnicity						
White	791	508	132	147	4	14,562
Rate*	11.4	11.5	10.6	11.6		10.6
95% C.I.	(10.6-12.2)	(10.5-12.6)	(8.8-12.6)	(9.7-13.7)		(10.4-10.8)
Black	68	62	5	1	0	2,091
Rate*	17.7	17.7				15.9
95% C.I.	(13.5-23.2)	(13.3-23.5)				(15.2-16.6)
Native American	5	2	2	1	0	59
Rate*						5.9
95% C.I.						(4.5-4.5)
Asian	19	17	0	1	1	1,365
Rate*	5.9	6.3				9.4
95% C.I.	(3.4-12.1)	(3.5-14.2)				(8.9-9.9)
Hispanic	33	24	5	4	0	1,324
Rate*	8.0	7.7				8.5
95% C.I.	(5.1-12.2)	(4.4-12.8)				(8.1-9.0)
Other/Unknown	1	1	0	0	0	75

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. Caution should be used when comparing rates for racial/ethnic groups to the National (SEER) rates. See Technical Notes for more information.

Table 235. Pancreatic Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

			County/Region	on of Residence		
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)
Total						
Cases	917	614	144	154	5	18,152
Rate*	9.9	9.8	8.8	11.2		9.8
95% C.I.	(9.2-10.5)	(9.0-10.5)	(7.4-10.2)	(9.5-13.0)		(9.7-9.9)
Age Group						
<1	0	0	0	0	0	
Rate*						
95% C.I.						
1-4	0	0	0	0	0	
Rate*						
95% C.I.						
5-14	1	0	1	0	0	5
Rate*						
95% C.I.						
15-24	2	2	0	0	0	14
Rate*						0.1
95% C.I.						(0.0-0.1)
25-34	1	1	0	0	0	80
Rate*						0.3
95% C.I.						(0.2-0.3)
35-44	14	9	3	2	0	470
Rate*	0.9					1.5
95% C.I.	(0.4-1.4)					(1.4-1.6)
45-54	91	63	13	15	0	1,625
Rate*	7.5	8.0	5.8	7.8		7.1
95% C.I.	(6.0-9.1)	(6.0-9.9)	(2.6-8.9)	(3.9-11.7)		(6.8-7.4)
55-64	208	144	31	32	1	3,029
Rate*	24.2	24.8	21.9	23.2		21.6
95% C.I.	(20.9-27.4)	(20.7-28.8)	(14.2-29.6)	(15.2-31.2)		(20.9-22.4)
65-74	304	200	48	55	1	5,327
Rate*	49.0	48.2	47.6	52.6		46.2
95% C.I.	(43.5-54.6)	(41.6-54.9)	(34.1-61.1)	(38.7-66.5)		(44.9-47.4)
75-84	232	155	38	36	3	5,342
Rate*	70.8	71.7	69.1	63.7		73.5
95% C.I.	(61.7-79.9)	(60.4-83.0)	(47.1-91.0)	(42.9-84.6)		(71.5-75.5)
85+	64	40	10	14	0	2,260
Rate*	90.8	93.4	69.4	106.1		91.1
95% C.I.	(68.6-113.1)	(64.4-122.3)	(26.4-112.4)	(50.5-161.7)		(87.4-94.9)
Unknown	0	0	0	0	0	0

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten and SEER numbers less than five. See Technical Notes for more information.

Table 236. Pancreatic Cancer Cases by County of Residence at Diagnosis, Nevada Residents, 1996-2000

County of			1996-2000 Incidence					
Residence	Cases	Rat	te*	Age-Adjusted Rate**				
at Diagnosis	Cases	Rate	95% C.I.	Rate	95% C.I. 0 (9.1-18.0) 5 (8.7-25.7) 3 (10.4-12.3) 2 (5.6-15.1) 3 (4.1-18.7) 2 (7.4-19.4) 2 (6.4-17.0)			
Carson City	38	15.5	(10.6-20.4)	13.0	(9.1-18.0)			
Churchill	16	13.6	(6.9-20.2)	15.5	(8.7-25.7)			
Clark	614	9.8	(9.0-10.5)	11.3	(10.4-12.3)			
Douglas	21	10.5	(6.0-15.0)	9.2	(5.6-15.1)			
Elko	10	4.4	(1.7-7.1)	9.3	(4.1-18.7)			
Esmeralda	1							
Eureka	1							
Humboldt	7							
Lander	2							
Lincoln	2							
Lyon	21	13.0	(7.4-18.5)	12.2	(7.4-19.4)			
Mineral	4							
Nye	23	15.5	(9.2-21.8)	10.2	(6.4-17.0)			
Pershing	0							
Storey	3							
Washoe	144	8.8	(7.4-10.2)	10.2	(8.6-12.1)			
White Pine	5							
Unknown	5							
Total	917	9.9	(9.2-10.5)	11.1	(10.4-11.9)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 237. Pancreatic Cancer Cases by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

			Ger	nder	
Race/Ethnicity		Male	Female	Other/ Unknown	Total
White	Incidence	406	385	0	791
	Rate*	12.4	10.5		11.4
	95% C.I.	(11.1-13.8)	(9.5-11.7)		(10.6-12.2)
Black	Incidence	36	32	0	68
	Rate*	17.9	16.4		17.7
	95% C.I.	(12.4-27.9)	(11.0-23.9)		(13.5-23.2)
Native	Incidence	3	2	0	5
American	Rate*				
	95% C.I.				
Asian	Incidence	6	13	0	19
	Rate*		6.9		5.9
	95% C.I.		(3.3-17.6)		(3.4-12.1)
Hispanic	Incidence	20	13	0	33
	Rate*	13.0	5.3		8.0
	95% C.I.	(6.5-24.0)	(2.7-10.1)		(5.1-12.2)
Other/Unkn	iown	0	1	0	1
Total	Incidence	471	446	0	917
	Rate*	12.3	10.3		11.1
	95% C.I.	(11.1-13.6)	(9.3-11.3)		(10.4-11.9)

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 238. Pancreatic Cancer Cases by Age Group and Gender, Nevada Residents, 1996-2000

Age		Gen	ider	
Group	Male	Female	Other/ Unknown	Total
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	1	0	1
Rate*				
95% C.I.				
15-24	1	1	0	2
Rate*				
95% C.I.				
25-34	0	1	0	1
Rate*				
95% C.I.				
35-44	8	6	0	14
Rate*				0.9
95% C.I.				(0.4-1.4)
45-54	58	33	0	91
Rate*	9.5	5.5		7.5
95% C.I.	(7.0-11.9)	(3.6-7.4)		(6.0-9.1)
55-64	112	96	0	208
Rate*	26.1	22.2		24.2
95% C.I.	(21.3-31.0)	(17.8-26.7)		(20.9-27.4)
65-74	172	132	0	304
Rate*	56.3	42.0		49.0
95% C.I.	(47.8-64.7)	(34.8-49.2)		(43.5-54.6)
75-84	89	143	0	232
Rate*	60.3	79.3		70.8
95% C.I.	(47.8-72.9)	(66.3-92.3)		(61.7-79.9)
85+	31	33	0	64
Rate*	136.7	69.1		90.8
95% C.I.	(88.6-184.9)	(45.5-92.6)		(68.6-113.1)
Unknown	0	0	0	0
Total	471	446	0	917
Rate*	10.0	9.8		9.9
95% C.I.	(9.1-10.9)	(8.8-10.7)		(9.2-10.5)

* Rates are per 100,000 age-specific population. Note: The "---" is used for rates calculated on numbers less than ten.

Table 239. Pancreatic Cancer Cases by Age Group and Stage, Nevada Residents, 1996-2000

A	C			St	tage		
Age	Group	In situ	Localized	Regional	Distant	Unstaged	Total
<1	Number	0	0	0	0	0	0
	Percent						
1-4	Number	0	0	0	0	0	0
	Percent						
5-14	Number	0	0	1	0	0	1
	Percent			100.0%			100.0%
15-24	Number	0	1	0	1	0	2
	Percent		50.0%		50.0%		100.0%
25-34	Number	0	0	1	0	0	1
	Percent			100.0%			100.0%
35-44	Number	0	1	5	7	1	14
	Percent		7.1%	35.7%	50.0%	7.1%	100.0%
45-54	Number	0	5	33	26	27	91
	Percent		5.5%	36.3%	28.6%	29.7%	100.0%
55-64	Number	0	16	64	64	64	208
	Percent		7.7%	30.8%	30.8%	30.8%	100.0%
65-74	Number	0	24	87	78	115	304
	Percent		7.9%	28.6%	25.7%	37.8%	100.0%
75-84	Number	0	18	42	66	106	232
	Percent		7.8%	18.1%	28.4%	45.7%	100.0%
85+	Number	0	10	13	6	35	64
	Percent		15.6%	20.3%	9.4%	54.7%	100.0%
Unknown	Number	0	0	0	0	0	0
	Percent						
Total	Number	0	75	246	248	348	917
	Percent		8.2%	26.8%	27.0%	37.9%	100.0%

Table 240. Pancreatic Cancer Cases by Stage and Race/Ethnicity, Nevada Residents, 1996-2000

			Race/Ethnicity						
Stage		White	Black	Native American	Asian	Hispanic	Other/ Unknown	Total	
In situ	Number	0	0	0	0	0	0	0	
	Percent								
Localized	Number	66	6	0	3	0	0	75	
	Percent	8.3%	8.8%		15.8%			8.2%	
Regional	Number	205	17	3	7	13	1	246	
	Percent	25.9%	25.0%	60.0%	36.8%	39.4%	100.0%	26.8%	
Distant	Number	212	22	0	2	12	0	248	
	Percent	26.8%	32.4%		10.5%	36.4%		27.0%	
Unstaged	Number	308	23	2	7	8	0	348	
	Percent	38.9%	33.8%	40.0%	36.8%	24.2%		37.9%	
Total	Number	791	68	5	19	33	1	917	
	Percent	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	


Table 241. Median Age at Diagnosis of Pancreatic Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

	Gender							
Race/Ethnicity	Ма	le	Fem	ale	То	tal		
	Incidence	Median Age	Incidence	Median Age	Incidence	Median Age		
White	406	68.0	385	71.0	791	70.0		
Black	36	66.0	32	69.0	68	67.0		
Native American	3		2		5	65.0		
Asian	6	64.0	13	68.0	19	66.0		
Hispanic	20	65.0	13	71.0	33	68.0		
Other/Unknown	0		1		1			
Total	471	68.0	446	71.0	917	69.0		

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES

Figure 157. Pancreatic Cancer Age-Adjusted (2000) Inpatient Discharge Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers and comparing inpatient hospital discharge rates to other data sources, because it is occurrence based data. See Technical notes for more information.

Figure 158. Pancreatic Cancer Age-Adjusted Inpatient Discharge Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 159. Median Charges for Pancreatic Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000




Figure 160. Average Length of Stay for Pancreatic Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000




Table 242. Pancreatic Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

		Coun	ty/Region of Resid	ence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	708	509	114	85	0
Rate*	8.6	9.3	8.2	6.2	
95% C.I.	(7.9-9.3)	(8.5-10.2)	(6.7-9.9)	(4.9-7.7)	
Gender					
Male	360	260	46	54	0
Rate*	9.2	10.0	6.9	8.4	
95% C.I.	(8.2-10.4)	(8.7-11.5)	(5.0-9.6)	(6.1-11.4)	
Female	348	249	68	31	0
Rate*	8.0	8.7	9.1	4.3	
95% C.I.	(7.2-8.9)	(7.6-9.9)	(7.0-11.5)	(2.9-6.2)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	narges (\$)				
Total Charges	\$26,724,783	\$21,294,562	\$3,783,187	\$1,647,034	
Average Charges	\$37,747	\$41,836	\$33,186	\$19,377	
Median Charges	\$23,371	\$26,167	\$23,196	\$10,024	
Discharge Length of S	tay (LOS) (Days)				
Total LOS	6,677	4,954	1,206	517	
Average LOS	9.4	9.7	10.6	6.1	
Median LOS	7.0	7.0	9.0	5.0	

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 243. Pancreatic Cancer Inpatient Discharges by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

	County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	
Total						
Discharges	708	509	114	85	0	
Rate*	7.6	8.1	7.0	6.2		
95% C.I.	(7.0-8.2)	(7.4-8.8)	(5.7-8.2)	(4.9-7.5)		
Age Group						
<1	0	0	0	0	0	
Rate*						
95% C.I.						
1-4	0	0	0	0	0	
Rate*						
95% C.I.						
5-14	0	0	0	0	0	
Rate*						
95% C.I.						
15-24	1	1	0	0	0	
Rate*						
95% C.I.						
25-34	2	2	0	0	0	
Rate*						
95% C.I.						
35-44	8	6	2	0	0	
Rate*						
95% C.I.						
45-54	80	63	9	8	0	
Rate*	6.6	8.0				
95% C.I.	(5.2-8.1)	(6.0-9.9)				
55-64	163	116	24	23	0	
Rate*	18.9	20.0	17.0	16.3		
95% C.I.	(16.0-21.8)	(16.3-23.6)	(10.2-23.8)	(9.6-22.9)		
65-74	240	168	41	31	0	
Rate*	38.7	40.5	40.7	30.7		
95% C.I.	(33.8-43.6)	(34.4-46.7)	(28.2-53.1)	(19.9-41.6)		
75-84	162	121	28	13	0	
Rate*	49.4	56.0	50.9	23.6		
95% C.I.	(41.8-57.0)	(46.0-65.9)	(32.0-69.7)	(10.8-36.5)		
85+	52	32	10	10	0	
Rate*	73.8	74.7	69.4	69.4		
95% C.I.	(53.7-93.9)	(48.8-100.6)	(26.4-112.4)	(26.4-112.4)		
Unknown	0	0	0	0	0	

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 244. Pancreatic Cancer Inpatient Discharges by Age Group and Gender, Nevada Residents, 1996-2000

Age	Gender				
Group	Male	Female	Total		
<1	0	0	0		
Rate*					
95% C.I.					
1-4	0	0	0		
Rate*					
95% C.I.					
5-14	0	0	0		
Rate*					
95% C.I.					
15-24	0	1	1		
Rate* 95% C.I.					
25-34	1				
Rate*			2		
95% C.I.					
35-44	5	3	8		
Rate*					
95% C.I.					
45-54	55	25	80		
Rate*	9.0	4.2	6.6		
95% C.I.	(6.6-11.4)	(2.5-5.8)	(5.2-8.1)		
55-64	81	82	163		
Rate*	18.9	19.0	18.9		
95% C.I.	(14.8-23.0)	(14.9-23.1)	(16.0-21.8)		
65-74	136	104	240		
Rate*	44.5	33.1	38.7		
95% C.I.	(37.0-52.0)	(26.7-39.5)	(33.8-43.6)		
75-84 Rate*	61 41.4	101	162 49.4		
95% C.I.	(31.0-51.7)	56.0 (45.1-66.9)	(41.8-57.0)		
85+	21	31	52		
Rate*	92.6	64.9	73.8		
95% C.I.	(53.0-132.2)	(42.0-87.7)	(53.7-93.9)		
Unknown	0	0	0		
Total	360	348	708		
Rate*	7.6	7.6	7.6		
95% C.I.	(6.8-8.4)	(6.8-8.4)	(7.0-8.2)		

^{*} Rates are per 100,000 age-specific population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 245. Pancreatic Cancer Inpatient Discharges by County/Region of Residence, Nevada Residents, 1996-2000

Country of	1996-2000 Inpatient Hospital Discharges							
County of Residence	Number	Rate*			Age-Adjusted Rate**			
	Number	Rate	95% C.I.	Rate	95% C.I.			
Carson City	8							
Churchill	8							
Clark	509	8.1	(7.4-8.8)	9.3	(8.5-10.2)			
Douglas	12	6.0	(2.6-9.4)	6.1	(2.9-11.8)			
Elko	8							
Esmeralda	1							
Eureka	1							
Humboldt	6							
Lander	0							
Lincoln	3							
Lyon	19	11.7	(6.5-17.0)	11.1	(6.5-18.1)			
Mineral	5							
Nye	12	8.1	(3.5-12.7)	5.3	(2.7-11.2)			
Pershing	0							
Storey	1							
Washoe	114	7.0	(5.7-8.2)	8.2	(6.7-9.9)			
White Pine	1							
Unknown	0							
Total	708	7.6	(7.0-8.2)	8.6	(7.9-9.3)			


Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 246. Pancreatic Cancer Inpatient Discharges by Age Group, Charges and Length of Stay, Nevada Residents, 1996-2000

Age	Discharges	Charges (\$)			Length of Stay (Days)		
Group	Discharges	Total	Average	Median	Total	Average	Median
<1	0						
1-4	0						
5-14	0						
15-24	1						
25-34	2						
35-44	8	1,400,083	175,010	66,057	219	27.4	16.0
45-54	80	2,924,157	36,552	25,531	762	9.5	7.5
55-64	163	6,259,195	38,400	24,179	1,587	9.7	7.0
65-74	240	8,865,908	36,941	24,672	2,151	9.0	7.0
75-84	162	5,780,018	35,679	22,578	1,489	9.2	7.0
85+	52	1,399,872	26,921	16,183	430	8.3	6.0
Unknown	0						
Total	708	26,724,783	37,747	23,371	6,677	9.4	7.0

MORTALITY

Figure 161. Pancreatic Cancer Age-Adjusted (2000) Mortality Rates, Nevada Residents, 1996-2000



Note: Rates are per 100,000 population and age-adjusted to 2000 US Standard population. Caution should be used when interpreting rates based upon small numbers. See Technical notes for more information.

Figure 162. Pancreatic Cancer Age-Adjusted Mortality Rates by County/Region of Residence, Nevada Residents, 1996-2000




Figure 163. Pancreatic Cancer Age-Adjusted Mortality Rates by Race/Ethnicity, Nevada Residents, 1996-2000




Table 247. Pancreatic Cancer Mortality by Gender, Race/Ethnicity and County/Region of Residence, Nevada Residents, 1996-2000

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Mortality	810	556	125	129				
Rate*	10.0	10.3	9.1	9.3				
95% C.I.	(9.3-10.7)	(9.5-11.3)	(7.6-10.9)	(7.8-11.2)				
Gender								
Male	420	284	66	70				
Rate*	11.0	11.4	10.1	10.6				
95% C.I.	(9.9-12.3)	(10.0-13.1)	(7.7-13.3)	(8.1-13.8)				
Female	390	272	59	59				
Rate*	9.1	9.6	8.0	8.2				
95% C.I.	(8.2-10.1)	(8.4-10.8)	(6.1-10.3)	(6.2-10.6)				
Other/Unknown	0	0	0	0				
Race/Ethnicity								
White	700	458	118	124				
Rate*	10.1	10.5	9.6	9.7				
95% C.I.	(9.4-11.0)	(9.5-11.5)	(7.9-11.6)	(8.0-11.6)				
Black	51	50	1	0				
Rate*	13.3	14.2						
95% C.I.	(9.7-18.2)	(10.3-19.6)						
Native American	6	2	2	2				
Rate*								
95% C.I.								
Asian	16	15	0	1				
Rate*	5.2	6.1						
95% C.I.	(2.8-11.4)	(3.3-14.0)						
Hispanic	36	30	4	2				
Rate*	8.4	9.0						
95% C.I.	(5.5-12.7)	(5.6-14.4)						
Other/Unknown	1	1	0	0				

^{*}Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten.

Table 248. Pancreatic Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	810	556	125	129
Rate*	8.7	8.8	7.6	9.4
95% C.I.	(8.1-9.3)	(8.1-9.6)	(6.3-9.0)	(7.8-11.0)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	0	0	0
Rate*				
95% C.I.				
15-24	1	1	0	0
Rate*				
95% C.I.				
25-34	2	1	1	0
Rate*				
95% C.I.				
35-44	7	6	1	0
Rate*				
95% C.I.				
45-54	76	59	10	7
Rate*	6.3	7.4	4.5	
95% C.I.	(4.9-7.7)	(5.5-9.3)	(1.7-7.2)	
55-64	169	122	23	24
Rate*	19.6	21.0	16.3	17.4
95% C.I.	(16.7-22.6)	(17.3-24.7)	(9.6-22.9)	(10.4-24.4)
65-74	280	184	42	54
Rate*	45.2	44.4	41.6	51.7
95% C.I.	(39.9-50.5)	(38.0-50.8)	(29.0-54.2)	(37.9-65.5)
75-84	210	141	36	33
Rate*	64.1	65.2	65.4	58.4
95% C.I.	(55.4-72.7)	(54.4-76.0)	(44.0-86.8)	(38.5-78.4)
85+	65	42	12	11
Rate*	92.3	98.0	83.2	83.4
95% C.I.	(69.8-114.7)	(68.4-127.7)	(36.1-130.3)	(34.1-132.6)
Unknown	0	0	0	0

^{*} Rates are per 100,000 age-specific population.

Table 249. Pancreatic Cancer Mortality by County of Residence, Nevada Residents, 1996-2000

Country of	1996-2000 Mortality							
County of Residence	Rate*			Age-Adjus	Age-Adjusted Rate**			
	Cases	Rate	95% C.I.	Rate	95% C.I.			
Carson City	32	13.1	(8.5-17.6)	10.8	(7.4-15.5)			
Churchill	10	8.5	(3.2-13.7)	8.9	(4.3-17.2)			
Clark	556	8.8	(8.1-9.6)	10.3	(9.5-11.3)			
Douglas	17	8.5	(4.5-12.5)	7.1	(4.0-12.5)			
Elko	11	4.8	(2.0-7.6)	9.9	(4.6-19.3)			
Esmeralda	0							
Eureka	1							
Humboldt	6							
Lander	2							
Lincoln	2							
Lyon	15	9.3	(4.6-14.0)	8.7	(4.7-15.2)			
Mineral	3							
Nye	20	13.5	(7.6-19.4)	8.8	(5.3-15.3)			
Pershing	2							
Storey	2							
Washoe	125	7.6	(6.3-9.0)	9.1	(7.6-10.9)			
White Pine	6							
Unknown	0							
Total	810	8.7	(8.1-9.3)	10.0	(9.3-10.7)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population. **Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 250. Pancreatic Cancer Mortality by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

		Gender					
Rac	ce/Ethnicity	Male	Female	Total			
White	Mortality	364	336	700			
	Rate*	11.1	9.3	10.1			
	95% C.I.	(9.9-12.5)	(8.3-10.3)	(9.4-11.0)			
Black	Mortality	28	23	51			
	Rate*	13.7	11.9	13.3			
	95% C.I.	(9.0-23.0)	(7.4-18.6)	(9.7-18.2)			
Native	Mortality	4	2	6			
American	Rate*						
	95% C.I.						
Asian	Mortality	3	13	16			
	Rate*		7.8	5.2			
	95% C.I.		(3.9-18.7)	(2.8-11.4)			
Hispanic	Mortality	20	16	36			
	Rate*	13.2	6.0	8.4			
	95% C.I.	(6.7-24.3)	(3.2-10.9)	(5.5-12.7)			
Other/Unkr	nown	1	0	1			
Total	Mortality	420	390	810			
	Rate*	11.0	9.1	10.0			
	95% C.I.	(9.9-12.3)	(8.2-10.1)	(9.3-10.7)			

Note: The "---" is used for rates calculated on numbers less than ten. *Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Table 251. Pancreatic Cancer Mortality by Age Group and Gender, Nevada Residents, 1996-2000

Age	Gender						
Group	Male	Female	Total				
<1	0	0	0				
Rate*							
95% C.I.							
1-4	0	0	0				
Rate*							
95% C.I.							
5-14	0	0	0				
Rate*							
95% C.I.							
15-24	1	0	1				
Rate*							
95% C.I.							
25-34	0	2	2				
Rate* 95% C.I.							
							
35-44 Rate*	3	4	1				
95% C.I.							
45-54	49	27	76				
Rate*	8.0	4.5	6.3				
95% C.I.	(5.8-10.2)	(2.8-6.2)	(4.9-7.7)				
55-64	92	77	169				
Rate*	21.5	17.8	19.6				
95% C.I.	(17.1-25.8)	(13.8-21.8)	(16.7-22.6)				
65-74	161	119	280				
Rate*	52.7	37.9	45.2				
95% C.I.	(44.5-60.8)	(31.1-44.7)	(39.9-50.5)				
75-84	87	123	210				
Rate*	59.0	68.2	64.1				
95% C.I.	(46.6-71.4)	(56.2-80.3)	(55.4-72.7)				
85+	27	38	65				
Rate*	119.1	79.5	92.3				
95% C.I.	(74.2-164.0)	(54.2-104.8)	(69.8-114.7)				
Unknown	120	0	0				
Total	420	390	810				
Rate* 95% C.I.	8.9 (8.0-9.7)	8.5 (7.7-9.4)	8.7 (8.1 ₋ 0.3)				
90% C.I.	(8.0-9.7)	(7.7-9.4)	(8.1-9.3)				

^{*} Rates are per 100,000 age-specific population.


Table 252. Median Age at Death from Pancreatic Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

	Gender								
Race/Ethnicity	Ма	le	Fem	nale	Total				
	Deaths	Median Age	Deaths	Median Age	Deaths	Median Age			
White	364	70.0	336	72.0	700	70.0			
Black	28	67.0	23	69.0	51	68.0			
Native American	4		2		6	67.5			
Asian	3		13	68.0	16	67.0			
Hispanic	20	65.0	16	69.5	36	67.0			
Other/Unknown	1		0		1				
Total	420	69.0	390	71.0	810	70.0			

Note: Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE

Figure 164. Survival Rates for Pancreatic Cancer by Race/Ethnicity, Nevada Residents, 1996-2000



Notes: The survival rate for those racial/ethnic groups not included in this chart could not be calculated due to small cell size.

Figure 165. Survival Rates for Pancreatic Cancer by Stage of Cancer at Diagnosis, Nevada Residents, 1996-2000




Table 253. Cause-Specific Survival Rates for Pancreatic Cancer by Race/Ethnicity and Gender, Nevada Residents, 1996-2000

Race/			Median				
Ethnicity and Gender	Number of Cases	One Year	Two Years	Three Years	Four Years	Five Years	Survival Time (years)
Total	584	21.9%	8.8%	5.9%	3.3%	3.3%	0.64
Male	308	21.7%	8.0%	5.7%	5.7%	5.7%	0.64
Female	276	22.1%	9.6%	6.1%	2.0%		0.64
Race/Ethnicity							
White	495	21.9%	8.6%	5.4%	2.7%	2.7%	0.64
Male	258	21.0%	7.2%	4.6%	4.6%	4.6%	0.63
Female	237	22.9%	10.0%	6.4%	2.1%		0.65
Black	50	20.9%	2.3%				0.63
Male	27						
Female	23						
Native American	2						
Male	1						
Female	1						
Asian	15						
Male	6						
Female	9						
Hispanic	21						
Male	16						
Female	5						

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 254. Cause-Specific Survival Rates for Pancreatic Cancer by Stage of Cancer at Diagnosis and Gender, Nevada Residents, 1996-2000

Surviv	/al Rate of Stage		Gender					
at Diagnosis		Total	Male	Female				
Total	Cases	584	308	276				
	One Year	21.9%	21.7%	22.1%				
	5 Years	3.3%	5.7%	0.0%				
	Median Survival	0.64	0.64	0.64				
Stage at D	iagnosis							
In situ	Cases	0	0	0				
	One Year							
	5 Years							
	Median Survival							
Localized	Cases	54	32	22				
	One Year	36.1%	34.5%	38.5%				
	5 Years	11.0%	8.0%	0.0%				
	Median Survival	0.78	0.76	0.81				
Regional	Cases	196	106	90				
	One Year	27.1%	24.8%	30.1%				
	5 Years	0.0%	0.0%	0.0%				
	Median Survival	0.69	0.66	0.71				
Distant	Cases	176	87	89				
	One Year	12.5%	13.6%	11.5%				
	5 Years	0.0%	0.0%	0.0%				
	Median Survival	0.57	0.58	0.56				
Unstaged	Cases	158	83	75				
	One Year	21.5%	21.6%	21.4%				
	5 Years	3.6%	8.2%	0.0%				
·	Median Survival	0.64	0.64	0.64				

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

ALL OTHER CANCERS

ALL OTHER CANCERS

Table 255. Cancer Incidence, Inpatient Hospital Discharges and Mortality by Type of Cancer, Nevada Residents, 1996-2000


Type of Cancer		Incidence	Hospital Admissions	Mortality
Total		38,261	32,109	16,806
R	ate*	449.2	372.2	207.6
95	5% C.I.	(444.6-453.9)	(368.1-376.4)	(204.4-210.9)
Skin		875	71	249
Ra	ate*	9.8	0.8	2.9
95	5% C.I.	(9.2-10.5)	(0.6-1.1)	(2.5-3.3)
Corpus Uteri & Uterus N	NOS	850	853	131
Ra	ate*	18.8	18.8	3.1
95	5% C.I.	(17.6-20.1)	(17.6-20.2)	(2.6-3.6)
Ovary		741	635	361
Ra	ate*	16.6	14.1	8.3
95	5% C.I.	(15.4-17.8)	(13.0-15.2)	(7.5-9.3)
Thyroid Gland		563	750	29
Ra	ate*	6.0	8.0	0.4
	5% C.I.	(5.6-6.6)	(7.4-8.6)	(0.2-0.5)
Brain and Other Centra	I Nervous	500	700	200
System	, ii.	560	728	320
	ate*	6.4	8.1	3.7
	5% C.I.	(5.9-7.0)	(7.5-8.7)	(3.3-4.2)
Stomach	- 1 - 4	544	571	326
	ate*	6.8	6.9	4.2
	5% C.I.	(6.3-7.5)	(6.3-7.5)	(3.7-4.7)
Liver and Intrahepatic E		501	338	388
	ate*	5.9	3.9	4.7
	5% C.I.	(5.4-6.5)	(3.5-4.3)	(4.3-5.3)
Cervix Uteri	ate*	497	611	133
		10.9	13.3	3.0
	5% C.I.	(9.9-11.9)	(12.3-14.4)	(2.5-3.6)
Esophagus	ate*	5.2	293 3.4	368 4.3
	ate 5% C.I.			
	5% C.I.	(4.7-5.7) 371	(3.0-3.8)	(3.8-4.7)
Larynx	ate*	4.3	2.5	1.6
	ate 5% C.I.	(3.8-4.7)	(2.2-2.9)	
Multiple Myeloma	5% C.I.	(3.6-4.7)	320	(1.4-1.9)
	ate*	4.0	3.7	2.8
	ате 5% С.І.	(3.6-4.5)	(3.3-4.1)	(2.4-3.2)
Hodgkin's Lymphoma	J 70 ℃.1.	(3.6-4.5)	(3.3-4.1)	39
	ate*	2.0	1.2	0.4
	5% C.I.	(1.7-2.3)	(1.0-1.5)	(0.3-0.6)
All Other Sites	J ,0 O.1.	3,145	7,626	2,015
	ate*	37.8	88.4	25.5
	5% C.I.	(36.4-39.1)	(86.4-90.5)	(24.3-26.7)
	2,3 0.1.	(00.4 00.1)	(55.4 56.5)	(24.0 20.1)

^{*} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender-specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten.

SKIN CANCER GENERAL PROFILE⁴

Figure 166. Anatomy of the Skin⁴



General Anatomy: The skin is the body's largest organ. It protects against heat, sunlight, injury, and infection. It helps regulate body temperature, stores water and fat, and produces vitamin D. The skin has two main layers: the outer epidermis and the inner dermis. The epidermis is mostly made up of flat, scalelike cells called squamous cells. Round cells called basal cells lie under the squamous cells in the epidermis. The lower part of the epidermis also contains melanocytes. The dermis contains blood vessels, lymph vessels, hair follicles, and glands. Some of these glands produce sweat, which helps regulate body temperature. Other glands produce sebum, an oily substance that helps keep the skin from drying out. Sweat and sebum reach the skin's surface through tiny openings called pores. Melanoma is one of the most common cancers and occurs when melanocytes (pigment cells) become malignant.

Risk Factors: Dysplastic nevi moles, many (more than 50) ordinary moles, fair skin, personal history of melanoma or skin cancer, family history of melanoma, weakened immune system, severe, blistering sunburns, and ultraviolet (UV) radiation.

Signs and Symptoms: Asymetrical, border, color, and diameter changes in a mole, and Dysplastic Nevi moles are common signs and symptoms.

Diagnosing the Cancer: Excisional biopsy.

Treatment: Treatment options include: surgery (Sentinel lymph node biopsy, Lymph node dissection), chemotherapy (Orally or injection or Isolated limb perfusion), biological therapy, or radiation therapy.

Table 256. Skin Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

		County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)				
Total										
Cases	875	538	183	154	0	28,292				
Rate*	9.4	8.5	11.2	11.2		15.3				
95% C.I.	(8.8-10.0)	(7.8-9.3)	(9.6-12.8)	(9.5-13.0)		(15.1-15.5)				
Age Group										
<1	0	0	0	0	0					
Rate*										
95% C.I.										
1-4	0	0	0	0	0	6				
Rate*										
95% C.I.										
5-14	1	0	0	1	0	51				
Rate*						0.2				
95% C.I.						(0.1-0.2)				
15-24	22	13	4	5	0	631				
Rate*	1.7	1.5				2.4				
95% C.I.	(1.0-2.4)	(0.7-2.3)				(2.3-2.6)				
25-34	70	51	12	7	0	2,327				
Rate*	4.9	5.0	4.8			8.0				
95% C.I.	(3.7-6.0)	(3.6-6.4)	(2.1-7.4)			(7.6-8.3)				
35-44	122	57	39	26	0	4,568				
Rate*	8.2	5.8	14.0	11.5		14.6				
95% C.I.	(6.7-9.6)	(4.3-7.2)	(9.6-18.5)	(7.1-15.9)		(14.2-15.0)				
45-54	161	87	41	33	0	5,493				
Rate*	13.3	11.0	18.3	17.2		24.0				
95% C.I.	(11.3-15.4)	(8.7-13.3)	(12.7-23.8)	(11.3-23.0)		(23.4-24.6)				
55-64	176	117	35	24	0	4,750				
Rate*	20.4	20.1	24.7	17.4		33.9				
95% C.I.	(17.4-23.5)	(16.5-23.8)	(16.5-32.9)	(10.4-24.4)		(33.0-34.9)				
65-74	187	122	30	35	0	5,292				
Rate*	30.2	29.4	29.7	33.5		45.9				
95% C.I.	(25.8-34.5)	(24.2-34.7)	(19.1-40.4)	(22.4-44.6)		(44.6-47.1)				
75-84	119	80	21	18	0	3,878				
Rate*	36.3	37.0	38.2	31.9		53.4				
95% C.I.	(29.8-42.8)	(28.9-45.1)	(21.8-54.5)	(17.1-46.6)		(51.7-55.0)				
85+	16	10	1	5	0	1,292				
Rate*	22.7	23.3				52.1				
95% C.I.	(11.6-33.8)	(8.9-37.8)				(49.3-54.9)				
Unknown	1	1	0	0	0	0				

^{*} Rates are per 100,000 age-specific population.

Table 257. Skin Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Discharges	71	52	8	11	0			
Rate*	0.8	0.9		0.7				
95% C.I.	(0.6-1.1)	(0.7-1.3)		(0.4-1.4)				
Gender								
Male	42	26	6	10	0			
Rate*	1.1	1.1		1.3				
95% C.I.	(0.7-1.6)	(0.7-1.8)		(0.6-2.8)				
Female	29	26	2	1	0			
Rate*	0.6	0.9						
95% C.I.	(0.4-0.9)	(0.6-1.3)						
Other/Unknown	0	0	0	0	0			
Inpatient Discharge Cl	harges (\$)							
Total Charges	\$968,720	\$747,948	\$82,084	\$138,688				
Average Charges	\$13,644	\$14,384	\$10,261	\$12,608				
Median Charges	\$11,084	\$11,139	\$9,973	\$11,084				
Discharge Length of S	Stay (LOS) (Days)							
Total LOS	238	190	29	19				
Average LOS	3.4	3.7	3.6	1.7				
Median LOS	2.0	3.0	3.5	1.0				

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.


Table 258. Skin Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Mortality	249	166	35	48			
Rate*	2.7	2.6	2.1	3.5			
95% C.I.	(2.3-3.0)	(2.2-3.0)	(1.4-2.8)	(2.5-4.5)			
Age Group							
<1	0	0	0	0			
Rate*							
95% C.I.							
1-4	0	0	0	0			
Rate*							
95% C.I.							
5-14	0	0	0	0			
Rate*							
95% C.I.							
15-24	1	1	0	0			
Rate*							
95% C.I.							
25-34	5	4	1	0			
Rate*							
95% C.I.							
35-44	28	17	7	4			
Rate*	1.9	1.7					
95% C.I.	(1.2-2.6)	(0.9-2.5)					
45-54	41	26	7	8			
Rate*	3.4	3.3					
95% C.I.	(2.4-4.4)	(2.0-4.5)					
55-64	53	36	5	12			
Rate*	6.2	6.2		8.7			
95% C.I.	(4.5-7.8)	(4.2-8.2)		(3.8-13.6)			
65-74	72	49	9	14			
Rate*	11.6	11.8		13.4			
95% C.I.	(8.9-14.3)	(8.5-15.1)		(6.4-20.4)			
75-84	41	29	6	6			
Rate*	12.5	13.4					
95% C.I.	(8.7-16.3)	(8.5-18.3)					
85+	8	4	0	4			
Rate*							
95% C.I.							
Unknown	0	0	0	0			

^{*} Rates are per 100,000 age-specific population.

UTERINE CANCER GENERAL PROFILE⁴

Figure 167. Anatomical Drawing of Female Reproductive System⁴



General Anatomy: The uterus is part of a woman's reproductive system. It is the hollow, pear-shaped organ where a baby grows. The uterus is in the pelvis between the bladder and the rectum. The narrow, lower portion of the uterus is the cervix. The broad, middle part of the uterus is the body, or corpus. The dome-shaped top of the uterus is the fundus. The fallopian tubes extend from either side of the top of the uterus to the ovaries.

The wall of the uterus has two layers of tissue. The inner layer, or lining, is the endometrium. The outer layer is muscle tissue called the myometrium. In women of childbearing age, the lining of the uterus grows and thickens each month to prepare for pregnancy. If a woman does not become pregnant, the thick, bloody lining flows out of the body through the vagina. This flow is called menstruation.

Risk Factors: Age (Women over 50), Endometrial hyperplasia, Hormone replacement therapy (HRT), Obesity and related conditions, Women taking the drug Tamoxifen, Race (White Females), and Inherited form of Colorectal Cancer.

Signs and Symptoms: Unusual vaginal bleeding or discharge, difficult or painful urination, pain during intercourse, and pain in the pelvic area.

Diagnosing the Cancer: Pelvic exam, Pap test, transvaginal ultrasound, and biopsy.

Treatment: Treatment options include: surgery (Hysterectomy), radiation therapy and hormonal therapy.

Table 259. Uterine Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)		
Total								
Cases	850	592	139	119	0	22,634		
Rate*	18.6	19.1	17.2	17.7		24.1		
95% C.I.	(17.3-19.8)	(17.6-20.7)	(14.4-20.1)	(14.5-20.9)		(23.8-24.4)		
Age Group								
<1	0	0	0	0	0			
Rate*								
95% C.I.								
1-4	0	0	0	0	0			
Rate*								
95% C.I.								
5-14	0	0	0	0	0			
Rate*								
95% C.I.								
15-24	1	1	0	0	0	16		
Rate*						0.1		
95% C.I.						(0.1-0.2)		
25-34	20	17	2	1	0	302		
Rate*	2.9	3.5				2.1		
95% C.I.	(1.6-4.2)	(1.8-5.1)				(1.8-2.3)		
35-44	47	35	5	7	0	1,374		
Rate*	6.5	7.4				8.8		
95% C.I.	(4.6-8.4)	(4.9-9.8)				(8.3-9.2)		
45-54	153	105	29	19	0	3,924		
Rate*	25.6	26.7	26.4	20.2		33.8		
95% C.I.	(21.6-29.7)	(21.6-31.8)	(16.8-36.1)	(11.1-29.3)		(32.7-34.8)		
55-64	208	152	34	22	0	5,573		
Rate*	48.1	51.5	48.8	32.7		76.5		
95% C.I.	(41.6-54.7)	(43.3-59.7)	(32.4-65.2)	(19.0-46.3)		(74.5-78.5)		
65-74	252	174	38	40	0	5,979		
Rate*	80.2	82.9	73.0	76.5		93.7		
95% C.I.	(70.3-90.1)	(70.6-95.2)	(49.8-96.3)	(52.8-100.2)		(91.3-96.0)		
75-84	146	95	26	25	0	4,276		
Rate*	81.0	80.3	82.6	81.9		97.8		
95% C.I.	(67.8-94.1)	(64.2-96.5)	(50.9-114.4)	(49.8-113.9)		(94.9-100.8)		
85+	23	13	5	5	0	1,188		
Rate*	48.1	44.3				68.3		
95% C.I.	(28.5-67.8)	(20.2-68.4)				(64.4-72.2)		
Unknown	0	0	0	0	0	0		

^{*} Rates are per 100,000 age-specific female population.

Table 260. Uterine Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Discharges	853	613	127	113	0			
Rate*	9.7	10.5	8.4	8.0				
95% C.I.	(9.1-10.4)	(9.7-11.4)	(7.0-10.1)	(6.6-9.7)				
Gender								
Male	0	0	0	0	0			
Rate*								
95% C.I.								
Female	853	613	127	113	0			
Rate*	18.8	20.3	16.3	15.6				
95% C.I.	(17.6-20.2)	(18.7-22.0)	(13.6-19.4)	(12.9-18.8)				
Other/Unknown	0	0	0	0	0			
Inpatient Discharge Ch	narges (\$)							
Total Charges	\$17,544,696	\$12,570,807	\$2,803,900	\$2,169,989				
Average Charges	\$20,568	\$20,507	\$22,078	\$19,203				
Median Charges	\$15,534	\$15,534	\$18,436	\$13,783				
Discharge Length of S	tay (LOS) (Days)							
Total LOS	3,738	2,735	545	458				
Average LOS	4.4	4.5	4.3	4.1				
Median LOS	3.0	3.0	3.0	3.0				

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.


Table 261. Uterine Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Cases	131	85	28	18				
Rate*	2.9	2.7	3.5	2.7				
95% C.I.	(2.4-3.4)	(2.2-3.3)	(2.2-4.8)	(1.4-3.9)				
Age Group								
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	0	0	0	0				
Rate*								
95% C.I.								
15-24	0	0	0	0				
Rate*								
95% C.I.								
25-34	1	1	0	0				
Rate*								
95% C.I.								
35-44	6	6	0	0				
Rate*								
95% C.I.								
45-54	15	11	4	0				
Rate*	2.5	2.8						
95% C.I.	(1.2-3.8)	(1.1-4.5)						
55-64	22	17	4	1				
Rate*	5.1	5.8						
95% C.I.	(3.0-7.2)	(3.0-8.5)						
65-74	37	19	9	9				
Rate*	11.8	9.1						
95% C.I.	(8.0-15.6)	(5.0-13.1)						
75-84	37	24	7	6				
Rate*	20.5	20.3						
95% C.I.	(13.9-27.1)	(12.2-28.4)						
85+	13	7	4	2				
Rate*	27.2							
95% C.I.	(12.4-42.0)	0	0					
Unknown	0	U	0	0				

^{*} Rates are per 100,000 age-specific female population.

OVARIAN CANCER GENERAL PROFILE⁴

Figure 168. Anatomical Drawing of Female Reproductive System⁴



General Anatomy: The ovaries are a pair of organs in the female reproductive system. They are located in the pelvis, one on each side of the uterus. Each ovary is about the size and shape of an almond. The ovaries have two functions: they produce eggs and female hormones (chemicals that control the way certain cells or organs function).

Every month, during the menstrual cycle, an egg is released from one ovary in a process called ovulation. The egg travels from the ovary through the fallopian tube to the uterus. The ovaries are also the main source of the female hormones estrogen and progesterone, which influence the development of a woman's breasts, body shape, and body hair. They also regulate the menstrual cycle and pregnancy.

Risk Factors: Family History, Age (Women over 50, especially over 60), Women who never had children, Personal history of Breast or Colorectal Cancer, Use of Fertility drugs, Use of Talc, and Hormone replacement therapy (HRT).

Signs and Symptoms: General abdominal discomfort and/or pain (gas, indigestion, pressure, swelling, bloating, cramps), Nausea, diarrhea, constipation, or frequent urination, Loss of appetite, Feeling of fullness even after a light meal, Weight gain or loss with no known reason, and Abnormal bleeding from the vagina.

Diagnosing the Cancer: Pelvic exam, ultrasound, CA-125 assay blood test, lower gastrointestinal (GI) series, or barium enema (Colon and Rectum X-rays), CT (or CAT) scan, and biopsy.

Treatment: Surgery (hysterectomy with bilateral Salpingo-oophorectomy), chemotherapy, radiation therapy, and clinical trials.

Table 262. Ovarian Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)			
Total									
Cases	741	507	140	94	0	15,611			
Rate*	16.2	16.4	17.3	14.0		16.6			
95% C.I.	(15.0-17.4)	(15.0-17.8)	(14.5-20.2)	(11.1-16.8)		(16.3-16.9)			
Age Group									
<1	0	0	0	0	0				
Rate*									
95% C.I.									
1-4	1	0	0	1	0	5			
Rate*									
95% C.I.									
5-14	1	1	0	0	0	67			
Rate*						0.5			
95% C.I.						(0.4-0.6)			
15-24	6	4	0	2	0	328			
Rate*						2.6			
95% C.I.						(2.3-2.9)			
25-34	34	24	6	4	0	836			
Rate*	4.9	4.9				5.7			
95% C.I.	(3.3-6.6)	(3.0-6.9)				(5.4-6.1)			
35-44	74	49	16	9	0	1,701			
Rate*	10.2	10.3	11.8			10.8			
95% C.I.	(7.9-12.6)	(7.4-13.2)	(6.0-17.5)			(10.3-11.4)			
45-54	123	83	28	12	0	2,962			
Rate*	20.6	21.1	25.5	12.8		25.5			
95% C.I.	(17.0-24.3)	(16.6-25.7)	(16.1-35.0)	(5.5-20.0)		(24.6-26.4)			
55-64	157	109	24	24	0	2,858			
Rate*	36.3	36.9	34.5	35.6		39.2			
95% C.I.	(30.7-42.0)	(30.0-43.9)	(20.7-48.2)	(21.4-49.9)		(37.8-40.7)			
65-74	196	135	34	27	0	3,334			
Rate*	62.4	64.3	65.4	51.7		52.2			
95% C.I.	(53.7-71.1)	(53.5-75.2)	(43.4-87.3)	(32.2-71.1)		(50.5-54.0)			
75-84	113	77	27	9	0	2,603			
Rate*	62.7	65.1	85.8			59.6			
95% C.I.	(51.1-74.2)	(50.6-79.6)	(53.5-118.2)			(57.3-61.8)			
85+	36	25	5	6	0	916			
Rate*	75.4	85.2				52.7			
95% C.I.	(50.7-100.0)	(51.8-118.7)				(49.3-56.1)			
Unknown	0	0	0	0	0	0			

^{*} Rates are per 100,000 age-specific female population.

Table 263. Ovarian Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Discharges	635	438	128	69	0			
Rate*	7.2	7.5	8.5	4.8				
95% C.I.	(6.7-7.8)	(6.8-8.3)	(7.1-10.2)	(3.7-6.2)				
Gender								
Male	0	0	0	0	0			
Rate*								
95% C.I.								
Female	635	438	128	69	0			
Rate*	14.1	14.6	16.4	9.6				
95% C.I.	(13.0-15.2)	(13.2-16.0)	(13.7-19.6)	(7.4-12.2)				
Other/Unknown	0	0	0	0	0			
Inpatient Discharge Ch	narges (\$)							
Total Charges	\$23,133,925	\$15,619,677	\$5,436,491	\$2,077,757				
Average Charges	\$36,431	\$35,661	\$42,473	\$30,112				
Median Charges	\$25,411	\$25,239	\$25,861	\$24,107				
Discharge Length of S	tay (LOS) (Days)							
Total LOS	4,956	3,459	1,086	411				
Average LOS	7.8	7.9	8.5	6.0				
Median LOS	6.0	6.0	6.0	5.0				

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.


Table 264. Ovarian Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region	of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Cases	361	259	66	36
Rate*	7.9	8.4	8.2	5.3
95% C.I.	(7.1-8.7)	(7.4-9.4)	(6.2-10.2)	(3.6-7.1)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	0	0	0
Rate*				
95% C.I.				
15-24	0	0	0	0
Rate*				
95% C.I.				
25-34	2	2	0	0
Rate*				
95% C.I.				
35-44	11	8	2	1
Rate*	1.5			
95% C.I.	(0.6-2.4)			
45-54	54	42	9	3
Rate*	9.0	10.7		
95% C.I.	(6.6-11.5)	(7.5-13.9)		
55-64	65	42	14	9
Rate*	15.0	14.2	20.1	
95% C.I.	(11.4-18.7)	(9.9-18.5)	(9.6-30.6)	
65-74	115	83	22	10
Rate*	36.6	39.5	42.3	19.1
95% C.I.	(29.9-43.3)	(31.0-48.1)	(24.6-60.0)	(7.3-31.0)
75-84	80	59	14	7
Rate*	44.4	49.9	44.5	
95% C.I.	(34.7-54.1)	(37.2-62.6)	(21.2-67.8)	
85+ Data*	34	23	5	6
Rate*	71.2	78.4		
95% C.I.	(47.2-95.1)	(46.4-110.5)		
Unknown	0	0	0	0

^{*} Rates are per 100,000 age-specific female population.

THYROID GLAND CANCER GENERAL PROFILE⁴

Figure 169. Anatomical Drawing of the Thyroid Gland⁴



General Anatomy: The thyroid is a gland in the neck. It has two kinds of cells that make hormones. Follicular cells make thyroid hormone, which affects heart rate, body temperature, and energy level. C cells make calcitonin, a hormone that helps control the level of calcium in the blood. The thyroid is shaped like a butterfly and lies at the front of the neck, beneath the voice box (larynx). It has two parts, or lobes. The two lobes are separated by a thin section called the isthmus. A healthy thyroid is a little larger than a quarter. It usually cannot be felt through the skin. A swollen lobe might look or feel like a lump in the front of the neck. A swollen thyroid is called a goiter. Most goiters are caused by not enough iodine in the diet.

Risk Factors: Exposure to radiation, Family history, Being female, Age (over 40), Race (Whites are more likely to be diagnosed with Thyroid Cancer than Blacks, as a racial/ethnic group,), and not enough iodine in the diet.

Signs and Symptoms: A lump, or nodule, in the front of the neck near the Adam's apple, hoarseness or difficulty speaking in a normal voice, swollen lymph nodes, especially in the neck, difficulty swallowing or breathing, or pain in the throat or neck.

Diagnosing the Cancer: Physical exam, blood tests, ultrasonography, radionuclide scanning, and fine-needle aspiration.

Treatment: surgery (Total thyroidectomy, Lobectomy), radioactive iodine, hormone treatment, external radiation, and chemotherapy.

Table 265. Thyroid Gland Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)			
Total									
Cases	563	373	113	77	0	11,885			
Rate*	6.1	5.9	6.9	5.6		6.4			
95% C.I.	(5.6-6.6)	(5.3-6.5)	(5.6-8.2)	(4.4-6.9)		(6.3-6.5)			
Age Group									
<1	0	0	0	0	0				
Rate*									
95% C.I.									
1-4	0	0	0	0	0				
Rate*									
95% C.I.									
5-14	2	2	0	0	0	68			
Rate*						0.3			
95% C.I.						(0.2-0.3)			
15-24	31	20	8	3	0	742			
Rate*	2.4	2.3				2.9			
95% C.I.	(1.6-3.3)	(1.3-3.3)				(2.7-3.1)			
25-34	116	82	23	11	0	2,089			
Rate*	8.1	8.0	9.1	6.9		7.1			
95% C.I.	(6.6-9.6)	(6.3-9.8)	(5.4-12.8)	(2.8-11.0)		(6.8-7.4)			
35-44	134	80	32	22	0	2,793			
Rate*	9.0	8.1	11.5	9.7		8.9			
95% C.I.	(7.5-10.5)	(6.3-9.8)	(7.5-15.5)	(5.7-13.8)		(8.6-9.3)			
45-54	133	82	31	20	0	2,495			
Rate*	11.0	10.4	13.8	10.4		10.9			
95% C.I.	(9.1-12.9)	(8.1-12.6)	(8.9-18.7)	(5.8-15.0)		(10.5-11.3)			
55-64	76	52	12	12	0	1,578			
Rate*	8.8	8.9	8.5	8.7		11.3			
95% C.I.	(6.8-10.8)	(6.5-11.4)	(3.7-13.3)	(3.8-13.6)		(10.7-11.8)			
65-74	41	32	5	4	0	1,212			
Rate*	6.6	7.7				10.5			
95% C.I.	(4.6-8.6)	(5.0-10.4)				(9.9-11.1)			
75-84	26	21	1	4	0	723			
Rate*	7.9	9.7				9.9			
95% C.I.	(4.9-11.0)	(5.6-13.9)				(9.2-10.7)			
85+	4	2	1	1	0	184			
Rate*						7.4			
95% C.I.						(6.3-8.5)			
Unknown	0	0	0	0	0	0			

^{*} Rates are per 100,000 age-specific population.

Table 266. Thyroid Gland Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Discharges	750	546	134	70	0			
Rate*	8.0	8.7	8.0	5.0				
95% C.I.	(7.4-8.6)	(7.9-9.4)	(6.7-9.6)	(3.9-6.4)				
Gender								
Male	167	120	26	21	0			
Rate*	3.6	3.9	3.2	2.9				
95% C.I.	(3.1-4.3)	(3.3-4.8)	(2.0-5.0)	(1.8-4.8)				
Female	583	426	108	49	0			
Rate*	12.6	13.7	13.0	7.2				
95% C.I.	(11.6-13.7)	(12.4-15.1)	(10.7-15.8)	(5.3-9.6)				
Other/Unknown	0	0	0	0	0			
Inpatient Discharge Cl	narges (\$)							
Total Charges	\$8,268,800	\$5,802,653	\$1,677,976	\$788,171				
Average Charges	\$11,025	\$10,628	\$12,522	\$11,260				
Median Charges	\$9,952	\$9,610	\$11,166	\$10,512				
Discharge Length of S	tay (LOS) (Days)							
Total LOS	1,673	1,205	304	164				
Average LOS	2.2	2.2	2.3	2.3				
Median LOS	2.0	2.0	2.0	2.0				

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 267. Thyroid Gland Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000


	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties			
Total							
Mortality	29	19	5	5			
Rate*	0.3	0.3	0.3	0.4			
95% C.I.	(0.2-0.4)	(0.2-0.4)	(0.0-0.6)	(0.0-0.7)			
Age Group							
<1	0	0	0	0			
Rate*							
95% C.I.							
1-4	0	0	0	0			
Rate*							
95% C.I.							
5-14	0	0	0	0			
Rate*							
95% C.I.							
15-24	0	0	0	0			
Rate*							
95% C.I.							
25-34	0	0	0	0			
Rate*							
95% C.I.							
35-44	0	0	0	0			
Rate*							
95% C.I.							
45-54	3	3	0	0			
Rate*							
95% C.I.							
55-64 D-4-*	7	5	1	1			
Rate*							
95% C.I.	 7	4	1	2			
65-74 Rate*	I	4		2			
							
95% C.I. 75-84	9	6	 1	2			
Rate*			I				
95% C.I.							
95 % C.I.	3	1	2	0			
Rate*							
95% C.I.							
Unknown	0	0	0	0			

^{*} Rates are per 100,000 age-specific population.

BRAIN AND OTHER CENTRAL NERVOUS SYSTEM CANCER

GENERAL PROFILE⁴

Figure 170. Anatomical Drawing of the Brain and Nearby Structures⁴



General Anatomy: The brain is a soft, spongy mass of tissue. It is protected by the bones of the skull and three thin membranes called meninges. Watery fluid called cerebrospinal fluid cushions the brain. This fluid flows through spaces between the meninges and through spaces within the brain called ventricles. A network of nerves carries messages back and forth between the brain and the rest of the body. Some nerves go directly from the brain to the eyes, ears, and other parts of the head. Other nerves run through the spinal cord to connect the brain with the other parts of the body. Within the brain and spinal cord, glial cells surround nerve cells and hold them in place.

Risk Factors: Being male, being white, age (over 70 years of age), family history, and exposure to: radiation or certain chemicals: formaldehyde, vinyl chloride, and acrylonitrile.

Signs and Symptoms: Headaches (usually worse in the morning), nausea or vomiting, changes in speech, vision, or hearing, problems balancing or walking, changes in mood, personality, or ability to concentrate, problems with memory, muscle jerking or twitching (seizures or convulsions), and numbness or tingling in the arms or legs.

Diagnosing the Cancer: Physical exam, neurologic exam, computed tomography (CAT) scan, magnetic resonance imaging (MRI), angiogram, skull x-ray, spinal tap, myelogram, and biopsy.

Treatment: surgery (Craniotomy), radiation therapy (Fractionation, Hyperfractionation, Stereotactic, 3-dimensional conformal, and Proton beam), and chemotherapy

Table 268. Brain and Other Central Nervous System Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)			
Total									
Cases	560	372	91	97	0	11,214			
Rate*	6.0	5.9	5.6	7.1		6.1			
95% C.I.	(5.5-6.5)	(5.3-6.5)	(4.4-6.7)	(5.7-8.5)		(5.9-6.2)			
Age Group									
<1	3	1	1	1	0	105			
Rate*						3.8			
95% C.I.						(3.1-4.5)			
1-4	15	13	1	1	0	403			
Rate*	2.7	3.4				3.6			
95% C.I.	(1.4-4.1)	(1.6-5.3)				(3.3-4.0)			
5-14	35	22	6	7	0	741			
Rate*	2.6	2.5				2.8			
95% C.I.	(1.8-3.5)	(1.4-3.5)				(2.6-3.0)			
15-24	20	11	4	5	0	499			
Rate*	1.6	1.3				1.9			
95% C.I.	(0.9-2.2)	(0.5-2.0)				(1.8-2.1)			
25-34	41	29	6	6	0	868			
Rate*	2.9	2.8				3.0			
95% C.I.	(2.0-3.7)	(1.8-3.9)				(2.8-3.2)			
35-44	55	35	7	13	0	1,264			
Rate*	3.7	3.5		5.8		4.0			
95% C.I.	(2.7-4.7)	(2.4-4.7)		(2.6-8.9)		(3.8-4.3)			
45-54	73	48	14	11	0	1,559			
Rate*	6.0	6.1	6.2	5.7		6.8			
95% C.I.	(4.7-7.4)	(4.3-7.8)	(3.0-9.5)	(2.3-9.1)		(6.5-7.2)			
55-64	105	69	19	17	0	1,749			
Rate*	12.2	11.9	13.4	12.3		12.5			
95% C.I.	(9.9-14.5)	(9.1-14.7)	(7.4-19.5)	(6.5-18.2)		(11.9-13.1)			
65-74	108	76	13	19	0	2,097			
Rate*	17.4	18.3	12.9	18.2		18.2			
95% C.I.	(14.1-20.7)	(14.2-22.5)	(5.9-19.9)	(10.0-26.4)		(17.4-19.0)			
75-84	84	54	15	15	0	1,554			
Rate*	25.6	25.0	27.3	26.6		21.4			
95% C.I.	(20.1-31.1)	(18.3-31.6)	(13.5-41.1)	(13.1-40.0)		(20.3-22.4)			
85+	21	14	5	2	0	375			
Rate*	29.8	32.7				15.1			
95% C.I.	(17.1-42.6)	(15.6-49.8)				(13.6-16.7)			
Unknown	0	0	0	0	0	0			

^{*} Rates are per 100,000 age-specific population.

Table 269. Brain and Other Central Nervous System Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown		
Total							
Discharges	728	510	115	102	1		
Rate*	8.1	8.5	7.5	7.3			
95% C.I.	(7.5-8.7)	(7.7-9.3)	(6.2-9.1)	(6.0-9.0)			
Gender							
Male	426	307	58	60	1		
Rate*	9.5	10.3	7.3	8.6			
95% C.I.	(8.6-10.6)	(9.1-11.7)	(5.5-9.8)	(6.5-11.4)			
Female	302	203	57	42	0		
Rate*	6.7	6.7	7.4	6.1			
95% C.I.	(6.0-7.5)	(5.8-7.7)	(5.6-9.6)	(4.4-8.3)			
Other/Unknown	0	0	0	0	0		
Inpatient Discharge Ch	arges (\$)						
Total Charges	\$25,861,154	\$19,244,597	\$3,538,484	\$3,072,021	\$6,052		
Average Charges	\$35,524	\$37,735	\$30,769	\$30,118	\$6,052		
Median Charges	\$29,375	\$30,644	\$27,692	\$27,401	\$6,052		
Discharge Length of St	tay (LOS) (Days)						
Total LOS	5,676	4,178	819	678	1		
Average LOS	7.8	8.2	7.1	6.6	1.0		
Median LOS	5.0	5.0	5.0	5.0	1.0		

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.


Table 270. Brain and Other Central Nervous System Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

	County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties		
Total						
Mortality	320	212	53	55		
Rate*	3.4	3.4	3.2	4.0		
95% C.I.	(3.1-3.8)	(2.9-3.8)	(2.4-4.1)	(3.0-5.1)		
Age Group						
<1	0	0	0	0		
Rate*						
95% C.I.						
1-4	3	3	0	0		
Rate*						
95% C.I.						
5-14	9	6	2	1		
Rate*						
95% C.I.						
15-24	3	1	1	1		
Rate*						
95% C.I.						
25-34	14	12	2	0		
Rate*	1.0	1.2				
95% C.I.	(0.5-1.5)	(0.5-1.8)				
35-44	30	21	4	5		
Rate*	2.0	2.1				
95% C.I.	(1.3-2.7)	(1.2-3.0)				
45-54	35	24	9	2		
Rate*	2.9	3.0				
95% C.I.	(1.9-3.9)	(1.8-4.2)				
55-64	72	52	9	11		
Rate*	8.4	8.9		8.0		
95% C.I.	(6.4-10.3)	(6.5-11.4)		(3.3-12.7)		
65-74	81	55	10	16		
Rate*	13.1	13.3	9.9	15.3		
95% C.I.	(10.2-15.9)	(9.8-16.8)	(3.8-16.1)	(7.8-22.8)		
75-84	58	32	11	15		
Rate*	17.7	14.8	20.0	26.6		
95% C.I.	(13.1-22.3)	(9.7-19.9)	(8.2-31.8)	(13.1-40.0)		
85+	15	6	5	4		
Rate*	21.3					
95% C.I.	(10.5-32.1)	0				
Unknown		0		0		

^{*} Rates are per 100,000 age-specific population.

STOMACH CANCER GENERAL PROFILE⁴

Figure 171. Anatomical Drawing of the Esophagus and Stomach⁵



General Anatomy: The stomach is part of the digestive system. It is located in the upper abdomen, under the ribs. The upper part of the stomach connects to the esophagus, and the lower part leads into the small intestine. When food enters the stomach, muscles in the stomach wall create a rippling motion that mixes and mashes the food. At the same time, juices made by glands in the lining of the stomach help digest the food. After about 3 hours, the food becomes a liquid and moves into the small intestine, where digestion continues.

Risk Factors: While the cause of Stomach Cancer is still unknown common some people are more likely to be diagnosed with Stomach Cancer. It is more common in: people over 55 years of age, males, Blacks as a racial/ethnic group, and people who have had stomach surgery or have pernicious anemia, achlorhydria, or gastric atrophy (which generally result in lower than normal amounts of digestive juices) have an increased risk. Stomach Cancer is also more common in parts of the world like Japan, Korea, parts of Eastern Europe, and Latin America than in the United States.

Signs and Symptoms: Indigestion or a burning sensation (heartburn), discomfort or pain in the abdomen, nausea and vomiting, diarrhea or constipation, bloating of the stomach after meals, loss of appetite, weakness and fatigue, and bleeding (vomiting blood or having blood in the stool).

Diagnosing the Cancer: Fecal occult blood test, upper gastrointestinal (GI) x-ray series, and endoscopy are some of the common ways of diagnosing Stomach Cancer.

Treatment: surgery (Gastrectomy), chemotherapy, radiation therapy, and biological therapy.

Table 271. Stomach Cancer Mortality by Age Group and County/Region of Residence at Diagnosis, Nevada Residents, 1996-2000

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)		
Total								
Cases	544	373	104	67	0	15,187		
Rate*	5.8	5.9	6.4	4.9		8.2		
95% C.I.	(5.4-6.3)	(5.3-6.5)	(5.1-7.6)	(3.7-6.1)		(8.1-8.3)		
Age Group								
<1	0	0	0	0	0			
Rate*								
95% C.I.								
1-4	0	0	0	0	0			
Rate*								
95% C.I.								
5-14	0	0	0	0	0			
Rate*								
95% C.I.								
15-24	2	1	1	0	0	25		
Rate*						0.1		
95% C.I.						(0.1-0.1)		
25-34	6	4	1	1	0	219		
Rate*						0.7		
95% C.I.						(0.6-0.8)		
35-44	23	16	4	3	0	748		
Rate*	1.5	1.6				2.4		
95% C.I.	(0.9-2.2)	(0.8-2.4)				(2.2-2.6)		
45-54	52	41	7	4	0	1,434		
Rate*	4.3	5.2				6.3		
95% C.I.	(3.1-5.5)	(3.6-6.8)				(5.9-6.6)		
55-64	102	66	21	15	0	2,387		
Rate*	11.8	11.4	14.8	10.9		17.0		
95% C.I.	(9.5-14.1)	(8.6-14.1)	(8.5-21.2)	(5.4-16.4)		(16.4-17.7)		
65-74	148	94	36	18	0	4,180		
Rate*	23.9	22.7	35.7	17.2		36.2		
95% C.I.	(20.0-27.7)	(18.1-27.3)	(24.0-47.4)	(9.3-25.2)		(35.1-37.3)		
75-84	159	112	26	21	0	4,276		
Rate*	48.5	51.8	47.2	37.2		58.8		
95% C.I.	(41.0-56.1)	(42.2-61.4)	(29.1-65.4)	(21.3-53.1)		(57.1-60.6)		
85+	52	39	8	5	0	1,914		
Rate*	73.8	91.0				77.2		
95% C.I.	(53.7-93.9)	(62.5-119.6)				(73.7-80.6)		
Unknown	0	0	0	0	0	0		

^{*} Rates are per 100,000 age-specific population.

Table 272. Stomach Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Discharges	571	410	106	55	0			
Rate*	6.9	7.6	7.5	3.9				
95% C.I.	(6.3-7.5)	(6.8-8.4)	(6.1-9.1)	(2.9-5.2)				
Gender								
Male	389	279	68	42	0			
Rate*	10.2	11.3	10.4	6.2				
95% C.I.	(9.1-11.4)	(9.9-13.0)	(7.9-13.6)	(4.4-8.7)				
Female	182	131	38	13	0			
Rate*	4.2	4.6	5.0	1.8				
95% C.I.	(3.6-4.8)	(3.8-5.4)	(3.6-7.0)	(1.0-3.2)				
Other/Unknown	0	0	0	0	0			
Inpatient Discharge Cl	Inpatient Discharge Charges (\$)							
Total Charges	\$27,949,044	\$20,978,443	\$4,570,239	\$2,400,362				
Average Charges	\$48,948	\$51,167	\$43,115	\$43,643				
Median Charges	\$34,005	\$35,556	\$30,752	\$28,316				
Discharge Length of S	tay (LOS) (Days)							
Total LOS	6,318	4,663	1,089	566				
Average LOS	11.1	11.4	10.3	10.3				
Median LOS	9.0	9.0	8.0	9.0				

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.


Table 273. Stomach Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	326	232	59	35
Rate*	3.5	3.7	3.6	2.6
95% C.I.	(3.1-3.9)	(3.2-4.2)	(2.7-4.5)	(1.7-3.4)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	0	0	0
Rate*				
95% C.I.				
15-24	0	0	0	0
Rate*				
95% C.I.				
25-34	2	2	0	0
Rate*				
95% C.I.				
35-44	14	11	3	0
Rate*	0.9	1.1		
95% C.I.	(0.4-1.4)	(0.5-1.8)		
45-54	30	25	2	3
Rate*	2.5	3.2		
95% C.I.	(1.6-3.4)	(1.9-4.4)		
55-64	56	41	12	3
Rate*	6.5	7.1	8.5	
95% C.I.	(4.8-8.2)	(4.9-9.2)	(3.7-13.3)	
65-74	82	55	14	13
Rate*	13.2	13.3	13.9	12.4
95% C.I.	(10.4-16.1)	(9.8-16.8)	(6.6-21.2)	(5.7-19.2)
75-84	109	76	20	13
Rate*	33.3	35.1	36.3	23.0
95% C.I.	(27.0-39.5)	(27.2-43.0)	(20.4-52.3)	(10.5-35.5)
85+	33	22	8	3
Rate*	46.8	51.4		
95% C.I.	(30.9-62.8)	(29.9-72.8)		
Unknown	0	0	0	0

^{*} Rates are per 100,000 age-specific population.

LIVER AND INTRAHEPATIC BILE DUCTS CANCER <u>GENERAL PROFILE</u>⁴

Figure 172. Anatomical Drawing of the Digestive System⁵



General Anatomy: The liver is the largest organ in the body. It is found behind the ribs on the right side of the abdomen. The liver has two parts, a right lobe and a smaller left lobe. The liver has many important functions that keep a person healthy. It removes harmful material from the blood. It makes enzymes and bile that help digest food. It also converts food into substances needed for life and growth. The liver gets its supply of blood from two vessels. Most of its blood comes from the hepatic portal vein. The rest comes from the hepatic artery.

Risk Factors: Chronic liver infection (hepatitis), cirrhosis, Aflatoxin (type of mold), being male, family history, and age (over 60 years of age).

Signs and Symptoms: Pain in the upper abdomen on the right side; the pain may extend to the back and shoulder, swollen abdomen (bloating), weight loss, loss of appetite and feelings of fullness, weakness or feeling very tired, nausea and vomiting, yellow skin and eyes and dark urine from jaundice, and fever.

Diagnosing the Cancer: Physical exam, blood tests, computed tomography (CAT) scan, ultrasound test, magnetic resonance imaging (MRI), angiogram, and biopsy.

Treatment: surgery (Hepatectomy, Transplantation), radio frequency ablation, percutaneous ethanol injection, cryosurgery, hepatic arterial infusion, chemoembolization, chemotherapy, and radiation therapy.

Table 274. Liver and Intrahepatic Bile Ducts Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

		County/Region of Residence								
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)				
Total										
Cases	501	360	70	70	1	9,504				
Rate*	5.4	5.7	4.3	5.1		5.1				
95% C.I.	(4.9-5.9)	(5.1-6.3)	(3.3-5.3)	(3.9-6.3)		(5.0-5.2)				
Age Group										
<1	2	2	0	0	0	30				
Rate*						1.1				
95% C.I.						(0.7-1.5)				
1-4	6	3	2	1	0	51				
Rate*						0.5				
95% C.I.						(0.3-0.6)				
5-14	1	0	0	1	0	27				
Rate*						0.1				
95% C.I.						(0.1-0.1)				
15-24	3	2	1	0	0	45				
Rate*						0.2				
95% C.I.						(0.1-0.2)				
25-34	0	0	0	0	0	98				
Rate*						0.3				
95% C.I.						(0.3-0.4)				
35-44	21	14	2	5	0	464				
Rate*	1.4	1.4				1.5				
95% C.I.	(0.8-2.0)	(0.7-2.2)				(1.3-1.6)				
45-54	75	62	6	6	1	1,402				
Rate*	6.2	7.8				6.1				
95% C.I.	(4.8-7.6)	(5.9-9.8)				(5.8-6.4)				
55-64	105	76	14	15	0	1,913				
Rate*	12.2	13.1	9.9	10.9		13.7				
95% C.I.	(9.9-14.5)	(10.1-16.0)	(4.7-15.1)	(5.4-16.4)		(13.1-14.3)				
65-74	154	106	27	21	0	2,662				
Rate*	24.8	25.6	26.8	20.1		23.1				
95% C.I.	(20.9-28.8)	(20.7-30.4)	(16.7-36.9)	(11.5-28.7)		(22.2-23.9)				
75-84	110	81	13	16	0	2,137				
Rate*	33.6	37.5	23.6	28.3		29.4				
95% C.I.	(27.3-39.8)	(29.3-45.6)	(10.8-36.5)	(14.4-42.2)		(28.2-30.6)				
85+	24	14	5	5	0	675				
Rate*	34.1	32.7				27.2				
95% C.I.	(20.4-47.7)	(15.6-49.8)				(25.2-29.3)				
Unknown	0	0	0	0	0	0				

^{*} Rates are per 100,000 age-specific population.

Table 275. Liver and Intrahepatic Bile Ducts Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

		Cour	ty/Region of Resid	lence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	338	271	41	26	0
Rate*	3.9	4.7	2.9	1.8	
95% C.I.	(3.5-4.3)	(4.1-5.3)	(2.0-4.0)	(1.2-2.7)	
Gender					
Male	234	192	24	18	0
Rate*	5.6	6.8	3.9	2.4	
95% C.I.	(4.8-6.4)	(5.8-8.0)	(2.4-6.3)	(1.4-4.2)	
Female	104	79	17	8	0
Rate*	2.3	2.7	2.2		
95% C.I.	(1.9-2.8)	(2.1-3.4)	(1.3-3.5)		
Other/Unknown	0	0	0	0	0
Inpatient Discharge Cl	harges (\$)				
Total Charges	\$8,504,961	\$7,505,425	\$642,474	\$357,062	
Average Charges	\$25,163	\$27,695	\$15,670	\$13,733	
Median Charges	\$17,071	\$18,867	\$13,155	\$10,258	
Discharge Length of S	stay (LOS) (Days)				
Total LOS	2,308	1,940	263	105	
Average LOS	6.8	7.2	6.4	4.0	
Median LOS	5.0	5.0	6.0	3.0	

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.


Table 276. Liver and Intrahepatic Bile Ducts Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	388	278	53	57
Rate*	4.2	4.4	3.2	4.2
95% C.I.	(3.8-4.6)	(3.9-4.9)	(2.4-4.1)	(3.1-5.2)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	1	0	0	1
Rate*				
95% C.I.				
5-14	1	0	0	1
Rate*				
95% C.I.				
15-24	3	2	0	1
Rate*				
95% C.I.				
25-34	1	1	0	0
Rate*				
95% C.I.				
35-44	8	7	0	1
Rate*				
95% C.I.				
45-54	56	48	5	3
Rate*	4.6	6.1		
95% C.I.	(3.4-5.8)	(4.3-7.8)		
55-64	72	50	10	12
Rate*	8.4	8.6	7.1	8.7
95% C.I.	(6.4-10.3)	(6.2-11.0)	(2.7-11.5)	(3.8-13.6)
65-74	126	86	23	17
Rate*	20.3	20.7	22.8	16.3
95% C.I.	(16.8-23.9)	(16.4-25.1)	(13.5-32.1)	(8.5-24.0)
75-84	91	63	11	17
Rate*	27.8	29.1	20.0	30.1
95% C.I.	(22.1-33.5)	(21.9-36.3)	(8.2-31.8)	(15.8-44.4)
85+	29	21	4	4
Rate*	41.2	49.0		
95% C.I.	(26.2-56.1)	(28.1-70.0)		
Unknown	0	0	0	0

^{*} Rates are per 100,000 age-specific population.

CERVICAL CANCER GENERAL PROFILE⁴

Figure 173. Anatomical Drawing of the Female Reproductive System⁴



General Anatomy: The cervix is the lower, narrow part of the uterus (womb). The uterus, a hollow, pear-shaped organ, is located in a woman's lower abdomen, between the bladder and the rectum. The cervix forms a canal that opens into the vagina, which leads to the outside of the body. Cells on the surface of the cervix sometimes appear abnormal but not cancerous. Scientists believe that some abnormal changes in cells on the cervix are the first step in a series of slow changes that can lead to cancer years later. If these changes form abnormal cells that spread deeper into the cervix or to other tissues or organs, the disease is then called cervical cancer, or invasive cervical cancer.

Risk Factors: Researchers believe that, in many cases, cervical cancer develops when two or more risk factors act together. These include: women who began having sexual intercourse before age 18, women who have had many sexual partners, women whose partners began having sexual intercourse at a young age, have had many sexual partners, or were previously married to women who had cervical cancer, some sexually transmitted human papillomaviruses (HPVs), smoking, women whose mothers were given the drug diethylstilbestrol (DES) during pregnancy to prevent miscarriage, weakened immune systems, and the use of oral contraceptives (the pill).

Signs and Symptoms: Precancerous changes of the cervix usually do not cause pain. In fact, they generally do not cause any symptoms until abnormal cervical cells become cancerous and invade nearby tissue, unless a woman has a pelvic exam and a Pap test. Symptoms include: abnormal bleeding (longer and heavier than usual), bleeding after menopause, and increased vaginal discharge is another symptom of cervical cancer.

Diagnosing the Cancer: Pap Smear tests (Early Detection), colposcopy, endocervical curettage, conization, dilation and curettage,

Treatment: Surgery (Hysterectomy), cryosurgery, cauterization, laser surgery, conization, radiation therapy, and chemotherapy.

Table 277. Cervical Cancer Screening by County/Region of Residence, Education, Age Group, and Income, Nevada Residents, 1996-2000

				Answers			
Responses		Yes		No			7.4.1
	Number	Percent*	95% C.I.	Number	Percent*	95% C.I.	Total
Total							
Responses	5,339	95.3%	(94.7%-95.9%)	244	4.7%	(4.1%-5.3%)	5,583
County/Region of Resid	dence						
Clark County	1,711	95.2%	(94.2%-96.2%)	82	4.8%	(3.8%-5.8%)	1,793
Washoe County	1,769	95.7%	(94.8%-96.6%)	79	4.3%	(3.4%-5.2%)	1,848
All Other Counties	1,859	95.7%	(94.8%-96.6%)	83	4.3%	(3.4%-5.2%)	1,942
Education							
Less than High School	457	88.6%	(85.8%-91.4%)	42	11.4%	(8.6%-14.2%)	499
High School	1,715	95.0%	(94.0%-96.0%)	95	5.0%	(4.0%-6.0%)	1,810
Some Post High School	1,885	96.2%	(95.4%-97.0%)	76	3.8%	(3.0%-4.6%)	1,961
College Graduate	1,270	97.3%	(96.4%-98.2%)	31	2.7%	(1.8%-3.6%)	1,301
Age Group							
18-24 years old	425	84.1%	(80.9%-87.3%)	83	15.9%	(12.7%-19.1%)	508
25-34 years old	1,008	96.1%	(94.9%-97.3%)	30	3.9%	(2.7%-5.1%)	1,038
35-44 years old	1,284	98.3%	(97.6%-99.0%)	22	1.7%	(1.0%-2.4%)	1,306
45-54 years old	1,033	98.6%	(97.9%-99.3%)	17	1.4%	(0.7%-2.1%)	1,050
55-64 years old	678	98.4%	(97.5%-99.3%)	14	1.6%	(0.7%-2.5%)	692
65+ years old	887	92.0%	(90.3%-93.7%)	76	8.0%	(6.3%-9.7%)	963
Income							
Less than \$15,000	605	92.9%	(90.9%-94.9%)	44	7.1%	(5.1%-9.1%)	649
\$15,000 - \$24,999	493	94.8%	(92.9%-96.7%)	33	5.2%	(3.3%-7.1%)	526
\$25,000 - \$34,999	820	95.2%	(93.8%-96.6%)	43	4.8%	(3.4%-6.2%)	863
\$35,000 - \$49,999	1,042	97.1%	(96.1%-98.1%)	21	2.9%	(1.9%-3.9%)	1,063
\$50,000 or More	1,546	98.0%	(97.3%-98.7%)	23	2.0%	(1.3%-2.7%)	1,569

^{*}Denominator is persons age 18-64 and excludes missing, don't know, and refused responses. Note: This table includes those respondents who answered "Yes" or "No" to the following question:

¹⁾ A Pap smear is a test for cancer of the cervix. Have you ever had a Pap smear?

Table 278. Cervical Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)			
Total									
Cases	497	366	83	48	0	9,206			
Rate*	10.9	11.8	10.3	7.1		9.8			
95% C.I.	(9.9-11.8)	(10.6-13.0)	(8.1-12.5)	(5.1-9.1)		(9.6-10.0)			
Age Group									
<1	0	0	0	0	0				
Rate*									
95% C.I.									
1-4	0	0	0	0	0				
Rate*									
95% C.I.									
5-14	0	0	0	0	0				
Rate*									
95% C.I.									
15-24	4	3	0	1	0	130			
Rate*						1.0			
95% C.I.						(0.9-1.2)			
25-34	59	42	11	6	0	1,390			
Rate*	8.6	8.6	9.0			9.6			
95% C.I.	(6.4-10.8)	(6.0-11.2)	(3.7-14.4)			(9.1-10.1)			
35-44	127	95	25	7	0	2,483			
Rate*	17.6	20.0	18.4			15.8			
95% C.I.	(14.5-20.7)	(16.0-24.1)	(11.2-25.6)			(15.2-16.4)			
45-54	112	82	16	14	0	2,020			
Rate*	18.8	20.9	14.6	14.9		17.4			
95% C.I.	(15.3-22.2)	(16.3-25.4)	(7.4-21.7)	(7.1-22.7)		(16.6-18.1)			
55-64	96	68	15	13	0	1,258			
Rate*	22.2	23.0	21.5	19.3		17.3			
95% C.I.	(17.8-26.7)	(17.6-28.5)	(10.6-32.4)	(8.8-29.8)		(16.3-18.2)			
65-74	63	49	10	4	0	1,033			
Rate*	20.1	23.3	19.2			16.2			
95% C.I.	(15.1-25.0)	(16.8-29.9)	(7.3-31.1)			(15.2-17.2)			
75-84	25	19	3	3	0	652			
Rate*	13.9	16.1				14.9			
95% C.I.	(8.4-19.3)	(8.8-23.3)				(13.8-16.1)			
85+	11	8	3	0	0	239			
Rate*	23.0					13.7			
95% C.I.	(9.4-36.6)					(12.0-15.5)			
Unknown	0	0	0	0	0	0			

^{*} Rates are per 100,000 age-specific female population.

Table 279. Cervical Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

		Coun	ty/Region of Resid	lence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	611	463	82	66	0
Rate*	6.6	7.5	5.0	4.6	
95% C.I.	(6.1-7.2)	(6.8-8.3)	(4.0-6.2)	(3.6-6.0)	
Gender					
Male	0	0	0	0	0
Rate*					
95% C.I.					
Female	611	463	82	66	0
Rate*	13.3	15.1	10.0	9.4	
95% C.I.	(12.3-14.4)	(13.8-16.6)	(7.9-12.5)	(7.2-12.0)	
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	narges (\$)				
Total Charges	\$12,449,843	\$9,340,499	\$1,949,138	\$1,160,206	
Average Charges	\$20,376	\$20,174	\$23,770	\$17,579	
Median Charges	\$15,940	\$15,893	\$19,656	\$12,092	
Discharge Length of S	stay (LOS) (Days)				
Total LOS	2,803	2,182	366	255	
Average LOS	4.6	4.7	4.5	3.9	
Median LOS	3.0	3.0	3.0	3.0	

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.


Table 280. Cervical Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Cases	133	99	21	13
Rate*	2.9	3.2	2.6	1.9
95% C.I.	(2.4-3.4)	(2.6-3.8)	(1.5-3.7)	(0.9-3.0)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	0	0	0
Rate*				
95% C.I.				
15-24	0	0	0	0
Rate*				
95% C.I.				
25-34	10	7	3	0
Rate*	1.5			
95% C.I.	(0.6-2.4)			
35-44	24	21	3	0
Rate*	3.3	4.4		
95% C.I.	(2.0-4.7)	(2.5-6.3)		
45-54	38	28	6	4
Rate*	6.4	7.1		
95% C.I.	(4.3-8.4)	(4.5-9.8)		
55-64	17	13	1	3
Rate*	3.9	4.4		
95% C.I.	(2.1-5.8)	(2.0-6.8)		
65-74	23	15	4	4
Rate*	7.3	7.1		
95% C.I.	(4.3-10.3)	(3.5-10.8)		
75-84	13	9	2	2
Rate*	7.2			
95% C.I.	(3.3-11.1)			
85+	8	6	2	0
Rate*				
95% C.I.				
Unknown	0	0	0	0

^{*} Rates are per 100,000 age-specific female population.

ESOPHAGEAL CANCER GENERAL PROFILE⁴

Figure 174. Anatomical Drawing of the Esophagus and Stomach⁵



General Anatomy: The esophagus is a hollow tube that carries food and liquids from the throat to the stomach. When a person swallows, the muscular walls of the esophagus contract to push food down into the stomach. Glands in the lining of the esophagus produce mucus, which keeps the passageway moist and makes swallowing easier. The esophagus is located just behind the trachea (windpipe). In an adult, the esophagus is about 10 inches long.

Risk Factors: Age, (over 60 years of age), being male, tobacco use, chronic and/or heavy alcohol use, Barrett's Esophagus (Long-term irritation from gastric reflux), medical history, and other types of irritation that cause significant irritation or damage to the lining of the esophagus (swallowing lye or other caustic substances) can increase the risk of developing esophageal cancer.

Signs and Symptoms: Difficult or painful swallowing, severe weight loss, pain in the throat or back, behind the breastbone or between the shoulder blades, hoarseness or chronic cough, vomiting, and coughing up blood are some common symptoms of Esophageal Cancer.

Diagnosing the Cancer: Barium swallow x-rays (also called an Esophagram), biopsy procedures (Esophagoscopy/Endoscopy), computed tomography (CAT) scan, bone scan, and bronchoscopy are common ways of diagnosing this type of cancer.

Treatment: Surgery (Esophagectomy), radiation therapy, chemotherapy, laser therapy, and photodynamic therapy (PDT).

Table 281. Esophageal Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)			
Total									
Cases	444	311	76	57	0	7,483			
Rate*	4.8	4.9	4.6	4.2		4.0			
95% C.I.	(4.3-5.2)	(4.4-5.5)	(3.6-5.7)	(3.1-5.2)		(3.9-4.1)			
Age Group									
<1	0	0	0	0	0				
Rate*									
95% C.I.									
1-4	0	0	0	0	0				
Rate*									
95% C.I.									
5-14	0	0	0	0	0				
Rate*									
95% C.I.									
15-24	0	0	0	0	0	6			
Rate*									
95% C.I.									
25-34	0	0	0	0	0	31			
Rate*						0.1			
95% C.I.						(0.1-0.1)			
35-44	16	11	3	2	0	205			
Rate*	1.1	1.1				0.7			
95% C.I.	(0.5-1.6)	(0.5-1.8)				(0.6-0.7)			
45-54	47	34	4	9	0	877			
Rate*	3.9	4.3				3.8			
95% C.I.	(2.8-5.0)	(2.8-5.7)				(3.6-4.1)			
55-64	138	92	30	16	0	1,641			
Rate*	16.0	15.8	21.2	11.6		11.7			
95% C.I.	(13.4-18.7)	(12.6-19.1)	(13.6-28.8)	(5.9-17.3)		(11.2-12.3)			
65-74	135	92	23	20	0	2,431			
Rate*	21.8	22.2	22.8	19.1		21.1			
95% C.I.	(18.1-25.5)	(17.7-26.7)	(13.5-32.1)	(10.8-27.5)		(20.2-21.9)			
75-84	90	72	11	7	0	1,747			
Rate*	27.5	33.3	20.0			24.0			
95% C.I.	(21.8-33.1)	(25.6-41.0)	(8.2-31.8)			(22.9-25.2)			
85+	18	10	5	3	0	544			
Rate*	25.6	23.3				21.9			
95% C.I.	(13.7-37.4)	(8.9-37.8)				(20.1-23.8)			
Unknown	0	0	0	0	0	0			

^{*} Rates are per 100,000 age-specific population.

Table 282. Esophageal Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

	County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown			
Total								
Discharges	293	216	42	35	0			
Rate*	3.4	3.7	2.9	2.4				
95% C.I.	(3.0-3.8)	(3.2-4.3)	(2.1-4.0)	(1.6-3.4)				
Gender								
Male	223	160	34	29	0			
Rate*	5.3	5.7	5.1	3.9				
95% C.I.	(4.6-6.2)	(4.8-6.9)	(3.5-7.6)	(2.6-6.0)				
Female	70	56	8	6	0			
Rate*	1.6	1.9						
95% C.I.	(1.2-2.0)	(1.4-2.5)						
Other/Unknown	0	0	0	0	0			
Inpatient Discharge Ch	arges (\$)							
Total Charges	\$12,470,581	\$9,972,796	\$1,316,354	\$1,181,431				
Average Charges	\$42,562	\$46,170	\$31,342	\$33,755				
Median Charges	\$24,270	\$24,457	\$25,724	\$21,466				
Discharge Length of S	tay (LOS) (Days)							
Total LOS	2,945	2,274	368	303				
Average LOS	10.1	10.5	8.8	8.7				
Median LOS	7.0	7.0	7.5	7.0				

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.


Table 283. Esophageal Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Regio	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	368	252	72	44
Rate*	4.0	4.0	4.4	3.2
95% C.I.	(3.6-4.4)	(3.5-4.5)	(3.4-5.4)	(2.3-4.2)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	0	0	0
Rate*				
95% C.I.				
15-24	0	0	0	0
Rate*				
95% C.I.				
25-34	0	0	0	0
Rate*				
95% C.I.				
35-44	11	9	2	0
Rate*	0.7			
95% C.I.	(0.3-1.2)			
45-54	29	22	3	4
Rate*	2.4	2.8		
95% C.I.	(1.5-3.3)	(1.6-3.9)		
55-64	119	79	24	16
Rate*	13.8	13.6	17.0	11.6
95% C.I.	(11.3-16.3)	(10.6-16.6)	(10.2-23.8)	(5.9-17.3)
65-74	115	72	26	17
Rate*	18.6	17.4	25.8	16.3
95% C.I.	(15.2-21.9)	(13.4-21.4)	(15.9-35.7)	(8.5-24.0)
75-84	82	65	12	5
Rate*	25.0	30.1	21.8	
95% C.I.	(19.6-30.4)	(22.8-37.4)	(9.5-34.1)	
85+	12	5	5	2
Rate*	17.0			
95% C.I.	(7.4-26.7)			
Unknown	0	0	0	0

^{*} Rates are per 100,000 age-specific population.

LARYNX CANCER GENERAL PROFILE⁴

Figure 175. Anatomy of the Oral Cavity⁵



General Anatomy: The larynx, also called the voice box, is a 2-inch-long, tube-shaped organ made of cartilage in the neck. We use the larynx when we breathe, talk, or swallow. The larynx is at the top of the windpipe (trachea). The large cartilage that forms the front of the larynx is sometimes called the Adam's apple. The vocal cords, two bands of muscle, form a "V" inside the larynx.

Risk Factors: Cancer of the larynx occurs most often in people over the age of 55, men, Blacks, as a racial/ethnic group,, smokers, and those who work with asbestos.

Signs and Symptoms: The symptoms of cancer of the larynx depend mainly on the size and location of the tumor. Most cancers of the larynx begin on the vocal cords. These tumors are seldom painful, but they almost always cause hoarseness or other changes in the voice. Tumors in the area above the vocal cords may cause a lump on the neck, a sore throat, or an earache. Tumors that begin in the area below the vocal cords are rare. They can make it hard to breathe, and breathing may be noisy.

A cough that doesn't go away or the feeling of a lump in the throat may also be warning signs of cancer of the larynx. As the tumor grows, it may cause pain, weight loss, bad breath, and frequent choking on food. In some cases, a tumor in the larynx can make it hard to swallow.

Diagnosing the Cancer: Direct and indirect laryngoscopy, computed tomography (CAT) scan, and magnetic resonance imaging (MRI) are some common ways of diagnosing cancer of the larynx.

Treatment: Radiation therapy, surgery (Partial or Total Laryngectomy), and chemotherapy are the most common treatment options for those diagnosed with Larynx Cancer.

Table 284. Larynx Cancer Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

		County/Region of Residence							
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)			
Total									
Cases	371	231	79	61	0	6,718			
Rate*	4.0	3.7	4.8	4.5		3.6			
95% C.I.	(3.6-4.4)	(3.2-4.1)	(3.8-5.9)	(3.3-5.6)		(3.5-3.7)			
Age Group									
<1	0	0	0	0	0				
Rate*									
95% C.I.									
1-4	0	0	0	0	0				
Rate*									
95% C.I.									
5-14	0	0	0	0	0				
Rate*									
95% C.I.									
15-24	0	0	0	0	0				
Rate*									
95% C.I.									
25-34	3	2	1	0	0	30			
Rate*						0.1			
95% C.I.						(0.1-0.1)			
35-44	11	4	5	2	0	282			
Rate*	0.7					0.9			
95% C.I.	(0.3-1.2)					(0.8-1.0)			
45-54	62	40	13	9	0	957			
Rate*	5.1	5.0	5.8			4.2			
95% C.I.	(3.9-6.4)	(3.5-6.6)	(2.6-8.9)			(3.9-4.4)			
55-64	111	82	15	14	0	1,777			
Rate*	12.9	14.1	10.6	10.1		12.7			
95% C.I.	(10.5-15.3)	(11.1-17.2)	(5.2-16.0)	(4.8-15.5)		(12.1-13.3)			
65-74	109	57	26	26	0	2,235			
Rate*	17.6	13.7	25.8	24.9		19.4			
95% C.I.	(14.3-20.9)	(10.2-17.3)	(15.9-35.7)	(15.3-34.4)		(18.6-20.2)			
75-84	62	39	16	7	0	1,192			
Rate*	18.9	18.0	29.1			16.4			
95% C.I.	(14.2-23.6)	(12.4-23.7)	(14.8-43.3)			(15.5-17.3)			
85+	13	7	3	3	0	239			
Rate*	18.5					9.6			
95% C.I.	(8.4-28.5)					(8.4-10.9)			
Unknown	0	0	0	0	0	0			

^{*} Rates are per 100,000 age-specific population.

Table 285. Larynx Cancer Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

		Coun	ty/Region of Resid	lence	
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown
Total					
Discharges	226	142	47	37	0
Rate*	2.5	2.4	3.0	2.5	
95% C.I.	(2.2-2.9)	(2.0-2.9)	(2.2-4.1)	(1.7-3.5)	
Gender					
Male	172	109	30	33	0
Rate*	4.0	4.0	3.8	4.5	
95% C.I.	(3.4-4.8)	(3.2-5.0)	(2.6-5.8)	(3.1-6.6)	
Female	54	33	17	4	0
Rate*	1.2	1.1	2.2		
95% C.I.	(0.9-1.6)	(0.7-1.5)	(1.3-3.6)		
Other/Unknown	0	0	0	0	0
Inpatient Discharge Ch	narges (\$)				
Total Charges	\$8,982,071	\$6,203,467	\$1,696,114	\$1,082,490	
Average Charges	\$39,744	\$43,686	\$36,088	\$29,256	
Median Charges	\$29,728	\$30,779	\$30,236	\$25,340	
Discharge Length of S	tay (LOS) (Days)				
Total LOS	2,174	1,387	467	320	
Average LOS	9.6	9.8	9.9	8.6	
Median LOS	7.0	7.0	9.0	7.0	

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.


Table 286. Larynx Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Regio	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	136	91	18	27
Rate*	1.5	1.4	1.1	2.0
95% C.I.	(1.2-1.7)	(1.1-1.7)	(0.6-1.6)	(1.2-2.7)
Age Group				
<1	0	0	0	0
Rate*				
95% C.I.				
1-4	0	0	0	0
Rate*				
95% C.I.				
5-14	0	0	0	0
Rate*				
95% C.I.				
15-24	0	0	0	0
Rate*				
95% C.I.				
25-34	0	0	0	0
Rate*				
95% C.I.				
35-44	1	1	0	0
Rate*				
95% C.I.				
45-54	12	9	1	2
Rate*	1.0			
95% C.I.	(0.4-1.6)			
55-64	33	26	2	5
Rate*	3.8	4.5		
95% C.I.	(2.5-5.1)	(2.8-6.2)		
65-74	54	33	7	14
Rate*	8.7	8.0		13.4
95% C.I.	(6.4-11.0)	(5.2-10.7)		(6.4-20.4)
75-84	27	19	4	4
Rate*	8.2	8.8		
95% C.I.	(5.1-11.3)	(4.8-12.7)		
85+	9	3	4	2
Rate*				
95% C.I.				
Unknown	0	0	0	0

^{*} Rates are per 100,000 age-specific population.

MULTIPLE MYELOMA GENERAL PROFILE⁴

Figure 176. Picture of Myeloma Cells⁴



General Anatomy: Multiple Myeloma affects certain white blood cells called plasma cells that are part of the body's immune system. Plasma cells begin their development in the bone marrow and help the immune system fight infection and disease by producing antibodies. When cancer involves plasma cells, the body keeps producing more and more of these cells. The unneeded plasma cells -- all abnormal and all exactly alike -- are called myeloma cells. Myeloma cells tend to collect in the bone marrow and in the hard, outer part of bones. Sometimes they collect in only one bone and form a single mass, or tumor, called a plasmacytoma. In most cases, however, the myeloma cells collect in many bones, often forming many tumors and causing other problems. When this happens, the disease is called multiple myeloma.

Risk Factors: While the cause is unknown most multiple myeloma patients are between 50 and 70 years of age and affects Blacks, as a racial/ethnic group, more often than whites and men more often than women. Those with a family history of multiple myeloma and those exposed to certain chemicals and radiation seem to have a slightly higher increase in the risk of developing this type of cancer. In most cases, people who develop multiple myeloma have no clear risk factors. The disease may be the result of several factors (known and/or unknown) acting together.

Signs and Symptoms: Symptoms of multiple myeloma depend on how advanced the disease is. In the earliest stage of the disease, there may be no symptoms. When symptoms do occur, patients commonly have: bone pain in the back or ribs, broken bones, weakness, fatigue, weight loss, or repeated infections. When the disease is advanced, symptoms may include nausea, vomiting, constipation, problems with urination, and weakness or numbness in the legs.

Diagnosing the Cancer: X-rays, blood and urine tests (high levels of antibody proteins), bone marrow aspiration and/or bone marrow biopsy.

Treatment: chemotherapy, radiation therapy, and secondary surgical procedures to help the individual recover from these types of therapy include: bone marrow transplantation, peripheral stem cell support, and treatment with colony-stimulating factors.

Table 287. Multiple Myeloma Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

		on of Residence				
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)
Total						
Cases	337	198	87	52	0	9,106
Rate*	3.6	3.1	5.3	3.8		4.9
95% C.I.	(3.2-4.0)	(2.7-3.6)	(4.2-6.4)	(2.8-4.8)		(4.8-5.0)
Age Group						
<1	0	0	0	0	0	
Rate*						
95% C.I.						
1-4	0	0	0	0	0	
Rate*						
95% C.I.						
5-14	0	0	0	0	0	
Rate*						
95% C.I.						
15-24	0	0	0	0	0	6
Rate*						
95% C.I.						
25-34	0	0	0	0	0	51
Rate*						0.2
95% C.I.						(0.1-0.2)
35-44	13	9	2	2	0	311
Rate*	0.9					1.0
95% C.I.	(0.4-1.3)					(0.9-1.1)
45-54	39	23	9	7	0	998
Rate*	3.2	2.9				4.4
95% C.I.	(2.2-4.2)	(1.7-4.1)				(4.1-4.6)
55-64	77	46	16	15	0	1,638
Rate*	8.9	7.9	11.3	10.9		11.7
95% C.I.	(6.9-10.9)	(5.6-10.2)	(5.8-16.9)	(5.4-16.4)		(11.1-12.3)
65-74	108	59	31	18	0	2,683
Rate*	17.4	14.2	30.7	17.2		23.3
95% C.I.	(14.1-20.7)	(10.6-17.9)	(19.9-41.6)	(9.3-25.2)		(22.4-24.1)
75-84	79	48	22	9	0	2,602
Rate*	24.1	22.2	40.0			35.8
95% C.I.	(18.8-29.4)	(15.9-28.5)	(23.3-56.7)			(34.4-37.2)
85+	20	12	7	1	0	817
Rate*	28.4	28.0				32.9
95% C.I.	(15.9-40.8)	(12.2-43.9)				(30.7-35.2)
Unknown	1	1	0	0	0	0

^{*} Rates are per 100,000 age-specific population.

Table 288. Multiple Myeloma Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

	County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	
Total						
Discharges	320	200	84	36	0	
Rate*	3.7	3.5	5.7	2.5		
95% C.I.	(3.3-4.1)	(3.0-4.0)	(4.5-7.1)	(1.7-3.5)		
Gender						
Male	189	115	51	23	0	
Rate*	4.6	4.2	7.7	3.2		
95% C.I.	(3.9-5.4)	(3.4-5.2)	(5.6-10.6)	(2.0-5.1)		
Female	131	85	33	13	0	
Rate*	2.9	2.9	4.2	1.8		
95% C.I.	(2.4-3.5)	(2.3-3.6)	(2.9-6.0)	(0.9-3.1)		
Other/Unknown	0	0	0	0	0	
Inpatient Discharge Ch	narges (\$)					
Total Charges	\$10,815,334	\$7,298,287	\$2,659,695	\$857,352		
Average Charges	\$33,798	\$36,491	\$31,663	\$23,815		
Median Charges	\$21,511	\$22,806	\$18,735	\$13,518		
Discharge Length of S	tay (LOS) (Days)					
Total LOS	2,970	1,879	828	263		
Average LOS	9.3	9.4	9.9	7.3		
Median LOS	7.0	7.0	7.0	7.0		

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.


Table 289. Multiple Myeloma Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Mortality	229	147	54	28				
Rate*	2.5	2.3	3.3	2.0				
95% C.I.	(2.1-2.8)	(2.0-2.7)	(2.4-4.2)	(1.3-2.8)				
Age Group								
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	0	0	0	0				
Rate*								
95% C.I.								
15-24	0	0	0	0				
Rate*								
95% C.I.								
25-34	0	0	0	0				
Rate*								
95% C.I.								
35-44	2	2	0	0				
Rate*								
95% C.I.								
45-54	19	13	4	2				
Rate*	1.6	1.6						
95% C.I.	(0.9-2.3)	(0.7-2.5)						
55-64	48	31	11	6				
Rate*	5.6	5.3	7.8					
95% C.I.	(4.0-7.2)	(3.5-7.2)	(3.2-12.4)					
65-74	77	46	20	11				
Rate*	12.4	11.1	19.8	10.5				
95% C.I.	(9.6-15.2)	(7.9-14.3)	(11.1-28.5)	(4.3-16.7)				
75-84	69	46	14	9				
Rate*	21.1	21.3	25.4					
95% C.I.	(16.1-26.0)	(15.1-27.4)	(12.1-38.8)					
85+	14	9	5	0				
Rate*	19.9							
95% C.I.	(9.5-30.3)							
Unknown	0	0	0	0				

^{*} Rates are per 100,000 age-specific population.

HODGKIN'S LYMPHOMA GENERAL PROFILE⁴

Figure 177. Anatomy of the Lymphatic System⁴



General Anatomy: Lymphoma is a general term for cancers that develop in the lymphatic system. The lymphatic system is part of the body's immune system that helps the body fight disease and infection and includes a network of thin tubes (lymphatic vessels) that branch, like blood vessels, into tissues throughout the body. These vessels carry lymph, a colorless, watery fluid that contains infection-fighting cells called lymphocytes. Along this network of vessels are small organs called lymph nodes that are found in the underarms, groin, neck, chest, and abdomen. Other parts of the lymphatic system are the spleen, thymus, tonsils, and bone marrow. Lymphatic tissue is also found in other parts of the body, including the stomach, intestines, and skin.

Hodgkin's disease, an uncommon lymphoma, accounts for less than 1 percent of all cases of cancer in the United States. This type of cancer tends to spread in a fairly orderly way from one group of lymph nodes to the next group. For example, Hodgkin's disease that arises in the lymph nodes in the neck spreads first to the nodes above the collarbones, and then to the lymph nodes under the arms and within the chest. Eventually, it can spread to almost any other part of the body.

Risk Factors: Common risk factors that are believed to be associated with the development of Hodgkin's Lymphoma are: age (between 15 and 34 and over 55 years of age), being male, family History, and certain viruses (Epstein-Barr virus).

Signs and Symptoms: A painless swelling in the lymph nodes in the neck, underarm, or groin, unexplained recurrent fevers, night sweats, unexplained weight loss, and itchy skin are some common symptoms that can be associated with Hodgkin's Lymphoma.

Diagnosing the Cancer: X-rays, computed tomography (CAT) scan, and magnetic resonance imaging (MRI), and biopsy (Reed-Sternberg cells in lymph node tissue).

Treatment: Radiation therapy and chemotherapy are the most common treatments, but others include: bone marrow transplantation, peripheral stem cell transplantation, and biological therapies are being studied in clinical trials.

Table 290. Hodgkin's Lymphoma Cases by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

		County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)	
Total							
Cases	187	122	35	30	0	5,019	
Rate*	2.0	1.9	2.1	2.2		2.7	
95% C.I.	(1.7-2.3)	(1.6-2.3)	(1.4-2.8)	(1.4-3.0)		(2.6-2.8)	
Age Group							
<1	0	0	0	0	0		
Rate*							
95% C.I.							
1-4	2	0	1	1	0	11	
Rate*						0.1	
95% C.I.						(0.0-0.2)	
5-14	5	4	0	1	0	211	
Rate*						0.8	
95% C.I.						(0.7-0.9)	
15-24	24	16	4	4	0	927	
Rate*	1.9	1.8				3.6	
95% C.I.	(1.1-2.6)	(0.9-2.7)				(3.4-3.8)	
25-34	43	30	10	3	0	1,228	
Rate*	3.0	2.9	4.0			4.2	
95% C.I.	(2.1-3.9)	(1.9-4.0)	(1.5-6.4)			(4.0-4.4)	
35-44	33	24	4	5	0	889	
Rate*	2.2	2.4				2.8	
95% C.I.	(1.5-3.0)	(1.5-3.4)				(2.7-3.0)	
45-54	31	19	8	4	0	569	
Rate*	2.6	2.4				2.5	
95% C.I.	(1.7-3.5)	(1.3-3.5)				(2.3-2.7)	
55-64	18	11	3	4	0	434	
Rate*	2.1	1.9				3.1	
95% C.I.	(1.1-3.1)	(0.8-3.0)				(2.8-3.4)	
65-74	23	12	5	6	0	376	
Rate*	3.7	2.9				3.3	
95% C.I.	(2.2-5.2)	(1.3-4.5)				(2.9-3.6)	
75-84	5	5	0	0	0	295	
Rate*						4.1	
95% C.I.						(3.6-4.5)	
85+	3	1	0	2	0	77	
Rate*						3.1	
95% C.I.						(2.4-3.8)	
Unknown	0	0	0	0	0	0	

^{*} Rates are per 100,000 age-specific population.

Table 291. Hodgkin's Lymphoma Inpatient Discharges by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown		
Total							
Discharges	116	89	18	9	0		
Rate*	1.2	1.4	1.1				
95% C.I.	(1.0-1.5)	(1.1-1.7)	(0.7-1.8)				
Gender							
Male	61	51	7	3	0		
Rate*	1.3	1.5					
95% C.I.	(1.0-1.7)	(1.2-2.2)					
Female	55	38	11	6	0		
Rate*	1.2	1.2	1.4				
95% C.I.	(0.9-1.6)	(0.9-1.7)	(0.7-2.5)				
Other/Unknown	0	0	0	0	0		
Inpatient Discharge Ch	narges (\$)						
Total Charges	\$4,306,209	\$3,302,741	\$716,230	\$287,238			
Average Charges	\$37,122	\$37,109	\$39,791	\$31,915			
Median Charges	\$18,413	\$18,383	\$20,569	\$16,777			
Discharge Length of S	tay (LOS) (Days)						
Total LOS	1,031	834	140	57			
Average LOS	8.9	9.4	7.8	6.3			
Median LOS	5.0	5.0	5.5	5.0			

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 292. Hodgkin's Lymphoma Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties				
Total								
Mortality	39	27	6	6				
Rate*	0.4	0.4	0.4	0.4				
95% C.I.	(0.3-0.6)	(0.3-0.6)	(0.1-0.7)	(0.1-0.8)				
Age Group								
<1	0	0	0	0				
Rate*								
95% C.I.								
1-4	0	0	0	0				
Rate*								
95% C.I.								
5-14	0	0	0	0				
Rate*								
95% C.I.								
15-24	2	2	0	0				
Rate*								
95% C.I.								
25-34	4	4	0	0				
Rate*								
95% C.I.								
35-44	4	3	1	0				
Rate*								
95% C.I.								
45-54	8	4	3	1				
Rate*								
95% C.I.								
55-64	3	2	0	1				
Rate*								
95% C.I.								
65-74	13	8	2	3				
Rate*	2.1							
95% C.I.	(1.0-3.2)							
75-84	4	4	0	0				
Rate*								
95% C.I.								
85+	1	0	0	1				
Rate*								
95% C.I.	 0	0	0	0				
Unknown		U	U	0				

^{*} Rates are per 100,000 age-specific population.

ALL OTHER SITES

Table 293. Cancer Cases for All Other Sites by Age Group and County/Region of Residence at Diagnosis, Nevada Residents (1996-2000) and SEER-11 (1995-1999)

	County/Region of Residence					
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown	SEER 11 (1995-1999)
Total						
Cases	3,145	1,798	790	556	1	57,829
Rate*	33.8	28.6	48.2	40.6		31.2
95% C.I.	(32.6-35.0)	(27.2-29.9)	(44.9-51.6)	(37.2-44.0)		(31.0-31.5)
Age Group						
<1	16	10	2	4	0	308
Rate*	11.5	10.2				11.1
95% C.I.	(5.8-17.1)	(3.9-16.5)				(9.9-12.4)
1-4	14	11	1	2	0	474
Rate*	2.6	2.9				4.3
95% C.I.	(1.2-3.9)	(1.2-4.6)				(3.9-4.6)
5-14	26	17	5	4	0	625
Rate*	2.0	1.9				2.3
95% C.I.	(1.2-2.7)	(1.0-2.8)				(2.2-2.5)
15-24	72	40	15	16	1	1,745
Rate*	5.6	4.6	6.6	8.8		6.8
95% C.I.	(4.3-6.9)	(3.2-6.0)	(3.3-10.0)	(4.5-13.2)		(6.4-7.1)
25-34	143	96	34	13	0	4,286
Rate*	10.0	9.4	13.5	8.2		14.6
95% C.I.	(8.4-11.6)	(7.5-11.3)	(8.9-18.0)	(3.7-12.6)		(14.2-15.1)
35-44	218	140	52	26	0	5,739
Rate*	14.6	14.1	18.7	11.5		18.4
95% C.I.	(12.7-16.5)	(11.8-16.5)	(13.6-23.8)	(7.1-15.9)		(17.9-18.8)
45-54	379	223	105	51	0	6,286
Rate*	31.3	28.2	46.8	26.5		27.5
95% C.I.	(28.2-34.5)	(24.5-31.8)	(37.8-55.7)	(19.2-33.8)		(26.8-28.1)
55-64	566	326	133	107	0	7,717
Rate*	65.7	56.1	94.0	77.6		55.1
95% C.I.	(60.3-71.2)	(50.0-62.2)	(78.0-110.0)	(62.9-92.3)		(53.9-56.3)
65-74	801	437	210	154	0	12,290
Rate*	129.2	105.4	208.2	147.4		106.5
95% C.I.	(120.3-138.2)	(95.5-115.3)	(180.1-236.4)	(124.1-170.7)		(104.6-108.4)
75-84	704	376	186	142	0	12,543
Rate*	214.8	173.9	338.0	251.4		172.6
95% C.I.	(198.9-230.7)	(156.3-191.4)	(289.4-386.6)	(210.1-292.8)		(169.5-175.6)
85+	206	122	47	37	0	5,816
Rate*	292.4	284.8	326.0	280.4		234.5
95% C.I.	(252.5-332.3)	(234.2-335.3)	(232.8-419.2)	(190.1-370.8)		(228.5-240.5)
Unknown	0	0	0	0	0	0

^{*} Rates are per 100,000 age-specific population.

Table 294. Inpatient Discharges for All Other Sites by Gender, Charges, Length of Stay, and County/Region of Residence, Nevada Residents, 1996-2000

	County/Region of Residence						
Category	Nevada Total	Clark	Washoe	All Other Counties	Unknown		
Total							
Discharges	7,626	5,382	1,290	951	3		
Rate*	88.4	93.4	88.8	67.6			
95% C.I.	(86.4-90.5)	(90.8-96.0)	(84.0-93.9)	(63.3-72.2)			
Gender							
Male	3,532	2,469	585	476	2		
Rate*	86.8	90.2	88.3	70.6			
95% C.I.	(83.7-89.9)	(86.4-94.1)	(80.9-96.5)	(64.1-77.8)			
Female	4,094	2,913	705	475	1		
Rate*	91.5	97.7	91.8	65.7			
95% C.I.	(88.7-94.4)	(94.2-101.4)	(85.1-98.9)	(59.9-71.9)			
Other/Unknown	0	0	0	0	0		
Inpatient Discharge Ch	narges (\$)						
Total Charges	\$204,669,570	\$152,850,142	\$31,503,531	\$20,190,179	\$125,718		
Average Charges	\$26,838	\$28,400	\$24,421	\$21,230	\$41,906		
Median Charges	\$18,143	\$19,205	\$16,959	\$13,765	\$14,655		
Discharge Length of S	tay (LOS) (Days)						
Total LOS	56,235	40,211	9,707	6,290	27		
Average LOS	7.4	7.5	7.5	6.6	9.0		
Median LOS	5.0	5.0	6.0	5.0	5.0		

^{*} Rates are per 100,000 population and are age-adjusted to the 2000 US Standard population. Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 295. All Other Sites Cancer Mortality by Age Group and County/Region of Residence, Nevada Residents, 1996-2000

		County/Region	n of Residence	
Category	Nevada Total	Clark	Washoe	All Other Counties
Total				
Mortality	2,015	1,255	382	378
Rate*	21.7	19.9	23.3	27.6
95% C.I.	(20.7-22.6)	(18.8-21.0)	(21.0-25.7)	(24.8-30.4)
Age Group				
<1	2	2	0	0
Rate*				
95% C.I.				
1-4	3	2	0	1
Rate*				
95% C.I.				
5-14	9	5	3	1
Rate*				
95% C.I.				
15-24	9	4	1	4
Rate*				
95% C.I.				
25-34	20	16	2	2
Rate*	1.4	1.6		
95% C.I.	(0.8-2.0)	(0.8-2.3)		
35-44	65	43	10	12
Rate*	4.4	4.3	3.6	5.3
95% C.I.	(3.3-5.4)	(3.0-5.6)	(1.4-5.8)	(2.3-8.3)
45-54	175	115	26	34
Rate*	14.5	14.5	11.6	17.7
95% C.I.	(12.3-16.6)	(11.9-17.2)	(7.1-16.0)	(11.7-23.6)
55-64	366	239	55	72
Rate*	42.5	41.1	38.9	52.2
95% C.I.	(38.2-46.9)	(35.9-46.3)	(28.6-49.2)	(40.1-64.2)
65-74	615	392	119	104
Rate*	99.2	94.6	118.0	99.5
95% C.I.	(91.4-107.0)	(85.2-103.9)	(96.8-139.2)	(80.4-118.7)
75-84	529	315	121	93
Rate*	161.4	145.7	219.9	164.7
95% C.I.	(147.6-175.2)	(129.6-161.7)	(180.7-259.1)	(131.2-198.1)
85+	222	122	45	55
Rate*	315.1	284.8	312.2	416.9
95% C.I.	(273.7-356.6)	(234.2-335.3)	(221.0-403.4)	(306.7-527.0)
Unknown		0	0	0

^{*} Rates are per 100,000 age-specific population.

APPENDIX A – CODES USED FOR GROUPING

One of the challenges of this report was to combine information on cancer from several different sources and develop a comprehensive report that details the burden and risk of cancer in the State of Nevada. To add to the complexity of it all, each data source did not use identical coding to identify each type of cancer.

The Nevada Central Cancer Registry uses the International Classification of Diseases – Oncology (ICD-O) coding system that is then broken down into the Topography, or Primary Site, as well as the Morphology of the specific cancer. The Topography section of the ICD-O coding structure is fairly comparable to the ICD-10 mortality classification system, with very little variation between the two systems. However, there are some variations, so this report uses the ICD-O coding structure as the primary source for identifying the type of cancer for this report.

The ICD-10 structure was implemented in 1999 for the coding of the underlying cause of death. However, for the 1996 to 1998 data that are used for this report, the mortality database used the ICD-9 mortality coding structure, which is a different structured system, but is fairly comparable to the ICD-10 revision. However, for this report, due to the variations between the ICD-0 and ICD-10 coding structures and the fact that the ICD-0 system is the primary one used, there have not been any adjustments made to account for potential coding differences that may have occurred due to the change from the ICD-9 to the ICD-10 system in 1999 for all mortality data used in this report.

The ICD-9 coding structure is also used by the inpatient hospital discharge (UB92) database that was used to provide the inpatient discharge statistics for this report. However, all of the 1996 to 2000 hospital discharge data listed in this report is based upon the ICD-9 coding system.

The following pages detail the codes used for each type of coding structure present in the data used for this report. The codes used to identify the leading types of cancer for this report are highlighted. Those not falling under any of the highlighted leading groups were categorized into the All Other Sites grouping.

Table 296. ICD-O Codes Used

	ICD-O Codes			
Type of Cancer	Topography	Morphology	Excluding	
Total	Sum	Sum	(M = Morphology)	
Total	Suili	Suili		
Lip, Oral Cavity and Pharynx	Sum of subgroups			
Lip	C00		M-9590:9989	
Base of Tongue	C01		M-9590:9989	
Other & Unspecified Parts of Tongue	C02		M-9590:9989	
Parotid Gland	C07		M-9590:9989	
Other & Unspecified Major Salivary glands	C08		M-9590:9989	
Floor of Mouth	C04 C03		M-9590:9989	
Gum Palate	C05		M-9590:9989 M-9590:9989	
	C05		M-9590:9989	
Other & Unspecified Parts of Mouth Nasopharynx	C11		M-9590:9989	
Tonsil	C09		M-9590:9989	
Oropharynx	C10		M-9590:9989	
Pyriform Sinus	C12		M-9590:9989	
Hypopharynx	C13		M-9590:9989	
Other & Unspecified Oral (Buccal) Cavity & Pharynx	C14		M-9590:9989	
Digestive System	Sum of Subgroups		W 0000.0000	
Esophagus	C15		M-9590:9989	
Stomach	C16		M-9590:9989	
Small Intestine	C17			
Colorectal	Sum of Colon, Rectum, Re	ectosigmoid Junction, Anus, A	Anal Canal and Anorectum	
Colon (excluding Rectum)	Sum of Subgroups			
Cecum	C18.0		M-9590:9989	
Appendix	C18.1		M-9590:9989	
Ascending Colon	C18.2		M-9590:9989	
Hepatic Flexure	C18.3		M-9590:9989	
Transverse Colon	C18.4		M-9590:9989	
Splenic Flexure	C18.5		M-9590:9989	
Descending Colon	C18.6		M-9590:9989	
Sigmoid Colon	C18.7		M-9590:9989	
Large Intestine, NOS	C18.8-C18.9, C26.0		M-9590:9989	
Rectum	C20		M-9590:9989	
Rectosigmoid Junction	C19		M-9590:9989	
Anus, Anal Canal and Anorectum	C21		M-9590:9989	
Liver	C22.0		M-9590:9989	
Intrahepatic Bile Ducts	C22.1		M-9590:9989	
Gallbladder	C23		M-9590:9989	
Other & Unspecified Biliary Tract	C24		M-9590:9989	
Pancreas	C25		M-9590:9989	
Retroperitoneum	C48.0		M-9590:9989	
Peritoneum, Omentum and Mesentery	C48.1-C48.2		M-9590:9989	
Other Digestive Organs	C26.8-C26.9, C48.8		M-9590:9989	
Respiratory System	Sum of Subgroups		M 0500,0000	
Nasal Cavity and Middle Ear	C30		M-9590:9989	
Accessory Sinuses	C31		M-9590:9989	
Larynx	C32 C34		M-9590:9989	
Lung and Bronchus Pleura	C38.4		M-9590:9989	
Trachea	C33		M-9590:9989 M-9590:9989	
	C38.1, C38.3, C38.8, C39			
Mediastinum and Other Respiratory Organs Bones, Joints and Articular Cartilage	Sum of Subgroups		M-9590:9989	
Bones, Joints and Articular Cartilage Bones, Joints & Articular Cartilage of Limbs	C40		M-9590:9989	
Bones, Joints & Articular Cartilage of Other & Unspec Sites	C40 C41		M-9590.9989	
Soft Tissue (Including Heart)	Sum of Subgroups		IVI-2020.2203	
Heart	C38.0		M-9590:9989	
Peripheral Nerves & Autonomic Nervous System	C36.0		M-9590:9989	
Connective, Subcutaneous & Other Soft Tissues	C49		M-9590:9989	
Commodato, Cabbattanioudo a Other Cont Hoodes	543			

Table 296. ICD-O Codes Used (Continued)

Skin (Excluding Basal And Squamous) Melanomas Of The Skin Other Non-Epithelial Skin Breast Female Genital System Cervix Uteri Sum of Sub	C44 8720-8790 C44 M-8000:800 8010:8045, 8050:808 8090:8110, 8720:879 C50 M-9590:998 C53 M-9590:998 rpus Uteri and Uterus, NOS C54 M-9590:998
Melanomas Of The Skin Other Non-Epithelial Skin Breast Female Genital System Cervix Uteri Corpus Uteri & Uterus, NOS Corpus Uteri Uterus, NOS Ovary	C44 8720-8790 C44 M-8000:800 8010:8045, 8050:808 8090:8110, 8720:879 C50 M-9590:998 C53 M-9590:998 rpus Uteri and Uterus, NOS C54 M-9590:998
Other Non-Epithelial Skin Breast Female Genital System Cervix Uteri Corpus Uteri & Uterus, NOS Corpus Uteri Uterus, NOS Ovary	C44 M-8000:800 8010:8045, 8050:808 8090:8110, 8720:879 C50 M-9590:998 bgroups C53 M-9590:998 rpus Uteri and Uterus, NOS C54 M-9590:998
Breast Female Genital System Cervix Uteri Corpus Uteri & Uterus, NOS Corpus Uteri Uterus, NOS Ovary	8010:8045, 8050:808 8090:8110, 8720:879 C50 M-9590:998 bgroups C53 M-9590:998 rpus Uteri and Uterus, NOS C54 M-9590:998
Female Genital System Cervix Uteri Corpus Uteri & Uterus, NOS Corpus Uteri Uterus, NOS Ovary	bgroups C53 M-9590:998 rpus Uteri and Uterus, NOS C54 M-9590:998
Cervix Uteri Corpus Uteri & Uterus, NOS Sum of Cor Corpus Uteri Uterus, NOS Ovary	C53 M-9590:998 rpus Uteri and Uterus, NOS C54 M-9590:998
Corpus Uteri & Uterus, NOS Sum of Cor Corpus Uteri Uterus, NOS Ovary	rpus Uteri and Uterus, NOS C54 M-9590:998
Corpus Uteri Uterus, NOS Ovary	C54 M-9590:998
Uterus, NOS Ovary	
Ovary	C55 M-9590:998
Vagina	C56 M-9590:998
- ugina	C52 M-9590:998
Vulva	C51 M-9590:998
Placenta	C58 M-9590:998
Other Female Genital Organs	C57 M-9590:998
Male Genital System Sum of Sut Prostate	C61 M-9590:998
Testis	C62 M-9590.998
Penis	C60 M-9590:998
Other Male Genital Organs	C63 M-9590:998
Urinary System Sum of Sub	bgroups
Urinary Bladder	C67 M-9590:998
	ney and Renal Pelvis
Kidney	C64 M-9590:998
Renal Pelvis Ureter	C65 M-9590:998
Other Urinary Organs	C66 M-9590:998 C68 M-9590:998
Eye and Orbit	C69
Brain and Other Central Nervous System Sum of Sub	
Brain	C71 M-9530:9539, 9590:998
Meninges	C70 M-9590:998
Spinal Cord, Cranial Nerves, & Other Parts of CNS	C72 C71 & M-9530:9539 M-9590:998
Endocrine System Sum of Suk	ogroups C73
Thyroid Gland Adrenal Gland	C74
Other Endocrine (Including Thymus)	C37, C75 M-9590:998
Hodgkin's Lymphoma	M-9650:9667
Non-Hodgkin's Lymphoma	M-9590:9595, C42.0, C42.1, C42 9670:9717, 9823:9827
Multiple Myeloma Leukemia Sum of sub	M-9731:9732
Lymphocytic Sum of sub	• .
Acute Lymphocytic	M-9821:9828
Chronic Lymphocytic C42.0,	, C42.1, C42.4 M-9823
Other Lymphocytic	M-9820, 9822, 9824:9826
Granulocytic (Myeloid) Sum of sub	
Acute Myeloid	M-9840, 9861, 9866,
Chronia Muolaid	9867, 9871:9874
Chronic Myeloid Other Myeloid	M-9863:9868 M-9860, 9862, 9864
Monocytic Sum of sub	
Acute Monocytic	M-9891
Chronic Monocytic	M-9893
Other Monocytic	M-9890, 9892, 9894
Other Sum of sub	
Other Acute Other Chronic Aleukemic, Subleukemic and NOS	M-9801, 9841, 9931, 9932 M-9803, 9842
, iioaiioiiio, Gabioakoiiio ana 1100	M-9800, 9802, 9804,
	9830, 9850, 9870, 9880,
	9900, 9910, 9930, 9940,
	, C42.1, C42.4 9941, 9827
Other, III-Defined and Unspecified Sites	All Others

Table 297. ICD-9 and ICD-10 Codes Used

Type of Cancer	ICD-9	ICD-10
Total	Sum	Sum
Lip, Oral Cavity and Pharynx	Sum of subgroups	Sum of subgroups
Lip	140	C00
Base of Tongue	141.0	C01
Other & Unspecified Parts of Tongue	141.1-141.9	C02
Parotid Gland	142.0	C07
Other & Unspecified Major Salivary glands	142.1-142.9	C08
Floor of Mouth	144	C04
Gum	143	C03
Palate Other & Unapposition Parts of Mouth	145.2-145.5 145.0, 145.1, 145.6-145.9	C05 C06
Other & Unspecified Parts of Mouth Nasopharynx	145.0, 145.1, 145.0-145.9	C11
Tonsil	146.0-146.2	C09
Oropharynx	146.3-146.9	C10
Pyriform Sinus	148.1	C12
Hypopharynx	148.0, 148.2-148.9	C13
Other & Unspecified Oral (Buccal) Cavity & Pharynx	149	C14
Digestive System	Sum of Subgroups	Sum of Subgroups
Esophagus	150	C15
Stomach	151	C16
Small Intestine	152	C17
Colorectal		nction, Anus, Anal Canal and Anorectum
Colon (excluding Rectum) Cecum	Sum of Subgroups 153.4	Sum of Subgroups C18.0
Appendix	153.5	C18.1
Ascending Colon	153.6	C18.2
Hepatic Flexure	153.0	C18.3
Transverse Colon	153.1	C18.4
Splenic Flexure	153.7	C18.5
Descending Colon	153.2	C18.6
Sigmoid Colon	153.3	C18.7
Large Intestine, NOS	153.8-153.9, 159.0	C18.8-C18.9, C26.0
Rectum	154.1	C20
Rectosigmoid Junction	154.0	C19
Anus, Anal Canal and Anorectum Liver	154.2-154.8 155.0, 155.2	C21 C22.0, C22.2-C22.4, C22.7, C22.9
Intrahepatic Bile Ducts	155.0, 155.2	C22.0, C22.2-C22.4, C22.7, C22.9
Gallbladder	156.0	C23
Other & Unspecified Biliary Tract	156.1-156.9	C24
Pancreas	157	C25
Retroperitoneum	158.0	C48.0
Peritoneum, Omentum and Mesentery	158.8-158.9	C45.1, C48.1, C48.2
Other Digestive Organs	159.8, 159.9	C26.8-C26.9, C48.8
Respiratory System	Sum of Subgroups	Sum of Subgroups
Nasal Cavity and Middle Ear	160.0, 160.1	C30
Accessory Sinuses	160.2-160.9	C31
Larynx	161	C32
Lung and Bronchus Pleura	162.2-162.9 163	C34 C38.4, C45.0
Trachea	162.0	C33
Mediastinum and Other Respiratory Organs	164.2-164.9, 165	C38.1, C38.3, C38.8, C39
Bones, Joints and Articular Cartilage	Sum of Subgroups	Sum of Subgroups
Bones, Joints & Articular Cartilage of Limbs	170.4, 170.5, 170.7, 170.8	C40
Bones, Joints & Articular Cartilage of Other & Unspec Sites	170.0-170.3, 170.6, 170.9	C41
Soft Tissue (Including Heart)	Sum of Subgroups	Sum of Subgroups
Heart	164.1	C38.0
Peripheral Nerves & Autonomic Nervous System		C47
Connective, Subcutaneous & Other Soft Tissues	171	C49

Table 297. ICD-9 and ICD-10 Codes Used (Continued)

Melanomas Of The Skin Other Non-Epithelial Skin Breast Female Genital System Sum Cervix Uteri Corpus Uteri & Uterus, NOS Sum Corpus Uteri Uterus, NOS Ovary Vagina	Topography of Subgroups 172 173, 176 174-175 of Subgroups 180 of Corpus Uteri and Uterus, NOS 182 179 183.0 184.0	Morphology Sum of Subgroups C43 C44, C46 C50 Sum of Subgroups C53 Sum of Corpus Uteri and Uterus, NOS C54 C55
Melanomas Of The Skin Other Non-Epithelial Skin Breast Female Genital System Sum Cervix Uteri Corpus Uteri & Uterus, NOS Sum Corpus Uteri Uterus, NOS Ovary Vagina	172 173, 176 174-175 of Subgroups 180 of Corpus Uteri and Uterus, NOS 182 179 183.0	C43 C44, C46 C50 Sum of Subgroups C53 Sum of Corpus Uteri and Uterus, NOS C54 C55
Melanomas Of The Skin Other Non-Epithelial Skin Breast Female Genital System Sum Cervix Uteri Corpus Uteri & Uterus, NOS Sum Corpus Uteri Uterus, NOS Ovary Vagina	172 173, 176 174-175 of Subgroups 180 of Corpus Uteri and Uterus, NOS 182 179 183.0	C44, C46 C50 Sum of Subgroups C53 Sum of Corpus Uteri and Uterus, NOS C54 C55
Breast Female Genital System Sum Cervix Uteri Corpus Uteri & Uterus, NOS Sum Corpus Uteri Uterus, NOS Ovary Vagina	174-175 of Subgroups 180 of Corpus Uteri and Uterus, NOS 182 179 183.0	C50 Sum of Subgroups C53 Sum of Corpus Uteri and Uterus, NOS C54 C55
Female Genital System Cervix Uteri Corpus Uteri & Uterus, NOS Corpus Uteri Uterus, NOS Ovary Vagina	of Subgroups 180 of Corpus Uteri and Uterus, NOS 182 179 183.0	Sum of Subgroups C53 Sum of Corpus Uteri and Uterus, NOS C54 C55
Cervix Uteri Corpus Uteri & Uterus, NOS Sum Corpus Uteri Uterus, NOS Ovary Vagina	180 of Corpus Uteri and Uterus, NOS 182 179 183.0	C53 Sum of Corpus Uteri and Uterus, NOS C54 C55
Corpus Uteri & Uterus, NOS Sum Corpus Uteri Uterus, NOS Ovary Vagina	of Corpus Uteri and Uterus, NOS 182 179 183.0	Sum of Corpus Uteri and Uterus, NOS C54 C55
Corpus Uteri Uterus, NOS Ovary Vagina	182 179 183.0	C54 C55
Uterus, NOS Ovary Vagina	179 183.0	C55
Ovary Vagina	183.0	
Vagina		
	104.0	C56 C52
Vulva	184.1-184.4	C51
Placenta	181	C58
Other Female Genital Organs	183.2-183.9, 184.8, 184.9	C57
	of Subgroups	Sum of Subgroups
Prostate	185	C61
Testis	186	C62
Penis	187.1-187.4	C60
Other Male Genital Organs	187.5-187.9	C63
	of Subgroups	Sum of Subgroups
Urinary Bladder	188	C67
	of Kidney and Renal Pelvis	Sum of Kidney and Renal Pelvis
Kidney Renal Pelvis	189.0 189.1	C64 C65
Ureter	189.2	C66
Other Urinary Organs	189.3-189.9	C68
Eye and Orbit	190	C69
•	of Subgroups	Sum of Subgroups
Brain	191	C71
Meninges	192.1, 192.3	C70
Spinal Cord, Cranial Nerves, & Other Parts of CNS	192.0, 192.2, 192.8, 192.9	C72
	of Subgroups	Sum of Subgroups
Thyroid Gland	193	C73
Adrenal Gland	194.0	C74 C37. C75
Other Endocrine (Including Thymus) Hodgkin's Lymphoma	164.0, 194.1-194.9 201	C37, C75
Non-Hodgkin's Lymphoma	200, 202.8, 202.9, 202.0-202.2	C82-C85.9, C96.3
Multiple Myeloma	200, 202.8, 202.9, 202.0-202.2	C90.0, C90.2
	of subgroups	Sum of subgroups
	of subgroups	Sum of subgroups
Acute Lymphocytic	204.0	C91.0
Chronic Lymphocytic	204.1	C91.1
Other Lymphocytic	204.2-204.9	C91.2, C91.3, C91.7, C91.9
, , ,	of subgroups	Sum of subgroups
Acute Myeloid	205.0	C92.4, C92.5, C92.0
Chronic Myeloid	205.1	C92.1
Other Myeloid	205.2-205.9	C92.2, C92.3, C92.7, C92.9
	of subgroups	Sum of subgroups
Acute Monocytic Chronic Monocytic	206.0 206.1	C93.0 C93.1
Other Monocytic	206.2-206.9	C93.2, C93.7, C93.9
·	of subgroups	093.2, 093.7, 093.9
Other Acute	207.0, 208.0	C94.0, C95.0
Other Chronic	207.1, 208.1	C94.1, C95.1
	4, 203.1, 207.2, 207.8, 208.2-208.9	C90.1, C94.7, C91.4, C91.5, C94.2,
	, , , , , , , , , , , , , , , , , , , ,	C94.5, C95.2, C95.7, C95.9
Other, III-Defined and Unspecified Sites All O	Others	All Others

APPENDIX B – FORMULAS

AGE-ADJUSTED RATE:

$$\frac{E_t}{S}$$
 ×100,000

$$E_t$$
 = Total Expected Number of Events = $\sum_{i=1}^{k} E_i$

$$S_t$$
 = Total Standard Population = $\sum_{i=1}^k S_i$

$$CR$$
 = Crude Rate = $\frac{N_t}{P_t} \times 100,000$

$$P_t$$
 = Total State Population = $\sum_{i=1}^{k} P_i$

$$N_t$$
 = Total Number of Events = $\sum_{i=1}^{k} N_i$

$$E_i$$
 = Age-Specific Expected Number of Events = $\frac{N_i}{P_i} \times S_i$

$$S_i$$
 = Standard Age-Specific Population

$$k$$
 = Number of Age Groups

AGE-ADJUSTED RATE CONFIDENCE INTERVALS:

$$w_{i} = \frac{stdmil_{i}}{\left(pop_{i} \times \sum_{j=x}^{y} stdmil_{j}\right)}$$

$$w_m = \max(w_i)$$

$$v = \sum_{i=x}^{y} (w_i^2 \times count_i)$$

$$CI_{low} = \left(\frac{v}{2 \times rate}\right) \times \left(ChiInv\left(\frac{p}{2}, \frac{\left(2 \times rate^{2}\right)}{v}\right)\right) \times 100,000$$

$$CI_{upper} = \left(\frac{v + w_m^2}{2(rate + w_m)}\right) \times \left(ChiInv\left(1 - \frac{p}{2}, \frac{2(rate + w_m)^2}{\left(v + w_m^2\right)}\right)\right) \times 100,000$$

AGE-ADJUSTED RATE STANDARD ERROR:

$$SE_{AArate} = \left[\sum_{i=x}^{y} \left(\frac{stdmil_{i}}{\sum_{j=x}^{y} stdmil_{j}} \right)^{2} \times \left(\frac{count_{i}}{population_{i}^{2}} \right) \right]^{\frac{1}{2}} \times 100,000$$

CAUSE SPECIFIC SURVIVAL RATE:

$$\begin{split} L_x &= L_{x-1} - D_{x-1} - U_{x-1} - W_{x-1} \\ L_x^* &= L_x - \frac{1}{2} \left(U_x + W_x \right) \\ P_x &= 1 - \frac{D_x}{L_x^*} \\ CP_x &= P_1, P_2, \dots, P_x \end{split}$$

 L_1 = Total number of cases included in table

 L_x = Number of cases alive at beginning of interval x

 L_x^* = Adjusted number of cases alive at during interval x

 D_x = Number of cases dying from Cancer during interval x

 U_x = Number of cases untraced (lost to follow up) during interval x, where the definition for "lost to follow up" is: alive with follow up date prior to some prescribed date

 W_x = Number of cases withdrawn alive during interval x, where the definition of "withdrawn alive" is: alive with follow up date later than some specified date (This is the same as in previous definition.)

 P_x = Cause specific survival rate for interval x

 CP_x = Cumulative cause specific survival rate

CRUDE RATE:

$$CR = \frac{Number of Events}{Population} \times 100,000$$

CRUDE RATE CONFIDENCE INTERVALS:

$$CI_{lower} = \left(\frac{100,000}{Population}\right) \times \left(Events - \left(1.96 \times \sqrt{Events}\right)\right)$$

$$CI_{upper} = \left(\frac{100,000}{Population}\right) \times \left(Events + \left(1.96 \times \sqrt{Events}\right)\right)$$

MEDIAN SURVIVAL RATE:

$$MedianSurvival = \left(Interval - 1\right) + \left(\frac{\left(CP_{x-1} - .5\right)}{\left(CP_{x-1} - CP_{x}\right)}\right)$$

ELSE IF: CP_x for first interval is less than .5, then median survival:

$$MedianSurvival = \frac{.5}{(1 - CP_x)}$$

ELSE IF: CP_x for interval is equal to .5, then median survival:

MedianSurvival = Interval

 CP_x = Cumulative cause specific survival rate for interval x

PERCENTAGE (BRFSS) CONFIDENCE INTERVALS:

$$CI_{lower} = Weighted\% - 1.96 \times \sqrt{\frac{Weighted\% \times (1 - Weighted\%)}{Total \text{Re sponses}}}$$

$$CI_{upper} = Weighted\% + 1.96 \times \sqrt{\frac{Weighted\% \times (1 - Weighted\%)}{Total \text{Re sponses}}}$$

REFERENCES

- 1). Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1973-1999), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2002, based on the November 2001 submission.
- 2). "ICD-9 to ICD-10" text document, ICD Conversion Programs, Surveillance, Epidemiology and End Results (SEER), National Cancer Institute, October 2002. http://seer.cancer.gov/tools/, 2002.
- National Cancer Institute, Surveillance, Epidemiology and End Results (SEER), February 2003. http://seer.cancer.gov/, 2003.
- 4). National Cancer Institute, "What you need to know about..." publications. http://cancer.gov/cancer_information/list.aspx?viewid=920AFA90-5547-4739-8D2D-89968F77A87D, 2003.
- 5). Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds). SEER Summary Staging Manual 2000: Codes and Coding Instructions, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001. http://seer.cancer.gov/tools/ssm/. 2003.

FEEDBACK AND SUGGESTIONS

In a continuing effort to provide an annual Cancer Report that is useful to the communities of Nevada, feedback and suggestions on the information contained in this report is welcome. An electronic form is also available for completion at: http://health2k.state.nv.us/nihds/cancer/1996-2000Report/feedback.

Please return the completed survey by mail, fax or email to:

Center for Health Data and Research Bureau of Health Planning and Statistics 505 E. King Street, Rm 102 Carson City, NV 89701 Fax: (775) 684-4156 tpollard@nvhd.state.nv.us

1.	How did you first find the	e report?					
	Hard Copy	Electronic	Сору		State Web	site	
2.	Please rate the overall va	lue of the rep	ort:				
	Extremely Valuable 5	4		3		2	No value 1
3.	Please rate the general in	formation in	cluded	in this repo	ort:		
	Type of Information	Extremely Helpful 5	4	Somewhat Helpful 3	2	Not Helpful 1	Not Applicable 0
	General Sections Overview						
	Cancer Incidence						
	Inpatient Discharge						
	Mortality						
	Survival Rate						

(PLEASE CONTINUE SURVEY ON NEXT PAGE)

4. Please rate the information on specific types of cancer included in this report:

Type of Information	Extremely Helpful 5	4	Somewhat Helpful 3	2	Not Helpful 1	Not Applicable 0
Type of Cancer All Cancers						
Lung and Bronchus						
Breast						
Prostate						
Colorectal						
Urinary Bladder						
Non-Hodgkin's Lymphoma						
Kidney & Renal Pelvis	;					
Leukemia						
Lip, Oral Cavity & Pharynx						
Pancreas						
All Other Cancers						
Other Comments:						
you would like to be put onto the mailing list for future editions of this report, please fill our e following information and return it to the address listed at the top of this survey:						
			ail Notificati	_		
Name:	ffiliation:					
City: Email Address:		S	tate:		Zip Code:_	